2023
ASRM PRESIDENT'S
GALA
Benefiting the
ASRM Research Institute

SUNDAY, OCTOBER 15, 2023
6:00 PM RECEPTION
7:00 PM DINNER, AWARDS, AND AUCTION
MUSIC AND DANCING UNTIL 11:00 PM

Hilton Riverside | New Orleans, LA
Black-Tie or Mardis Gras Attire Optional

TABLE OF 10: $5,000 | SINGLE TICKET: $500

The last day to purchase a ticket is September 30. A portion of every sponsorship and ticket is tax deductible. You can purchase your ticket when you register for ASRM 2023 or by visiting https://ASRMgala23.givesmart.com.
OUR WEEKEND BEGINS with an exciting lineup of on-site postgraduate courses. The Postgraduate Program Committee has collaborated with our affiliated societies, professional and special interest groups, as well as domestic and international Society Partners, to present a wide range of multi-disciplinary postgraduate courses designed to meet the needs of all our members. Course topics range from ethical considerations in reproductive medicine, coding for maximum reimbursement, understanding federal regulations, self-care for providers, translating bench research into the clinical management of recurrent pregnancy, reproductive injustice, sexual health, gender identity, counseling about genetics, and growing your practice. Additionally, this year, we will have a PG course taught in Spanish and will focus on the debated issues in ART. Our lineup also includes multiple hands-on courses, a social media summit, and the SREI Practice Retreat meeting.

In keeping with our ASRM 2023 Scientific Congress theme of “The Past, The Present, The Pipeline,” we have invited a diverse group of dynamic plenary speakers this year who will engage us in a variety of topics. These include privacy in our current climate, transgender medicine, male contraception, non-hormonal contraceptives targeting AMHR2, the intersection of REI and racism, equity and inclusion, sexual function, menopause, and many more. We are finalizing a talk from one of my personal friends from the entertainment industry, who will discuss similarities between the medical world and the movie business when it comes to mentorship and developing future leaders.

The Scientific Congress Continuing Medical Education (CME) course offerings will include morning plenary and dual-afternoon lectures, symposia, and interactive sessions. You will hear innovative lectures that focus on communicating about genetics to patients, diversifying the reproductive medicine workforce, human genome editing, dietary and exercise implications on male reproduction, moving novel therapies from bench to bedside, and fertility preservation for our transgender patients. CME sessions will be complemented by non-CME activities, including intimate roundtable luncheons covering the breadth and depth of reproductive medicine. Oral and poster talks will take place throughout each day of the Scientific Congress, bringing a new format to these presentations.

We welcome our members, trainees, and colleagues from around the world to the ASRM 2023 Scientific Congress & Expo! We look forward to seeing you in person and value your participation and engagement in all the educational and networking opportunities provided.

I look forward to seeing you in the engaging historic city of New Orleans! I also hope you will join us on Sunday night, October 15, 2023, at the President’s Gala Celebration in support of the ASRM Research Institute. You won’t want to miss this Mardi Gras-themed event.

Sincerely,

Michael A. Thomas, MD
ASRM President, 2022-2023
JOIN US FOR OUR

Opening Ceremony

Monday, October 16
7:45 am – 8:30 am

President’s Guest Plenary will immediately follow in the same room.

A complimentary continental breakfast will be available
7:00 am – 7:45 am

Inside this Program

<table>
<thead>
<tr>
<th>ASRM President's Gala</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASRM Welcome</td>
<td>3</td>
</tr>
<tr>
<td>Opening Ceremony</td>
<td>4</td>
</tr>
<tr>
<td>Spotlight Events</td>
<td>5</td>
</tr>
<tr>
<td>ASRM Scientific Congress Policies and Disclaimers</td>
<td>6</td>
</tr>
<tr>
<td>Registration and Meeting Information</td>
<td>6</td>
</tr>
<tr>
<td>Housing Information</td>
<td>7</td>
</tr>
<tr>
<td>Ticketed Events</td>
<td>8</td>
</tr>
<tr>
<td>ASRM Scientific Congress Planning Committees</td>
<td>13</td>
</tr>
<tr>
<td>ASRM Officers and Board of Directors</td>
<td>13</td>
</tr>
<tr>
<td>ASRM 2023 Awards</td>
<td>14-21</td>
</tr>
<tr>
<td>Schedule-at-a-Glance</td>
<td>24-28</td>
</tr>
<tr>
<td>Scientific Congress Daily Schedule</td>
<td>29-34</td>
</tr>
<tr>
<td>Continuing Medical Education/Continuing Education</td>
<td>38-39</td>
</tr>
<tr>
<td>Postgraduate Program</td>
<td>40-57</td>
</tr>
<tr>
<td>Needs Assessment and Learning Objectives</td>
<td>57</td>
</tr>
<tr>
<td>Speaker Index</td>
<td>58-60</td>
</tr>
<tr>
<td>Speaker Disclosures</td>
<td>61-63</td>
</tr>
<tr>
<td>Categories</td>
<td>64</td>
</tr>
<tr>
<td>Roundtables</td>
<td>67-70</td>
</tr>
<tr>
<td>Video Abstracts</td>
<td>73-74</td>
</tr>
<tr>
<td>Oral Abstracts</td>
<td>75-88</td>
</tr>
<tr>
<td>Poster Abstracts</td>
<td>89-114</td>
</tr>
<tr>
<td>Abstract Disclosures</td>
<td>115-124</td>
</tr>
<tr>
<td>ASRM is Paperless</td>
<td>129</td>
</tr>
<tr>
<td>Exhibition</td>
<td>130-133</td>
</tr>
<tr>
<td>Future ASRM Scientific Congress &amp; EXPO Dates</td>
<td>136</td>
</tr>
</tbody>
</table>
What you should know about the ASRM 2023 Scientific Congress & Expo

• **Advocacy Day**—Advocacy is Everywhere! Unleash the activist within you by visiting our four Advocacy stations on Tuesday, October 17.

• Multiple social and networking opportunities, including **Society Social Hour** and the **Networking Lounge**.

• Join ASRM for our third annual **Giving Day** on Tuesday, October 17, benefitting the ASRM Advocacy in Action Fund.

• **The Postgraduate Program**, consisting of 17 diverse courses. This year, all skills courses are listed as **Hands-On Courses**. Separate registration is required.

• **Lunch** is at a designated time, 12:20 PM - 1:20 PM, for either a ticketed lunchtime activity or for you to grab lunch and network with colleagues. All ticketed lunchtime activities will require your physical ticket, which you will receive at registration. New Orleans offers many local spots to enjoy close to the convention center!
  – Check out our ticketed Roundtable discussions – Monday, Tuesday, and Wednesday!

• **Our fully interactive and very useful meeting app** is a must-have for all Congress attendees. Complete your in-app profile and network with other attendees, locate your next in-person session easily with directions from where you are to where you need to be, build a personalized schedule in the app of events you want to attend, and download to view offline.

• **Poster Café and in-person e-poster presentations** – all posters will be available online and through our meeting mobile app on our virtual Poster Wall, including audio for each poster.

• **The President’s Gala** will be in-person on Sunday, October 15. Tickets are $500 per person with all proceeds benefiting the ASRM Research Institute. Purchase your ticket at www.asrmcongress.org when you register for the Congress. For larger groups or table sales, contact Holly Hilton at hhilton@asrm.org.

• Make your Congress experience more interactive with our featured games and activities! Expand your knowledge with **QBoost Live**, showcase your participation with the **Passport Game**, and get physical with our **Step Challenge**.

• Show your ASRM spirit! Visit **Shop ASRM**, a pop-up shop featuring select merchandise from our online store. Come browse our notebooks, mugs, stickers, exclusive meeting t-shirts, and more!
ASRM Scientific Congress Policies and Disclaimers

CANCELLATION POLICY
The American Society for Reproductive Medicine reserves the right to cancel this activity due to unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to the registrant.

REFUND/NON-ATTENDANCE POLICY
Cancellations received on or before September 11, will receive a full refund minus a $150 processing fee. Cancellation requests must be submitted in writing. Cancellations received after September 11 will not be eligible for a refund.

ADA STATEMENT
The American Society for Reproductive Medicine fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Accommodations for Disabilities: Please notify Lee Pearce at lpearce@asrm.org a minimum of 10 working days in advance of the event if a reasonable accommodation for a disability is needed.

EQUAL OPPORTUNITY STATEMENT
The American Society for Reproductive Medicine values and promotes diversity among its members, officers, and staff. The Society prohibits discrimination toward any member or employee due to race, color, religion, age, gender, sexual orientation, national origin, citizenship, disability, military status, or other basis prohibited by law. ASRM strives to achieve gender, racial, and ethnic balance in hiring and governance. ASRM maintains policies, procedures, and personnel actions that conform to the letter and spirit of all laws and regulations pertaining to equal opportunity and nondiscrimination in employment, appointments, and elections to office.

DISCLAIMER STATEMENT
The content and views presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of the American Society for Reproductive Medicine. This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity to make clinical decisions about individual patients.

Registration and Information
Choices may be limited on-site. Pre-registration is recommended.

**ON-SITE REGISTRATION DESK:**
NEW ORLEANS CONVENTION CENTER
Saturday, October 14 ............... 8:30 AM – 5:00 PM
Sunday, October 15 ............... 6:30 AM – 6:00 PM
Monday, October 16 ............... 6:30 AM – 6:00 PM
Tuesday, October 17 ............... 7:00 AM – 5:00 PM
Wednesday, October 18 .......... 7:00 AM – 12:00 PM

**BE SURE TO VISIT THE EXPO HALL**
Monday, October 16 ............... 9:00 AM – 4:30 PM
Tuesday, October 17 ............... 9:00 AM – 4:30 PM
Wednesday, October 18 .......... 9:00 AM – 2:00 PM

Children under 16 are allowed on the Expo Floor only when accompanied/supervised by an adult. No strollers allowed.
SATURDAY, OCTOBER 14, 2023

Postgraduate Courses

SUNDAY, OCTOBER 15, 2023

Postgraduate Courses

Hands-On Courses
(Limited in-person access only)

Society for Reproductive Endocrinology and Infertility (SREI) Members’ Retreat: Improving Today with an Eye on the Future
8:00 PM – 12:00 PM
$250 for SREI Members / $300 for Non-SREI Members

ASRM & CADE Foundation Social Media Summit
8:00 AM – 11:00 AM | $25 registration required

ASRM 2023 President’s Gala
6:00 PM - 11:00 PM
Tickets are $500 per person

DAILY

Resident Learning Sessions
KEEPR Program
Monday, Tuesday, and Wednesday
(Lunch provided • registration required)

Roundtable Luncheons
Monday, Tuesday, and Wednesday
12:20 PM - 1:20 PM | $75/day
See pages 48-51 for a list of roundtable titles and speakers

TUESDAY, OCTOBER 17, 2023

Women’s Council Breakfast
6:45 AM - 7:45 AM | $70 Fee
Discounted ASRM Membership for Reproductive Care Specialists in Low- and Lower-Middle Income Countries

Residence in low-income countries: 75% discount
Residence in lower-middle income countries: 25% discount

Individuals joining or renewing membership in ASRM that reside in low or low-middle income countries (as defined by the World Bank) now receive discount on ASRM membership!

Members receive online access to Fertility and Sterility and other society journals, free access to our extensive library of single ASRM Academy™ modules, discounts on certificate courses and the ASRM Scientific Congress & Expo, and more!

To join at a discounted rate:

1. Go to www.asrm.org and log in to your ASRM account.
2. Click on the “My Account” tab and click the red “Join” button.
3. Choose the appropriate membership that includes the online journal.
4. Complete information and pay. (The discounted price will show at checkout.)
The Premier Supporters of the ASRM 2023 Exhibition

**DIAMOND SPONSORS**
- EMD Serono
- Ferring Pharmaceuticals, Inc.
- Organon, LLC

**PLATINUM SPONSORS**
- Cooper Surgical

**GOLD SPONSORS**
- REPROLIFE/Cryotech Japan
- Vitrolife, Inc.
- Inception Fertility, LLC

**SILVER SPONSORS**
- Astellas Pharma US, Inc.
- Hamilton Thorne, Inc.
- Kitazato Corporation
- North Star Fertility Partners, LLC
- Thermo Fisher Scientific
- ZyMōt Fertility, Inc.
Designed for ASRM members who are passionate about making a real impact, PRIMED offers a one-of-a-kind opportunity to become trailblazers in reproductive medicine advocacy. Participants will gain comprehensive, skill-based training through a hybrid of in-person and online modules spanning approximately ten weeks. From the fundamental aspects of policymaking to mastering message crafting and media relations, PRIMED will equip participants with the tools to become influential voices in shaping the future of reproductive medicine.

Participation will be open to 12 current ASRM members with a vested interest in advancing domestic policy work and demonstrable skills and expertise that will further the underlying mission and priorities of the ASRM CPL. The application will open in early November, and the program will begin for selected applicants in early 2024.

ASRM’s Center for Policy and Leadership (CPL) is excited to announce the launch of an innovative training initiative in 2024: The PRIMED (Preparing Experts in Reproductive Medicine to Engage Decisionmakers) Advocacy Program!

Look for more info in the coming weeks. Stop by the ASRM Booth to learn more!
Committees and Awards

- ASRM Scientific Congress Planning Committee 13
- ASRM Officers and Board of Directors 13
- ASRM Awards 14-21
- Schedule-at-a-Glance 24-28
- Daily Schedule 29-34
ASRM 2023 Scientific Congress Program Planning Committees

Michael A. Thomas, MD, ASRM 2023 President
Ruben Alvero, MD, 2023 Scientific Congress Program Chair
Genevieve Neal-Perry, MD, PhD, 2023 Interactive Sessions Chair
Danny Schust, MD, 2023 Roundtables Chair
Samantha Butts, MD, MSCE, Postgraduate Program Chair
Erica Marsh, MD, MSCI, FACOG, Postgraduate Co-Chair
Divya Shah, MD, Med, Postgraduate Co-Chair
Sangita Jindal, PhD, SART Representative
Kathleen Hwang, MD, SMRU Representative
Marina Gvakhari, MD, PhD, HCLD, ELD, SRBT Representative
Erica Johnstone, MD, SREI Representative
Mindy Christianson, MD, SRS Representative
Haryanto Hokianto, MBA, ARM Representative
Amber Gamma, MS, CGC, GCPG Representative
Nidhi Desai, JD, LPG Representative
Julie Bindeman, PsyD, MHPG Representative
Tamara Tobias, NP, APPPG Representative
Kriston Ward, MSN, NPG Representative
Jared C. Robins, MD, MBA, Chief Executive Officer (Ex Officio)
Chevis N. Shannon, DrPH, MBA, MPH, MERC, CESO (Ex Officio)
Callie Armstead, MA, ASRM Staff

ASRM Officers and Board of Directors 2022 – 2023

ASRM OFFICERS
Michael A. Thomas, MD, President
Paula Amato, MD, President-Elect
Elizabeth Ginsburg, MD, Vice President
Marcelle I. Cedars, MD, Immediate Past President
Hugh S. Taylor, MD, Past President
James P. Toner, MD, PhD, Secretary/Treasurer

ASRM BOARD OF DIRECTORS
AT-LARGE MEMBERS
Alan S. Penzias, MD
Akanksha Mehta, MD
Ruben Alvero, MD
Lauri A. Pasch, PhD
Kim L. Thornton, MD
Eve Feinberg, MD

ASRM BOARD OF DIRECTORS
AFFILIATED SOCIETY MEMBERS
Sangita Jindal, PhD (SART)
James Smith, MD (SMRU)
Brad Milette, BS (SRBT)
Steven L. Young, MD, PhD (SREI)
J. Preston Parry, MD (SRS)

ASRM CHIEF EXECUTIVE OFFICER
Jared C. Robins, MD, MBA

ASRM CHIEF EDUCATION AND SCIENCE OFFICER
Chevis Shannon, DrPH, MBA, MPH, MERC
LIFETIME ACHIEVEMENT AWARD
WILLIAM E. GIBBONS, MD

This award honors a member of the American Society for Reproductive Medicine who has made exemplary contributions to the field of reproduction during his/her career. Dr. William E. Gibbons is a world-renowned pioneer of reproductive medicine and in vitro fertilization. Over the course of his nearly half-century-long career, he has made exceptional contributions to the field of reproductive biology and infertility and has published more than 140 peer-reviewed journal articles. He is a sought-after teacher and mentor and has trained more than 50 REI fellows. Additionally, he has served as the President of ASRM, the Society for Reproductive Endocrinology and Infertility (SREI), and the Society for Assisted Reproductive Technology (SART). Dr. Gibbons currently serves as a distinguished Professor Emeritus at Baylor College of Medicine.

ARNOLD P. GOLD FOUNDATION HUMANISM IN MEDICINE AWARD FOR PRACTICING PHYSICIANS
SIGAL KLIPSTEIN, MD

Dr. Sigal Klipstein is a clinician specializing in reproductive endocrinology and infertility. She practices at InVia Fertility Specialists in Chicago. She completed her residency and fellowship at Harvard University, during which time she was selected to join the Medical Ethics Fellowship at the Harvard Center for Bioethics. In addition to running a clinical practice, she writes and lectures on reproductive ethics, fertility over forty, and oocyte cryopreservation. She formerly chaired the ACOG Committee on Ethics and is currently the Chair of the ASRM Ethics Committee. She feels strongly that her clinical care informs her ethics work and vice versa, and is pleased to be able to unite these two interests as she continues to pursue her clinical and academic careers. Dr. Klipstein is a member of the newly established Donor Conceived People Task Force and has previously contributed to the Embryo Research Task Force for ASRM. She enjoys participating in medical student and resident education in her role as assistant professor at the University of Chicago Pritzker School of Medicine.

SUHEIL J. MUASHER, MD, DISTINGUISHED SERVICE AWARD
supported by an endowment from Suheil J. Muasher, MD
LEE RUBIN COLLINS, JD

Each year, ASRM honors individuals who have provided distinguished service to ASRM. Recipients are selected based on their scientific, leadership, organizational, political, or societal service contributions to ASRM, reproductive medicine, and/or reproductive medicine patients. Lee Rubin Collins, JD, is known for over two decades of advocacy to make fertility treatment universally accessible and to keep it legal. A graduate of Harvard College and Harvard Law School, she began her career at Ropes & Gray in Boston, one of the country’s preeminent law firms, where she was one of the first women litigators to make partner. Her personal experience of secondary infertility, however, motivated her to change careers and dedicate herself to infertility awareness, equity, and policy change.

Ms. Collins was asked to join the Board of Directors of RESOLVE: The National Infertility Association in 2002. In that role, she launched RESOLVE’s advocacy to repel threats to reproductive medicine, first from the President’s Council on Bioethics and then from the growing “embryo-personhood” movement. In 2014, she received RESOLVE’s highest honor, the Barbara Eck Founder’s Award. In 2019, she became the first patient advocate elected to ASRM’s Board of Directors. During her three-
year term, her work on the Board Publications Committee inspired a deep interest in issues of research integrity and misconduct. It led her to help found ASRM’s groundbreaking Research Integrity Committee, which she now co-chairs.

Ms. Collins was honored to serve on the ASRM Ethics Committee from 2014-2019, where she contributed in particular to the Society’s first opinions on disparities in access to care and on the ethics of planned oocyte cryopreservation. Ms. Collins previously has served on the boards of The Howard and Georgeanna Jones Foundation, RESOLVE of the Bay State, and the New England Fertility Society. She has numerous publications and presentations on access to care and advocacy, including her TEDx talk, “Infertility and Politics.” She is grateful to ASRM and to the outstanding mentors and friends in this field who gave her the chance to contribute to advancing reproductive justice.

KAVOUSSI FAMILY OUTSTANDING TEACHER AWARD

This award is made possible through an educational endowment from K.M. Kavoussi, MD, Homa Kavoussi, Shahryar Kavoussi, MD, MPH, Mehryar Kavoussi, JD, Parviz Kavoussi, MD, and Austin Fertility & Reproductive Medicine/Westlake IVF.

CLAUDIO A. BENADIVA, MD, ELD, HCLD (ABB)

This award honors an ASRM member who is recognized as an outstanding educator in undergraduate, graduate, postgraduate, professional, or patient education in the area of basic and/or clinical reproductive biology and medicine. Dr. Claudio Benadiva is the Medical Director of the Center for Advanced Reproductive Services. In addition to being a Professor of Ob/Gyn at the University of Connecticut, he is a Fellow of the American College of Ob/Gyn and Board Certified in Obstetrics & Gynecology and Reproductive Endocrinology and Infertility since 1998. He is among the very few physicians who are certified by the American Board of Bioanalysis as a high complexity laboratory director, making him uniquely suited to integrate both clinical and laboratory protocols in an IVF program. He received the Family Building Award from the American Fertility Association in 2004 and has been awarded "Best Doctor in America" every year since 2001 and the ASRM Star Award yearly since 2012. He graduated from the University of Buenos Aires School of Medicine in 1981 and completed his residency in Ob/Gyn at the University of Connecticut Health Center in 1993. He completed a fellowship in Reproductive Biology and Endocrinology at the University of Pennsylvania School of Medicine and a Clinical Fellowship in Reproductive Endocrinology at The New York Hospital-Cornell Medical Center.

Dr. Benadiva has done extensive research in Reproductive Biology and Endocrinology and IVF since 1986. His work has resulted in over 85 peer-reviewed articles, 170 abstract presentations and several invited book chapters. He has mentored and trained many residents and generations of REI fellows since 1999. He continues to lecture nationally and internationally, with a special interest in ovulation induction for IVF, PGT, GnRH agonist trigger, and methods for prevention of OHSS.

ASRM DISTINGUISHED RESEARCHER AWARD

SHOUKHRAT MITALIPOV, PHD

This award recognizes an ASRM member who has made outstanding contributions to clinical or basic research in reproduction published during the previous 10 years. Dr. Shoukhrat Mitalipov earned his MS in reproduction in 1987 and his PhD in Human Genetics in 1994 from the Research Center for Medical Genetics in Moscow. In 1995, he moved to the US and completed a postdoctoral training at Utah State University, and, in 1998, he joined Oregon Health & Science University as faculty. Currently, Dr. Mitalipov is a director of Center for Embryonic and Gene Therapy at Oregon Health & Science University. His research is focused on investigating and developing novel cell and gene therapy approaches in the area of reproductive medicine.

Dr. Mitalipov’s laboratory pioneered the concept of mitochondrial/cytoplasmic replacement therapy (MRT), allowing replacement of defective cytoplasm or mutant mtDNA in patient eggs prior to fertilization. MRT approaches have been initially developed and tested in a nonhuman primate model and more recently extended to clinical trials for treatment of female infertility that resulted in birth of healthy children. MRT was also successfully used to prevent the transmission
of pathogenic, maternally inherited mtDNA mutations from mothers to their children. His laboratory is also exploring applications of in vitro gametogenesis (IVG) as a future therapy for infertility. He is also investigating novel gene editing strategies that would allow repairing gene defects in gametores or early preimplantation embryos and thus prevent passage of thousands of heritable genetic disorders from parents to their children.

IRA AND ESTER ROSENWAKS NEW INVESTIGATOR AWARD

supported by an endowment from Zev Rosenwaks, MD

KATE DEVINE, MD

This year the Ira and Ester Rosenwaks New Investigator Award goes to Kate Devine, MD. This award recognizes a member of the American Society for Reproductive Medicine who has made outstanding contributions to clinical or basic research in reproductive sciences published within 10 years of receiving a doctoral degree or completing residency/postdoctoral/fellowship training. Dr. Devine, a board-certified Reproductive Endocrinologist, cares for patients in Washington, DC, and has served as Research Director at Shady Grove Fertility since 2014 and as Medical Director and Chief Research Officer of USFertility since 2022. She is Clinical Professor of Obstetrics and Gynecology at George Washington University and Associate Program Director for the Reproductive Endocrinology and Infertility Fellowship at the National Institutes of Health (NIH). She supports the research efforts of fellows from 5 USF affiliated fellowship programs.

Dr. Devine serves as Chair of the Society for Reproductive Endocrinology and Infertility (SREI) Research Committee, Chair of the Society for Assisted Reproductive Technology (SART) Quality Assurance Committee, and on the Editorial Board of Fertility and Sterility. She has authored more than 40 peer-reviewed publications, received numerous research grants and awards, and spoken nationally and internationally on the topic of her research, which focuses primarily on endometrial receptivity and optimization of frozen embryo transfer protocols. She has conducted multiple RCTs on this topic, including the Sustain Study, which received the 2018 ASRM Scientific Congress Prize Paper and the Synchrony Study, which was published in JAMA in December of 2022.

She earned her BA from Columbia University and MD from Albert Einstein College of Medicine. She completed residency at New York University Medical Center and fellowship at the NIH.
2023 ASRM Star Award

The ASRM Star Award recognizes members who have presented during at least nine of the ASRM Scientific Congresses/Annual Meetings from 2013-2022. Presentations may include postgraduate courses/seminars, Scientific Program symposia, posters and/or oral abstracts.

2023 ASRM Star Award Recipients

- Kelly Acharya, MD
- Ashok Agarwal, PhD
- Ali Ahmady, MD
- Ayman Al-Hendy, MD, PhD
- Ruben Alvero, MD
- David Archer, MD
- Yoshimasa Asada, MD, PhD
- Baris Ata, MD
- Awoniyi Awonuga, MBBS
- Johnny Awwad, MD
- Valerie Baker, MD
- G. David Ball, PhD
- David Barad, MD
- Kurt Barnhart, MD
- Jason Barratt, MD
- Alison Bartolucci, PhD
- Mohamed Bedaiwy, MD, PhD
- Barry Behr, PhD
- Valerie Bishop, PhD
- Mohammed Bedaiwy, MD, PhD
- Barry Behr, PhD
- Angeline Beltos, MD
- Claudio Benadiva, MD, HCLD
- Kristin Bendikson, MD
- Dara Berger, PhD
- Cecily Bishop, MD
- Christina Boots, MD
- Edson Borges, MD, PhD
- Charles Bormann, PhD
- Christine Briton-Jones, PhD
- William Buckett, MBBC, MD
- Samantha Butts, MD
- Erkan Buyuk, MD
- William Catherino, MD, PhD
- Marcelle Cedars, MD
- Gerard Celis, PhD
- Tiencheng Arthur Chang, PhD, HCLD, ELD
- Samuel Chantilis, MD
- Jorge Chavarro, MD, DSc
- Jerome Check, MD
- Stephanie Cheung, MS
- Mindy Christianson, MD, MBA
- Alicia Christy, MD
- Ana Cobo, PhD
- Amber Cooper, MD
- Alan Cooperman, MD
- Christos Coutifaris, MD, PhD

- Latasha Craig, MD
- Susan Crockin, JD
- Michael Dahlan, MD
- Svetlana Dambaeva, MD, PhD
- Said Daneshmand, MD
- Alan Decherney, MD
- Nina Desai, PhD, HCLD
- Laura Detti, MD
- Kate Devine, MD
- Kate Devine, MD
- Michael Diamond, MD
- Anuja Dokras, MD, PhD
- Alice Domar, PhD
- Kevin Doody, MD
- Daniel Dumesic, MD
- Randall Dunn, MD
- Jennifer Eaton, MD
- Michael Eisenberg, MD
- Roni Elias, MD
- Lawrence Engmann, MD
- Navid Estandiari, PhD, HCLD
- Tommaso Falcone, MD
- Tarek Farghaly, MD
- Eve Feinberg, MD
- Rebecca Flyckt, MD
- Eric Forman, MD, HCLD
- Aisaku Fukuda, MD, PhD
- Noritaka Fukunaga, PhD
- Ravi Gada, MD, MBA
- Juan Garcia-Velasco, MD
- Forest Garner, MS
- Audrey Gaskins, ScD
- William Gibbons, MD
- Elizabeth Ginsburg, MD
- Norbert Gleicher, MD
- Jeffrey Goldberg, MD
- Kara Goldman, MD
- Marc Goldstein, MD
- Frank Gonzalez, MD
- Linnea Goodman, MD
- Clarisa Gracia, MD
- Elizabeth Grill, PsyD
- Sajal Gupta, MD
- Karl Hansen, MD, PhD

- Avner Hershlag, MD
- Micah Hill, DO
- Jennifer Hirshfeld-Cytron, MD
- Kathleen Hong, MD
- James Hotaling, MD
- Heather Huddleston, MD
- Bradley Hurst, MD
- Kathleen Hwang, MD
- Anthony Imudia, MD
- Mohamad Irani, MD
- Tomomoto Ishikawa, MD, PhD
- Daylon James, PhD
- Jeffery Jensen, DO
- Sangita Jindal, PhD
- Emily Jungheim, MD
- Semra Kahraman, BA
- Mandy Katz-Jaffee, PhD
- Leah Kaye, MD
- David Keefe, MD
- Zaraq Khan, MD
- Chung-Hoon Kim, MD, PhD
- Sacha Krieg, MD, PhD
- Rashmi Kudesia, MD
- Vitaly Kushnir, MD
- Joanne Kwak-Kim, MD
- Koichi Kyono, MD
- Dolores Lamb, PhD
- Michael Lanham, MD
- Ruth Lathi, MD
- Angela Lawson, PhD
- Maw-Sheng Lee, MD
- Richard Legro, MD
- Bruce Lessey, MD, PhD
- Joseph Letourneau, MD
- Michael Levy, MD
- Clifford Libbach, MD
- Frederick Licciardi, MD
- Steven Lindheim, MD
- Martha Luna Rojas, MD
- Monica Mainigi, MD
- Limor Man, MD
- Erica Marsh, MD
- Caroline McCaffrey, PhD, HCLD
- David McCullough, PhD
2023 ASRM Service Milestone Award

The ASRM Service Milestone Award recognizes 10, 15, and 20-year milestones for service on boards and/or committees of ASRM or its affiliated societies, professional groups, or special interest groups.

20-Year ASRM Service Milestone Award Recipient
Elizabeth Ginsburg, MD

15-Year ASRM Service Milestone Award Recipients
Richard Reindollar, MD
Tienchung Arthur Chang, PhD, HCLD, ELD
Philip Li, MD
Tamara Tobias, NP

10-Year ASRM Service Milestone Award Recipients
Barry Witt, MD
Silvina Bocca, MD
Steven Young, MD, PhD
Karl Hansen, MD, PhD
Ranjith Ramasamy, MD
Lee Collins, JD
Margareta Pisarska, MD

2023 AWARDS

Dana McQueen, MD
Akanksha Mehta, MD
Zaheer Merhi, MD
Katrina Merrion, MS
Jennifer Mersereau, MD
Marcos Meseguer, MD
Stacey Missetter, ScD
Molly Moravek, MD
Eduardo Motta, MD
Tanmay Mukherjee, MD
Christine Mullin, MD
Sunni Mumford, PhD
Kanad Dev Nayar, MD
Taranah Nazem, MD
Scott Nelson, MBBS, MD
Nicole Noyes, MD
John Nulsen, MD
Kutluk Oktay, MD, PhD
Kenan Omurtag, MD
Kyle Orwig, PhD
Lubna Pal, MBBS
Gianpiero Palermo, MD, PhD
Pasquale Patrizio, MD
Richard Paulson, MD
Mary Ellen Pavone, MD
Mary Peavey, MD
Antonio Pellicier, MD
Lindsay Penrose, PhD
Alan Penzias, MD
John Petrozza, MD
Samantha Pfeifer, MD
Simon Phillips, PhD
Margareta Pisarska, MD
Staci Pollack, MD
Alex Polotsky, MD

Samuel Prien, PhD
Elizabeth Puscheck, MD
Catherine Racowsky, PhD
Kevin Richter, PhD
Lisa Rinehart, JD, RN
Randal Robinson, MD
Zev Rosenwaks, MD
Carmen Rubio Lluesa
Ginny Ryan, MD
Denny Sakkas, PhD
Mary Sammel, DSc
Benjamin Sandler, MD
Jay Sandlow, MD
Nanette Santoro, MD
Glenn Schattman, MD
Mitchell Schieve, PhD
Peter Schlegel, MD
William Schoolcraft, MD
Richard Scott, MD
James Segars, MD, FACOG
David Seifer, MD
Lucky Sekhon, MD
Emre Seli, MD
Suneeta Senapati, MD
Divya Shah, MD, MEd
Bruce Shapiro, MD, PhD
Fady Sharara, MD
Carlos Simon, PhD
Ov Slayden, PhD
James Smith, MD
Murat Sonmez, MD
Irene Souter, MD
Steven Spandorfer, MD
Amy Sparks, PhD
Laurel Stadtmuhr, MD, PhD

Frank Stanczyk, PhD
Daniel Stein
Anne Steiner, MD
Judy Stern, PhD
Irene Su, MD
Jason Swain, PhD
Takumi Takeuchi, MD, PhD
Reshef Tal, MD, PhD
Atsushi Tanaka, MD, PhD
Xin Tao, PhD, HCLD
Tyl Taylor, PhD
Hugh Taylor, MD
Michael Thomas, MD
Nathan Treff, PhD
Michael Tucker, PhD
Bradley Van Voorhis, MD
Denis Vaughan, MBBS
Matthew Vermilyea, PhD, HCLD
Erica Wang, MD
Ethan Wantman
Rachel Weinerman, MD
Dagan Wells, PhD
Marie Werner, MD
Brooke Wertz, MD
Brian Whitcomb, PhD
Eric Widra, MD
Robert Wild, MD
Lauren Wise, ScD
Steven Young, MD, PhD
Nikica Zaninovic, PhD
John Zhang, MD, PhD
Shane Zozula, BS
SOCIETY FOR MALE REPRODUCTION AND UROLOGY TRAVELING SCHOLARS PROGRAM

The annual Society for Male Reproduction and Urology Traveling Scholars Program allows a diverse group of young clinical physicians and basic science researchers the opportunity to explore a career in male reproductive medicine. The primary purpose of the program is to stimulate the scientific interests of residents and fellows in the study of male reproduction. Scholars are selected by the SMRU Research Committee based on the scores of their abstracts submitted for the Scientific Congress. The recipient for 2023 is Nicholas Deebel, MD, for Oral Prednisone As A Rescue Intervention For Deteriorating Sperm Parameters Following Vasovasostomy.

CAPPY ROTHMAN, M.D., CHUCK SIMS, M.D., AND THE CALIFORNIA CRYOBANK TRAVELING SCHOLAR AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2023 is Aaron Brant, MD, for Variability In Self-Pay Pricing For Vasectomy Among United States Hospitals.

SMRU LIPSHULTZ/LAMB TRAVELING SCHOLAR AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2023 is Rosella Cannarella, MD, PhD, for SPERM MESODERM SPECIFIC TRANSCRIPT GENE METHYLATION STATUS IN INFERTILE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

WEILL CORNELL MALE REPRODUCTIVE SURGERY AND UROLOGY TRAVELING FELLOW AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The 2023 recipient is Joginder Bidhan, MS, for Quantification Of Genetic Variants in Sperm After Radio Frequency Electromagnetic Radiation (RF-EMR) Exposure.

SMRU LIFETIME ACHIEVEMENT AWARD

Marc Goldstein, MD

SMRU OUTSTANDING SERVICE AWARD

Craig Niederberger, MD

SMRU OUTSTANDING YOUNG INVESTIGATOR

James Hotaling, MD

ARM PRIZE PAPER

Marco Mouanness, MD

And More Cost-Effective Alternative to the Injectable GnRH Antagonist For Ovulation Suppression in InVitro Fertilization

MHPG PRIZE PAPER (BEST OVERALL)

Joanna Scheib, PhD

NOW WHAT? DONOR-CONCEIVED ADULT FEELINGS AND CHOICES AFTER LEARNING THE DONOR’S IDENTITY THROUGH AN OPEN-IDENTITY PROGRAM

MHPG PRIZE PAPER (MOST IMPACTFUL)

Kirby Adlam, Phd, APRN, CNM

UNDERSTANDING PARENTS EMOTIONS SURROUNDING DISCLOSURE TO THEIR DONOR-CONCEIVED CHILDREN DURING PARTICIPATION IN THE TELL TOOL INTERVENTION

NPG PRIZE PAPER IN RESEARCH

Stephanie M. Elliott, MSN, NP, RN

INCREASING FERTILITY PATIENT HYPERTENSION SCREENING: A QUALITY IMPROVEMENT PROJECT

SART PRIZE PAPER

Angela H. Liu, MD

TROPHECTODERM BIOPSYS IS ASSOCIATED WITH LOWER RISKS OF MODERATE TO EXTREME PRETERM BIRTHS AND LOW BIRTH WEIGHTS: A SART CORS ANALYSIS OF 45,712 SINGLETON LIVE BIRTHS FROM FROZEN BLASTOCYST TRANSFERS

SMRU PRIZE PAPER

Kristin Brogaard, PhD

A NOVEL EPIGENETIC-BASED TEST TO PREDICT TESE AND MTESE OUTCOMES

SREI PRIZE PAPER

Runxin Gan, MD

REDUCED SMOKING ATTENUATES THE EFFECT OF GENETIC PREDISPOSITION ON PREMATURE OVARIAN AGING: A LARGE POPULATION-BASED LONGITUDINAL STUDY

SRBT PRIZE PAPER

Philip Xie, BSc

DIFFERENTIATION OF PUTATIVE MALE GAMETES FROM MOUSE EMBRYONIC STEM CELLS (MESCE) ENCAPSULATED IN CALCIUM ALGINATE SPHERES

SRBT PRIZE PAPER

Blair R. McCallie, PhD

ALTERED ICM TRANSCRIPTION IN APA-DERIVED BLASTOCYSTS HIGHLIGHT THE SUSCEPTIBILITY OF THE FUTURE FETUS TO ADVERSE HEALTH OUTCOMES

SRS PRIZE PAPER

Susanna Mito, PhD

LONG-TERM RISK OF REINTERVENTION AFTER UTERINE PRESERVING SURGICAL FIBROID TREATMENTS AND VARIATION BY SOCIODEMOGRAPHIC FACTORS
SRS IN-TRAINING AWARDS FOR RESEARCH
Rebecca Chung, MD
AMNIOGRAFT PLACEMENT AT THE TIME OF HYSTEROSCOPY FOR INTRAUTERINE ADHESIONS (IUA) MAY IMPROVE PREGNANCY RATE (PR) AND LIVE BIRTH RATE (LBR) IN SEVERE CASES WITH HISTORY OF FAILED HYSTEROSCOPY

SRS IN-TRAINING AWARDS FOR RESEARCH
Emily Frisch, MD
INCIDENCE AND MANAGEMENT OF RECURRENT IMPLANTATION FAILURE FOR UTERUS TRANSPLANTATION RECIPIENTS IN THE UNITED STATES

SRS IN-TRAINING AWARDS FOR RESEARCH
Kathryn Coyne, MD
RISK OF HISTERECTOMY AT THE TIME OF MYOMECTOMY – AN UNDERESTIMATED SURGICAL RISK

SRS TRAVELING SCHOLARS FOR REPRODUCTIVE SURGERY
Diego Manavella, MD, PhD
HYSTEROSCOPIC FINDINGS IN PATIENTS WITH INFERTILITY AND ABNORMAL UTERINE BLEEDING: UNVEILING THE PREVALENCE OF SUBTLE UTERINE LESIONS

SRS/SMRU TRAVELING SCHOLAR
Matheus F. Gröner, MD
ADOLESCENT VARICOCELECTOMY IMPROVES LONG-TERM FERTILITY POTENTIAL

DECHERNEY-NEZHAT TRAVELING SCHOLAR AWARD
Kathryn Coyne, MD
RISK OF HISTERECTOMY AT THE TIME OF MYOMECTOMY – AN UNDERESTIMATED SURGICAL RISK

DRS. CAMRAN, FARR, AND CEANA NEZHAT TRAVEL SCHOLAR AWARD FOR ENDOMETRIOSIS
Leigh Humphries, MD
BEYOND RACE AND ETHNICITY: UTILIZING GENETIC ANCESTRY AND MEASURES OF SOCIAL VULNERABILITY IN A DIVERSE POPULATION TO CHARACTERIZE DISPARITIES IN THE DIAGNOSIS OF ENDOMETRIOSIS

ENDOSIG – BEST BASIC SCIENCE
Ana Laura Almonte, PhD Candidate
ENDOMETRIAL SUBCELLULAR ALTERATIONS IN ENDOMETRIOSIS IDENTIFIED BY SINGLE-CELL ANALYSIS ACROSS THE MENSTRUAL

ENDOSIG – BEST IN CLINICAL/POPULATION SCIENCE
Nguyen Tuong Ho, MD
GONADOTROPIN-RELEASING HORMONE AGONIST ADMINISTRATION PRIOR TO FROZEN-THAWED EMBRYO TRANSFER IMPROVES PREGNANCY OUTCOMES IN WOMEN WITH OVARIAN ENDOMETRIOSIS: A RETROSPECTIVE COHORT STUDY

RISIG (REPRODUCTIVE IMMUNOLOGY)
Sarah Baumgarten, BA
SYSTEMIC IMMUNE DIFFERENCES IN PATIENTS UNDERGOING FROZEN EMBRYO TRANSFERS THAT RESULT IN LIVE BIRTH

NUTRISIG (NUTRITION)
Jenny George, MD
THE IMPACT OF OBESITY ON IN VITRO FERTILIZATION (IVF), OBSTETRICAL, AND NEONATAL OUTCOMES IN PATIENTS UNDERGOING IVF

HDSIG (HEALTH DISPARITIES)
Sloane Mebane, MD
A SURVEY STUDY EVALUATING DONOR GAMETE UTILIZATION RATES, PATIENT SATISFACTION AND FERTILITY TREATMENT OUTCOMES ACCORDING TO DESIRED RACE AND ETHNICITY OF THE GAMETE DONOR

FSIG (FIBROID)
Mohamed Ali, PhD
DECIPHERING THE NEGATIVE IMPACTS OF UTERINE FIBROIDS ON ENDOMETRIAL RECEPTIVITY USING 3D ORGANOID SYSTEM; MOLECULAR MECHANISMS AND POTENTIAL THERAPEUTICS

FPSIG (FERTILITY PRESERVATION)
Karine Malevossian, DO
THE EFFECTS OF THE BRCA1 AND 2 MUTATIONS ON OVARIAN RESERVE AND AGING

EPSIG (EARLY PREGNANCY)
Pardis Hosseinizadeh, MD
ASSOCIATION OF FOLLICULAR PHASE LENGTH (FPL) AND EARLY PREGNANCY LOSS (EPL) IN WOMEN WITH UNEXPLAINED INFERTILITY UNDERGOING OVARIAN STIMULATION WITH INTRAUTERINE INSEMINATION (OS-IUI) CYCLES.

EPSIG (EARLY PREGNANCY)
Chantal Durgana, BS
A SLOWER HUMAN CHORIONIC GONADOTROPIN (HCG) RISE IN EARLY PREGNANCY WAS NOT ASSOCIATED WITH THE DEVELOPMENT OF ABNORMAL PLACENTATION IN PATIENTS WHO CONCEIVED USING ASSISTED REPRODUCTIVE TECHNOLOGY

LGBTQSIG
Austin Johnson, MD
DECISIONAL REGRET REGARDING PREOPERATIVE FERTILITY
2023 AWARDS

RESIDENT IN-TRAINING AWARD
Sara Phillips, MD, MPH
FERTILITY TREATMENT IS ASSOCIATED WITH AN INCREASE IN ADVERSE MATERNAL OUTCOMES ACROSS RACIAL AND ETHNIC POPULATIONS

IN-TRAINING AWARDS FOR RESEARCH
Emily Gleason, BA
EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST PHARMACOTHERAPY ON WEIGHT LOSS IN PATIENTS WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME

IN-TRAINING AWARDS FOR RESEARCH
Yanye Zhang, PhD
FSH/FSHR/TGF-Beta1/SMADS SIGNALING CASCADE MEDIATES OVARIAN FIBROSIS RESULTING IN OVARIAN AGING

IN-TRAINING AWARDS FOR RESEARCH
Emily Jacobs, MD
REDUCTION IN TIME TO PREGNANCY FOLLOWING IVF WITH A FRESH EMBRYO TRANSFER IN YOUNG WOMEN WITH HIGH RESPONSE TO CONTROLLED OVARIAN STIMULATION: AN ANALYSIS OF CYCLES FROM SART DATABASE FROM 2014 – 2019

IN-TRAINING AWARDS FOR RESEARCH
Emily Zaniker, BA
HARNESSING FUNCTIONAL AND MOLECULAR ASYMMETRY DURING EX VIVO OVULATION FOR NON-HORMONAL CONTRACEPTIVE

IN-TRAINING AWARDS FOR RESEARCH
Quetrell Heyward, MD, MBA
INTRAUTERINE INSEMINATION (IUI): MORE IS NOT ALWAYS BETTER

VIDEO PRESENTATION AWARD FIRST PLACE
Sarah Capelouto Cromack, MD
INTRAMYOMETRIAL CARBOPROST TROMETHAMINE (HEMABATE) FOR Hysteroscopic RESECTION OF FIGO TYPE 2 UTERINE FIBROADS

VIDEO PRESENTATION AWARD SECOND PLACE
David Boedeker, DO, MHA
A CASE REPORT OF CONJOINED CEPHALOPAGUS TWINS DIAGNOSED AT 7 WEEKS GESTATIONAL AGE FOLLOWING IVF/ICSI

VIDEO PRESENTATION AWARD THIRD PLACE
Kathryn D Coyne, MD
SURGICAL APPROACH TO THE OBLITERATED POSTERIOR CUL-DE-SAC
NEW OFFERINGS FROM ASRM ACADEMY ONLINE

**Counseling for Contemporary Family-Building Training Module**
Training that addresses considerations for mental health professionals’ counseling surrounding third-party reproduction, diverse patient populations, and genetics.

**Leadership in Access to Care Course**
Designed for healthcare professionals with diverse experiences, this course offers practical applications to address the gaps in reproductive and infertility care.

**ASRM 2023 Recorded Content Bundle**
Recorded content from the ASRM 2023 Scientific Congress, including 12 plenaries, 22 symposia, 9 clinical sessions, and 19 interactive sessions.

ASRM Academy Online
Grow your knowledge and excel in your career through our selection of certificate courses and training modules offered through ASRM Academy Online! Practical training within a comprehensive curriculum offers professionals and trainees the essential expertise and skills needed to enhance patient care, drive better outcomes, and stay updated with the latest developments in the field.

To explore ASRM Academy, scan the QR code below.
ASRM Academy: Learn Your Way!

Whether you seek in-depth insights or quick, digestible sessions, in-person or online, there are ASRM Academy offerings designed for you.

ASRM Academy Meetings and In-Person Training

Experience transformative, live education that not only builds your skills and knowledge but also introduces new professional connections! ASRM Academy Meetings and In-Person Trainings include the ASRM Scientific Congress, postgraduate courses, hands-on courses, resident learning sessions (KEEPR), and other valuable activities that help you stay up-to-date and grow in your career.

ASRM Academy On the Go

Get straight to the takeaway! ASRM Academy On the Go gives you tools and resources that allow you to quickly acquire and retain valuable information, including MedTalks, MedFacts, the ASRM Müllerian Anomaly Classification tool (MAC2021), and the new EDGE tool for embryologists. Advance your knowledge at your own pace, on your own time, from anywhere in the world!

ASRM Academy Digital

Follow the latest news and take a deeper dive into reproductive health topics with offerings from ASRM Academy Digital, including ACE Webinars (Active Content Engagement) and ASRM's family of podcasts. Interact with and learn from experts as you gain a better understanding of the field!

ASRM ACADEMY DIGITAL PRESENTS:

Genetic Counseling Professional Group (GCPG) Case Conference Series

Provides a space for genetic counselors in reproductive medicine and other health care professionals to discuss topics, research, and challenging cases in reproductive genetics.
# SCHEDULE-AT-A-GLANCE  POSTGRADUATE

## SATURDAY, OCTOBER 14, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1:00 PM - 5:00 PM | PG01: IVF Laboratory Grand Rounds: Real Cases, Real Challenges, Real Solutions  
                    | PG02: Healer Heal Thyself: Self-Care in an Ever-Changing Field Applied, Interactive & Didactic Exploration  
                    | PG03: How To Stay Out of Trouble with the FDA, CAP, TJC and Other Friendly Regulators  
                    | PG04: The Effect of a Changing Legal and Genetic Landscape on Ethical Considerations in Reproductive Medicine |

## SUNDAY, OCTOBER 15, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 AM - 12:00 PM | PG05: Interactive Workshop on Proper Coding: Reimbursement for Procedures, Laboratory, Telemedicine and More  
                    | PG06: Ready, Set, Grow (Responsibly): The Business of Infertility Treatment |
| 8:00 AM - 5:00 PM | PG07: MEFS: ART Access for All: A Value-Based Analysis  
                    | PG08: Sexual Health: Identification, Support and Treatment  
                    | PG09: A Window Into Healthspan and Lifespan: Harnessing Ovarian Aging Research to Improve Reproductive Longevity and Systemic Health  
                    | PG10: ESHRE The Past, the Present and the Pipeline of Uterus Malformations. Do We Talk the Same Language?  
                    | PG11: Fertility Preservation in Pediatric and Adolescent Age Groups: Clinical and Laboratory Approaches  
                    | PG12: Back to the Future: Counseling Skills About Genetics for Patient Family Building Choices Considerations  
                    | PG13: Translating Bench Research to the Clinical Management of Recurrent Pregnancy Loss  
                    | PG14: SSR: Differences in Sexual Development and Gender Identity – Recent Developments and Prospects for Reproductive Medicine  
                    | PG15: AMMR/ALMER: Hot Topics in ART- Debates with a Transcontinental Point of View (SPANISH) |
| 1:00 PM - 5:00 PM | PG16: Reproductive Injustice: The Past, The Present, and Opportunities for Change  
                    | PG17: Ready, Set, Grow (Responsibly): The Science of Infertility Treatment |

# SCHEDULE-AT-A-GLANCE  SUNDAY, OCTOBER 15, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 11:00 AM</td>
<td>3rd Annual Social Media Summit</td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>3D/4D Imaging in Reproductive Medicine: A Hands-On Course</td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>SREI Practice Retreat: Improving Today With an Eye on the Future</td>
</tr>
<tr>
<td>8:00 AM - 5:00 PM</td>
<td>Office Hysteroscopy: Essentials for Success from Start-Up to Optimizing Efficiency and Patient Satisfaction: A Hands-On Course</td>
</tr>
<tr>
<td>8:00 AM - 5:00 PM</td>
<td>Embryo Transfer Simulation: A Hands-On Course</td>
</tr>
<tr>
<td>6:00 PM - 11:00 PM</td>
<td>ASRM 2023 President's Gala</td>
</tr>
</tbody>
</table>
**ASRM 2023 Closing Ceremony**

6:45 AM - 7:45 AM  
ASRM 2023 Opening Ceremony Continental Breakfast

7:45 AM - 8:30 AM  
ASRM 2023 Opening Ceremony

8:30 AM - 9:15 AM  
Plenary  
President's Guest Plenary Lecture: From Privacy to Prohibition: Giant Steps in the Wrong Direction

9:15 AM - 10:00 AM  
Plenary  
Herbert H. Thomas Plenary Lecture: Somewhere over the Rainbow...Lessons in Leadership

10:00 AM - 10:45 AM  
Break

10:45 AM - 11:45 AM  
Clinical Sessions  
MHPG Clinical Session: Cultural Diversity and Considerations for Psychological Assessment When Screening Oocyte Donors and Gestational Carriers: What are the Limitations of Our Data?

NPG Clinical Session: Oncofertility: Optimizing Care for Fertility Preservation Patients

APPPG Clinical Session: Utilization of Advanced Practice Providers in REI Medicine

10:45 AM - 11:45 AM  
Interactive Sessions  
Managing Great Expectations: What To Do When Patient Preference and Provider Counsel Diverges

PGT-M in the Genomic Era: Complex Cases and How to Handle Them

Uterine Transplantation: Lessons Learned and Future Directions

10:45 AM - 12:00 PM  
Symposia  
KY Cha Symposium: The Future is Now: Innovative Stem Cell-based Therapeutics for Difficult Infertility Conditions

ESHRE Symposium: Modelling the Maternal Embryo Interface

Surgical Sperm Procurement for Male Factor Infertility: Techniques to Optimize ART Outcomes

10:45 AM - 12:15 PM  
Abstract Sessions  
Scientific Congress Prize Paper Session 1

Oral Abstract Sessions

Poster Abstract Sessions

Video Abstract Session 1

11:30 AM - 1:20 PM  
Resident Learning  
KEEPR Speed Networking: Residents with REI Program Directors Event

11:45 AM - 12:15 PM  
Abstract Sessions  
Oral Abstract Sessions

12:20 PM - 1:20 PM  
Lunch Break

12:20 PM - 1:20 PM  
Journal Club Global: The Association of Ovarian Reserve Marker and Embryo Aneuploidy

12:20 PM - 1:20 PM  
Industry Sponsored  
Lunch: Cooper Surgical (NON CME)

Lunch: Astellas Pharma (NON CME)

12:20 PM - 1:20 PM  
Roundtables  
RTM 01 - RTM 25

1:30 PM - 2:30 PM  
Interactive Sessions  
Breaking Bad...News: Managing Your Own Feelings and Being Mindful of Your Patient

Challenges in Male Fertility Preservation: Difficult Case Discussions- How Important is Timing?

1:30 PM - 2:45 PM  
Abstract Sessions  
Scientific Congress Prize Paper Session 2

Oral Abstract Sessions

Poster Abstract Sessions

1:30 PM - 2:45 PM  
Symposia  
Cognition, Aging & Menopause

Growing the Industry: Investment, Innovation, Mergers and Acquisitions
### SCHEDULE-AT-A-GLANCE  
**MONDAY, OCTOBER 16, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 PM - 2:45 PM</td>
<td>Symposia</td>
<td>Uncovering and Investigating Mechanisms in Embryo Development: Effective Research and Publication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Perils of Using at Home Sperm Donation with an Internet Donor: Facilitating a Path for Lesbian Couples to Clinics, Attorneys, and Mental Health Professionals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management of Adenomyosis for Infertility and Recurrent Pregnancy Loss: Surgical and Medical Treatment Options</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Infertility Care and the Demise of Roe v. Wade: How it started, How it’s going</td>
</tr>
<tr>
<td>2:45 PM - 3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:30 PM - 4:15 PM</td>
<td>Plenaries</td>
<td>Samuel Pang LGBTQ+ Leadership in Education and Research Keynote- Transgender Medicine: Gender Affirming Hormone Therapy Across the Life Spectrum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AUA Bruce Stewart Memorial Lecture: Male Contraception Update-Progress Towards Addressing an Unmet Public Health Need</td>
</tr>
<tr>
<td>3:30 PM - 4:45 PM</td>
<td>Abstract Sessions</td>
<td>Top Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Poster Abstracts</td>
</tr>
<tr>
<td>3:30 PM - 4:45 PM</td>
<td>Symposia</td>
<td>Ethical Perspectives of Different Cultures in Infertility Care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>When Your Aunt or Uncle Is Your Donor: Family Building and Disclosure in Known Third Party Reproductive Arrangements</td>
</tr>
<tr>
<td>4:30 PM - 6:00 PM</td>
<td>SMRU Early Career &amp; Fellows Symposium</td>
<td></td>
</tr>
<tr>
<td>4:45 PM - 6:15 PM</td>
<td>Society Social Hour</td>
<td></td>
</tr>
</tbody>
</table>

### SCHEDULE-AT-A-GLANCE  
**TUESDAY, OCTOBER 17, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 7:30 AM</td>
<td></td>
<td>2023 Corporate Member Council Industry Session: The Need for Advocacy in an Ever-Evolving Environment</td>
</tr>
<tr>
<td>7:00 AM - 7:45 AM</td>
<td></td>
<td>ASRM/SSR Scientist and Physicians Advancing Reproductive Knowledge (SPARK) Program Breakfast</td>
</tr>
<tr>
<td>8:00 AM - 8:45 AM</td>
<td>Plenary</td>
<td>Camran Nezhat, M.D., Lectureship in Innovations in Medicine: Development of Novel Non-Hormonal Contraceptives Targeting AMHR2</td>
</tr>
<tr>
<td>8:45 AM - 10:00 AM</td>
<td>Plenary</td>
<td>But What I Really Want to Do Is Direct -- Lessons From a Life Behind the Camera</td>
</tr>
<tr>
<td>10:00 AM - 10:45 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 AM - 11:45 AM</td>
<td>Clinical Sessions</td>
<td>Embryology: The Basics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Navigating the Uncertainty of Infertility using Acceptance and Commitment Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Credentialing, Billing, and Patient Satisfaction with Advance Practice Providers in REI Medicine</td>
</tr>
<tr>
<td>10:45 AM - 11:45 AM</td>
<td>Interactive Sessions</td>
<td>Cesarean Scar Isthmoceles: When and How to Diagnose and Treat Surgically</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geneticist in the House: The Importance and Limitations of Genetic Counseling for IVF Patients</td>
</tr>
</tbody>
</table>
### SCHEDULE-AT-A-GLANCE

**TUESDAY, OCTOBER 17, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM - 12:00 PM</td>
<td>Symposia</td>
<td>Emerging Legal-Political, Geographical, and Financial Barriers to Accessing Fertility Preservation Care: Offering the Gold Standard While Navigating a Moving Target</td>
</tr>
<tr>
<td>10:45 AM - 12:15 PM</td>
<td>Abstract Sessions</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>11:45 AM - 12:15 PM</td>
<td>Abstract Sessions</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>12:00 PM - 1:20 PM</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>12:20 PM - 1:20 PM</td>
<td>Industry Sponsored</td>
<td>Lunch: Thermo Fisher (NON CME)</td>
</tr>
<tr>
<td>12:20 PM - 1:20 PM</td>
<td>Roundtables</td>
<td>RR01-24</td>
</tr>
<tr>
<td>12:20 PM - 1:20 PM</td>
<td>Roundtables</td>
<td>Carlos Simón Research Symposium</td>
</tr>
<tr>
<td>1:30 PM - 2:30 PM</td>
<td>Interactive Sessions</td>
<td>Medical and Psychological Issues Associated with Fertility Preservation for Transgender Individuals</td>
</tr>
<tr>
<td>1:30 PM - 2:45 PM</td>
<td>Symposia</td>
<td>Study Design, Peer Review and Seminal Papers in Reproductive Medicine</td>
</tr>
<tr>
<td>1:30 PM - 2:45 PM</td>
<td>Abstract Sessions</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>1:30 PM - 4:00 PM</td>
<td>Resident Learning</td>
<td>KEEPPR Hands-on Suturing Workshop &amp; Surgical Presentations</td>
</tr>
<tr>
<td>2:45 PM - 3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:45 PM - 4:00 PM</td>
<td>Resident Learning</td>
<td>KEEPPR Roving Mic Follow-Up: Beyond the Pill - Young People with PCOS</td>
</tr>
<tr>
<td>3:30 PM - 4:15 PM</td>
<td>Plenaries</td>
<td>Contraception Keynote Lecture: Where Are We Going? Advances in Contraceptive Technology and Access</td>
</tr>
<tr>
<td>3:30 PM - 4:30 PM</td>
<td>Interactive Sessions</td>
<td>The Business Case for Fertility Genetic Counseling: Clinical, Financial, and Legal Value</td>
</tr>
<tr>
<td>3:30 PM - 4:45 PM</td>
<td>Abstract Sessions</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>3:30 PM - 4:45 PM</td>
<td>Symposia</td>
<td>When They Don’t Know What Questions to Ask – Welcoming and Guiding Male Couples Planning Family Building into an ART Practice</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Topic</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00 AM - 8:45 AM</td>
<td>Plenary</td>
<td>Menopause Keynote Lecture: I Don't Want It But I Wish I Wanted It: Female Sexual Function and Dysfunction in Menopause</td>
</tr>
<tr>
<td>8:45 AM - 9:15 AM</td>
<td></td>
<td>ASRM 2023 Members Business Meeting</td>
</tr>
<tr>
<td>9:15 AM - 10:00 AM</td>
<td>Plenary</td>
<td>Deconstructing and Reconstructing the Endometriosis/Adenomyosis Patient, with Systems Biology and Organs-On-Chips</td>
</tr>
<tr>
<td>10:00 AM - 10:45 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 AM - 11:45 AM</td>
<td>Clinical</td>
<td>Updates in Third Party Reproduction: A Review</td>
</tr>
<tr>
<td></td>
<td>Sessions</td>
<td>Beyond Kubler-Ross: Current trends and the Ethics in Grief Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Horses or Zebras? Exploring the Relative Risk of ART Emergencies and How to Distinguish Them from Common Differential Diagnosis</td>
</tr>
<tr>
<td>10:45 AM - 11:45 AM</td>
<td>Interactive</td>
<td>No Good Deed Goes Unpunished, or Why We Should Stick with Professional Guidelines</td>
</tr>
<tr>
<td>10:45 AM - 12:15 PM</td>
<td>Abstract</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td></td>
<td>Sessions</td>
<td>Poster Abstracts</td>
</tr>
<tr>
<td>11:45 AM - 12:15 PM</td>
<td>Abstract</td>
<td>Oral Abstracts</td>
</tr>
<tr>
<td>12:15 PM - 1:20 PM</td>
<td>Resident</td>
<td>KEEPR Engaging with the Experts: Deconstructing &amp; Reconstructing the Endometriosis/Adenomyosis Patient</td>
</tr>
<tr>
<td>Learning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 PM - 1:20 PM</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>12:20 PM - 1:20 PM</td>
<td>Roundtables</td>
<td>RTW01-25</td>
</tr>
<tr>
<td>1:30 PM - 2:30 PM</td>
<td>Interactive</td>
<td>Rethinking the Use of Race as a Risk Factor and Implications for Care</td>
</tr>
<tr>
<td></td>
<td>Sessions</td>
<td>Testicular Tissue Cryopreservation for Prepubertal Males: Best Practices and Future Directions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Fertility Patient with A Uterine Septum: Hysteroscopic Treatment or Expectant Management?</td>
</tr>
<tr>
<td>1:30 PM - 2:45 PM</td>
<td>Symposia</td>
<td>Beyond GLP1 Agonists: A Weight-Inclusive Approach to Fertility</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Howard and Georgeanna Jones Symposium on ART: Should IVF PGTA be Offered Routinely as Management of Recurrent Pregnancy Loss?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IFS/ISAR: Uterine Pathology &amp; Fertility - Clinical Dilemmas and Solutions</td>
</tr>
<tr>
<td>2:45 PM - 3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:30 PM - 4:15 PM</td>
<td>Plenaries</td>
<td>SSR Keynote Lecture: To Biopsy or Not To Biopsy: Epigenetic Lessons from a Mouse ART Model</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SRS Keynote Lecture: Understanding the Uterus: A Journey Through Uterine Mysteries</td>
</tr>
<tr>
<td>3:30 PM - 4:30 PM</td>
<td>Interactive</td>
<td>New Kids on the Block: Should PGT for Polygenic Disease be Offered to All – or None?</td>
</tr>
<tr>
<td></td>
<td>Sessions</td>
<td>Fad Technologies In IVF - Separating the Evidence-Based From Empirical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Environmental Reproductive Health: An Important Arbiter for Health Disparities</td>
</tr>
</tbody>
</table>
# Daily Schedule Key to Abbreviations

<table>
<thead>
<tr>
<th>AFFILIATED SOCIETIES</th>
<th>PROFESSIONAL GROUPS</th>
<th>SPECIAL INTEREST GROUPS</th>
<th>PARTNER GROUPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>SART</td>
<td>APPPG</td>
<td>AESIG</td>
<td>AE-PCOS Society</td>
</tr>
<tr>
<td>SMRU</td>
<td>ARM</td>
<td>AISIG</td>
<td>ALMER</td>
</tr>
<tr>
<td>SRBT</td>
<td>GCPG</td>
<td>ATCSIG</td>
<td>AMMER</td>
</tr>
<tr>
<td>SREI</td>
<td>LPG</td>
<td>CIMSIG</td>
<td>ASPIRE</td>
</tr>
<tr>
<td>SRS</td>
<td>MHPG</td>
<td>ChSIG</td>
<td>ASRM 2023 SCIENTIFIC CONGRESS &amp; EXPO</td>
</tr>
<tr>
<td></td>
<td>NPG</td>
<td>CFPSIG</td>
<td>ASRM 2023</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EndoSIG</td>
<td>SCIENTIFIC CONGRESS &amp; EXPO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPSIG</td>
<td>EXPO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ERSIG</td>
<td>NEW ORLEANS, LOUISIANA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FPSIG</td>
<td>OCTOBER 14-18, 2023</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FSIG</td>
<td>2023 ASRM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HDSIG</td>
<td>DAILY SCHEDULE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IRMSIG</td>
<td>Daily Schedule</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ISIG</td>
<td>Key to ...</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IVMSIG</td>
<td>Abbreviations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LGBTSIG</td>
<td>Indicates a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MOISIG</td>
<td>ticketed event</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NutriSIG</td>
<td>Indicates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAGSIG</td>
<td>session offers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PGTSIG</td>
<td>education</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSSIg</td>
<td>credits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RISIG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RMSCBSIG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SocMeSIG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TSIG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>WC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Indicates a ticketed event

Indicates session offers education credits

Special Interest Groups are ASRM-member groups centered around a specific topic.

- AESIG: Androgen Excess Special Interest Group
- AISIG: Artificial Intelligence Special Interest Group
- ATCSIG: Access to Care Special Interest Group
- CIMSIG: Complementary and Integrative Medicine Special Interest Group
- ChSIG: Chinese Special Interest Group
- CFPSIG: Complex Family Planning Special Interest Group
- EndoSIG: Endometriosis Special Interest Group
- EPSIG: Early Pregnancy Special Interest Group
- ERSIG: Environment and Reproduction Special Interest Group
- FPSIG: Fertility Preservation Special Interest Group
- FSIG: Fibroids Special Interest Group
- HDSIG: Health Disparities Special Interest Group
- IRMSIG: Imaging in Reproductive Medicine Special Interest Group
- ISIG: Indian Special Interest Group
- IVMSIG: In Vitro Maturation Special Interest Group
- LGBTSIG: LGBTQ Special Interest Group
- MOISIG: Menopause and Ovarian Insufficiency Special Interest Group
- NutriSIG: Nutrition Special Interest Group
- PAGSIG: Pediatric and Adolescent Gynecology Special Interest Group
- PGTSIG: Preimplantation Genetic Testing Special Interest Group
- PSSIg: Physician-Scientists’ Special Interest Group
- RISIG: Reproductive Immunology Special Interest Group
- RMSCBSIG: Regenerative Medicine and Stem Cell Biology Special Interest Group
- SocMeSIG: Social Media Special Interest Group
- TSIG: Turkish Special Interest Group
- WC: Women’s Council
SUNDAY, OCTOBER 15, 2023

8:00 AM – 11:00 AM
3rd Annual Social Media Summit

6:00 PM – 11:00 PM
ASRM 2023 President's Gala

MONDAY, OCTOBER 16, 2023

6:45 AM – 7:45 AM
ASRM 2023 Opening Ceremony
Continental Breakfast

7:45 AM – 8:30 AM
ASRM 2023 Opening Ceremony
Michael A. Thomas, MD
University of Cincinnati

8:30 AM – 9:15 AM
Plenary
President’s Guest Plenary Lecture: From Privacy to Prohibition: Giant Steps in the Wrong Direction
Endowed by a 1987 grant from Ortho Women’s Health
Anita L. Allen, PhD
University of Pennsylvania

9:15 AM – 10:00 AM
Plenary
Herbert H. Thomas Plenary Lecture: Somewhere over the Rainbow...Lessons in Leadership
Valerie C. Montgomery Rice, MD
Morehouse School of Medicine

10:00 AM – 10:45 AM
Clinical Sessions
MH PG Clinical Session: Cultural Diversity and Considerations for Psychological Assessment When Screening Oocyte Donors and Gestational Carriers: What are the Limitations of Our Data?
Wiyatta Fahnbulleh, PsyD, (Chair)
Dr. Wiyatta Psychology Corporation
Pamela Blackwell, PSYD, LMSW

NPG Clinical Session: Oncofertility: Optimizing Care for Fertility Preservation Patients
Emily Ehlers, BSN, RN, (Chair)

KindBody
Mindy S. Christanson, MBA, MD
Johns Hopkins University School of Medicine

APPPG Clinical Session: Utilization of Advanced Practice Providers in REI Medicine
Tamara Tobias, NP, (Chair)
Seattle Reproductive Medicine
Shana Perman, PA-C
Shady Grove Fertility

10:00 AM – 10:45 AM
Interactive Sessions
Managing Great Expectations: What To Do When Patient Preference and Provider Counsel Diverges
Julia T. Woodward, PhD, (Chair)
Duke University Health System

PGT-M in the Genomic Era: Complex Cases and How to Handle Them
Andria G. Besser, MS, (Chair)
NYU Langone Fertility Center

Uterine Transplantation: Lessons Learned and Future Directions
Kathleen O’Neill, MD, (Chair)
University of Pennsylvania

ESHRE Symposium: Modelling the Maternal Embryo Interface
Jan Joris Brasens, PhD, MD, (Chair)
Warwick Medical School
Nicolas Rivron, PhD
Carlos Simon, MD, PhD
Professor Obstetrics and Gynecology, University of Valencia; Senior Lecturer PT, BIDMC Harvard University; President Carlos Simon Foundation

Surgical Sperm Procurement for Male Factor Infertility: Techniques to Optimize ART
Outcomes
Peter N. Schlegel, MD, (Chair)
Weill Cornell Medicine
Dolores J. Lamb, PhD
Weill Cornell Medical College
Amin S. Herati, MD
John Hopkins University School of Medicine

10:45 AM - 12:15 PM
Scientific Congress Prize Paper Session 1
Oral Abstract Sessions
Poster Abstract Sessions
Video Abstract Session 1

11:30 AM – 1:20 PM
Interactive Sessions
Managing Great Expectations: What To Do When Patient Preference and Provider Counsel Diverges
Julia T. Woodward, PhD, (Chair)
Duke University Health System

PGT-M in the Genomic Era: Complex Cases and How to Handle Them
Andria G. Besser, MS, (Chair)
NYU Langone Fertility Center

Uterine Transplantation: Lessons Learned and Future Directions
Kathleen O’Neill, MD, (Chair)
University of Pennsylvania

10:45 AM – 12:00 PM
Symposia
KY Cha Symposium: The Future is Now: Innovative Stem Cell-based Therapeutics for Difficult Infertility Conditions
Hang-Soo Park, PhD, (Chair)
The University of Chicago

Embryo Interface

Video Abstract Session 1
Innovation, Mergers and Acquisitions
Growing the Industry: Investment, University of Colorado School of Medicine
Nanette Santoro, MD
University of North Carolina
Genevieve S. Neal-Perry, MD, PhD
Yale University
Lubna Pal, MBBS, (Chair)
Cognition, Aging & Menopause
Symposia
1:30 PM – 2:45 PM
Poster Abstract Sessions
Oral Abstract Sessions
Scientific Prize Paper Session 2
1:30 PM – 2:45 PM
Northwestern University Feinberg School of Medicine
Joshua A. Halpern, MD, MS
Boston IVF
Denny Sakkas, PhD
University of Southern California
James F Smith , MD, MS, (Chair)
University of California
Denny Sakkas, PhD
Boston IVF
Joshua A. Halpern, MD, MS
Northwestern University Feinberg School of Medicine

1:30 PM – 2:30 PM
Interactive Sessions
Breaking Bad...News: Managing Your Own Feelings and Being Mindful of Your Patient
Winifred Mak, MD, PhD, (Chair)
UT Medicine Fertility Center
Julie Bindeman, PsyD
Independent Practice
Challenges in Male Fertility Preservation: Difficult Case Discussions- How Important is Timing?
James F Smith , MD, MS, (Chair)
University of California
Denny Sakkas, PhD
Boston IVF
Joshua A. Halpern, MD, MS
Northwestern University Feinberg School of Medicine

1:30 PM – 2:45 PM
Scientific Prize Paper Session 2
Oral Abstract Sessions
Poster Abstract Sessions
1:30 PM – 2:45 PM
Symposia
Cognition, Aging & Menopause
Lubna Pal, MBBS, (Chair)
Yale University
Genevieve S. Neal-Perry, MD, PhD
University of North Carolina
Nanette Santoro, MD
University of Colorado School of Medicine
Growing the Industry: Investment, Innovation, Mergers and Acquisitions
Hary Hokianto, MBA, (Chair)
Boston IVF
David Stern, MBA
Boston IVF
Lisa Van Dolah, MBA
Ivy Fertility
David B. Sable, BS, MD
Columbia University
Uncovering and Investigating Mechanisms in Embryo Development: Effective Research and Publication
David F. Albertini, PhD, MS, (Chair)
Bedford Research Foundation
Tiencheng Arthur Chang, PhD, HCLD, ELD, (Chair)
University of Texas Health Science Center
Renee J. Chosed, BS, PhD
University of South Carolina School of Medicine
Greenville
The Perils of Using at Home Sperm Donation with an Internet Donor: Facilitating a Path for Lesbian Couples to Clinics, Attorneys, and Mental Health Professionals
Angela K. Lawson, PhD, (Chair)
Northwestern University
Heather E. Ross, JD
Ross & Zuckerman, LLP
Management of Adenomyosis for Infertility and Recurrent Pregnancy Loss: Surgical and Medical Treatment Options
Mohamed Ali Bedaiwy, MD, PhD, (Chair)
University of British Columbia
Linnea R. Goodman, MD, VA
Fertility and IVF
Joseph Findlay, MD
University Hospital Cleveland Medical Center, Case Western
The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Infertility Care and the Demise of Roe v. Wade: How it started, How it’s going
Judith Daar, JD, (Chair)
Sean Tipton, MA
ASRM
Seema Mohapatra, JD, MPH, BA
SMU Dedman School of Law

2:45 PM – 3:30 PM
Break
3:30 PM – 4:15 PM
Plenary
Samuel Pang LGBTQ+ Leadership in Education and Research Keynote- Transgender Medicine: Gender Affirming Hormone Therapy Across the Life Spectrum
Vin Tangpricha, MD, PhD
AUA Bruce Stewart Memorial Lecture: Male Contraception Update-Progress Towards Addressing an Unmet Public Health Need
Stephanie Page, MD
University of Washington
3:30 PM – 4:45 PM
Top Poster Session
Poster Abstract Sessions

TUESDAY, OCTOBER 17, 2023
All Day
ASRM Giving Day
Advocacy is Everywhere
7:00 AM – 7:30 AM
2023 ASRM Corporate Member Council Industry Session: The Need for Advocacy in an Ever-Evolving Environment
7:00 AM – 7:45 AM
ASRM/SSR Scientist and Physicians Advancing Reproductive Knowledge
How to Diagnose and Treat Surgically
Cesarean Scar Isthmoceles: When and Interactive Sessions

RMA
Jessica Kestler, APN, WHNP-BC
RMANJ
Providers in REI Medicine
APPPG Clinical: Credentialing, Billing, and
Charlandra Consulting and Counseling
Anna Flores Locke, MA, (Chair)
Commitment Therapy of Infertility using Acceptance and
MHPG Clinical: Navigating the Uncertainty
Dow, PhD
Clinical Sessions

10:45 AM – 11:45 AM

Plenary

Lessons From a Life Behind the Camera
Ken Kwapis

10:00 AM – 10:45 AM

Break

10:45 AM – 11:45 AM

Clinical Sessions

NPG Clinical: Embryology: The Basics
Emily Ehlers, BSN, RN, (Chair) KindBody Mark PD
Dow, PhD

MHPG Clinical: Navigating the Uncertainty of Infertility using Acceptance and
Commitment Therapy
Anna Flores Locke, MA, (Chair)
Charlendra Consulting and Counseling
Danielle A. Kaplan, PhD, (Chair)
NYU Langone

APPPG Clinical: Credentialling, Billing, and Patient Satisfaction with Advance Practice
Providers in REI Medicine
Lauren Nervi, NP, (Chair)
RMANJ
Jessica Kestler, APN, WHNP-BC
RMA

Interactive Sessions

Cesarean Scar Isthmoceles: When and How to Diagnose and Treat Surgically
Zaraq Khan, MD, (Chair)
2023 SCIENTIFIC CONGRESS
DAILY SCHEDULE

To Store or Not to Store: Embryo Disposition in the Era of Mosaicism and Segmental Aneuploidy
Marisa V. Andrews, MD, (Chair)
Washington University School of Medicine

New York Langone Fertility Center
Susan L. Crook, JD
Georgetown Law Center, Crook Law & Policy Group

Optimization of Male Endocrinopathies
Prior to ART: Challenging Cases
Ryan P. Smith, MD, (Chair)
University of Virginia
Denise Asadu-Adjei, MD, MPH
Loyola University Chicago, Stritch School of Medicine
Sevann Helo, MD
Mayo Clinic

1:30 PM - 2:45 PM
Oral Abstract Sessions
Poster Abstract Sessions
Resident Learning

KEEPR Hands-on Suturing Workshop & Surgical Presentations
John C. Petrosza, MD
Massachusetts General Hospital Fertility Center
Zaraq Khan, MD
Mayo Clinic
Samantha M. Pfeifer, MD
Weill Medical College of Cornell University
Divya Kelath Shah, MD, MME, (Co-Chair)
Hospital of the University of Pennsylvania
Mindy S. Christianson, MBA, MD, (Co-Chair)
Johns Hopkins University School of Medicine

KEEPR Surgical Track Scholars Resident Review

2:45 PM - 3:30 PM
Break

2:45 PM - 4:00 PM
Resident Learning

KEEPR Roving Mic Follow-Up: Beyond the Pill - Young People with PCOS
Heather S. Hipp, MD, (Chair)
Emory University School of Medicine
Heather Burks MD, (Co-Chair)
Hackensack Meridian School of Medicine

3:30 PM - 4:15 PM
Plenary

Contraception Keynote Lecture: Where Are We Going? Advances in Contraceptive Technology and Access
Carolyn L. Westhoff, MD, MSc

Columbia University

David and Rosemary Adamson Excellence in Reproductive Medicine Lecture: “The Silence of Our Friends”: At the Intersection of REI and Racism, Equity, and Inclusion
Erica E. Marsh, MD, MS
University of Michigan

3:30 PM - 4:45 PM
Interactive Sessions

The Business Case for Fertility Genetic Counseling: Clinical, Financial, and Legal Value
Emily L. Mounts, MS, (Chair)
Juno Genetics US
Mark P. Leonidres, BA, MD
Illume Fertility
Jessica Medvedich, MBA, BSN, RN, NE-BC
IVI RMA
Steven Katz, MD
retired REI Protect LLC

3:30 PM - 4:45 PM
Oral Abstract Sessions
Poster Abstract Sessions

3:30 PM - 4:30 PM
Symposia
When They Don’t Know What Questions to Ask – Welcoming and Guiding Male Couples Planning Family Building into an ART Practice
Michael Lanham, MD, (Chair)
University of Michigan
Lynn J. Bodi, JD
The Law Center for Children & Families
Silvia Schneider Fox, PsyD
Independent Practice

WEDNESDAY, OCTOBER 18, 2023

8:00 AM - 8:45 AM
Plenary

Menopause Keynote Lecture: I Don’t Want It But I Wish I Wanted It: Female Sexual Function and Dysfunction in Menopause
Karen E. Adams, MD
Stanford Medicine

8:45 AM - 9:15 AM
ASRM 2023 Members Business Meeting

9:15 AM - 10:00 AM
Plenary
10:45AM - 12:00 PM  
Symposia

Controversies and Updates in Differences of Sex Differentiation: Gynecology & Genetics Perspective
Katherine G Hayes, MD, (Chair)
Rama Kastury, DO
National Institute of Child Health and Human Development
Alla Vash-Margota, MD
Yale University School of Medicine

Ovarian Tissue Cryopreservation: Best Practices from Harvest to Transplantation to Coordination with Assisted Reproductive Technologies
Mindy S. Christianson, MBA, MD, (Chair)
Johns Hopkins University School of Medicine
Kutluk H. Oktay, MD, PhD
Yale University School of Medicine
Samir Babayev, MD
Vickie Schafer, PhD, PLLC
Angela Thyer, MD, (Chair)
Cleveland Clinic Foundation

10:45 AM - 12:15 PM  
Oral Abstracts

11:45 AM - 12:15 PM  
Oral Abstracts

12:15 PM - 1:20 PM  
Resident Learning

KEEPR Engaging with the Experts: Deconstructing & Reconstructing the Endometriosis/Adenomyosis Patient
Heather S. Himp, MD, (Chair)
Emory University School of Medicine
Linda G. Griffith, PhD, BS
Massachusetts Institute of Technology
Alexander M. Quaas, MD, PhD, (Co-Chair)
Reproductive Partners Fertility Center

12:20 PM - 1:20 PM  
Lunch Break

12:20 PM - 1:20 PM  
Roundtables

1:30 PM - 2:30 PM  
Interactive Sessions

Rethinking the Use of Race as a Risk Factor and Implications for Care
Luwam Ghiede, MD, MSCI, (Chair)
Reproductive Specialists of the Carolinas
Gabriella Mayne, MA
University of Colorado Denver
Genevieve S. Neal-Perry, MD, PhD
University of North Carolina

Testicular Tissue Cryopreservation for Prepubertal Males: Best Practices and Future Directions
Kathleen Hwang, MD, (Chair)
University of Pittsburgh
Kyle E. Orwig, PhD
University of Pittsburgh School of Medicine
Sarah C. Vij, MD
Cleveland Clinic Foundation

1:30 PM - 2:45 PM  
Symposia

Beyond GLP1 Agonists: A Weight-Inclusive Approach to Fertility
Angela Thyer, MD, (Chair)
Vickie Schaefer, PhD, PLCC
Samantha B. Schon, MD, MS
University of Michigan
Judy Simon, MS, RD
Mind Body Nutrition, PLLC

The Howard and Georgeanna Jones Symposium on ART: Should IVF PGTA be Offered Routinely as Management of Recurrent Pregnancy Loss?
Steven D. Spandorfer, MD, (Chair)
New York-Presbyterian Hospital/Weill Cornell Medical Center
Dana B. McQueen, MD
IVIRMA
Rachel Susan Weinerman, MD
University Hospitals Fertility Center/Case Western University

The Fertility Patient with a Uterine Septum: Hysteroscopic Treatment or Expectant Management?
Divya Kelath Shah, MD, MME(Chair)
Hospital of the University of Pennsylvania
Jenna M. Rehmer, MD
Cleveland Clinic
John Preston Parry, MD, MPH,
Parryscape Fertility

2:45 PM - 3:30 PM  
Break

3:30 PM - 4:15 PM  
Plenary

SSR Keynote Lecture: To Biopsy or Not To Biopsy: Epigenetic Lessons from a Mouse ART Model
Marisa Bartolomei, PhD
University of Pennsylvania

SRS Keynote Lecture: Understanding the Uterus: A Journey Through Uterine Mysteries
Luis Alonso, MD, PhD
Centro Gutenberg

3:30 PM - 4:30 PM  
Interactive Sessions

New Kids on the Block: Should PGT for Polygenic Disease be Offered to All – or None?
Todd Lencz, PhD, (Chair)
Zucker School of Medicine at Hofstra/Northwell
Nathan R. Trisch, PhD
Genomic Prediction, Inc.
Cengiz Cinnioglu, PhD
NextGen Genetics

Fad Technologies in IVF- Separating the Evidence-Based From Empirical
Kutluk H. Oktay, MD, PhD, (Chair)
Yale University School of Medicine
Elnur Babayev, MD, MSc
Northwestern University Feinberg School of Medicine
Heather S. Himp, MD
Emory University School of Medicine

Environmental Reproductive Health: An Important Arbiter for Health Disparities
Pauline Mendola, MS, PhD, (Chair)
University of Buffalo
Victor Y. Fujimoto, MD
University of California, San Francisco
Michael S. Bloom, PhD, MS
George Mason University

Neena Malhotra, MD DNB, FRCOG, FAMS, (Chair)
All India Institute of Medical Sciences
Kanad Dev Nayyar, MD, AKANKSHA, IVF CENTRE
Rishma Dhillion Pari, MD, FRCOG (UK), DNB, DGO, FCPS, FICOG
Ulvitati Hospital
Nandida Palshetkar, MD
Ulaviati Hospital & Research Centre
Kuldeep Jain, MD, fellowship, ART
KJIVF and LAPAROSCOPY CENTER
Your company is invited to become a member of the ASRM Corporate Member Council

The Mission of the ASRM Corporate Member Council reflects a partnership between the ASRM Officers and Directors and the Corporate Members and is designed to facilitate open and ongoing dialogue between the two; to identify and maximize common interests related to reproductive medicine; and to develop collaborative educational initiatives which serve to enhance the practice of reproductive medicine.

WHY BECOME A CORPORATE MEMBER?
- Participation in Collaborative Initiatives
- Visibility
- Networking
- Website Link on ASRM Website
- Interaction/Collaboration with ASRM Board of Directors
- Special Recognition
- Preferred Support Opportunities
- Two (full) ASRM Memberships (CMC Representatives)

MAKING A DIFFERENCE ONE INITIATIVE AT A TIME
- Patient Education Fact Sheets
- Patient Education Videos
- www.ReproductiveFacts.org
- In-Training Awards
- Question-based Learning Program
- Webinar Training
- Industry-Specific Sessions

For more information please contact Keith Ray at kray@asrm.org or call 205-978-5001

2023 ASRM Corporate Member Council

AbbVie
Cooper Surgical Companies
EMD Serono, Inc.
Ferring Pharmaceuticals, Inc.
International Fertility Law Group
INVO Bioscience
LabCorp
Natera
North Star Fertility Partners
Organon
Univfy
VirtaMed
The F&S Family of Journals offer a comprehensive range of peer-reviewed articles in reproductive medicine and science, promoting excellence in research and clinical practice.

FREE ACCESS WITH YOUR ASRM MEMBERSHIP!
Continuing Education & CME

- Continuing Professional Development 38
- How to Claim Credits 39
- Postgraduate Program 40-56
- Needs Assessment & Learning Objectives 57
- Speaker Index 58-60
- Disclosures 61-63
- Categories 64
ASRM Continuing Education Programs

The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice best medicine, and provide the best, most current care to patients. ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). CME activities must address specific, documented, clinically important gaps in physician knowledge, competence, or performance; be documented to be effective at increasing physician knowledge, competence, performance, or outcomes; and conform to the ACCME Standards for Commercial Support. All planners and presenters must disclose commercial and financial relationships pertaining to reproductive medicine. These disclosures were reviewed by the Subcommittee for Standards for Commercial Support of the ASRM CME Committee and the Executive Program Committee, which resolved perceived potential conflicts of interest.

How to Claim

Continuing Medical Education/Continuing Education Credits or Print a Certificate of Attendance

For Postgraduate (PG) Courses:

- Access the evaluation site using the link received from registration or ASRM meeting app. Log in with Registration ID, name, or email address. (used to register)
- Select credit type you are claiming.
- Complete evaluation for all Postgraduate courses listed to claim credits.
- Please verify the total number of credits claimed.
- Download, print or email your credit certificate(s) or certificate of attendance.

For the Scientific Congress (SC):

- Access the evaluation site using the link received from registration or ASRM meeting app. Log in with Registration ID, name, or email address. (used to register)
- Select credit type you are claiming.
- Select all session(s) for which you wish to claim credits.
- Please remember you must complete an assessment for each session, for which you are claiming credits.
- Please verify the total number of credits claimed.
- Download, print or email your credit certificate(s) or certificate of attendance.

Final date to claim credit for ASRM 2023 is November 3, 2023.

Email questions to education@asrm.org.

The following may receive honoraria and/or discounted or free registration: Plenary, Symposia, and Interactive Session speakers, and Pre-Congress faculty. Honoraria are not provided for Roundtable presenters, Oral and Poster Abstract presenters, and Video presenters.

Disclosures of faculty and presenters for the Post Graduate and Scientific Congress may be in a presentation slide, printed material, or oral statement, and will be printed in the ASRM Final Program. Abstract authors’ disclosures will be printed in the 2023 Program. Roundtable and Expert Encounter presenters should provide a copy of their disclosure to participants at their table.
How to Claim Continuing Medical Education/ Continuing Education Credits

ASRM CONTINUING EDUCATION PROGRAMS
The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice best medicine, and provide the best, most current care to patients. ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). CME activities must address specific, documented, clinically important gaps in physician knowledge, competence, or performance; be documented to be effective at increasing physician knowledge, competence, performance, or outcomes; and conform to the ACCME Standards for Commercial Support. All planners and presenters must disclose commercial and financial relationships pertaining to reproductive medicine. These disclosures were reviewed by the Subcommittee for Standards for Commercial Support of the ASRM CME Committee and the Executive Program Committee, which resolved perceived potential conflicts of interest.

THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (ACCME)
The American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASRM 2023 SCIENTIFIC CONGRESS DESIGNATION STATEMENT
The American Society for Reproductive Medicine designates this activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASRM 2023 POSTGRADUATE PROGRAM DESIGNATION STATEMENT
The American Society for Reproductive Medicine designates Post Graduate Courses 05-17 for a maximum range of 5.5 to 6.75 AMA PRA Category 1 Credits™ per course. Post Graduate Courses 01-04 are approved for a maximum range of 3.0 to 3.5 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS
The American College of Obstetricians and Gynecologists has assigned 16 Cognates to the Scientific Congress; 6.75 Cognates to Hand-Ons course 2. 6.50 Cognates each to Post Graduate Courses 7, 9, 13. 3.25 Cognates to course 1.

AMERICAN BOARD OF BIOANALYSIS (ABB)
The American Society for Reproductive Medicine has been approved to provide Professional Enrichment Education Renewal (PEER) credit through the American Board of Bioanalysis for this event. Up to 0.95 PEER CEUs (9.5 hours) will be recognized for Post-Graduate Courses 1, 3 and 4. Scientific Congress has been approved for up to 18.50 hours or 1.85 CEUs. The American Board of Bioanalysis (ABB) certification examination will be held at the Hilton New Orleans Riverside Hotel on Saturday, October 14, 7 am-5 pm. To sit for the ABB examination, applicants must apply online at www.abbcert.org; submit all required documentation, and be approved by the ABB Board. The application and required documentation must be received by ABB no later than August 11, 2023, to be considered for the October 14 exam. For more information, contact ABB by telephone: 314-241-1445, email: abb@abbcert.org, or visit www.abbcert.org.

NURSING CREDITS: NATIONAL ASSOCIATION OF NURSE PRACTITIONERS IN WOMEN’S HEALTH (NPWH)
The Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health has evaluated and approved the following continuing education credits. Post Graduate Courses PG02; Healer Heal Thyself: Self-Care in an Ever-Changing Field Applied, Interactive & Didactic Exploration for 3.25 contact hours; PG09: A Window Into Healthspan and Lifespan: Harnessing Ovarian Aging Research to Improve Reproductive Longevity and Systemic Health; PG12: Back to the Future: Counseling Skills About Genetics for Patient Family Building Choices Considerations; PG 13: Translating Bench Research to the Clinical Management of Recurrent Pregnancy Loss and PG14: SSR: Differences in Sexual Development and Gender Identity – Recent Developments and Prospects for Reproductive Medicine each for 6.50 contact hours. ASRM 2022 Congress, all Clinical Sessions have been for up to 11.25 contact hours, including 0.25 contact hours of pharmacology content. NPWH Activity no. 23-14.

AMERICAN BOARD OF BIOANALYSIS (ABB)
The American Society for Reproductive Medicine has been approved to provide Professional Enrichment Education Renewal (PEER) credit through the American Board of Bioanalysis for this event. Up to 0.95 PEER CEUs (9.5 hours) will be recognized for Post-Graduate Courses 1, 3 and 4. Scientific Congress has been approved for up to 18.50 hours or 1.85 CEUs. The American Board of Bioanalysis (ABB) certification examination will be held at the Hilton New Orleans Riverside Hotel on Saturday, October 14, 7 am-5 pm. To sit for the ABB examination, applicants must apply online at www.abbcert.org; submit all required documentation, and be approved by the ABB Board. The application and required documentation must be received by ABB no later than August 11, 2023, to be considered for the October 14 exam. For more information, contact ABB by telephone: 314-241-1445, email: abb@abbcert.org, or visit www.abbcert.org.

NURSING CREDITS: NATIONAL ASSOCIATION OF NURSE PRACTITIONERS IN WOMEN’S HEALTH (NPWH)
The Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health has evaluated and approved the following continuing education credits. Post Graduate Courses PG02; Healer Heal Thyself: Self-Care in an Ever-Changing Field Applied, Interactive & Didactic Exploration for 3.25 contact hours; PG09: A Window Into Healthspan and Lifespan: Harnessing Ovarian Aging Research to Improve Reproductive Longevity and Systemic Health; PG12: Back to the Future: Counseling Skills About Genetics for Patient Family Building Choices Considerations; PG 13: Translating Bench Research to the Clinical Management of Recurrent Pregnancy Loss and PG14: SSR: Differences in Sexual Development and Gender Identity – Recent Developments and Prospects for Reproductive Medicine each for 6.50 contact hours. ASRM 2022 Congress, all Clinical Sessions have been for up to 11.25 contact hours, including 0.25 contact hours of pharmacology content. NPWH Activity no. 23-14.

AMERICAN PSYCHOLOGICAL ASSOCIATION (APA)
The Mental Health Professional Group (MHPG) of the American Society for Reproductive Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. MHPG maintains responsibility for this program and its content. CE credits will be available for select sessions of Scientific Congress; Post Graduate Courses 02, 04, 08, 12, and 14; MHPG Clinical Sessions CS02, CST02, and CSW02.

NATIONAL ASSOCIATION OF SOCIAL WORKERS (NASW)
The National Association of Social Workers has approved the following continuing education credits, Approval # 886496548-7689. Postgraduate courses PG02; Healer Heal Thyself: Self-Care in an Ever-Changing Field Applied, Interactive & Didactic Exploration; PG12: Back to the Future: Counseling Skills About Genetics for Patient Family Building Choices Considerations. Selected ASRM Congress sessions and Clinicals have also been approved.

NATIONAL SOCIETY OF GENETIC COUNSELORS (NSGC)
The National Society of Genetic Counselors (NSGC) has authorized American Society for Reproductive Medicine to offer up to 2.4 CEUs or 24 Category 1 contact hours for the activity ASRM 2023 Scientific Congress & Expo, which include Post Graduate Courses 02, 04, 06, 07, 08, 09, 11, 12, 13, 14, 16. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification. Participants requesting NSGC CEUs will have a service fee of $30 added to their meeting registration to cover payment to the National Society of Genetic Counselors for the filing and awarding of CEU certificates.

Legal Credits
ASRM Legal Professional Group has identified select sessions in the Scientific Congress for continuing legal education credits totaling 5 contact hours. The postgraduate courses selected are PG01, PG04 each 3.25, and PG12-6.50 credits hours. CLE sessions/courses are identified in meeting schedules. Attendees are responsible for verifying the acceptance of continuing education credits with the specific regulatory boards.

Legal Credits
ASRM Legal Professional Group has identified select sessions in the Scientific Congress for continuing legal education credits totaling 5 contact hours. The postgraduate courses selected are PG01, PG04 each 3.25, and PG12-6.50 credits hours. CLE sessions/courses are identified in meeting schedules. Attendees are responsible for verifying the acceptance of continuing education credits with the specific regulatory boards.

Final date to claim credit is November 3, 2023.
Questions? email education@asrm.org
The CME icon designates that continuing education credits are available, check the online schedule or app to see which types are available for that session.
PG01  IVF Laboratory Grand Rounds: Real Cases, Real Challenges, Real Solutions

Legal Professional Group (LPG), Society for Assisted Reproductive Technology (SART) and Society of Reproductive Biologists and Technologists (SRBT)

Faculty
Joe Conaghan, BSc, PhD, HCLD, (Chair)
San Francisco State University
Denny Sakka, PhD
Boston IVF
Margaret Swain, BA, RN, JD
Law offices of Margaret Swain

Target Audience
Embryologists, Andrologists, REI Physicians, IVF Nurses, Genetic Counselors, Administrators

Credit Type
ABB-PEER, LPG, CME

Needs Assessment
With improved access to care and growing demands for fertility preservation, many IVF clinics are facing sharp increases in their case volumes. Our colleagues are reporting difficulties with overflow of frozen material and storage option challenges. High procedure volumes and stressful work environments call for even tighter control of quality, error prevention, efficiency, and general safety at our clinics. In line with ASRM’s 2023 theme (The Past, The Present, and The Pipeline), this course is designed to analyze past experiences, review current challenges, and explore future options in following important areas in IVF: 1. Management of frozen embryo inventory and its overflow. Policies regarding disposition of abandoned embryos/gametes; Legal and technical challenges. 2. Importance of standardized approach to embryology work and the new tool to help with this important area: The new SRBT/SART IVF Atlas – A novel tool to assist embryologists and clinicians with staff training and standardization of their work. 3. Safety and reliability in the IVF laboratory and clinic: challenges, troubleshooting, emergent situations, teamwork, and error prevention tactics.

Description
We will start with the review of one of the central challenges in today’s IVF laboratories: technical and legal aspects of the disposition of the abandoned embryos along with ever-growing and overcrowded embryo storage. The new online training and competency tool - “SRBT/SART IVF Atlas” will be presented and discussed. In “IVF Grand Rounds” section, audience will be invited to participate in case studies related to challenges, troubleshooting, emergent situations, teamwork, and error prevention tactics.

ACGME Competencies
Interprofessional: Teams and Teamwork
Interprofessional: Communication
Interprofessional: Roles-Responsibilities
Interprofessional: Values-Ethics
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Medical Knowledge
Physician: Systems-based Practice

Learning Objectives
1. Describe the management of frozen embryo inventory and its overflow. Name policies regarding the disposition of abandoned embryos/gametes and associated legal and technical challenges. 2. Utilize the novel “IVF Atlas” as a useful tool for training and competency assessments. 3. Explain IVF laboratory and clinical team management: cohesion, staff training, and management. Use real-life cases to improve understanding of safety and reliability in the IVF laboratory and clinic: challenges, troubleshooting, emergent situations, and error prevention tactics.
**Healer Heal Thyself: Self-Care in an Ever-Changing Field Applied, Interactive & Didactic Exploration**

Complementary and Integrative Medicine SIG, LGBTQ SIG and Mental Health Professional Group (MHPG)

**Faculty**
- Kim Bergman, PhD, (Chair)
- Leigh Lewis, ND, MS
- Angela Lawson, PhD
- Jennifer Wood, BSN, AAS

**Description**
This experiential, interactive and didactic course will explore practitioner self-care from multiple perspectives providing participants with knowledge, research, strategies, and tools to reduce stress and burn out. We all take courses to help our patients, in this course we turn our attention to our own self-care, ultimately making us better clinicians. Emphasis will be on mind-body techniques that contribute to the strength and success of fertility care providers as well as best practices to improve patient care particularly in stressful, challenging times.

**ACGME Competencies**
- Interprofessional: Teams and Teamwork
- Interprofessional: Communication
- Interprofessional: Values-Ethics
- Physician: Professionalism
- Physician: Interpersonal and Communication Skills
- Physician: Patient Care and Procedural Skills
- Physician: Practice-based Learning and Improvement

**Needs Assessment**
Data from multiple studies over the past few years clearly establish that fertility care providers are under a tremendous amount of stress. Even before a worldwide pandemic threw fertility patients onto a roller coaster and clinicians along with them, fertility care professionals have been expected to manage their patients’ hopes and dreams, disappointments, and tragedies. Trained to take care of others, but often at the expense of ourselves, clinicians frequently ignore their own stress and burn out, resulting not only in mental and physical health issues but also detracting from best patient care. Fertility clinicians regularly must provide bad news and confront their patient’s profound disappointment and sorrow. Increased self-care not only results in improved outcomes for individuals but it also increases teamwork and empathy among teammates. ASRM has identified gaps in knowledge related to imparting bad news to patients, best practices during COVID-19, mind-body techniques, improved empathy of team, and supporting patients who have negative outcomes and pregnancy loss. This course will address these gaps from the perspective of patient care and clinician self-care to improve outcomes for all.

**Target Audience**
MHP, Nurses, Practice Managers, Physicians, and Attorneys

**Credit Type**
APA, NSGC, CME, NASW, NPWH

**Learning Objectives**
1. Identify their own personal triggers for stress in their workplace.
2. List multiple techniques for self-care to improve their quality of life.
3. Demonstrate best practices for working with patients during challenging and sometimes tragic circumstances while maintaining their own mental health.
4. Outline resources for managing self-care.
5. Name changes that they can make in their own practices to reduce stress and burnout.
6. Summarize the contributors of and possible solutions to professional quality of life indicators among fertility professionals.
7. Develop tools to better cope with workplace stress.
How To Stay Out of Trouble with the FDA, CAP, TJC and Other Friendly Regulators
Society for Assisted Reproductive Technology (SART) and Society of Reproductive Biologists and Technologists (SRBT)

Faculty
Sharon Anderson, PhD, (Chair)
Allegheny Health Network Center for Reproduction
Marybeth Gerrity, MBA, PhD
Reproductive Biology Resources, Inc
Amy Johnson, BS, CTBS
EVERSANA

Target Audience
Embryologists, Lab Directors, and Reproductive Endocrinologists

Credit Type
ABB-PEER, CME

Needs Assessment
Accreditation of embryology laboratories is done by either the College of American Pathologists (CAP) or The Joint Commission (TJC). Accreditation by CAP or TJC is associated with best laboratory practice and adherence to numerous requirements for staffing, quality management and quality control. The US Food and Drug Administration (FDA) has oversight of third-party reproduction in the USA, and it issues specific guidance on subjects such as donor eligibility and labeling/storage requirements of sperm, oocytes and embryos. CAP, TJC and FDA conduct regular on-site inspections of fertility clinics and laboratories, that are rigorous with numerous requirements. Staff who are busy with day-to-day management of patient care have indicated gaps in knowledge for inspection readiness and preparation. The inspection process, guidance for inspection readiness and updates to requirements will be reviewed for each regulatory agency.

Description
CAP and TJC will compared and contrasted as accrediting agencies for assisted reproductive technology laboratories. Requirements for accreditation will be explained, and any updates will be highlighted and reviewed. FDA oversight of third-party reproduction will be described and FDA requirements for recovery, screening, testing, packaging, processing, storing, labeling, and distribution will be reviewed. The audience will have opportunities to interact with the speakers regarding specific case scenarios.

ACGME Competencies
Interprofessional: Teams and Teamwork
Interprofessional: Communication
Interprofessional: Roles-Responsibilities
Interprofessional: Values-Ethics
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Systems-based Practice

Learning Objectives
1- Explain the mission and accreditation requirements of CAP for embryology laboratories.
2- Describe the mission and accreditation requirements of TJC for embryology laboratories.
3- Explain the mission and compliance requirements of FDA for third-party reproduction in the IVF clinic and laboratory.
4- Summarize the most recent updated requirements for CAP and TJC accreditation.
5- Interpret specific inspection cases studies during panel discussion.
PG04  The Effect of a Changing Legal and Genetic Landscape on Ethical Considerations in Reproductive Medicine
ASRM Committee and ASRM Ethics Committee Other

Faculty
Sigal Klipstein, MD, (Chair)
InVia Fertility
Susan L. Crockin, JD
Georgetown Law Center, Crockin Law & Policy Group
Katherine E. Cameron, MD
Johns Hopkins University School of Medicine
Julia T. Woodward, PhD
Duke University Health System

Target Audience
Clinicians, Nurses, Mental Health Professionals, Lawyers, and All Involved in Third Party Arrangements

Credit Type
ABB-PEER, LPG, APA, NSGC, CME

Needs Assessment
As the options in reproductive medicine become ever more complex, so too do the ethical considerations. This post-graduate course will present an interactive forum in which to discuss issues of the changing reality of donor anonymity, issues related to gestational carriers, and the effect of Roe v. Wade on the treatment of embryos. It will address the Gap Analysis needs of "Embryo Disposition and Donation" as well as "Knowledge on how offspring feel about open vs. Closed gamete donation." Participants will learn how to incorporate the principles of medical ethics into real world patient care. They will develop a deeper understanding of the ethical issues that patients and the health care team face on an ongoing bases, in a field that is becoming ever more complex.

Description
This 1/2 day post-graduate course will provide an interactive forum, including small group discussions and role playing, in order to help participants delve deeply into the many ethical conundrums that clinicians, mental health professionals, nurses and lawyers face on a regular basis. The topics will include an understanding of the new gamete donor nomenclature, and the effect of legislation on clinical care vis a vis embryo disposition and gestational carrier arrangements.

ACGME Competencies
Interprofessional: Values-Ethics
Physician: Interpersonal and Communication Skills
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1. Describe the principles of medical ethics.
2. List the potential impacts of the overturning of Roe v. Wade on embryo disposition and gestational carrier arrangements.
3. Illustrate ethical considerations taken in clinical care.
4. Define the following principles of medical ethics: Autonomy, beneficence, non-maleficence and justice.
5. Discuss the “special status” and other characterizations of the preimplantation embryo.
6. Discuss the potential impact of the end of Roe v. Wade on embryo disposition decisions.
7. Describe the impact of abortion restrictions on the decisions of gestational carriers and intended parents.
8. Discuss whether cryopreserving gametes over embryos will be preferable in light of abortion restrictions.
9. Cite the impact of Roe v. Wade on patient counseling regarding reproductive care.
10. Discuss the role of compassionate transfer in a post Roe v. Wade environment.
SUNDAY, OCTOBER 15, HALF DAY COURSE  8:00 AM - 12:00 PM

PG05  Interactive Workshop on Proper Coding: Reimbursement for Procedures, Laboratory, Telemedicine, and More  
ASRM Committee and ASRM Coding Committee Other

Faculty
John Queenan, MD, (Chair)  
University of Rochester Medical Center  
George Hill, MD  
Nashville Fertility Center  
Silvina Bocca, MD, PhD, HCLD  
Eastern Virginia Medical School

Target Audience
MDs and Mid-Level Providers in REI, Practice Managers, ART Lab Directors, Office Billers, Endocrinology Lab Supervisors

Credit Type
ABB-PEER, CME

Needs Assessment
The rules of billing for medical practices in 2023 are complex. Most providers will learn how to bill for office base evaluation and management services. Practitioners in Reproductive Endocrinology also need to know how to bill for Gynecologic surgery, office procedures, radiology, andrology, endocrinology and various ART laboratory services. Providers need to use ICD-10 (diagnosis) codes and CPT (procedure) codes and have the proper documentation to support their claims. This information is not taught adequately in residencies and fellowship. The rules are set by the AMA and change every year. Therefore a knowledge gap always exists. Improper billing leads to denied claims, delayed reimbursement and in some instances, audits for possible fraud and abuse. This half day course will solicit the specific needs of its attendees in advance and then we will tailor the course content to address these knowledge gaps.

Description
The format for this half-day course will be interactive. Attendees will be surveyed in advance and topics will be solicited. A panel of three experts will address each topic and prepare comprehensive answers and teaching points for all in attendance. The topics covered will include: Gyn surgery, ART laboratory coding, Radiology codes used in RE practices, diagnosis and procedure codes, Coding changes brought about by COVID, billing for non-fertility encounters, prevention of fraud, and appealing denied claims.

ACGME Competencies
Physician: Professionalism

Learning Objectives
1. Explain what changes to REI practices have come about with the COVID pandemic and telemedicine.
2. Name the rules of billing for ART laboratories, andrology laboratories and endocrinology laboratories.
3. Describe how to apply the rules of correct coding to radiologic procedures such as Gyn ultrasound, early Ob ultrasound, doppler, HSG, and SIS.
4. Explain how to code for non-fertility related visits.
5. Demonstrate how to appeal denied claims and avoid billing practices that expose you to increased risk for audits.
PG06 Ready, Set, Grow (Responsibly): The Business of Infertility Treatment
Association of Reproductive Managers (ARM) and Society for Assisted Reproductive Technology (SART)

Faculty
Hary Hokianto, MBA, (Chair)
Boston IVF
April Rutter
Missouri Fertility
Paul Lin, MD
Seattle Reproductive Medicine

Target Audience
Managers, Owners, Supervisors, Physicians, Clinicians, and Other Professionals Involved in the Business of Infertility Treatment

Description
This course focuses on the Business of Medicine: Provide tips and techniques to consider as we experience rapid industry growth and evolution with significant investment being poured into new technology development as well as practice consolidation/Creation of new networks. Individual practices are evolving as well in order to adapt to the new environment, focusing on current successes, managing business growth, organizational development and innovation, and addressing the state of insurance and employer benefits coverage in the US while continuing to focus on patient access.

ACGME Competencies
Interprofessional: Teams and Teamwork
Interprofessional: Communication
Interprofessional: Roles-Responsibilities
Interprofessional: Values-Ethics
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1- Demonstrate a basic understanding of management consideration on growing a practice responsibly and ethically.
2- List some tips and tools that could be beneficial in managing the business of medicine.
3- Describe some general patient finance challenges and how we may be able to reduce such barrier as an industry.
4- Summarize best practices for motivation and retention of your workforce.
5- Summarize the state of the current IVF industry in the United States: different practice models, networks, services offered.
6- Describe how an IVF clinic is managed (Clinical Operations, Business Operations).
7- Examine the important factors to consider when expanding your center.

Needs Assessment
The issue of infertility affects not only individuals but also the global environment and some might say, human evolution (Think genetics). Practice managers, owners, clinicians, and scientists in the REI field are privileged to be in a position to lead. That said, keep in mind that with power, comes responsibility. As the field of REI continues to evolve and grow rapidly, it is very important for leaders to continue to evaluate and cautiously define what Success is from a variety of perspectives - Business, Clinical, Scientific, and how these measurements of success could have an impact on the quality of patient care and the industry’s initiative to improving access to anyone who needs treatment. Having a good understanding of what has worked in the past, how things have evolved to what we are today, and having the ‘right’ vision of success (Given the rapid growth) is crucial.
and unproven methodologies which increase prices without offering protocols by eliminating redundancies in diagnostic testing, add-ons.

With looming global economic recession and rising inflation, the impact of financial disparities by improving affordability without compromising pregnancy outcomes. The non-judicious use of diagnostic tests, add-ons, and unproven methodologies have also contributed to the high price tag of infertility treatment long before the availability of sufficient data to support clinical benefit. Mindful of financial obstacles which limit the access to fertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes. Passing the cost savings along to patients would be expected to reduce the financial burden of infertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes.

The non-judicious use of diagnostic tests, add-ons, and unproven methodologies have also contributed to the high price tag of infertility treatment long before the availability of sufficient data to support clinical benefit. Mindful of financial obstacles which limit the access to fertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes. Passing the cost savings along to patients would be expected to reduce the financial burden of infertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes.

The non-judicious use of diagnostic tests, add-ons, and unproven methodologies have also contributed to the high price tag of infertility treatment long before the availability of sufficient data to support clinical benefit. Mindful of financial obstacles which limit the access to fertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes. Passing the cost savings along to patients would be expected to reduce the financial burden of infertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes.

The non-judicious use of diagnostic tests, add-ons, and unproven methodologies have also contributed to the high price tag of infertility treatment long before the availability of sufficient data to support clinical benefit. Mindful of financial obstacles which limit the access to fertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes. Passing the cost savings along to patients would be expected to reduce the financial burden of infertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes.

The non-judicious use of diagnostic tests, add-ons, and unproven methodologies have also contributed to the high price tag of infertility treatment long before the availability of sufficient data to support clinical benefit. Mindful of financial obstacles which limit the access to fertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes. Passing the cost savings along to patients would be expected to reduce the financial burden of infertility care for many patients, health care providers and workers are invited in this course to rethink the ways in which infertility care is delivered, and to propose measures to reduce the impact of financial disparities by improving affordability without compromising pregnancy outcomes.
SUNDAY, OCTOBER 15, FULL DAY COURSES  8:00 AM - 5:00 PM

PG08  Sexual Health: Identification, Support, and Treatment
Mental Health Professional Group (MHPG), Society for Male Reproduction and Urology (SMRU) and Society of Reproductive Surgeons (SRS)

Faculty
Kathleen Hwang, MD, (Chair)
University Pittsburgh, Urology
Lawrence Jenkins, MD, MBA
Tulane University, School of Medicine
William Petok, PhD
Thomas Jefferson University
Maria Uloko, MD
University of California- San Diego

Target Audience
Reproductive Urologist, Reproductive Endocrinologist, APPs, Nurses, Fellows, Residents

Credit Type
APA, NSGC, CME, ACOG, NPWH

Needs Assessment
Women and men’s sexual health is a key component to their overall physical and mental wellness. Sexual dysfunction is highly prevalent in both men and women and often overlooked. One third of women have low sexual desire. Over 40% of women have sexual dysfunction, and 52% of men between the ages of 40-70 years old have erectile dysfunction. Coupled with the demands and stressors of working thru infertility the combination is impactful and a real clinical challenge. This course directly addresses a gap identified on the 2022-2023 needs assessment: Identification, support, and treatment of patients and couples with sexual dysfunction in the space of infertility is clearly highlighted.

Description
- Communicating with their female and male patients about their sexual health.
- Reviewing the most common male and female sexual dysfunctions.
- Approaching to male and female sexual dysfunction.
- Discussing medical, surgical and alternative therapies for treatment of male and female sexual dysfunction.
- Reviewing the guidelines and rationale for treatment of hypogonadism in males and hormone replacement therapy in females.
- Assessing pelvic floor dysfunction to improve patient symptoms.
- Highlighting the role of the reproductive urologist in the modern ART practice.

ACGME Competencies
Interprofessional: Communication
Physician: Interpersonal and Communication Skills
Physician: Medical Knowledge
Physician: Patient Care and Procedural Skills

Learning Objectives
1- Define the most common female and male sexual dysfunction and their etiologies.
2- Distinguish pelvic floor dysfunction and understand how this is relevant for both male and female sexual dysfunction.
3- Discuss dietary and lifestyle modifications to support complimentary strategies for management.
4- Identify the benefits of sexual therapy and psychological support for infertile couples.
The objective of this course is to review the relationship between reproductive and systemic aging and to review the implications of ovarian aging on an individual and population level. Ovarian aging will be reviewed from “cradle to grave,” reviewing ovarian health from a chronologic perspective while applying evidence from fundamental science and translational science. This course will provide an overview of the intersection of ovarian health and systemic health. Participants will gain an understanding of how the intersection of two fields—systemic aging and reproductive aging—can be harnessed to answer “age-old” questions.

ACGME Competencies
Interprofessional: Teams and Teamwork, Communication, Roles-Responsibilities
Physician: Interpersonal and Communication Skills, Medical Knowledge, Systems-based Practice, Practice-based Learning and Improvement

Learning Objectives
1- Explain the relationship between ovarian aging and systemic aging, using the "Hallmarks of Aging" to identify unified mechanisms driving both reproductive and somatic aging.
2- Define the progression of ovarian aging chronologically, reviewing oocyte and ovarian health from "cradle to grave."
3- Explain how the ovarian microenvironment and macroenvironment contribute to ovarian aging.
4- Summarize wisdom gained from the study of postmenopausal ovaries.
5- Define mechanisms of follicle activation and consider the role of pharmacologic agents in promoting reproductive longevity.
6- Describe the power of an interdisciplinary team, from the clinic to the embryology lab and the bench, to study ovarian aging across the age continuum.
7- Explain the relationship between ovarian aging and systemic aging, using the "Hallmarks of Aging" to identify unified mechanisms driving both reproductive and somatic aging.
8- Examine the progression of ovarian aging chronologically, reviewing oocyte and ovarian health from "cradle to grave."
9- Explain how the ovarian microenvironment and macroenvironment contribute to ovarian aging.
10- Discuss wisdom to be gained from the study of postmenopausal ovaries.
11- Identify mechanisms of follicle activation and consider the role of pharmacologic agents to promote reproductive longevity.
12- Utilize the power of an interdisciplinary team, from the clinic to the embryology lab and the bench, to study ovarian aging across the age continuum.

Description
The objective of this course is to review the relationship between ovarian aging and systemic aging. It will provide an overview of the intersection of ovarian health and systemic health. Participants will gain an understanding of how the intersection of two fields—systemic aging and reproductive aging—can be harnessed to answer “age-old” questions.
PG10  ESHRE The Past, the Present and the Pipeline of Uterus Malformations. Do We Talk the Same Language?

ESHRE

Faculty
Maribel Acién, Prof Dr, (Chair)
San Juan University Hospital, Miguel Hernandez University
Artur Ludwin, MD, PhD
Warsaw Medical University
Attilio Di Spiezio Sardo, MD, PhD
University of Naples Federico II
Grigoris Grimbizis, MD
Aristotle University of Thessaloniki

Target Audience
Clinicians, Surgeons, and Practice Managers

Credit Type
CME

Needs Assessment
Malformations of female genital tract, mainly those affecting the uterus, have a clear impact in reproduction. Unfortunately, even after several efforts, there’s a lack of agreement on diagnosing and management of common uterine malformations. With some research papers showing contradictory results, clinicians still need to elaborate the path on how to diagnose and treat Müllerian anomalies to improve reproductive outcomes, how to prioritize and the pros/cons of ART or diagnostic and surgical treatments. Obstructive anomalies additionally provoke severe pain symptoms at adolescence. Unfortunately, there’s a common lack of understanding on how malformations develop with an impact on acknowledging associated pathologies. The preoperative diagnosis work-up of these teens and the correct understanding of embryology should help decide the best surgical approach with the long-term reproductive performance needing to be considered.

Description
This course will address the educational needs that healthcare professionals in reproductive medicine face on their daily practice; outline best strategies for ruling out the common uterine malformations and improve their knowledge on how the different tools can help them with the diagnosis, classification and treatment, potentially improving their patient’s reproductive performance. In terms of practice management, the course will address the usefulness of ultrasound and endoscopic techniques in the management of uterine malformations, but also the preoperative preparation, imaging, and review of surgical treatments of complex obstructive anomalies presenting at younger ages.

ACGME Competencies
Physician: Medical Knowledge
Physician: Patient Care and Procedural Skills

Learning Objectives
1- Appraise the paper on understanding embryology to diagnose female genital tract malformations correctly.
2- Define the usefulness of 3D ultrasound in surgery planning, intraoperative guidance, and assessment of healing outcomes of malformations.
3- Summarize the paper on hysteroscopy diagnostic evaluation and treatment of uterine malformations.
4- Debate and update the alternatives when classifying female genital tract malformations.
5- Discuss minimal invasive approaches to solve obstructive anomalies.
6- Explain the importance of Wolffian ducts as well as the female gubernaculum in the correct formation of the uterus.
7- Discuss the origin of the vagina and its relationship with the urinary system formation.
8- Illustrate how to perform measurements to classify most common uterine malformations by different classification and criteria (normal/arcuate, septate, bicornoreal/bicornuate, T-shaped uterus)
9- Outline how to assess complex and obstructive malformations by 3D ultrasound.
10- Name the different classifying systems for genital malformations
11- Discuss the advantages and disadvantages of each classifying system for genital malformations, clinical applicability and surgical implications.
12- List the tips and tricks and clinical results of hysteroscopic surgery of uterine malformations.
13- Discuss different approaches and their clinical results for solving complex genital malformations.
PG11  Fertility Preservation in Pediatric and Adolescent Age Groups: Clinical and Laboratory Approaches
Pediatric and Adolescent Gynecology SIG and Turkish SIG

Faculty
Kutluğ Oktay, MD,PhD, (Chair)
Yale University School of Medicine
Alla Vash-Margita, MD
Yale University School of Medicine
Kyle Orwig, PhD
University of Pittsburgh
Kirsten Tryde Macklon, MD, PhD
University Hospital of Copenhagen, Rigshospitalet

Target Audience
REI Specialists, Fellows, Fertility Nurses, Embryologists, Pediatric Adolescent Gynecologists, FP Researchers, and Any Support Personnel Involved with FP in the Pediatric and Adolescent Age Group

Credit Type
ABB-PEER, NSGC, CME

Needs Assessment
Fertility preservation approaches have evolved for adults with medical indications with most procedures are now considered non-experimental. The progress in adult fertility preservation is now reflected in the progress with fertility preservation in pediatric and adolescent (PA) age groups. However, there are significant differences in approach to fertility preservation between adults and the PA group. Reproductive Medicine specialists are encountering increasingly larger number of children for fertility preservation but the knowledge and competence in this area are lagging. The 2022-2023 ASRM GAP analysis identified fertility preservation in the PA age group as a priority area. Given the growing number of PA children needing fertility preservation due to cancer, hematologic conditions, genetic disorders such as Turner Syndrome and Galactosemia as well as radical surgery, there is a great need to educate the reproductive health professionals on the current approaches to fertility preservation in the PA group.

Description
The proposed course will educate reproductive health care personnel on the impact of cancer treatments and genetic conditions on ovarian reserve and testicular function, counselling for FP, current progress and future aspects of FP and post-cancer reproductive care of pediatric and adolescent boys and girls. In addition, guidance will be provided in establishing a PAG-FP program and on the laboratory aspects of ovarian and testicular tissue cryopreservation. The program will be strengthened with practical tips and case discussions.

ACGME Competencies
Interprofessional: Teams and Teamwork
Physician: Medical Knowledge
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1- Demonstrate how to counsel pediatric and adolescent girls and boys and their parents on the impact of their medical condition on future gonadal function and fertility.
2- Explain how to set up a multi-disciplinary fertility preservation program for the pediatric-adolescent age group.
3- Illustrate the current and prospects of fertility preservation approaches in the pediatric and adolescent age group.
4- Explain the impact of chemotherapy and radiation treatments on fertility.
5- Summarize the unique fertility preservation challenges in children.
6- Describe standard and experimental options to preserve fertility.
7- Describe experimental stem cell and tissue transplant therapies for treating infertility.
8- Explain the approach to the reproductive needs of young cancer survivors.
9- Summarize modern aspects of ovarian tissue freezing in children.
10- Name the oocyte freezing approaches in children.
11- Explain the early and late reproductive consequences of cancer on children with cancer.
12- Discuss the basic mechanisms of chemotherapy-induced damage to gonadal function.
13- Develop a systemic approach to fertility preservation counseling in children.
SUNDAY, OCTOBER 15, FULL DAY COURSES  8:00 AM - 5:00 PM

PG12  Back to the Future: Counseling Skills About Genetics for Patient Family Building Choices Considerations  
Genetic Counseling Professional Group (GCPG), Legal Professional Group (LPG), Mental Health Professional Group (MHPG), Nurses' Professional Group (NPG) and Society for Reproductive Endocrinology & Infertility (SREI)

Faculty
Andrea Braverman, PhD, (Chair)
Jefferson OBGYN
Lisa Rinehart, JD, RN
US Fertility
Lorna Marshall, MD
Pacific NW Fertility
Pamela Callum, MS
Tandem Genetics

Target Audience
Reproductive Urologist, Reproductive Endocrinologist, APPs, Nurses, Fellows, Residents

Credit Type
LPG, NASW, APA, NSGC, CME, NPWH

Needs Assessment
The field and impact of genetic testing has exploded in recent years, continues to grow at enormous speed, and all professionals in the field need to be abreast of what is available to patients as well as the potential and probable implications for themselves and their families. Increased genetic testing of donors and others now routinely provides patients with an enormous, and at times bewildering array of information. Direct-to-consumer testing has led to recent consensus that anonymity with donor gametes no longer exists as well as raises new medical, psychosocial, legal and ethical issues as individuals seeking genetic connections also discover their potential for inheritance for disease. Assisted reproductive technology is a ‘team sport’ involving counseling on these issues from doctors, nurses, genetic counselors, mental health professionals and other allied professionals. Best practices are unclear as issues emerge rapidly with implications across professions as we counsel our recipient and donor patients, and donor-conceived offspring. This course will address important counseling skills and explore how best to frame and anticipate patient concerns and needs.

Description
This course will explore how best to frame, anticipate and meet patient concerns and needs surrounding genetic testing and counseling by mental health professionals, nurses, genetics counselors and physicians, for donors, donor-conceived, and intended parents about the implications of genetic testing. Lectures and panels will provide participants with inter-professional knowledge as to: the current genetic testing available, counseling strategies and skills needed, and implications for both current issues, e.g. identification of gamete donors and heritability, and future medical concerns for patients and beyond. Participants will learn how to develop timely team-based strategies for interprofessional care.

ACGME Competencies
Interprofessional: Communication
Physician: Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills

Learning Objectives
1- Identify counseling strategies to support decision-making around genetic testing.
2- Examine the dilemmas posed by donor-linked contact.
3- Identify and anticipate future developments in genetic testing.
4- Define the nurses’ role in assisting patients with genetic testing.
5- Discuss methods to reduce risk exposure when counseling patients on genetic testing.
6- Define the nurses’ role in assisting patients with genetic testing.
7- Identify possible pitfalls in the genetic testing process.
8- List different types of genetic tests and technologies utilized in ART and reproductive genetics.
9- Evaluate the outcomes and genetic counseling considerations of genetic testing on patients, gamete donor applicants, and donor-conceived individuals.
10- Identify psychosocial implications of genetic testing in third-party reproduction.
11- Examine new and emerging genetic test offerings and their impact on reproductive patients’ experience.
12- Hypothesize strategies for developing evidence-based, consensus process for guideline development which may be applied to reproductive patient care.
13- Define strategies for interprofessional patient care.
PG13  Translating Bench Research to the Clinical Management of Recurrent Pregnancy Loss

Early Pregnancy SIG

**Faculty**
Winifred Mak, MD, PhD, (Chair)
UT Medicine Fertility Center
Dana McQueen, MD
Northwestern University, IVIRMA
Aleksandar Stanic-Kostic, MD, PhD
University of Wisconsin-Madison
Erin Masaba, MD
University of Rochester

**Target Audience**
Physicians, Scientists, Nurses, ART Laboratory Personnel

**Credit Type**
NSGC, CME, ACOG, NPWH

**Needs Assessment**
Recurrent Pregnancy Loss is a devastating condition affecting 5% of couples and only 50% of couples find a cause. The other 50% of couples will be labeled as unexplained RPL. Therefore, continued bench research in RPL is essential to advance our management of these couples. ASRM has identified a gap in our knowledge regarding the science regarding RPL and the need to address continuing education in RPL. Furthermore, with the unrivalled access of patients to the internet where they can explore RPL research independently, there is a need for physicians in practice to keep informed of new research developments as their patients are likely to seek their expert opinion.

**Description**
This course will highlight promising new avenues of basic science research in the field of RPL in a digestible format for physicians. The topics covered will include maternal factors: chronic endometritis, microbiome, endometrial stem cell senescence, reproductive immunology; paternal factor: sperm DNA fragmentation and epigenetics; embryo factors – defects in trophoblasts, genetic abnormalities beyond aneuploidy. In addition, we will discuss the relevance of the research presented and how physicians can educate their patients regarding these topics. Finally, we will discuss the future direction of RPL research from both a scientist and physician perspectives.

**ACGME Competencies**
Physician: Medical Knowledge
Physician: Systems-based Practice
Physician: Patient Care and Procedural Skills

**Learning Objectives**
1. Discuss the impact of the endometrial microbiome on pregnancy outcome.
2. Explain the impact of stem cell senescence on pregnancy outcome.
3. Describe the immune paradigms as they apply to reproduction (tolerance, immune privilege, immune modulation).
4. Describe the research directions in cutting-edge reproductive immunology.
5. Explain model systems used in the immunology of RPL research.
6. Discuss clinical and translational advances in RPL immunology.
7. Discuss the direction of RPL immune research in the near future.
8. Explain how sperm epigenetics/DNA methylation can contribute to pregnancy loss.
9. Explain how whole exome and genome sequencing can be used to evaluate pregnancy loss.
10. Describe how perturbances in epigenetics, such as DNA methylation, can cause abnormal placentation and RPL.
11. List several cutting-edge basic research topics occurring in the RPL field.
12. Describe in broad terms pertinent novel research findings in RPL.
SSR: Differences in Sexual Development and Gender Identity – Recent Developments and Prospects for Reproductive Medicine

The Society for the Study of Reproduction

Faculty
Blanche Capel, PhD, (Chair)
Duke University Medical Center
Eric Vilain, MD, PhD
University of California, Irvine
Margaret McCarthy, PhD
University of Maryland School of Medicine
Melissa Hines, PhD
Cambridge University
Thomas D. Steensma, PhD
Amsterdam UMC

Target Audience
Clinicians, Basic Scientists, Trainees, Health Care Professionals, Geneticists, Toxicologists, Epidemiologists

Credit Type
APA, NSGC, CME, NPWH

Needs Assessment
While most babies are born with the physical features of a boy or girl, in some cases the sex of the baby cannot be clearly identified. Furthermore, during childhood or puberty, a child’s sense of gender identity may be discordant with their physical phenotype, even when physical features can be clearly classified as male or female. It has become more and more difficult to navigate this spectrum of sexual differences in a manner sensitive to the needs of patients and their parents. This course will aim to explain how physical differences in sexual development arise, how they are diagnosed, and when helpful treatments when indicated. It will also address the gap in knowledge surrounding sex-specific brain development and gender identity.

Description
The course is meant to enhance participants’ understanding of Differences in Sexual Development (DSDs). Participants will be provided the latest information regarding the diagnosis, causality, and terminology around DSDs. The morning session will be dedicated to physiological DSDs that affect morphogenesis of the testis, ovary, reproductive ducts, and external genitalia as well as sex differences in brain development. The afternoon session will be devoted to psychological DSDs centered around how children develop a sense of gender identity. Consideration of gender development in transgender, gender non-conforming, and intersex children and the factors that contribute to this class of DSDs.

ACGME Competencies
Physician: Medical Knowledge
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1- Identify physiological DSDs and their likely causes based on genetic analysis, endocrine measurements, and imaging.
2- Develop appropriate terminology to discuss these cases with patients and parents.
3- Identify best treatment practices leading to well-being for families with DSDs.
4- Explain how physical differences in sex development arise.
5- Name the types of molecular, cellular, and anatomical sex differences that can exist in the brain based on animal models.
6- Discuss how hormones and immune cells establish sex differences in discrete regions of the developing brain.
7- Illustrate how those discrete brain regions contribute to adult reproductive behaviors.
8- List methods for diagnosing causes and management options for DSDs.
9- Explain how human sex/gender development involves multiple outcomes (e.g., sexual orientation, gender identity, childhood gender role behaviors, cognition, personality).
10- Discuss how prenatal androgen exposure contributes to many of these outcomes.
11- Explain that prenatal androgen exposure acts with other factors (e.g., postnatal socialization, culture) in different ways for different outcomes in different individuals.
12- Define the developmental paths in children and adolescents with gender incongruence.
13- Name the factors that influence the development of pre-pubertal children with gender incongruence.
14- Choose the means of assessment and psychological counseling for children and adolescents with gender incongruence.
15- Discuss possible medical interventions and the evaluation of this treatment in adolescents with gender incongruence.
AMMR/ALMER: Hot Topics in ART - Debates with a Transcontinental Point of View (SPANISH) CME
AMMR, REDLARA, ALMER

Faculty
Ruben Tlapanco, MD, (Chair)
MEXICO CITY, DF
Armando Roque-Sanchez, MD
Instituto Nacional de Perinatología
Jorge Rodríguez-Purata, MD
Carlos G. Salazar Lopez, MD
Instituto Español
Martha Luna Rojas, MD
RMA of New York, International Mexico, SC

Target Audience
Health Providers Focusing in Reproductive Medicine

Credit Type
CME

Needs Assessment
This PG course is designed to address some of the actual Hot-Tops in reproduction. We will address some of the ASRM gaps such as • Endometrial receptivity, including the interaction between implantation and placentation • Emerging technology in embryo implantation and uterine receptivity • Definition of mosaic embryo low/high grade • Lack of knowledge and best practices in utilizing non-invasive PGT • Counseling to support patients with mosaicism embryos • PGT-A technology information • Should we continue to perform PGT-A in more patients? As well as the state of art of the following topics: • Ovarian rejuvenation • Add-ons and antioxidants • In vitro activation • Recurrent miscarriage • Progesterone primed ovarian stimulation cycles

Description
The objectives of the course will be: • Foment the interaction and exchange of ideas, approaches, and points of view from different health providers in Latin America • The debate about the recent hot topics in reproduction medicine such as ovarian rejuvenation, universal PGT-A, Add-ons, recurrent miscarriage, and embryo implantation • The participants will benefit from this course by acquiring a trans-continental point of view in difficult and novel topics and increase its own knowledge, competence and performance

ACGME Competencies
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Medical Knowledge

Learning Objectives
1- List the alternatives in the management of patients with a low ovarian reserve and evaluate their real utility.
2- Evaluate the real utility of alternatives in the management of patients with a low ovarian reserve.
3- Explain the use of routine PGT-A for IVF patients.
4- Question the utility of non-invasive PGT and determine the fate of mosaic embryos.
5- Describe the relationship between recurrent implantation failure and recurrent miscarriage.
6- Debate the utility of diagnostic tests and treatment options in relation to recurrent implantation failure and recurrent miscarriage.
Reproductive Injustice: The Past, The Present, and Opportunities for Change

Faculty
Gloria Richard-Davis, MD, (Chair)
University of Arkansas
Torie Plowden, MD, MPH
NICHD
Amanda Adeleye, MD
The University of Chicago

Target Audience
MD, Advance Practice, and Mental Health Providers

Credit Type
NSGC, CME

Needs Assessment
Historic injustice in reproductive medicine is well documented, dating back to Dr. J. Marion Simms experimenting on enslaved women including Lucy, Betsey and Anarcha, without informed consent. In the modern context, remnants of these injustices persist. Stereotypes of minority women as hyper-fertile and over-sexualized contribute to the disparities seen in the reproductive needs of Black and brown women, including evaluation and treatment of infertility. Black and Hispanic women delay seeking fertility care, have poorer treatment outcomes, and discontinue care at rates higher than their white counterparts, for a myriad of reasons. Although socioeconomic factors remain a principal factor, consistent data highlights the impact of structural racism, implicit bias, covert and overt discrimination, and lack of representation as significant barriers to care. After achieving pregnancy, the similar factors contribute to higher rates of maternal and neonatal morbidity and mortality in minority women. Data concludes that racial concordant care improves patient outcomes, supporting the need for an equipped and diverse physician workforce. This course is designed to raise awareness of historic reproductive injustice, update the issues faced today and provide clinicians and healthcare systems with the tools to enact change.

Description
This course consists of three components. First, we will review historical examples of how racism and discrimination contribute to the reproductive health disparities seen today. Second, we will highlight under-appreciated modern disparities, including the intersectionality of trans minority health, and the impact of restrictions on abortion care on minority health. Lastly, we turn toward the future with interactive team-based learning on anti-racism and a focus on how to strengthen the college-to-REI provider pipeline.

ACGME Competencies
Interprofessional: Teams and Teamwork
Interprofessional: Communication
Interprofessional: Values-Ethics
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Medical Knowledge
Physician: Systems-based Practice
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1. Illustrate the historical and contemporary context of reproductive health disparities in the United States.
2. Explain modern racial/ethnic disparities as a way to highlight lesser unknown/understood aspects of health care disparities.
3. List the crossroads between race and reproductive justice.
4. Define the intersectionality between LGBTQ+ and race on reproductive care.
5. Name strategies to improve the recruitment and retention of BIPOC physicians in reproductive medicine.
6. Explain the importance of mentoring and sponsorship in the professional development of perspective leaders in REI.
7. Discuss the unique needs of transgender patients of color.
SUNDAY, OCTOBER 15, HALF DAY COURSES 1:00 PM - 5:00 PM

PG17 Ready, Set, Grow (Responsibly): The Science of Infertility Treatment

Association of Reproductive Managers (ARM), Genetic Counseling Professional Group (GCPG) and Society for Assisted Reproductive Technology (SART)

Faculty
Hary Hokianto, MBA, (Chair)
Boston IVF
April Rutter
Missouri Fertility
Paul Lin, MD
Seattle Reproductive Medicine
Teresa Cacchione, MS, CGC
Reproductive Medicine Associates of New York

Target Audience
Practice Managers, Owners, Supervisors, Physicians, Clinicians, Genetic Counselor, Researchers, Legal Professionals, and Mental Health Professionals

Credit Type
CME

Needs Assessment
The issue of infertility affects not only individuals but also the global environment and some might say, human evolution (Think genetics). Practice managers, owners, clinicians, and scientists in the REI field are privileged to be in a position to lead. That said, keep in mind that with power, comes responsibility. As the field of REI continues to evolve and grow rapidly, it is very important for leaders to continue to evaluate and cautiously define what Success is from a variety of perspectives - Business, Clinical, Scientific, and how these measurements of success could have an impact on the quality of patient care and the industry’s initiative to improving access to anyone who needs treatment. Having a good understanding of what has worked in the past, how things have evolved to what we are today, and having the ‘right’ vision of success (Given the rapid growth) is crucial.

Description
This course will focus on the Science of Infertility Treatment including the continuing evolution of laboratory and clinical services being offered to patients such as genetic testing and egg banking. Important considerations must be made to ensure that we are moving forward with new technology while considering patient care, safety, as well as ethical considerations.

ACGME Competencies
Interprofessional: Teams and Teamwork
Interprofessional: Communication
Interprofessional: Roles-Responsibilities
Interprofessional: Values-Ethics
Physician: Professionalism
Physician: Interpersonal and Communication Skills
Physician: Patient Care and Procedural Skills
Physician: Practice-based Learning and Improvement

Learning Objectives
1- Demonstrate a basic understanding of management consideration on growing a practice responsibly and ethically.
2- Develop a basic understanding of current and future role of Genetics in IVF.
3- Discuss some of ASRM and SART guidelines as they relate to managing a growing practice.
4- Summarize some of the potential benefits of egg-banking.
Needs Assessment and Description

This year’s ASRM Scientific Congress & Expo theme is THE PAST, THE PRESENT, THE PIPELINE. The program is designed to address the educational and practice needs of physicians, advanced practice providers, nurses, andrology and embryology laboratory personnel, genetic counselors, mental health practitioners, and practice managers, as well as practitioners in public health, allied health, law, and ethics.

The Postgraduate Program Committee has collaborated with our affiliated societies, professional and special interest groups, as well as domestic and international Society Partners, to present a wide range of multi-disciplinary Postgraduate Courses designed to meet the needs of all our members. Course topics range from ethical considerations in reproductive medicine, coding for maximum reimbursement, understanding federal regulations, self-care for providers, translating bench research into the clinical management of recurrent pregnancy, reproductive injustice, sexual health, gender identity, counseling about genetics, and growing your practice. Additionally, this year we will have a PG course taught in Spanish and will focus on the debated issues in ART. Our lineup also includes multiple hands-on courses, a social media summit, and the SREI practice retreat meeting.

In keeping with our ASRM 2023 Scientific Congress theme of “The Past, The Present, The Pipeline,” we have invited a diverse group of dynamic plenary speakers this year who will engage us in a variety of topics. These include privacy in our current climate, transgender medicine, male contraception, non-hormonal contraceptives targeting AMHR2, the intersection of REI and racism, equity and inclusion, sexual function, menopause, and many more. We are finalizing a talk from a prominent producer/director from the entertainment industry who will discuss similarities between the medical world and the movie business when it comes to mentorship and developing future leaders.

The Scientific Congress Continuing Medical Education (CME) course offerings will include morning plenary and dual-afternoon lectures, symposia, and interactive sessions. You will hear innovative lectures that focus on communicating about genetics to patients, diversifying the reproductive medicine workforce, human genome editing, dietary and exercise implications on male reproduction, moving novel therapies from bench to bedside, and fertility preservation for our transgender patients. CME sessions will be complemented by non-CME activities, including intimate roundtable luncheons covering the breadth and depth of reproductive medicine. Oral and poster talks will take place throughout each day of the Scientific Congress, bringing a new format to these presentations.

Learning Objectives

At the conclusion of the Scientific Congress, participants should be able to:

1. Describe the ethical, legal, and psychosocial ramifications of third-party reproduction.
2. Discuss the intersection of REI and racism, equity, and inclusion.
3. Outline diversity, equity, and inclusion considerations related to reproductive care and access to services.
4. Apply strategies that simplify technology, reduce costs, and broaden accessibility.
5. Explain the relevance of genetics and genomics to reproductive care.
6. Discuss current knowledge of endometriosis, fibroids, adenomyosis, contraception, and polycystic ovary syndrome.
7. Review the latest scientific advances in embryo biology and assessment of the optimization of embryo transfer.
8. Propose appropriate treatments for reproductive dysfunctions in females and males at different ages throughout life—childhood, adolescence, adulthood, and reproductive senescence.
9. Discuss current knowledge of endometriosis, fibroids, adenomyosis, contraception, and polycystic ovary syndrome.
<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abboud, Randa</td>
<td>RTW-24</td>
</tr>
<tr>
<td>Abhari, Sina</td>
<td>INW-02</td>
</tr>
<tr>
<td>Aboulghar, Mohamed</td>
<td>PG-07</td>
</tr>
<tr>
<td>Acién, Maribel</td>
<td>PG-10</td>
</tr>
<tr>
<td>Adams, Karen</td>
<td>PLW-01</td>
</tr>
<tr>
<td>Adamson, Geoffrey</td>
<td>INW-01</td>
</tr>
<tr>
<td>Adeleye, Amanda</td>
<td>PG-16</td>
</tr>
<tr>
<td>Ainsworth, Alessandra</td>
<td>INT-03</td>
</tr>
<tr>
<td>Al-Hendy, Ayman</td>
<td>SYM-01</td>
</tr>
<tr>
<td>Albertini, David</td>
<td>SYM-06, SYT-04</td>
</tr>
<tr>
<td>Albrecht, Mahshid</td>
<td>RTM-03</td>
</tr>
<tr>
<td>Allen, Anita</td>
<td>PLM-01</td>
</tr>
<tr>
<td>Allen, Christine</td>
<td>RTM-11</td>
</tr>
<tr>
<td>Alonso, Luis</td>
<td>HOC-02, PLW-04</td>
</tr>
<tr>
<td>Andrews, Marisa</td>
<td>SYT-05</td>
</tr>
<tr>
<td>Asafu-Adjei, Denise</td>
<td>SYT-07</td>
</tr>
<tr>
<td>Awwad, Johnny</td>
<td>PG-07</td>
</tr>
<tr>
<td>Awwad, Rawan</td>
<td>RTW-09</td>
</tr>
<tr>
<td>Babayev, Elnur</td>
<td>PG-09, INW-07</td>
</tr>
<tr>
<td>Babayev, Samir</td>
<td>INT-03, SYW-06</td>
</tr>
<tr>
<td>Bakken, Jennifer</td>
<td>RTT-09</td>
</tr>
<tr>
<td>Bar-Chama, Nathan</td>
<td>RTW-20</td>
</tr>
<tr>
<td>Barnhart, Kurt</td>
<td>SYT-04</td>
</tr>
<tr>
<td>Bartolomei, Marisa</td>
<td>PLW-03</td>
</tr>
<tr>
<td>Bedaiwy, Mohamed</td>
<td>SYM-08</td>
</tr>
<tr>
<td>Bergman, Kim</td>
<td>PG-02</td>
</tr>
<tr>
<td>Besser, Andria</td>
<td>INM-02</td>
</tr>
<tr>
<td>Bhagavath, Bala</td>
<td>INT-01</td>
</tr>
<tr>
<td>Bindeman, Julie</td>
<td>INM-04, RTM-08</td>
</tr>
<tr>
<td>Blackwell, Pamela</td>
<td>CSM-02</td>
</tr>
<tr>
<td>Bloom, Michael</td>
<td>INW-08</td>
</tr>
<tr>
<td>Bozoa, Silvina</td>
<td>PG-05</td>
</tr>
<tr>
<td>Bodi, Lynn</td>
<td>SYT-09</td>
</tr>
<tr>
<td>Booras, Ruby</td>
<td>CSW-03</td>
</tr>
<tr>
<td>Boots, Christina</td>
<td>INT-05</td>
</tr>
<tr>
<td>Bormann, Charles</td>
<td>INM-01</td>
</tr>
<tr>
<td>Bortoletto, Pietro</td>
<td>RTT-17</td>
</tr>
<tr>
<td>Braverman, Andrea</td>
<td>PG-12</td>
</tr>
<tr>
<td>Brosens, Jan</td>
<td>SYM-02</td>
</tr>
<tr>
<td>Burks, Heather</td>
<td>RLST-02</td>
</tr>
<tr>
<td>Cacchione, Teresa</td>
<td>PG-17</td>
</tr>
<tr>
<td>Callahan, Nicole</td>
<td>RTT-02</td>
</tr>
<tr>
<td>Callum, Pamela</td>
<td>PG-12</td>
</tr>
<tr>
<td>Cameron, Katherine</td>
<td>PG-04</td>
</tr>
<tr>
<td>Capel, Blanche</td>
<td>PG-14</td>
</tr>
<tr>
<td>Chang, Tienceng Arthur</td>
<td>RTW-07, SYM-06</td>
</tr>
<tr>
<td>Chosed, Renee</td>
<td>SYM-06</td>
</tr>
<tr>
<td>Christianson, Mindy</td>
<td>CSM-01, HOC-02, SYW-06</td>
</tr>
<tr>
<td>Cinnioglu, Cengiz</td>
<td>INW-06</td>
</tr>
<tr>
<td>Conaghan, Joe</td>
<td>PG-01</td>
</tr>
<tr>
<td>Costello, Michael</td>
<td>SYT-03</td>
</tr>
<tr>
<td>Cote, Diane</td>
<td>PG-02</td>
</tr>
<tr>
<td>Craig, LaTasha</td>
<td>RTW-15, RLST-01</td>
</tr>
<tr>
<td>Crockin, Susan</td>
<td>PG-04, SYT-05</td>
</tr>
<tr>
<td>Curchoe, Carol</td>
<td>RTM-18</td>
</tr>
<tr>
<td>Cymet Lansi, Ariadna</td>
<td>CSW-02, INT-05</td>
</tr>
<tr>
<td>Daar, Judith</td>
<td>SYM-09</td>
</tr>
<tr>
<td>Davies, Darlene</td>
<td>RTW-12</td>
</tr>
<tr>
<td>DeMayo, Francesco</td>
<td>SYT-02</td>
</tr>
<tr>
<td>Desai, Nidhi</td>
<td>SYT-01</td>
</tr>
<tr>
<td>Detti, Laura</td>
<td>HOC-01</td>
</tr>
<tr>
<td>Di Spiezio Sardo, Atilio</td>
<td>PG-10</td>
</tr>
<tr>
<td>Dippaola, Kathleen</td>
<td>CSM-01</td>
</tr>
<tr>
<td>Dokras, Anuja</td>
<td>SYT-03</td>
</tr>
<tr>
<td>Dow, Mark</td>
<td>CST-01</td>
</tr>
<tr>
<td>Doyle, Nicole</td>
<td>RTW-08</td>
</tr>
<tr>
<td>Duncan, Francesca</td>
<td>PG-09</td>
</tr>
<tr>
<td>Eaton, Jennifer</td>
<td>RTT-07</td>
</tr>
<tr>
<td>Ehlers, Emily</td>
<td>CSM-01, CST-01</td>
</tr>
<tr>
<td>Elias, Rony</td>
<td>INW-02</td>
</tr>
<tr>
<td>Fahnbulleh, Wiyatta</td>
<td>CSM-02</td>
</tr>
<tr>
<td>Ferrero, Simone</td>
<td>RTT-15</td>
</tr>
<tr>
<td>Findley, Joseph</td>
<td>SYM-08</td>
</tr>
<tr>
<td>Finerty, Jacalyn</td>
<td>RTT-19</td>
</tr>
<tr>
<td>Flores, Valerie</td>
<td>RTW-14</td>
</tr>
<tr>
<td>Fox, Silvia</td>
<td>CSW-02, SYT-09</td>
</tr>
<tr>
<td>Fujimoto, Victor</td>
<td>INW-08</td>
</tr>
<tr>
<td>Furgoch, Mira</td>
<td>INM-02</td>
</tr>
<tr>
<td>Gamma, Amber</td>
<td>INT-02</td>
</tr>
<tr>
<td>Garrison, Jennifer</td>
<td>PG-09</td>
</tr>
<tr>
<td>Gaskins, Audrey</td>
<td>LIW-02</td>
</tr>
<tr>
<td>Gerrity, Marybeth</td>
<td>PG-03</td>
</tr>
<tr>
<td>Ghidei, Luwam</td>
<td>INW-03</td>
</tr>
<tr>
<td>Gilchrist, Robert</td>
<td>RTW-11</td>
</tr>
<tr>
<td>Ginsburg, Elizabeth</td>
<td>RLSTM-01</td>
</tr>
<tr>
<td>Goldman, Kara</td>
<td>PG-09, RTM-23, SYT-01</td>
</tr>
<tr>
<td>Goodman, Linnea</td>
<td>SYM-08</td>
</tr>
<tr>
<td>Gorson, Staci</td>
<td>RTM-15</td>
</tr>
<tr>
<td>Green, Lisa</td>
<td>RTW-23</td>
</tr>
<tr>
<td>Griffith, Linda</td>
<td>PLW-02</td>
</tr>
<tr>
<td>Grimbizis, Grigoris</td>
<td>PG-10</td>
</tr>
<tr>
<td>Gvakaharia, Marina</td>
<td>RTT-13</td>
</tr>
<tr>
<td>Halpern, Joshua</td>
<td>INM-05</td>
</tr>
<tr>
<td>Horton, Gary</td>
<td>RTW-02</td>
</tr>
<tr>
<td>Hayes, Katherine</td>
<td>SYW-01</td>
</tr>
<tr>
<td>Heitmann, Ryan</td>
<td>HOC-03</td>
</tr>
<tr>
<td>Helo, Sevann</td>
<td>SYT-07</td>
</tr>
<tr>
<td>Herati, Amin</td>
<td>SYM-03</td>
</tr>
<tr>
<td>Hickman, Timothy</td>
<td>RTM-06</td>
</tr>
<tr>
<td>Hill, George</td>
<td>PG-05</td>
</tr>
<tr>
<td>Hill, Jessie</td>
<td>RTT-14</td>
</tr>
<tr>
<td>Hines, Melissa</td>
<td>PG-14</td>
</tr>
<tr>
<td>Hipp, Heather</td>
<td>INW-07, RLSTM-01, RLST-02</td>
</tr>
<tr>
<td>Hoechst, Judith</td>
<td>RTM-21</td>
</tr>
<tr>
<td>Hokianto, Hary</td>
<td>PG-06, PG-17, SYM-05</td>
</tr>
<tr>
<td>Hotaling, James</td>
<td>RTM-17</td>
</tr>
<tr>
<td>Hwang, Kathleen</td>
<td>PG-08, INW-04</td>
</tr>
<tr>
<td>Isley, Lauren</td>
<td>CSW-01</td>
</tr>
<tr>
<td>Jain, Kuldeep</td>
<td>SYW-05</td>
</tr>
<tr>
<td>Jain, Tarun</td>
<td>RTW-06</td>
</tr>
<tr>
<td>Jenkins, Lawrence</td>
<td>PG-08</td>
</tr>
<tr>
<td>Jenkins, Tim</td>
<td>SYT-02</td>
</tr>
<tr>
<td>Speaker</td>
<td>Code</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Jindal, Sangita</td>
<td>INW-01</td>
</tr>
<tr>
<td>Johannesson, Liza</td>
<td>INM-03</td>
</tr>
<tr>
<td>Johnson, Amy</td>
<td>PG-03</td>
</tr>
<tr>
<td>Jukic, Anne Marie</td>
<td>RTM-16</td>
</tr>
<tr>
<td>Kaplan, Danielle</td>
<td>CST-02</td>
</tr>
<tr>
<td>Kastury, Rama</td>
<td>SYW-01</td>
</tr>
<tr>
<td>Katz, Steven</td>
<td>INT-06</td>
</tr>
<tr>
<td>Kelley, Erika</td>
<td>RTW-10</td>
</tr>
<tr>
<td>Kestler, Jessica</td>
<td>CST-03</td>
</tr>
<tr>
<td>Khan, Zaraq</td>
<td>INT-01, RLST-01</td>
</tr>
<tr>
<td>Klipstein, Sigal</td>
<td>PG-04, INM-02</td>
</tr>
<tr>
<td>Kornfield, Molly</td>
<td>RLSM-01</td>
</tr>
<tr>
<td>Krieg, Sachines</td>
<td>RLSM-01</td>
</tr>
<tr>
<td>Ku, Seung-Yup</td>
<td>SYM-01</td>
</tr>
<tr>
<td>Kubikova, Nada</td>
<td>RTM-01</td>
</tr>
<tr>
<td>Kudesia, Rashmi</td>
<td>INT-05</td>
</tr>
<tr>
<td>Kwak-Kim, Joanne</td>
<td>RTW-05</td>
</tr>
<tr>
<td>Kwapis, Ken</td>
<td>PLT-02</td>
</tr>
<tr>
<td>Lamb, Dolores</td>
<td>SYM-03, SYW-02</td>
</tr>
<tr>
<td>Lanham, Michael</td>
<td>SYT-09</td>
</tr>
<tr>
<td>Lathi, Ruth</td>
<td>RLSM-01</td>
</tr>
<tr>
<td>Laven, Joop</td>
<td>INT-04</td>
</tr>
<tr>
<td>Lawson, Angela</td>
<td>PG-02, INT-03, SYM-07</td>
</tr>
<tr>
<td>Legro, Richard</td>
<td>SYT-03</td>
</tr>
<tr>
<td>Lencz, Todd</td>
<td>INW-06</td>
</tr>
<tr>
<td>Leondires, Mark</td>
<td>INT-06</td>
</tr>
<tr>
<td>Lewis, Leigh</td>
<td>PG-02</td>
</tr>
<tr>
<td>Lucciardi, Frederick</td>
<td>RLSM-01</td>
</tr>
<tr>
<td>Lin, Paul</td>
<td>PG-06, PG-17, INW-02</td>
</tr>
<tr>
<td>Locke, Anna</td>
<td>CST-02</td>
</tr>
<tr>
<td>Ludwin, Artur</td>
<td>PG-10</td>
</tr>
<tr>
<td>Lujan, Marla</td>
<td>SYT-03</td>
</tr>
<tr>
<td>Luna Rojas, Martha</td>
<td>PG-15</td>
</tr>
<tr>
<td>Macklon, Kirsten</td>
<td>PG-11</td>
</tr>
<tr>
<td>Madjunkova, Svetlana</td>
<td>RTM-02</td>
</tr>
<tr>
<td>Maher, Jacqueline</td>
<td>RRT-06</td>
</tr>
<tr>
<td>Mainigi, Monica</td>
<td>SYT-04</td>
</tr>
<tr>
<td>Mak, Winifred</td>
<td>PG-13, INM-04, RTW-22</td>
</tr>
<tr>
<td>Malhotra, Neena</td>
<td>SYW-05</td>
</tr>
<tr>
<td>Mallik, Rachelle</td>
<td>RTM-12</td>
</tr>
<tr>
<td>Malmsten, Jonas</td>
<td>RTW-19</td>
</tr>
<tr>
<td>Marsh, Erica</td>
<td>PLT-04</td>
</tr>
<tr>
<td>Marshall, Lorna</td>
<td>PG-12</td>
</tr>
<tr>
<td>Masaba, Erin</td>
<td>PG-13</td>
</tr>
<tr>
<td>Masterson, Thomas</td>
<td>RTM-14</td>
</tr>
<tr>
<td>Mayne, Gabriella</td>
<td>INW-03</td>
</tr>
<tr>
<td>McBain, Lindsey</td>
<td>RTT-05</td>
</tr>
<tr>
<td>McCaffrey, Caroline</td>
<td>SYT-05</td>
</tr>
<tr>
<td>McCarthy, Margaret</td>
<td>PG-14</td>
</tr>
<tr>
<td>McQueen, Dana</td>
<td>PG-13, RTW-21, SYW-04</td>
</tr>
<tr>
<td>Meagher, Vicki</td>
<td>PG-03</td>
</tr>
<tr>
<td>Medvedich, Jessica</td>
<td>INT-06</td>
</tr>
<tr>
<td>Mehta, Akanksha</td>
<td>RTT-20</td>
</tr>
<tr>
<td>Mendola, Pauline</td>
<td>INW-08</td>
</tr>
<tr>
<td>Messerlian, Carmen</td>
<td>RTW-13</td>
</tr>
<tr>
<td>Miller, Charles</td>
<td>INT-01</td>
</tr>
<tr>
<td>Minguiez-Alarcon, Lidia</td>
<td>RTM-10</td>
</tr>
<tr>
<td>Mitalipov, Shoukrat</td>
<td>RTT-11</td>
</tr>
<tr>
<td>Mohapatra, Seema</td>
<td>SYM-09</td>
</tr>
<tr>
<td>Monseur, Brent</td>
<td>RTT-22</td>
</tr>
<tr>
<td>Montgomery Rice, Valerie</td>
<td>PLM-02</td>
</tr>
<tr>
<td>Mooney, Sara</td>
<td>RTW-04</td>
</tr>
<tr>
<td>Morelli, Sara</td>
<td>HOC-03</td>
</tr>
<tr>
<td>Morris, Randy</td>
<td>RTT-18</td>
</tr>
<tr>
<td>Mounts, Emily</td>
<td>INT-06</td>
</tr>
<tr>
<td>Nayar, Kanad Dev</td>
<td>SYW-05</td>
</tr>
<tr>
<td>Neal-Perry, Genevieve</td>
<td>SYM-04, INW-03</td>
</tr>
<tr>
<td>Neblett, Michael</td>
<td>RTW-17</td>
</tr>
<tr>
<td>Nervi, Lauren</td>
<td>CST-03</td>
</tr>
<tr>
<td>Nolan, Patty</td>
<td>PG-01</td>
</tr>
<tr>
<td>Nowak Groll, Lorie</td>
<td>PG-05</td>
</tr>
<tr>
<td>O'Neill, Kathleen</td>
<td>INM-03</td>
</tr>
<tr>
<td>Oktay, Kutluk</td>
<td>PG-11, INW-07, RTW-16, SYW-06</td>
</tr>
<tr>
<td>Orwig, Kyle</td>
<td>PG-11, INW-04, LIVW-02</td>
</tr>
<tr>
<td>Page, Stephanie</td>
<td>PLM-04</td>
</tr>
<tr>
<td>Pai, Rishma</td>
<td>SYW-05</td>
</tr>
<tr>
<td>Pal, Lubna</td>
<td>SYM-04</td>
</tr>
<tr>
<td>Palshetkar, Nandita</td>
<td>RTT-23, SYW-05</td>
</tr>
<tr>
<td>Park, Hang-Soo</td>
<td>SYM-01</td>
</tr>
<tr>
<td>Parry, John Preston</td>
<td>HOC-02, INW-05</td>
</tr>
<tr>
<td>Patil, Madhuri</td>
<td>RTW-25</td>
</tr>
<tr>
<td>Patki, Ameet</td>
<td>SYW-05</td>
</tr>
<tr>
<td>Paul, Soumen</td>
<td>SYT-02</td>
</tr>
<tr>
<td>Penzias, Alan</td>
<td>PG-07</td>
</tr>
<tr>
<td>Pépin, David</td>
<td>PLT-01</td>
</tr>
<tr>
<td>Perman, Shana</td>
<td>CSM-03, RTW-01</td>
</tr>
<tr>
<td>Petok, William</td>
<td>PG-08</td>
</tr>
<tr>
<td>Petrozza, John</td>
<td>RLST-01</td>
</tr>
<tr>
<td>Pfeifer, Samantha</td>
<td>HOC-03, RLST-01</td>
</tr>
<tr>
<td>Phillips, Katherine</td>
<td>PG-02</td>
</tr>
<tr>
<td>Plowden, Torie</td>
<td>PG-16</td>
</tr>
<tr>
<td>Pollack, Staci</td>
<td>RTM-19</td>
</tr>
<tr>
<td>Price, Jeanine</td>
<td>CSW-01</td>
</tr>
<tr>
<td>Queenan, John</td>
<td>PG-05</td>
</tr>
<tr>
<td>Raheem, Omer</td>
<td>RTM-05</td>
</tr>
<tr>
<td>Rapp, Hayley</td>
<td>CSW-03</td>
</tr>
<tr>
<td>Rehmer, Jenna</td>
<td>INW-05</td>
</tr>
<tr>
<td>Reinecke, Joyce</td>
<td>SYT-01</td>
</tr>
<tr>
<td>Richard-Davis, Gloria</td>
<td>PG-16</td>
</tr>
<tr>
<td>Richards, Elliott</td>
<td>INM-03</td>
</tr>
<tr>
<td>Rinehart, Lisa</td>
<td>PG-12, RTM-04</td>
</tr>
<tr>
<td>Ringler, Guy</td>
<td>SYM-11</td>
</tr>
<tr>
<td>Rivron, Nicolas</td>
<td>SYM-02</td>
</tr>
<tr>
<td>Rodriguez-Purata, Jorge</td>
<td>PG-15</td>
</tr>
<tr>
<td>Roque-Sanchez, Armando</td>
<td>PG-15, RTM-24</td>
</tr>
<tr>
<td>Ross, Heather</td>
<td>SYM-07</td>
</tr>
<tr>
<td>Rutter, April</td>
<td>PG-06, PG-17</td>
</tr>
</tbody>
</table>
# SPEAKER INDEX

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan, Ginny</td>
<td>INM-01</td>
</tr>
<tr>
<td>Ryniec, Jessica</td>
<td>RTW-18</td>
</tr>
<tr>
<td>Sable, David</td>
<td>SYM-05</td>
</tr>
<tr>
<td>Sadruddin Ali, Sheela</td>
<td>INT-02</td>
</tr>
<tr>
<td>Sakkas, Denny</td>
<td>PG-01, INM-05</td>
</tr>
<tr>
<td>Salazar Lopez, Carlos G</td>
<td>PG-15</td>
</tr>
<tr>
<td>Santoro, Nanette</td>
<td>SYM-04</td>
</tr>
<tr>
<td>Schafer, Vickie</td>
<td>SYW-03</td>
</tr>
<tr>
<td>Schiff, Mark</td>
<td>SYM-11</td>
</tr>
<tr>
<td>Schlegel, Peter</td>
<td>SYM-03</td>
</tr>
<tr>
<td>Schon, Samantha</td>
<td>RTT-16, SYW-03</td>
</tr>
<tr>
<td>Sekhon, Lucky</td>
<td>RTM-22</td>
</tr>
<tr>
<td>Seli, Emre</td>
<td>RTT-03</td>
</tr>
<tr>
<td>Shah, Divya</td>
<td>INW-05, RLST-01</td>
</tr>
<tr>
<td>Shenoy, Chandra</td>
<td>INT-03</td>
</tr>
<tr>
<td>Simon, Carlos</td>
<td>SYM-02</td>
</tr>
<tr>
<td>Simon, Judy</td>
<td>SYW-03</td>
</tr>
<tr>
<td>Simoni, Michael</td>
<td>RTM-20</td>
</tr>
<tr>
<td>Singer, Tomer</td>
<td>HOC-01</td>
</tr>
<tr>
<td>Smith, James</td>
<td>INM-05</td>
</tr>
<tr>
<td>Smith, Ryan</td>
<td>SYT-07</td>
</tr>
<tr>
<td>Spandonfer, Steven</td>
<td>SYW-04</td>
</tr>
<tr>
<td>Stadtmauer, Laurel</td>
<td>HOC-01</td>
</tr>
<tr>
<td>Stanic-Kastic, Aleksandar</td>
<td>PG-13, INW-01</td>
</tr>
<tr>
<td>Steensma, Thomas D.</td>
<td>PG-14</td>
</tr>
<tr>
<td>Stern, David</td>
<td>SYM-05</td>
</tr>
<tr>
<td>Stones, Rebecca</td>
<td>PG-01</td>
</tr>
<tr>
<td>Suh, Yousin</td>
<td>PG-09</td>
</tr>
<tr>
<td>Surrey, Mark</td>
<td>RTT-08</td>
</tr>
<tr>
<td>Swain, Margaret</td>
<td>PG-01, INT-02</td>
</tr>
<tr>
<td>Sycz, Lindsay</td>
<td>SYM-10</td>
</tr>
<tr>
<td>Tangpricha, Vin</td>
<td>PLM-03</td>
</tr>
<tr>
<td>Thyer, Angela</td>
<td>SYW-03</td>
</tr>
<tr>
<td>Tipton, Sean</td>
<td>SYM-09</td>
</tr>
<tr>
<td>Tapanco, Ruben</td>
<td>PG-15</td>
</tr>
<tr>
<td>Tobias, Tamara</td>
<td>CSM-03</td>
</tr>
<tr>
<td>Toner, James</td>
<td>HOC-03</td>
</tr>
<tr>
<td>Tongel, Lisa</td>
<td>RTT-01</td>
</tr>
<tr>
<td>Treff, Nathan</td>
<td>INW-06</td>
</tr>
<tr>
<td>Tur-Kaspa, Ilan</td>
<td>HOC-01, RTT-12</td>
</tr>
<tr>
<td>Uloko, Maria</td>
<td>SYM-10</td>
</tr>
<tr>
<td>Van Dolah, Lisa</td>
<td>SYM-05</td>
</tr>
<tr>
<td>Vance, Amy</td>
<td>RTM-07</td>
</tr>
<tr>
<td>Varzoni, Julius</td>
<td>PG-04</td>
</tr>
<tr>
<td>Vash-Margita, Alla</td>
<td>PG-11, SYW-01</td>
</tr>
<tr>
<td>Vaughn, Richard</td>
<td>SYM-11</td>
</tr>
<tr>
<td>Verrastro, Paul</td>
<td>PG-03</td>
</tr>
<tr>
<td>Vij, Sarah</td>
<td>INW-04</td>
</tr>
<tr>
<td>Vilain, Eric</td>
<td>PG-14</td>
</tr>
<tr>
<td>Viotti, Manuel</td>
<td>RTW-03</td>
</tr>
<tr>
<td>Vuong, Lan</td>
<td>RTM-09</td>
</tr>
<tr>
<td>Walker, Zachary</td>
<td>RLSM-01</td>
</tr>
<tr>
<td>Wang, Christina</td>
<td>SYW-02</td>
</tr>
<tr>
<td>Ward, Kriston</td>
<td>SYM-10</td>
</tr>
<tr>
<td>Watson, Janelle</td>
<td>RTT-10</td>
</tr>
<tr>
<td>Weinerman, Rachel</td>
<td>RTT-21, SYW-04, RLSM-01</td>
</tr>
<tr>
<td>Weiss, Marissa</td>
<td>RTM-13</td>
</tr>
<tr>
<td>Wells, Dagan</td>
<td>RTT-04</td>
</tr>
<tr>
<td>Westhoff, Carolyn</td>
<td>PLT-03</td>
</tr>
<tr>
<td>Wild, Robert</td>
<td>INT-04</td>
</tr>
<tr>
<td>Wood, Jennifer</td>
<td>PG-02</td>
</tr>
<tr>
<td>Woodward, Julia</td>
<td>PG-04, INM-01</td>
</tr>
<tr>
<td>Zhang, Songying</td>
<td>RTT-24</td>
</tr>
<tr>
<td>Zhang, Wanyu</td>
<td>RTM-25</td>
</tr>
</tbody>
</table>
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the 2023 ASRM Scientific Congress were required to complete a disclosure form. Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

<table>
<thead>
<tr>
<th>Disclosures</th>
<th>Name</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Company Officer</td>
<td>Adamson, G. D.</td>
<td>ARC Fertility; Cooper’s International Committee for Monitoring ART (ICMART); Labcorp; World Endometriosis Research Foundation (WERF)</td>
</tr>
<tr>
<td>2Direct Stockholder</td>
<td>Adeleye, A.</td>
<td>Carrot; Flo Health</td>
</tr>
<tr>
<td>3Full-Time Company Employee</td>
<td>Allen, A. L.</td>
<td>Future of Privacy Forum (Director, Board); National Constitution Center (Director, Board)</td>
</tr>
<tr>
<td>4Grant Recipient</td>
<td>Allen, C. S.</td>
<td>cryofuture; NSEB</td>
</tr>
<tr>
<td>5Honoraria</td>
<td>Bedaiwy, M. A.</td>
<td>Abbvie; Baxter; Ferring (Research Grant); Pfizer</td>
</tr>
<tr>
<td>6Paid Consultant</td>
<td>Bergman, K.</td>
<td>Growing Generations</td>
</tr>
<tr>
<td>7Speaker’s Bureau</td>
<td>Callum, P.</td>
<td>Cooper Surgical; NorthStar Fertility/Everie; Tandem Genetics (Part Time Employee); Tandem Genetics (Part Time Employee)</td>
</tr>
<tr>
<td>8Other</td>
<td>Cameron, K. E.</td>
<td>Becton Dickinson</td>
</tr>
<tr>
<td>9Self</td>
<td>Cinnioglu, C.</td>
<td>NextGen Genetics</td>
</tr>
<tr>
<td>aInstitution</td>
<td>Conaghan, J.</td>
<td>American Board of Bioanalysis; Irvine Scientific</td>
</tr>
<tr>
<td>bImmediate Family Member</td>
<td>Craig, L. B.</td>
<td>Ferring Pharmaceutical (site investigator for a study); Ferring Pharmaceuticals</td>
</tr>
<tr>
<td>2Company Officer</td>
<td>Davies, D.</td>
<td>SRBT and NEFS (board member (member at large))</td>
</tr>
<tr>
<td>3Full-Time Company Employee</td>
<td>Dokras, A.</td>
<td>Ablacare/Mayhealth; AEPiS Society (Associate Executive Director); EliLilly; Ferring; GSK/Haleon; Veera Health</td>
</tr>
<tr>
<td>4Grant Recipient</td>
<td>Ehlers, E.</td>
<td>Kindbody</td>
</tr>
<tr>
<td>5Honoraria</td>
<td>Flores, V. A.</td>
<td>Abbvie; Myovant</td>
</tr>
<tr>
<td>aInstitution</td>
<td>Furgoch, M.</td>
<td>CooperSurgical</td>
</tr>
<tr>
<td>bImmediate Family Member</td>
<td>Garrison, J.</td>
<td>American Aging Association (Board of Directors); Evernow</td>
</tr>
<tr>
<td>cInstitution</td>
<td>Gaskins, A. J.</td>
<td>Doveras Fertility, Inc. (I am an advisor to and hold stock options in this company)</td>
</tr>
<tr>
<td>2Company Officer</td>
<td>Gerrity, M.</td>
<td>Reproductive Biology Resources, Inc.</td>
</tr>
<tr>
<td>3Full-Time Company Employee</td>
<td>Gilchrist, R. B.</td>
<td>City Fertility</td>
</tr>
<tr>
<td>4Grant Recipient</td>
<td>Goodman, L. R.</td>
<td>LiNA Medical</td>
</tr>
<tr>
<td>5Honoraria</td>
<td>Griffith, L. G.</td>
<td>Genentech; NovoNordisk</td>
</tr>
<tr>
<td>bImmediate Family Member</td>
<td>Grimbizis, G. F.</td>
<td>European Society for Gynaecological Endoscopy (Chair, Board of Directors)</td>
</tr>
<tr>
<td>2Company Officer</td>
<td>Harton, G. L.</td>
<td>A IVF; BioSkryb Genomics; Cryos International</td>
</tr>
<tr>
<td>3Full-Time Company Employee</td>
<td>Herati, A. S.</td>
<td>Leaf (Non paid advisor); Roman Health ventures; Televflex</td>
</tr>
<tr>
<td>4Grant Recipient</td>
<td>Hotaling, J. M.</td>
<td>abbvie, pfizer, novartis, elli lilly (wife as rheumatologist); Advanced Conceptions; Andro360; Carrot Fertility; FirmTech; inherent bio; Maximus; Paterna bio; StreamDx; Turtle Health</td>
</tr>
<tr>
<td>5Honoraria</td>
<td>Hwang, K.</td>
<td>Reprotech; SSMR (Officer)</td>
</tr>
<tr>
<td>3Full-Time Company Employee</td>
<td>Isley, L.</td>
<td>CooperSurgical</td>
</tr>
</tbody>
</table>
Jenkins, L. C. Hims and Her's Inc (Medical Advisory Board); Innovative Biopharma 6a; Sexual Medicine Society of North America 1a

Jindal, S. K. TMRW 8a (Advisory Board)

Johnson, A. EVERSANA Life Science Services 2a; Midwest Reproductive Symposium International 5a

Katz, S. TMRW 8a

Kubikova, N. Juno Genetics 3b

Kunin-Leavitt, S. HCA 2b

Lathi, R. B. BioRad 5a

Legro, R. S. Covis 5a; Guerbet 4a; Insudd 6a; Novo Nordisk 6a

Lencz, T. American College of Neuropsychopharmacology 8a (Web Editor); International Society of Psychiatric Genetics 8a (Co-Chair, Ethics, Positions, and Public Policy Committee)

Leondires, M. P. EMD Serono 7a; Next Gen Genetics 2a

Mehta, A. Posterity Health 8a (Medical Advisory Board Member)

Miller, C. E. Abbieve 6a; AbiCare 6a; Allergena; Blue Seas Med Spa 6a (Investor); Gynecoson 26a; LiNA Medical 6a; Medtronic 6a; Olympus 6a; RF Medical, Co. Ltd. 6a; Seikagaku Corporation 6a; Temple Therapeutics B.V. 2a (Advisory Board)

Mohapatra, S. American Society of Law, Medicine, and Ethics 8a (Board Member); Population Connection 8a (Board Member)

Montgomery Rice, V. C. 23andme 8a (Board Member); CAREUSA 8a (Board Member); Chartis 8a (Board Member); GeoVax 8a (Health Equity Advisory Committee); Macy Foundation 8a (Board Member); Moffit Cancer Center 8a (Board Member); Nemours 8a (Board Member); UGH 8a (Board Member)

Mounts, E. L. Juno Genetics 3a

Neal-Perry, G. S. Astella 8a (Scientific Board Member); Merck 4a

Nervi, L. Ferring 6a

Oktay, K. H. Innovation Fertility 1a

Pal, L. Ferring pharmaceutical 8a (Advisory board); Flo health 4a

Parry, J. ACOG 8a (Chair, Mississippi ACOG- nonfinancial but an officer of another organization); Parryscope Fertility 8a (Founder with intellectual property rights for devices not on the market or to be discussed)

Petrozzi, J. C. IMMA 8a (Unpaid consultant); NESA 6a

Pfeifer, S. M. ASAPIRA 8a; ASAPIRA 8a; Granata Bio 6b

Quaas, A. M. Ferring Pharmaceuticals 5a

Rapp, H. E. IVI RMA 7a; NPWH 4a

Rivron, N. dawn-bio 2a; ISSCR 8a (Member of the ethics task)

Rutter, A. M. Hera Fertility 12a; Missouri Fertility Foundation 2a

Sadruddin Ali, S. ASRM QA Committee 8a (Committee member); Progenesis, Inc. 3a; SRBT 8a (Committee Member)

Sakkas, D. ALIFE 8d (Options); EMD Serono 7a; Legacy 8a (Options)

Schiff, M. Growing Generations 6a

Seli, E. Foundation for Embryonic Competence 6b

Shin, D. Fellow Health 2a

Simon, C. Igenomix 12a

Simon, J. Mind Body Nutrition, PLCC 8a (Owner Mind Body Nutrition, PLLC provide medical nutrition therapy)
<table>
<thead>
<tr>
<th>Name</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith, J. F.</td>
<td>Fellow Health¹; Inherent Biosciences²⁸a(Scientific advisor); Posterity Health²⁸a(Scientific Advisor)</td>
</tr>
<tr>
<td>Stern, D.</td>
<td>Alife²; Boston IVF¹; Genomic Prediction²; LabCorp²(Advisory Boardmember)</td>
</tr>
<tr>
<td>Swain, M.</td>
<td>Academy of Adoption and Assisted Reproduction Attorneys¹⁰</td>
</tr>
<tr>
<td>Thyer, A.</td>
<td>Alto Series E²; Pinnacle Fertility²; Seattle Reproductive Medicine³</td>
</tr>
<tr>
<td>Tobias, T.</td>
<td>Ferring Pharmaceuticals⁸(Speaker)</td>
</tr>
<tr>
<td>Tongel, L. K.</td>
<td>Lisa Tongel Acupuncture, LLC¹⁰</td>
</tr>
<tr>
<td>Treff, N. R.</td>
<td>EMD Serono⁴; FutureLife⁵⁰; Genomic Prediction Inc¹²</td>
</tr>
<tr>
<td>Tur-Kaspa, I.</td>
<td>Embryonics ⁸(Medical Advisory Board); Ferring ⁸(Advisory Boards)</td>
</tr>
<tr>
<td>van der Poel, S.</td>
<td>ASRM⁶a</td>
</tr>
<tr>
<td>Van Dolah, L.</td>
<td>CapexMD²⁸a; EMD Serono⁸(Ad Board); TMRW²⁸a</td>
</tr>
<tr>
<td>Vash-Margita, A.</td>
<td>Bayer Pharmaceutical, Inc⁷</td>
</tr>
<tr>
<td>Wells, D.</td>
<td>Juno Genetics⁶</td>
</tr>
<tr>
<td>Westhoff, C. L.</td>
<td>Bayer⁸(DSMB member); HRA Pharma⁶; Mayne⁷</td>
</tr>
</tbody>
</table>

**CHEERS! to new connections**

After a day of intense learning on Monday, kick back and mingle with leaders of ASRM’s affiliated societies, professional groups, special interest groups, as well as the F&S team at the Society Social Hour! Explore ASRM’s diverse interests while seeing familiar faces and cultivating new connections. This is your chance to discover your community within ASRM, so don’t miss it!
Scientific Congress Categories
asrmcongress.org

Click the links below to view all sessions in each category.

ART
Business of Medicine
Complex Family Planning
Fertility Preservation
Genetics
Infertility
Mental Health/Psychological
Nursing
Patient Centric

Pre-Clinical & Basic Research
Professional Development
Recurrent Pregnancy Loss
Reproductive Justice
Reproductive Medicine (non-infertility)
Reproductive Urology
Special Populations
Surgery

Mental Health
Professional Education

Increase your knowledge with these three online training modules from ASRM Academy:

Basic Infertility
Treatment Interventions
Counseling for Contemporary Family-Building

Learn More
ASRM’s Dedication to Resident Education Continues!

ASRM introduces KEEPR: Knowledge through Engagement & Education Program for Residents, a dynamic program exclusively for residents, emphasizing engagement with complex topics relevant to residents preparing for a career in reproductive health and medicine. KEEPR* is open to any resident attending the ASRM Scientific Congress. Programming especially designed for residents includes:

- Invitation-only interactive workshops
- Skill-building activities
- Advanced independent study
- ‘Hot topic’ discussions
- Evidence-based & bias-free learning
- Professional networking opportunities with peers, faculty, program directors, & giants in the field

*Free for residents with advanced registration required; boxed lunch provided daily for participants
Residents completing 2 full days of KEEPR activities & submitting all required “KEEPR Takeaways” receive a KEEPR Cohort 2023 Participation Packet, Certificate, & 1 year FREE ASRM membership!

Questions about the program or scheduling? Email Dr. Michelle Landrum, ASRM Resident Liaison: mlandrum@asrm.org.
Non-CME Educational Sessions

- Roundtable Discussions 67-70
- Video Abstract Sessions 73-74
- Oral Abstract Sessions 75-88
- Poster Presentations and Abstracts 89-114
- Disclosures 115-124
Roundtable Discussions

MONDAY, OCTOBER 16, 2023

Preimplantation Genetic Testing
Special Interest Group

RTM01
How Far Are We from Using Genome
Editing to Correct Mutations in Gametes or
Embryos?
Nada Kubikova, PhD
University of Oxford

RTM02
Transcriptomics and Other Emerging
Methods for Embryo Selection
Svetlana Madjunkova, MD, MSC, PhD
Create Family Centre

Association of
Reproductive Managers

RTM03
Building a Strong Bridge between
Managers and Clinical Staff
Mashid Albrecht, MBA
UC San Diego Health

Society for Assisted
Reproductive Technology

RTM04
SART Model Consent Forms and Your
Practice: Creating Synergies for Improving
Informed Consent
Lisa A. Rinehart, JD, RN
LegalCare Consulting, Inc.

Regenerative Medicine and Stem Cell
Biology Special Interest Group

RTM05
Mesenchymal Stem Cells-Based Novel
Approach for Fertility Preservation in Boys
Omer Rahim, MD, MSC

Society for Assisted
Reproductive Technology

RTM06
How Can SART Improve Your Practice? - a
Roundtable for Practice Managers
Timothy N. Hickman, MD, MSC
CCRM-Houston

Genetic Counseling Professional
Group

RTM07
Carrier Risks on ECS: How to Address &
Follow-Up on Them
Amy C. Vance, MS, CGC
Bay Area Genetic Counseling

Society of Reproductive Surgeons

RTM08
Mental Health Professional Group

RTM09
Abortion’s Trickle Down Effect: All Hands
on Deck on the Reproductive Front
Julie Bindeman, PsyD

Integrative Therapy of Greater Washington

Fertility Preservation Special Interest
Group, Society for Assisted Reproductive
Technology and Society for Reproductive
Endocrinology & Infertility

RTM10
Meet the IVM Clinical Expert: “Patient
selection: Who May Benefit from IVM?”
Lan Vuong, MD
University of Medicine and Pharmacy at Ho
Chi Minh City, Vietnam

Androgen Excess Special Interest Group/
AE-PCOS Society

RTM11
PCOS and Long-Term Health
Lidia Minguez-Alacorn, MPH, PhD
Harvard T.H. Chan School of Public Health

Fertility Preservation Special Interest
Group, Society for Assisted Reproductive
Technology and Society of Reproductive
Biologists and Technologists

RTM12
360 Safety AI Management in Cryogenics
Automation: From the Cryo Room into the
Full IVF Lab, All-In-One Lab Management
Tool
Christine Allen, MS, PhD
Elite IVF; NSEB; CryoFuture

Nutrition Special Interest Group

RTM13
Beyond Weight Loss: How to Provide
Weight-Inclusive Nutrition Counseling for
Patients with Infertility
Rachelle Mallik, MA, RD, LDN
The Food Therapist, LLC

Society for Reproductive
Endocrinology & Infertility

RTM14
Varicocelectomy Repair Prior to Assisted
Reproductive Technology: When to
Recommend and Patient Selection
Thomas Masterson, MD
University of Miami Miller School of
Medicine

Advanced Practice Providers Professional
Group and Nurses’ Professional Group

RTM15
APP’s in the REI Setting.
Staci Gorson, BSN, MS, RN
Kindbody

Environment and Reproduction Special
Interest Group

RTM16
What Environmental Exposures Can My
Phone Measure?
Anne Marie Jukic, PhD
The National Institute of Environmental
Health Sciences

Society for Assisted Reproductive
Technology, Society for Male Reproduction
and Urology, Society for Reproductive
Endocrinology & Infertility and Society of
Reproductive Biologists and Technologists

RTM17
Sperm Selection: Is Microfluidics the
Answer?
James Hotaling, MD, MS
University of Utah

Artificial Intelligence Special Interest Group

RTM18
AI-Driven Quality Control and Assurance
Carol Curchoe, PhD, HCLD
CCRM Network-Orange County AIVF

Pediatric and Adolescent Gynecology
Special Interest Group

RTM19
Bricks and Mortar: Helping Teens
Understand and Manage Amenorrhea and
Irregular Menstrual Cycles
Staci Pollack, MD, MS
Albert Einstein College of Medicine

Marissa Weiss, MD, MSC
University of Pennsylvania

Endocrinology & Infertility and Society of
Reproductive Biologists and Technologists

RTM10
Androgen Excess Special Interest Group/
AE-PCOS Society

RTM09
Meet the IVM Clinical Expert: “Patient
selection: Who May Benefit from IVM?”
Lan Vuong, MD
University of Medicine and Pharmacy at Ho
Chi Minh City, Vietnam

Androgen Excess Special Interest Group/
AE-PCOS Society

RTM10
PCOS and Long-Term Health
Lidia Minguez-Alacorn, MPH, PhD
Harvard T.H. Chan School of Public Health

Fertility Preservation Special Interest
Group, Society for Assisted Reproductive
Technology and Society of Reproductive
Biologists and Technologists

RTM11
360 Safety AI Management in Cryogenics
Automation: From the Cryo Room into the
Full IVF Lab, All-In-One Lab Management
Tool
Christine Allen, MS, PhD
Elite IVF; NSEB; CryoFuture

Nutrition Special Interest Group

RTM13
Beyond Weight Loss: How to Provide
Weight-Inclusive Nutrition Counseling for
Patients with Infertility
Rachelle Mallik, MA, RD, LDN
The Food Therapist, LLC

Society for Reproductive
Endocrinology & Infertility

RTM14
Varicocelectomy Repair Prior to Assisted
Reproductive Technology: When to
Recommend and Patient Selection
Thomas Masterson, MD
University of Miami Miller School of
Medicine

Advanced Practice Providers Professional
Group and Nurses’ Professional Group

RTM15
APP’s in the REI Setting.
Staci Gorson, BSN, MS, RN
Kindbody

Environment and Reproduction Special
Interest Group

RTM16
What Environmental Exposures Can My
Phone Measure?
Anne Marie Jukic, PhD
The National Institute of Environmental
Health Sciences

Society for Assisted Reproductive
Technology, Society for Male Reproduction
and Urology, Society for Reproductive
Endocrinology & Infertility and Society of
Reproductive Biologists and Technologists

RTM17
Sperm Selection: Is Microfluidics the
Answer?
James Hotaling, MD, MS
University of Utah

Artificial Intelligence Special Interest Group

RTM18
AI-Driven Quality Control and Assurance
Carol Curchoe, PhD, HCLD
CCRM Network-Orange County AIVF

Pediatric and Adolescent Gynecology
Special Interest Group

RTM19
Bricks and Mortar: Helping Teens
Understand and Manage Amenorrhea and
Irregular Menstrual Cycles
Staci Pollack, MD, MS
Albert Einstein College of Medicine
**Roundtable Discussions**

**Health Disparities Special Interest Group**
**RTM20**  
Cost-Effective Strategies and Alternative Funding Strategies to Expand Reproductive Health Access  
Michael Simoni, MD  
Clinical Fellow, RMA of NJ  

**Legal Professional Group**
**RTM21**  
Navigating Informed Consent in a Post-Dobbs World  
Judith Hoechst, BA, JD, RN, RNC  
KUNIN LAW GROUP  

**Social Media Special Interest Group**
**RTM22**  
Using Social Media to Empower Patients and Dispel Myths  
Lucky Sekhon, MD  
Icahn School of Medicine at Mount Sinai, Reproductive Medicine Associates of New York  

**Fertility Preservation Special Interest Group**
**RTM23**  
Optimizing Fertility Preservation Care in our Most Vulnerable Populations: Care Strategies for our Medically-Compromised, High-Risk, and Very Young Patients  
Kara Goldman, MD  
Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility  

**Association of Reproductive Managers, Genetic Counseling Special Interest Group, Society for Assisted Reproductive Technology and Society for Reproductive Endocrinology & Infertility**
**RTM24**  
Controversies in the use of the PGT-A (SPANISH)  
Armando Roque-Sanchez, MD  
Instituto Nacional de Perinatologia  

**Complementary and Integrative Medicine Special Interest Group**
**RTT01**  
Bearing the Unbearable: Providing Support After Negative Outcomes Using Acupuncture and Integrative Medicine  
Lisa Tongel, MAcOM  
LISA TONGEL ACUPUNCTURE, LLC  

**Advanced Practice Providers Professional Group**
**RTT02**  
Care of the Bleeding OB Patient - Giving Concrete Information and Providing a lot of TLC  
Nicole Callahan, MS, NP  
Mayo Clinic  

**Preimplantation Genetic Testing Special Interest Group**
**RTT03**  
Can Analysis of the Embryo Methylome Give Insights into Embryo Health and Viability?  
Emre Seli, MD  
Yale School of Medicine, IVI RMA New Jersey  

**Preimplantation Genetic Testing Special Interest Group**
**RTT04**  
Mitochondrial Replacement Therapies to Avoid Inherited mtDNA Disorders: Are They Safe and Efficacious?  
Dagan Wells, BSc, PhD  
Juno Genetics  

**Association of Reproductive Managers**
**RTT05**  
The Issue of Supply Chain Management – Finding the Right Balance  
Lindsey McBain, BA  
Reproductive Associates of New Jersey  

**Health Disparities Special Interest Group, Menopause and Ovarian Insufficiency Special Interest Group, Mental Health Professional Group - Scientific Congress, Pediatric and Adolescent Gynecology Special Interest Group, Regenerative Medicine and Stem Cell Biology Special Interest Group and Society for Reproductive Endocrinology & Infertility**
**RTT06**  
Genetic Causes of POI in Adolescents and Fertility Preservation  
Jacqueline Maher, BS, MA, MD  
National Institute of Child Health and Human Development  

**Society for Assisted Reproductive Technology**
**RTT07**  
Submitting a SART CORS Research Proposal: Set Yourself Up for Success  
Jennifer Eaton, MD, MS, MSc  
Warren Alpert Medical School of Brown University; Women & Infants Hospital, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility  

**Access to Care**
**RTT08**  
The Role of Reproductive Surgery in a World of Assisted Reproductive Technology  
Mark Surrey, MD  
Southern California Reproductive Center  

**Mental Health Professional Group**
**RTT09**  
Trainee Access to Fertility Services  
Jennifer Bakkensen, MD  
Northwestern University  

**Turkish Special Interest Group**
**RTT11**  
In vitro Gametogenesis or Making Sperm and Eggs from Skin Cells
Roundtable Discussions

Shoukhrat Mitalipov, PhD
Henry G. Bennett Jr. Fertility Institute
Imaging in Reproductive Medicine Special Interest Group

RTT12
Saline Infusion Sonogram (SIS) or Hysteroscopy for Uterine Cavity Evaluation
Ilan Tur-Kaspa, MD
Institute for Human Reproduction (IHR), Pinnacle Fertility

Society for Assisted Reproductive Technology and Society of Reproductive Biologists and Technologists

RTT13
How to Ace Your ABB TS/HCLD Certification Exam
Marina Gvakharia, PhD
PAMF Fertility Physicians of Northern California

Complex Family Planning Special Interest Group

RTT14
One Year Later: How Has the Dobbs Decision Impacted Fertility Care?
Jessie Hill, JD
Case Western Reserve University School of Law

Endometriosis Special Interest Group

RTT15
Deep Endometriosis Surgery: Aid or Alternative to IVF?
Daniel C. Martin, MD
IRCCS Ospedale Policlinico San Martino

Society for Reproductive Endocrinology & Infertility

RTT16
Moving Beyond “Eat Less, Exercise More”: Obesity Management in Women with Infertility
Samantha Schon, MD, MS
Reproductive Endocrinology and Infertility, University of Michigan

Society of Reproductive Surgeons

RTT17
Taking Operative Hysteroscopy from the OR to the Clinic: Managing Polyps, Fibroids, and Missed Abortion in the Outpatient

Setting
Pietro Bortolotto, MD, MSc
Boston IVF-The Eugin Group

Early Pregnancy Special Interest Group

RTT18
How to Evaluate Recurrent Biochemical Pregnancies?
Randy Morris, MD
IVF1

LGBTQ Special Interest Group and Nurses’ Professional Group

RTT19
Special Reproductive Considerations for the LGTBQ+ Community
Jacalyn Finerty, BA, BSN, MSc, NP
Women & Infants Hospital

Society for Assisted Reproductive Technology, Society for Male Reproduction and Urology, Society for Reproductive Endocrinology & Infertility and Society of Reproductive Biologists and Technologists

RTT20
Sperm DNA Fragmentation: What Do We Really Know and How Do We Use It?
Akanksha Mehta, MD, MS
Early Pregnancy Special Interest Group

RTT21
Individualizing the Care of Recurrent Pregnancy Loss Patients: When Evidence-Based Strategies Aren’t Enough
Rachel Weinerman, MD
University Hospitals Fertility Center/Case Western University

LGBTQ Special Interest Group

RTT22
A History of LGBTQ+ Family Building in the United States
Brent Monseur, MD, ScM
Stanford University School of Medicine

Indian Special Interest Group

RTT23
Combating Recurrent Pregnancy Loss
Nandita Palshetkar, MD
Bloom IVF, Lilavati Hospital & Research Centre

WEDNESDAY, OCTOBER 18, 2023

Advanced Practice Providers Professional Group

RTW01
Multiples Mean Multiple Questions: Key Conversation Points When Diagnosing Twins by Early Ultrasound
Shana Perman, PA-C
Shady Grove Fertility

Preimplantation Genetic Testing Special Interest Group

RTW02
Non-invasive PGT: A Clinically Useful Tool or a Method of Inadequate Accuracy?
Gary Harton, PhD
Progyny, Harton Consulting

RTW03
Latest Understanding of the Incidence and Clinical Relevance of Chromosomal Mosaicism
Manuel Viotti, PhD
Sir Run Run Shaw Hospital, Zhejiang KindLabs (Kindbody)/Zouves Foundation

Association of Reproductive Managers

RTW04
Company Culture – It’s 2023: What’s In and What’s Out
Sara Mooney, BA

Reproductive Immunology Special Interest Group

RTW05
Immunological Testing and Treatment for Recurrent Pregnancy Loss
Joanne Kwak-Kim, MD, MPH, FCRI
Rosalind Franklin University of Medicine and Science, Obstetrics and Gynecology, Clinical Sciences Department

NEW ORLEANS, LOUISIANA | OCTOBER 14-18, 2023
Roundtable Discussions

Society for Assisted Reproductive Technology

RTW06
Lupron Trigger and the End of OHSS
Tarun Jain, MD
Northwestern University Center for Fertility & Reproductive Medicine

Regenerative Medicine and Stem Cell Biology Special Interest Group

RTW07
Artificial Embryo: Technical Advancements and Ethical Challenges
Tiencheng Arthur Chang, PhD., HCLD, ELD
University of Texas Health Science Center

Society for Assisted Reproductive Technology

RTW08
Preimplantation Genetic Testing for Aneuploidy (PGT-A) for Embryos Derived from Donor Oocytes
Nicole Doyle, MD, PhD
Shady Grove Fertility

Genetic Counseling Professional Group

RTW09
The Rise and Fall of Carrier Screenings: Considerations for Clinicians & Gamete Banks
Rawan Awwad, MS, CGC
FairFax EggBank

Mental Health Professional Group

RTW10
Universal Screening or Universal Precaution: Identification and Management of Sexual Assault History in Fertility Clinics
Erika Kelley, PhD
University Hospitals Cleveland Medical Center

Fertility Preservation Special Interest Group and Society for Assisted Reproductive Technology

RTW11
Meet the IVM Embryologist Expert: “How to Set Up an IVM Program in the ART Lab?”
Robert Gilchrist, PhD
School of Clinical Medicine, University of New South Wales Sydney

Society for Assisted Reproductive Technology and Society of Reproductive Biologists and Technologists

RTW12
The Twists and Turns of Your Career in Embryology - How to Navigate Your Path
Darlene Davies, BS

Environment and Reproduction Special Interest Group

RTW13
Reproductive Medicine in the Face of Climate Change
Carmen Messerlian, PhD
Harvard Chan School of Public Health

Endometriosis Special Interest Group

RTW14
Endometriosis and In Vitro Fertilization: Unique Considerations in the Approach to Fertility Treatment
Valerie Flores, MD
Yale School of Medicine

Society for Reproductive Endocrinology & Infertility

RTW15
Building Our Future: Pearls on Starting an REI Fellowship
LaTasha Craig, MD
The University of Oklahoma Health Sciences Center

Turkish Special Interest Group

RTW16
Ovarian Tissue Freezing To Delay Reproductive Aging: Is It Prime Time?
Kutluk Oktay, MD, PhD
Yale University School of Medicine

Society of Reproductive Surgeons

RTW17
Fibroids & Fertility: When to Proceed with Myomectomy Prior to ART and Best Practices for Myomectomy
Michael Neblett, MD
Emory University

Social Media Special Interest Group

RTW18
How to Make an Educational Tiktok or Instagram Reel: Meeting Patients Where They Get Their Reproductive Health Education
Jessica Ryniec, MD

Artificial intelligence Special Interest Group

RTW19
Integration and Use of Artificial Intelligence (AI) in Electronic Health Record (EHR) Systems
Jonas Malmsten, DPS
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine

Access to Care, Society for Assisted Reproductive Technology, Society for Male Reproduction and Urology and Society for Reproductive Endocrinology & Infertility

RTW20
Breaking Down Barriers to the Male Fertility Evaluation in the Reproductive Clinic: Optimizing New Technologies
Natan Bar-Chama, MD
Reproductive Medicine Associates of New York

Early Pregnancy Special Interest Group

RTW21
Defining Chronic Endometritis and How to Treat
Dana McQueen, MD
Northwestern University IVIRMA

Health Disparities Special Interest Group

RTW22
How to Work Up Men with Recurrent Pregnancy Loss?
Winifred Mak, MD, PhD
UT Health San Antonio

LGBTQ Special Interest Group

RTW23
Supporting Transfeminine Patients During the Fertility Preservation Process
Randa Abboud, BS
Northwestern University, Feinberg School of Medicine

Indian Special Interest Group

RTW24
Fertility Preservation in Today’s Era
Madhuri Patil, MBBS, MD
Dr.Patil’s Fertility & Endoscopy Clinic
The Advocacy in Action fund supports ASRM’s Office of Public Affairs and its efforts to promote policies that uphold reproductive health and rights. In the first half of 2023 alone, we sent letters to 49 Statehouses, signed-on to 23 federal coalition letters, signed on to 5 Amicus briefs, and endorsed 9 Federal bills! Learn more at asrm.org.

Tuesday, October 17, 2023
Benefiting the ASRM Advocacy in Action Fund
Scan the QR code below to make a Giving Day donation, which supports ASRM’s Advocacy in Action Fund.

About ASRM’s Advocacy and Policy Work
The Advocacy in Action fund supports ASRM’s Office of Public Affairs and its efforts to promote policies that uphold reproductive health and rights. In the first half of 2023 alone, we sent letters to 49 Statehouses, signed-on to 23 federal coalition letters, signed on to 5 Amicus briefs, and endorsed 9 Federal bills! Learn more at asrm.org.
New to ASRM 2023: Unleash the activist within you by visiting our four Advocacy stations during the Congress on Tuesday, October 17! Here’s what’s in store:

**STATION 1**

HEAR FROM EXPERT ADVOCATES ALL DAY LONG! Step up to our soapbox and immerse yourself in dynamic, bite-sized presentations from invited experts throughout the day. Gain valuable insights on topics relevant to your practice and patients, fueling your passion for advocacy.

**STATION 2**

SIGN OUR ASRM 2023 SIGNATURE WALL! Proudly leave your mark by signing your name, organization, or a meaningful message. Capture the moment with social media-worthy photos, becoming part of the living timeline of ASRM 2023.

**STATION 3**

GET LOCAL! Discover the power of local advocacy as our experts guide you in locating and contacting your local and national elected officials. Embrace your role as a change-maker for reproductive health providers and engage in meaningful, community-based advocacy.

**STATION 4**

GET LOUD! Raise your voice with ease at our letter-writing and voter registration booth. Verify your voter registration and access practical examples to communicate with your elected officials effectively. Leave equipped and ready to make a difference.

Join us in this transformative journey of education, empowerment, and activism. Because together, we will shape a brighter future for reproductive health!
瞩目了，这是一项十分重要的工作。
### VIDEO SESSIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
<th>Organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:24 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:29 AM</td>
<td>V-9 AUTOMATED DISH PREPARATION SYSTEM FOR IVF AND EMBRYO CULTURE</td>
<td>Yan Zhu, PhD, Huai L. Feng, DPhil, MD, PhD, and Manxi Jiang, PhD</td>
<td>(1) Guangdong Province Second General Hospital, Guangzhou, China, (2) New York Fertility Center affiliated with Queens Hospitals, New Hyde Park, NY, (3) Center for Reproductive Medicine, Guangdong Province Second General Hospital, Guangzhou, China</td>
</tr>
<tr>
<td>11:31 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:36 AM</td>
<td>V-10 “CAN’T TOUCH THIS!”: LAPAROSCOPIC MANAGEMENT OF AN OBSTRUCTED UTERUS DIDELPHYS BEFORE AND AFTER TREATMENT FOR PELVIC INFLAMMATORY DISEASE</td>
<td>Shelun Tsai, MD, Phillip A. Romanski, MD, MSc, Pietro Bortoletto, MD, MSc, and Samantha M. Pfeifer, MD</td>
<td>(1) Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY, (2) Shady Grove Fertility, New York, NY, (3) Arlington, MA, (4) Weill Medical College of Cornell University, New York, NY</td>
</tr>
<tr>
<td>11:43 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:48 AM</td>
<td>V-11 A HIGH-RISK PREGNANCY IN A PATIENT WITH SWYER SYNDROME: A CASE REPORT AND REVIEW OF THE LITERATURE</td>
<td>Annalyn Welp, MD, Marissa H Rayner, BS, Rebecca Rieck, MD, and Linnea R. Goodman, MD</td>
<td>(1) University of Virginia Medical Center, Charlottesville, VA, (2) Charlottesville, VA, (3) University of Virginia, Charlottesville, VA, (4) VA Fertility and IVF, Charlottesville, VA</td>
</tr>
<tr>
<td>11:56 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:01 PM</td>
<td>V-12 TRANSMYOMETRIAL EMBRYO TRANSFER (TMET) IN A PATIENT WITH A HISTORY OF RADICAL TRACHELECTOMY</td>
<td>Claire Jones, BSc, MD, Justin Tan, BSc, MD, MPH, Pat Chronis-Brown, BSc, MSc, and Nigel Pereira, MD</td>
<td>(1) Mount Sinai Fertility, Sinai Health System, Toronto, ON, Canada, (2) Mount Sinai Fertility, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>

---

**Thank you to the following for in-kind educational support of the ASRM 2023 Hands-On Courses**

- Cooper Surgical Companies
- GE Healthcare
- Hologic
- Karl Storz Endoscopy USA
- LiNA Medical
## 2023 Scientific Congress Prize Paper Session (1 of 2)

The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the 2023 Scientific Congress Prize Paper (2 of 2) session Monday from 1:30 PM - 2:45 PM. 

**Moderator:** Ruben Alvero, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-1 Clinical Evaluation of a Machine Learning Model for Embryo Selection: A Double-Blinded Randomized Comparative Reader Study</td>
<td>Oleksii O. Barash, PhD</td>
</tr>
<tr>
<td>10:56 AM</td>
<td>O-2 Reduced Smoking Attenuates the Effect of Genetic Predisposition on Premature Ovarian Aging: A Large Population-Based Longitudinal Study</td>
<td>Runxin Gan, MD</td>
</tr>
<tr>
<td>11:07 AM</td>
<td>O-3 Determination of Ploidy Level Integrated into the Common Preimplantation Genetic Testing for Aneuploidy (PGT-A) and Association with the Pronuclei Number</td>
<td>Natalia Cagnin, PhD</td>
</tr>
<tr>
<td>11:18 PM</td>
<td>O-4 Good Obstetrical Outcome Is Compromised in Pregnancies Resulting from Single Frozen-Thawed Euploid Embryo Transfers (FET) in Women With PCOS</td>
<td>Satu Kuokkanen, MD</td>
</tr>
<tr>
<td>11:29 AM</td>
<td>O-5 Method of Spermatozoa Recovery Does Not Correlate with Embryonic Mosaicism in Patients With Severe Male Factor Infertility</td>
<td>Tamar Alkon-Meadows, MD</td>
</tr>
</tbody>
</table>

---

## OSM-02 Art Lab 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-7 Microfluidic Sperm Selection (MFSS) Improves Euploidy Rates Compared to Density Gradient Centrifugation (DGC) Across a Broader Patient Population That Utilized Intracytoplasmic Sperm Injection (ICSI)</td>
<td>Mary C. Mahony, PhD</td>
</tr>
<tr>
<td>10:56 AM</td>
<td>O-8 Change in Embryo Score Post Cryopreservation and Embryo Transfer Success Rates</td>
<td>Keri Bergin, BS, MD</td>
</tr>
<tr>
<td>11:07 PM</td>
<td>O-9 Low Anti-Müllerian Hormone (AMH) Significantly Related to Low Number of Total Blastocysts and Low Number of Euploid Blastocyst Development</td>
<td>Samuel Yongxin Sun, PhD</td>
</tr>
<tr>
<td>11:18 AM</td>
<td>O-10 Does Microfluidic-Based Semen Processing Improve the Functional Quality of Recovered Sperm?</td>
<td>Amanda das Neves Ribeiro, BSc</td>
</tr>
<tr>
<td>11:29 AM</td>
<td>O-11 Sperm Cryopreservation Is Associated with an Increased Incidence of Abnormally-Fertilized Embryos in In Vitro Fertilization Cycles (IVF) Using Intracytoplasmic Sperm Injection (ICSI)</td>
<td>Alvin To, MD, MPh</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>O-12 The Assessment of Sperm Retrieval Rates and Clinical Outcomes with Testicular Sperm Extraction with Respect to the Etiology of Azoospermia</td>
<td>Yuka Iwamoto, BS</td>
</tr>
<tr>
<td>11:51 AM</td>
<td>O-13 Use of Calcium Ionophore Oocyte Activation Post-ICSI Results in Higher Blastocyst Formation</td>
<td>Julia G Kim, MD, MPh</td>
</tr>
<tr>
<td>12:02 PM</td>
<td>O-14 Blastocyst Diameter and Inner Cell Mass Area As Embryo Parametersto Predict Blastocyst Quality and Pregnancy</td>
<td>Marta Ribeiro Hentschke, MD, PhD</td>
</tr>
</tbody>
</table>

---

## OSM-03 Fertility Preservation - Infertility & Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-15 Variations in Approaches to Sperm Banking in Adolescent Boys With Can-</td>
<td></td>
</tr>
</tbody>
</table>
CER: A MIXED METHODS STUDY Gwendolyn P. Quinn, PhD, BS, MS

10:56 AM O-16 BEST PRACTICES FOR SPERM CRYOPRESERVATION PRIOR TO GONADOTOXIC TREATMENT: RECOMMENDATIONS FROM LEADERS IN FERTILITY PRESERVATION James F. Smith, MD, MS

11:07 AM O-17 SHORT-TERM ORAL SUPPLEMENTATION WITH NICOTINAMIDE MONONUCLEOTIDE RESTORES OOCYTE QUALITY IN CHEMOTHERAPY-INDUCED OVARIAN DAMAGE MOUSE MODELS Sonia Herraiz, PhD

11:18 AM O-18 OPTIMIZING THE TESTIS TISSUE CULTURE POST CYCLOPHOSPHAMIDE TREATMENT BY COMBINED ANTIOXIDANT SUPPLEMENTS Amirhesam Eskafinoghani, PhD

11:29 AM O-19 THE LANDSCAPE OF ONCOFERTILITY NAVIGATORS IN NORTH AMERICA Kristin N. Smith, BS

11:40 AM O-20 ASSOCIATION OF GERMLINE PATHOGENIC VARIANTS WITH ANTI-MÜLLERIAN HORMONE LEVELS IN YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE, PAN-CANADIAN STUDY Kimia Sorouri, MD, MPh

11:51 AM O-21 THE EFFECTS OF THE BRCA1 AND 2 MUTATIONS ON OVARIAN RESERVE AND AGING Karine Matevossian, DO

12:02 PM O-22 CUMULATIVE LIVE-BIRTH RATE AFTER OOCYTE VITRIFICATION FOR FERTILITY PRESERVATION (FP) IN ONCOLOGIC OR BENIGN CONDITIONS: A RETROSPECTIVE COMPARATIVE MONOCENTRIC STUDY Judith Dreyfuss, MD

OSM-04 Reproductive Justice

10:45 AM O-23 LEGAL AND ETHICAL IMPLICATIONS OF ASSISTED REPRODUCTIVE TECHNOLOGY IN THE POST-DOBBS ERA Melody A. Rasouli, MD MBA

10:56 AM O-24 ANALYSIS OF U.S. ALLOPATHIC AND OSTEOPATHIC MEDICAL SCHOOLS’ OFFICIAL STATEMENTS CONCERNING DOBBS V. JACKSON WOMEN’S HEALTH ORGANIZATION Carmen Conroy, BA

11:07 AM O-25 DOES RESTRICTIVE ABORTION LEGISLATION RELY ON INACCURATE AND MISLEADING ANATOMICAL, EMBRYOLOGICAL, AND MEDICAL INFORMATION? Rachel N Feltman, BS

11:18 AM O-26 INFERTILITY PATIENT REACTIONS TO THE DOBBS DECISION ON SOCIAL MEDIA Claire M Schenken, BS, MPh

11:29 AM O-27 THE FATE OF SUPERNUMERARY CRYOPRESERVED EMBRYOS: INSIGHTS INTO THE PATIENT DECISION-MAKING PROCESS Valeriya Prytkova, BS

11:40 AM O-28 CHANGE IN EMBRYO DISPOSITION PREFERENCES OF SUPERNUMERARY EMBRYOS FROM THE INITIAL CONSENT FORM TO THE FINAL DISPOSITION DECISION Caroline Cherston, MD

11:51 AM O-29 THE LEGAL LANDSCAPE OF REPRODUCTION IN THE WAKE OF DOBBS V JACKSON WOMEN’S HEALTH ORGANIZATION Elena Hogenesch, MD

12:02 PM O-30 POLYGENIC EMBRYO SCREENING: PATIENT INTEREST AND CLINICIAN RESERVATIONS Dorit Barlevy, PhD

OSM-05 Special Populations

10:45 AM O-31 BREAKING DOWN BARRIERS FOR SAME SEX FEMALE COUPLES BUILDING FAMILIES: IN VITRO FERTILIZATION UTILIZATION SINCE THE ENACTMENT OF 2021 NEW YORK STATE LEGISLATION Samantha Lauren Estevez, MD

10:56 AM O-32 A DECADE OF OOCYTE CRYOPRESERVATION FOR TRANSMASCULINE AND NONBINARY AFAB (ASSIGNED FEMALE AT BIRTH) INDIVIDUALS: EXPERIENCES FROM A HIGH-VOLUME FERTILITY PRESERVATION PROGRAM Sarah Capelouto Cromack, MD

11:07 AM O-33 SHORT- AND LONG-TERM TESTOSTERONE TREATMENT INDUCE REVERSIBLE SUBFERTILITY IN A MOUSE MODEL OF GENDER-AFFIRMING HORMONE THERAPY Daniel Pfau, PhD

11:18 AM O-34 DECISIONAL REGRET REGARDING PREOPERATIVE FERTILITY PRESERVATION CHOICES FOLLOWING GENDER-AFFIRMING SURGERY AMONG TRANSGENDER MEN/GENDER NON-BINARY PERSONS Austin Johnson, MD

11:29 AM O-35 SPERM BANKING FOR TRANSFEMININE/ NONBINARY AMAB (ASSIGNED MALE AT BIRTH) PATIENTS: A REVIEW OF TRENDS FROM 2016-2022 AT AN ACADEMIC FERTILITY PRESERVATION PROGRAM Sarah Capelouto Cromack, MD

11:40 AM O-36 ARTIFICIAL REPRODUCTIVE TECHNOLOGY IN TRANSGENDER MEN AND CISGENDER WOMEN: DOES TESTOSTERONE ADMINISTRATION BEFORE OVARIAN STIMULATION HAVE AN IMPACT ON IVF EMBRYOLOGICAL AND CLINICAL
OUTCOMES?
Mireia Florensa Bargallo, MSc

11:51 AM O-37 SEXUAL ORIENTATION AFFECTS EVALUATION AND INTRAUTERINE INSEMINATION SUCCESS RATES: EVIDENCE FOR SYSTEMIC BIAS Ella M. Berger

12:02 PM O-38 QUEER REPRODUCTIVE HEALTH – BARRIERS AND FACILITATORS TO QUALITY CARE Jacquelyn Shaw, MD

OSM-06 Mental Health 1

11:45 AM O-39 NOW WHAT? DONOR-CONCEIVED ADULT FEELINGS AND CHOICES AFTER LEARNING THE DONOR’S IDENTITY THROUGH AN OPEN-IDENTITY PROGRAM Joanna Scheib, PhD

11:56 AM O-40 UNDERSTANDING ANXIETY AND DEPRESSION BEFORE A DIAGNOSIS OF INFERTILITY Wael H. Salem, MD, MPhil

OSM-07 Nursing 1

11:45 AM O-41 A FIRST LOOK AT PARENTS SEQUENTIAL DECISIONS WHEN CO-CREATING A TELLING PLAN TO INFORM THEIR DONOR CONCEIVED CHILDREN ABOUT THEIR BIRTH ORIGINS: RESULTS FROM THE TELL TOOL INTERVENTION TRIAL Patricia Hershberger, PhD, RN, FNP-BC, FAAN

11:56 AM O-42 ASSOCIATIONS OF INFERTILITY WITH SYMPTOMS OF PREGNANCY-RELATED ANXIETY AND DEPRESSION DURING PREGNANCY AND 6-MONTHS POSTPARTUM Melissa Perez Capotosto, PhD, RN, WHNP-BC

Monday, October 16, 2023

1:30 PM - 2:45 PM

2023 SCIENTIFIC CONGRESS PRIZE PAPER SESSION (2 OF 2)

These papers are candidates for the ASRM Scientific Congress Prize Paper Awards.
Moderator: Ruben Alvero, MD

1:30 PM O-43 ALTERED ICM TRANSCRIPTION IN APA-DERIVED BLASTOCYSTS HIGHLIGHT THE SUSCEPTIBILITY OF THE FUTURE FETUS TO ADVERSE HEALTH OUTCOMES Blair R. McCallie, PhD

1:41 PM O-44 PLATELET-RICH PLASMA AND COLONY-STIMULATING FACTOR ARE NON SUPERIOR TO PLACEBO IN IMPROVING ENDOMETRIAL QUALITY DURING FROZEN EMBRYO ICSI CYCLES - A DOUBLE-BLIND RCT.” Wael Saad Elbanna, MBBCH, MSc

1:52 PM O-45 A NATIONWIDE ASSESSMENT OF PERMANENT CONTRACEPTION TRENDS IN RELATION TO CHANGES IN ABORTION LAWS Jessica Schardin, MD, MS

2:03 PM O-46 DIFFERENTIATION OF PUTATIVE MALE GAMETES FROM MOUSE EMBRYONIC STEM CELLS (mESC) ENCAPSULATED IN CALCIUM ALGINATE SPHERES Philip Xie, BSc

2:14 PM O-47 ASSESSING THE RISK-BENEFIT OF MOSAIC EMBRYO TRANSFERS USING 3,500+ CLINICAL OUTCOME DATAPOINTS Manuel Viotti, PhD

2:25 PM O-48 FERTILITY TREATMENT IS ASSOCIATED WITH AN INCREASE IN ADVERSE MATERNAL OUTCOMES ACROSS RACIAL AND ETHNIC POPULATIONS Sara Phillips, MD, MPH
OSM-09 Genetics- Genetic Counseling
1:30 PM O-49 IMPACT OF ANEUPLOIDY ON REPRODUCTIVE SUCCESS IN A POPULATION OF YOUNGER INFERTILE WOMEN: PROSPECTIVE INTENT TO TREAT ANALYSIS. Carly Peterson, MS, CGC

1:41 PM O-50 SINGLE THAWED NON-MOSAIC SEGMENTAL ANEUPLOID EMBRYO TRANSFER RESULTS IN ONGOING PREGNANCY AND NORMAL PRENATAL DIAGNOSIS. Julia Buldo-Licciardi, MD

1:52 PM O-51 INSIGHTS INTO GENETIC COUNSELORS (GCS) IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CLINICS IN THE UNITED STATES: A SURVEY STUDY ON PRACTICES, RESPONSIBILITIES AND BILLING STRATEGIES. Amber Gamma, BSc, MS

2:03 PM O-52 PREIMPLANTATION GENETIC TESTING AND PLACENTAL ABNORMALITIES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Isaac J. Chamani, MD

2:14 PM O-53 MODELING-BASED GENETIC COUNSELING FOR MITOCHONDRIAL DNA DISEASES. Dongmei Ji, doctor

2:25 PM O-54 PARENTAL ORIGIN OF SEGMENTAL ANEUPLOIDY IN HUMAN BLASTOCYSTS. Diego Marin, PhD

OSM-10 Patient Centric
1:30 PM O-55 TWO CASES OF OVARIAN TORSION AFTER CONTROLLED OVARIAN HYPERSTIMULATION (COH) CYCLES WITH A PROLONGED RECOVERY STATE (PRS). Alyson Dennis, BA

1:41 PM O-56 BLACK FERTILITY MATTERS TOO: COMMUNITY CENTERED SEMINARS IMPROVE FERTILITY KNOWLEDGE. Alexis Brooke Hood, MD

1:52 PM O-57 THE MOST USED AND THE TOP RATED FERTILITY APPLICATIONS AROUND THE WORLD: DO THEY HAVE AN OFFICIAL APPROVAL? Mariam Barsaghyan, MD, MSc

2:03 PM O-58 RANDOMIZED CONTROLLED TRIAL OF A VIDEO-BASED EDUCATIONAL PLATFORM PRIOR TO IN-PERSON VASECTOMY CONSULT. Solomon Hayon, MD

2:14 PM O-59 RE-USE OF DISPOSABLE SPECULA: A PATIENT PREFERENCE AND EXPERIENCE STUDY. Felicia von Von Estorff, Medical student

2:25 PM O-60 LACK OF ADEQUATE COUNSELING ABOUT PREGNANCY COMPLICATIONS IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS). Anne E. Kim, MD

OSM-11 Complex Family Planning
1:30 PM O-61 PELVIC INFECTION RISK AFTER INSERTION OF A NOVEL LOW-DOSE COPPER IUD WITH A FLEXIBLE NITINOL FRAME IN PARTICIPANTS WITH A HISTORY OF CHLAMYDIA TRACHOMATIS (CT) OR NEISSERIA GONORRHOEAE (NG). David K. Turok, MD, MPH

1:41 PM O-62 UNINTENDED CONSEQUENCES OF THE ANTI-ABORTION MOVEMENT AND ITS EFFECT ON FERTILITY COUNSELING AND RECOMMENDATIONS: A NATIONAL SURVEY OF FERTILITY SPECIALISTS. Aileen Portugal, MD

1:52 PM O-63 DOCUMENTATION OF CONTRACEPTIVE AND HPV VACCINATION COUNSELING AND USE IS LOW IN YOUNG ADULT SURVIVORS OF PEDIATRIC CANCER. Jenna Reich, MD

2:03 PM O-64 HYPERGLYCOXYLATED HUMAN CHORIONIC GONADOTROPIN (H-HCG) AS AN EARLY PREDICTOR OF BIOCHEMICAL AND CLINICAL PREGNANCY LOSS: A PROSPECTIVE ANALYSIS OF SINGLE, EUPLOID, FROZEN EMBRYO TRANSFERS. Andres Reig, MD

2:14 PM O-65 COMPARISON OF OOCYTE CRYOPRESERVATION RETRIEVAL OUTCOMES AMONG PATIENTS WITH PROGESTIN-SECRETING, COPPER, OR NO INTRAUTERINE DEVICE. Haggag Zoe Aspitz, MD, BS

2:25 PM O-66 CHARACTERIZING SERUM HUMAN CHORIONIC GONADOTROPIN (HCG) RISE PARADIGM IN THE SETTING OF SINGLE, EUPLOID, FROZEN EMBRYO TRANSFER (FET) PREGNANCIES FROM 3,543 PREGNANCIES. Stephanie Willson, MD

OSM-12 Male Reproduction and Urology
1:30 PM O-67 SPERM MESODERM SPECIFIC TRANSCRIPT GENE METHYLATION STATUS IN INFERTILE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Rossella Cannarella, MD, PhD

1:41 PM O-68 VARIABILITY IN SELF-PAY PRICING FOR VASECTOMY AMONG UNITED STATES HOSPITALS. Aaron Brant, MD

1:52 PM O-69 ORAL PREDNISONE AS A RESCUE INTERVENTION FOR DETERIORATING SPERM PARAMETERS FOLLOWING 78
ORAL ABSTRACTS

VASOVASOSTOMY Nicholas Deebel, MD
2:03 PM O-70 QUANTIFICATION OF GENETIC VARIANTS IN SPERM AFTER RADIO FREQUENCY ELECTROMAGNETIC RADIATION (RF-EMR) EXPOSURE Joginder Bidhan, MS
2:14 PM O-71 ADOLESCENT VARICOCELECTOMY IMPROVES Matheus Ferreira Gröner, MD

Monday, October 16, 2023

OSM-13 Professional Development
3:30 PM O-72 THE OBGYN RESIDENT EXPERIENCE IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY: A SURVEY OF OBGYN RESIDENTS AND RECENT GRADUATES Kaitlin A. Doody, MD
3:41 PM O-73 HOW SHOULD WE MEET THE INCREASING NEED FOR FERTILITY SERVICES? Elizabeth Clain, MD
3:52 PM O-74 ATTITUDES AMONG 2023 UROLOGY RESIDENCY APPLICANTS REGARDING DOBBS V. JACKSON WOMEN’S HEALTH ORGANIZATION Sophie Kauderer, MPH
4:03 PM O-75 A CASE-BASED EDUCATION APPROACH TO MENSTRUAL CYCLE PHYSIOLOGY FOR OB/GYN RESIDENTS Molly S. Kornfield, MD
4:14 PM O-76 A SURVEY STUDY TO ASSESS THE IMPACT OF ROE V. WADE REVERSAL ON REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWS Katherine E. Kostroun, MD
4:25 PM O-77 DIVERSIFYING THE FUTURE: ANALYZING REI FELLOWSHIP WEBSITES AND THEIR DIVERSITY STATEMENTS IN COMPARISON TO OTHER OBGYN FELLOWSHIPS Karissa Rajagopal, DO

OSM-15 Fertility Preservation- General 1
3:30 PM O-84 FROZEN PERKS: HOW RESIDENCY EMPLOYER COVERAGE OF EGG FREEZING AFFECTS MEDICAL STUDENTS’ PERCEPTIONS AND RANK LISTS Alexie Lessing, BA
3:41 PM O-85 PAUSING THE PILL: TAKING A BREAK FROM ORAL CONTRACEPTIVE PILLS (OCP) BEFORE FERTILITY PRESERVATION (FP) DOES NOT IMPACT THE METAPHASE II OOCYTE (M2) YIELD Sarah D Cascante, MD, BA
3:52 PM O-86 ROBUST AND SIMPLE IN VITRO MATURATION OF OVARIAN TISSUE OOCYTES Sherman Silber, MD
4:03 PM O-87 HOW MANY FROZEN EGGS DO I NEED TO GET ONE EUPLOID EMBRYO? AN ANALYSIS OF 450 AUTOLOGOUS OOCYTE THAW PATIENTS Shilpa Kalluru, MD, MPH
4:14 PM O-88 AMH ACTIVITY IS MEDIATED BY AMHR2-LOCALIZED IN FIBROBLASTS OF OVARIAN STROMA. NOVEL RESULTS OF HUMAN AND MOUSE STUDY Itay Spektor, Dr
4:25 PM O-89 PATIENT CHARACTERISTICS, TRENDS AND PREDICTIVE FACTORS ASSOCIATED WITH DECISION OUTCOMES OF PATIENTS SEEKING PLANNED OOCYTE CRYOPRESERVATION (POC) BEFORE/DURING THE COVID-19 PANDEMIC AT AN IVF CENTER Rima Kharonsky, NP, MN
OSM-16 Recurrent Pregnancy Loss 1

3:30 PM  O-90 AN ANALYSIS OF RECURRENT BIOCHEMICAL PREGNANCY LOSS AS IT COMPARES TO CLINICAL PREGNANCY LOSS IN EUPLOID VERSUS UTESTED FROZEN EMBRYO TRANSFERS (FETs) Cheri K Margolis, MD

3:41 PM  O-91 RESTORING THE DELICATE IMMUNOLOGICAL BALANCE AT THE TIME OF IMPLANTATION MAY IMPROVE OUTCOMES FOR RECURRENT MISCARRIAGE AND REPEATED IMPLANTATION FAILURE Mandy Katz-Jaffe, PhD

3:52 PM  O-92 NEONATAL OUTCOMES OF PATIENTS WITH RECURRENT PREGNANCY LOSS UNDERGOING FROZEN EMBRYO TRANSFER: A SART CORS STUDY Virginia-Arlene Acosta Go, MD

4:03 PM  O-93 THE INFERTILE FEMALE WITH A HISTORY OF RECURRENT IMPLANTATION FAILURE AND RECURRENT MISCARRIAGE HAS LACKED DYNAMIC CHANGES AND NETWORK WITH IMMUNE MARKERS DURING THE MENSTRUAL CYCLE Kiyotaka Kawai, MD, PhD

4:14 PM  O-94 COVID-19 INFECTION AND RECURRENT PREGNANCY LOSS: A RETROSPECTIVE COHORT STUDY Bao Quoc Nguyen, MD

4:25 PM  O-95 MAINTAINING THE IMMUNE EQUILIBRIUM: THE DYNAMIC INTERACTION OF PHOSPHOGLYCERATE KINASE 1 AND INTER-TRYPSIN INHIBITOR HEAVY CHAIN 4 IN MODULATING CYTOKINE BALANCE Kwang-Hyun Baek, PhD

OSM-17 Non-ART Artificial Intelligence

3:30 PM  O-96 APPLYING ARTIFICIAL INTELLIGENCE (AI) TO EMBRYOS: CAN A DEEP LEARNING ALGORITHM PREDICT THE CHROMOSOMAL STATUS OF AN EMBRYO? Carla Gimenez-Rodriguez, PhD Student

3:41 PM  O-97 SIMULATED COHORT ANALYSES SHOWED THAT AN AUTOMATIC ARTIFICIAL INTELLIGENCE (AI) SCORE REDUCED THE NUMBER OF CYCLES NEEDED TO ACHIEVE LIVE BIRTH AND INCREASED THE FIRST-CYCLE SUCCESS RATES Carla Gimenez-Rodriguez, PhD Student

3:52 PM  O-98 TESTING THE ABILITY OF AN ARTIFICIAL INTELLIGENCE (AI) ALGORITHM IN PREDICTING IMPLANTATION AND ONGOING PREGNANCY POTENTIAL OF VITRIFIED-WARMED BLASTOCYSTS FROM A SINGLE IMAGE Lucia Murria, PhD Student

4:03 PM  O-99 OPTIMIZING WORKLOAD BY BALANCING ANTAGONIST PROTOCOL RETRIEVALS USING ARTIFICIAL INTELLIGENCE ALGORITHM FOR ANTAGONIST TRIGGER DAY DECISION Ariel Hourvitz, MD

4:14 PM  O-100 ROBUST CLASSIFICATION OF MAMMALIAN EMBRYOS AND OOCYTES BASED ON LABEL-FREE HYPERSPECTRAL IMAGING AND ARTIFICIAL INTELLIGENCE Samuel Ojosnegros, PhD

4:25 PM  O-101 ARTIFICIAL INTELLIGENCE OOCYTE IMAGE ANALYSIS PREDICTS FERTILIZATION, BLASTOCYST DEVELOPMENT, AND LIVE BIRTH OUTCOMES PER COHORT Lucía Murria, PhD Student

Tuesday, October 17, 2023

OST-01 Pre-Clinical & Basic Research- Animal & Experimental

10:45 AM O-102 HARNESING FUNCTIONAL AND MOLECULAR ASYMMETRY DURING EX VIVO OVULATION FOR NON-HORMONAL CONTRACEPTIVE DISCOVERY Emily Zaniker, BA

10:56 AM O-103 MATERNAL CXXCR4 DELETION RESULTS IN PLACENTAL DEFECTS AND PREGNANCY LOSS MEDIATED BY IMMUNE DYSREGULATION Fang Lyu, PhD

11:07 PM O-104 SINGLE CELL TRANSCRIPTOMICS REVEALS CELL POPULATIONS WITH UNIQUE MOLECULAR IDENTITIES OVER THE TIME COURSE OF OVULATION IN VIVO Caroline E. Kratka, BA

11:18 AM O-105 CAN IL-22 POTENTIATE SECONDARY...
ORAL ABSTRACTS

INFERTILITY TREATMENT BY ITS REGENERATIVE POWER? Amanda das Neves Ribeiro, BSc

11:29 AM O-106 VARICOCELE INDUCTION DIRECTLY ALTERS THE TESRICULAR AND EPIDIDYMAL MICROBIOME IN A RODENT MICROSURGICAL MODEL Paul J. Oh, MD

11:40 AM O-107 OVARIAN SUPPORT CELLS DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS ALLOW IN VITRO MATURATION OF OOCYTES AND EMBRYO DEVELOPMENT IN A MOUSE MODEL Christian Kramme, BS, PhD

11:51 AM O-108 CHRONIC ORAL EXPOSURE TO BONNY LIGHT CRUDE OIL (BLCO) AFFECTS ESTRUS CYCLE, REPRODUCTIVE HORMONES AND ORGANS IN FEMALE WISTAR RATS Louis C. C. Ajonuma, MD, PhD

12:02 PM O-109 LPS-INDUCED INFLAMMATION DIFFERENTIALLY MODULATES IMPLANTATION FAILURE AND PROGESTERONE REGULATION IN WILD-TYPE (WT) AND PROGESTERONE RECEPTOR B- KNOCKOUT (PRBKO) MICE Rebecca K. Chung, MD

OST-02 Fertility Preservation- General 2

10:45 AM O-110 SEVEN-YEAR FOLLOW-UP OF PLANNED OOCYTE CRYOPRESERVATION OF WOMEN WITH DIMINISHED OVARIAN RESERVE AND/OR ADVANCED AGE: RETURN RATES AND CYCLE OUTCOMES Aylin P. Cil, MD

10:56 AM O-111 SPIRONOLACTONE USE AND OOCYTE MATURATION IN PATIENTS UNDERGOING OOCYTE CRYOPRESERVATION Caroline Gellman, MD

11:07 PM O-112 CAN OVARIAN TISSUE CRYOPRESERVATION DELAY MENOPAUSE IN HEALTHY WOMEN? A MATHEMATICAL MODELING ANALYSIS Joshua Johnson, PhD

11:18 AM O-113 INVESTIGATING THE ROLE OF PI3K/AKT MEDIATED OVARIAN FOLLICLE DEPLETION IN CLASSIC GALACTOSEMIA Taylor Badger, BS

11:29 AM O-114 OOCYTE CRYOPRESERVATION ON TIKTOK AND INSTAGRAM: WHO IS TEACHING WHOM? Alexandra Herweck, MD, MPH

11:40 AM O-115 DOES BODY MASS INDEX EFFECT ELECTIVE FERTILITY PRESERVATION OUTCOMES? A 2016-2020 NATIONAL STUDY OF OVER 39,000 CYCLES Karine Matevossian, DO

11:51 AM O-116 ADVANCED MATERNAL AGE WOMEN EXPERIENCE FAVORABLE CLINICAL OUTCOMES UPON RETURNING FOR TREATMENT FOLLOWING AUTOLOGOUS OOCYTE VITRIFICATION FOR NON MEDICAL FERTILITY PRESERVATION Keelee J. McCarty, PhD

12:02 PM O-117 FIRST OVARY ALLOTRANSPLANT TO A TURNER’S SYNDROME PATIENT: IMMUNOSUPPRESSION AND IVM Sherman Silber, MD

OST-03 Genetics- PGT 1

10:45 AM O-118 COMPARISON OF LOW PASS NEXT GENERATION SEQUENCING AND HIGH-THROUGHPUT SNP ARRAY BASED PGT-A Diego Marin, PhD

10:56 AM O-119 NONINVASIVE PRENATAL TESTING (NIPT) AFTER EUPLOID EMBRYO TRANSFER SHOWS HIGH CONCORDANCE WITH PGT-A RESULTS AND LOW NIPT PREDICTIVE VALUES Mitko Madjunkov, MD

11:07 PM O-120 VALIDATION OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) USING TARGETED NEXT GENERATION SEQUENCING Vanessa Guo, BS

11:18 AM O-121 COMPARISON OF PREGNANCY OUTCOMES BETWEEN SINGLE-BIOPSIED AND REBIOPSIED EUPLOID EMBRYOS Rebecca Zhuo, MD

11:29 AM O-122 TROPHECTODERM BIOPSY HAS NO DISCERNIBLE EFFECT ON BIRTHWEIGHT OR GESTATIONAL AGE AT BIRTH: A MATCHED STUDY OF SINGLETON BIRTHS Carrie E. Bedient, MD

11:40 AM O-123 HOW DO DIFFERENT CUT-OFFS FOR Mosaicism AFFECT CLINICAL OUTCOMES OF PGT-A? Murat Cetinkaya, MD, PhD

11:51 AM O-124 PGT-M FOR DE NOVO VARIANTS: DELETION BREAKPOINT SEQUENCING Avner Hershlag, MD

12:02 PM O-125 INNER CELL MASS QUALITY DETERMINES THE DEVELOPMENTAL POTENTIAL OF EUPLOID EMBRYOS Rina Abramov, MSc

OST-04 Infertility- Diagnosis & Treatment 1

10:45 AM O-126 INTRAUTERINE INSEMINATION (IUI): MORE IS NOT ALWAYS BETTER Quetrell Heyward, MD, MBA

10:56 AM O-127 LEVERAGING ELECTRONIC MEDICAL RECORDS REVEALS COMORBIDITIES SIGNIFICANTLY ASSOCIATED WITH MALE INFERTILITY Sarah Woldemariam, PhD
ORAL ABSTRACTS

11:07 AM O-128 FERTILITY SUPPLEMENTS: AN ANALYSIS OF MOST COMMON INGREDIENTS Nicholas Stansbury, MD

11:18 AM O-129 QUALITY AND ACCESSIBILITY OF CONSUMER INFORMATION FOR COMMERCIALIZED AVAILABLE AT-HOME AND MAIL-IN SEMEN ANALYSIS PRODUCTS John Fernandez, BA

11:29 AM O-130 ASSESSMENT OF ADVERSE PREGNANCY AND FERTILITY OUTCOMES AMONG CANADIAN FEMALE PHYSICIANS Sahra Nathoo, MD, MSc

11:40 AM O-131 EVALUATING THE ASSOCIATION BETWEEN SALINE-INFUSION SONOGRAM DURING AN INTRAUTERINE INSEMINATION CYCLE AND PREGNANCY OUTCOME Adriana J. Wong, MD, MPH

11:51 AM O-132 SHIPPED EMBRYOS: AN EVALUATION OF PREGNANCY OUTCOMES Jasmyn Johal, MD

12:02 PM O-133 VALIDATION OF A MAIL-IN DELAYED SEMEN ANALYSIS PROTOCOL FOR HOME COLLECTION Karen Racicot, PHD

OST-05 ART- Third Party Reproduction

10:45 AM O-134 TROPHECTODERM BIOPSY IS ASSOCIATED WITH LOWER RISKS OF MODERATE TO EXTREME PRETERM BIRTHS AND LOW BIRTH WEIGHTS: A SART CORS ANALYSIS OF 45,712 SINGLETON LIVE BIRTHS FROM FROZEN BLASTOCYST TRANSFERS Angela H. Liu, MD

10:56 AM O-135 LIVE BIRTH OUTCOMES FOLLOWING THE ULTRAFAST BLASTOCYST WARMING TECHNIQUE Victoria S. Jiang, MD

11:07 AM O-136 ULTRA-FAST VITRIFICATION (UFV) AND RAPID ELUTION (RE) OF HUMAN GERMINAL VESICLE (GV) OOCYTES: SURVIVAL, MATURATION AND SPINDLE INTEGRITY Kathryn Wozniak, MS


11:29 AM O-138 IMPACT OF GROUP EMBRYO CULTURE ON HIGH QUALITY BLASTOCYST DEVELOPMENT AND CUMULATIVE LIVE BIRTH OUTCOMES Hadi Ramadan, MD

11:40 AM O-139 ANALYSIS OF INFLAMMATORY CYTOKINE PROFILE OF FOLLICULAR FLUID FROM PATIENTS WITH ENDOMETRIOSIS AND IMPACT ON SPERM MOTILITY Priyanka Suryavanshi, MSc

11:51 AM O-140 FAST AND FURIOUS: PREGNANCY OUTCOME WITH A RAPID WARMING PROTOCOL Kristina Hrvojevic, MD

12:02 PM O-141 A NEW ULTRASOUND SIGN TO PREDICT DIFFICULT EMBRYO TRANSFER Imad Z. Aboujaoude, MD

Tuesday, October 17, 2023

OST-06 Mental Health 2

11:45 AM O-142 IMPACT OF PSYCHOSOCIAL SUPPORT WITH MEDITATION ON IVF/ICSI CLINICAL OUTCOMES: A PROSPECTIVE COHORT STUDY Poonam Nayar, PhD

OST-07 Nursing 2

11:45 AM O-144 PATIENT-REPORTED OUTCOMES OF A PROSPECTIVE STUDY OF ENDOMETRIOSIS PATIENTS Laura Courtright, MSN, RN

11:56 AM O-145 DEVELOPMENT OF AN EDUCATIONAL PORTAL OF IN VITRO FERTILIZATION WITH DONATED OOCYTES AND ITS ONE-YEAR IMPACT. Fernanda KUNRATH Robin, Master Nursing
ORAL ABSTRACTS

Tuesday, October 17, 2023

OST-08 Reproductive Medicine (Non-Infertility)- Benign Gynecological Disease

1:30 PM  O-146 ENDOMETRIAL SUBCELLULAR ALTERATIONS IN ENDOMETRIOSIS IDENTIFIED BY SINGLE-CELL ANALYSIS ACROSS THE MENSTRUAL CYCLE Ana Laura Almonte, PhD student

1:41 PM  O-147 UTERINE FIBROIDS AND HYPERTENSIVE DISORDERS IN PREGNANCY- A SYSTEMATIC REVIEW AND META ANALYSIS Susan Nasab, MD

1:52 PM  O-148 LONG-TERM THERAPY OF ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY James A. Simon, MD

2:03 PM  O-149 MAPPING THE WAY TO SUCCESSFUL EUPLOID FROZEN EMBRYO TRANSFER: A PROSPECTIVE PILOT STUDY OF UTERINE SHEAR WAVE ELASTOGRAPHY (SWE) Cheri K. Margolis, MD

2:14 PM  O-150 TELOMERE LENGTH AND RISK OF FEMALE REPRODUCTIVE CONDITIONS: A MENDELIAN RANDOMIZATION STUDY Yaoyao Zhang, MD, PhD

2:25 PM  O-151 PREGNANCY AND PERINATAL OUTCOMES IN WOMEN WITH DIFFERENT PHENOTYPES OF ADENOMYOSIS Wan Yang, Dr

OST-09 Genetics- PGT 2

1:30 PM  O-152 ABNORMAL POC RESULTS AFTER SINGLE EUPLOID BLASTOCYST TRANSFER EXPOSES THE PREVALENCE OF CONTRIBUTING FETAL CHROMOSOMAL MOSAICISM Mandy Katz-Jaffe, PhD

1:41 PM  O-153 EMBRYO RESCUE: EUPLOID AND WHOLE CHROMOSOME ANEUPLOIDY RATES IN EMBRYOS INITIALLY CATEGORIZED AS 0 PN AND 1 PN AT FERTILIZATION CHECK Anjali R. Jotwani, MD, MS

1:52 PM  O-154 WHAT IS THE REPRODUCTIVE POTENTIAL OF EUPLOID DAY-6 AND DAY-7 BLASTOCYSTS COMPARED TO EUPLOID DAY-5 BLASTOCYSTS? Marja Brolinson, MD

2:03 PM  O-155 UNBALANCED TRANSLLOCATION RATE ACCORDING TO GENDER OF CARRIERS AND TYPES OF CHROMOSOMAL REARRANGEMENT IN PGT-SR BASED ON NEXT-GENERATION SEQUENCING (NGS) Eun Jeong Yu, MD, PhD

2:14 PM  O-156 BIOLOGICAL AND MOLECULAR MECHANISMS BEHIND PLOIDY ABNORMALITIES DETECTED IN BLASTOCYST STAGE EMBRYOS USING AN NGS BASED PGT-A PLATFORM WITH GENOTYPING DATA Ludovica Picchetta, MSc

2:25 PM  O-157 PREGNANCY OUTCOMES OF EMBRYOS DIAGNOSED AS PUTATIVE MOSAIC (PM) USING PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A): A MULTI-SITE BLINDED NON-SELECTION STUDY Pavan Gill, MD

OST-10 Pre-Clinical & Basic Research- General

1:30 PM  O-158 DEPLETION CLPX FROM OOCYTE CAUSES MITOCHONDRIAL DYSFUNCTION, LEADING TO IMPAIR OOCYTE FERTILIZATION AND EARLY EMBRYO DEVELOPMENT IN MICE Renwu Hua, PhD

1:41 PM  O-159 OPTIMIZATION OF EMBRYO VITRIFICATION MEDIA USING STEM CELL DERIVED HUMAN BLASTOIDS Elizabeth A. Jannaman, BS

1:52 PM  O-160 SPERM-CARRIED IGF2: TOWARDS THE DISCOVERY OF THE SPARK THAT GIVES RISE TO LIFE Rossella Cannarella, MD, PhD

2:03 PM  O-161 DUAL ROLES OF MITOCHONDRIAL AKT IN GRANULOSA CELLS DURING OVARIAN FOLLICULOGENESIS AND DEVELOPMENT OF METABOLIC SYNDROME Hui-Wen Lo, MD

2:14 PM  O-162 UTILIZATION OF A 3D IN VITRO CO-CULTURE SYSTEM TO CHARACTERIZE THE EMBRYONIC MECHANISMS ASSOCIATED WITH IMPLANTATION FAILURE Keelee J. McCarty, PhD

2:25 PM  O-163 USING IN SITU GENE EXPRESSION TO CREATE A THREE-DIMENSIONAL MAP OF HUMAN BLASTOCYSTS Riwa Sabbagh, MD

OST-11 Infertility- Diagnosis & Treatment 2

1:30 PM  O-164 WHEN IS IT THE SPERM’S FAULT? THE INCIDENCE OF LOW FERTILIZATION IN MATCHED DONOR EGG CYCLES Denny Sakkas, PhD

1:41 PM  O-165 DECODING THE FOUNTAIN OF YOUTH: HOW GRANULOSA CELL DNA METHYLATION CAN REVEAL YOUR AGING PACE AND HEALTH RISKS Alexandra Herweck, MD, MPH

1:52 PM  O-166 THE IMPACT OF INTERMITTENT FASTING ON SPERM PARAMETERS Nabil Sayme, MD
2:03 PM O-167 POST-TRIGGER PROGESTERONE MONITORING: A NOVEL PROTOCOL FOR MODIFIED NATURAL CYCLE FROZEN EMBRYO TRANSFER Jennifer B. Bakkensen, MD

2:14 PM O-168 DIENOGEST AS A FEASIBLE ALTERNATIVE FOR LUTEINIZING HORMONE SUPPRESSION IN PROGESTIN-PRIMED OVARIAN STIMULATION Buo Jia Lu, MD

2:25 PM O-169 INTRAOVARIAN INJECTION OF PLASMA RICH IN GROWTH FACTORS IMPROVES FOLLICLE GROWTH AND OOCYTE QUALITY AFTER COS IN AGED WOMEN WITH DIMINISHED OVARIAN RESERVE Sonia Herraiz, PhD

Ost-12 Business of Medicine

1:30 PM O-170 CONGENITAL ANOMALIES AFTER FIRST-TRIMESTER DYDROGESTERONE THERAPY DURING IN VITRO FERTILIZATION Wan Yang, Dr

1:41 PM O-171 THE VALIDATION AND IMPLEMENTATION OF A SUCCESSFUL PATIENT RETENTION PROGRAM Candi Petersma, BA

1:52 PM O-172 GONADOTROPIN UTILIZATION REMAINS WELL-CORRELATED WITH UNITED STATES (US) PUBLIC REGISTRIES AND DOCUMENTS A POST-PANDEMIC RETURN TO INCREASING

Tuesday, October 17, 2023

Ost-13 ART- Artificial Intelligence

3:30 PM O-176 DEVELOPMENT OF AN AUTOMATED SYSTEM FOR MORPHOLOGICAL CLASSIFICATION OF EMBRYOS USING IMAGE-BASED ARTIFICIAL INTELLIGENCE Jonathan M. M. Hall, BSc, PhD

3:41 PM O-177 WHAT HAPPENS WHEN THE EMBRYOLOGIST’S OPINION DOES NOT MATCH THE DECISION MADE BY AN ARTIFICIAL INTELLIGENCE-BASED MODEL? Marco Toschi, MSc

3:52 PM O-178 EVALUATING THE INTEGRATION OF TWO INDEPENDENTLY-DEVELOPED ARTIFICIAL INTELLIGENCE TOOLS FOR PREDICTING OUTCOMES IN OVARIAN STIMULATION Michael Fanton, PhD

4:03 PM O-179 DEVELOPMENT OF A NON-INVASIVE ARTIFICIAL INTELLIGENCE ALGORITHM FOR IDENTIFICATION OF EUPLOID EMBRYOS WITH HIGH MORPHOLOGICAL QUALITY DURING IVF Matthew VerMilyea, HCLD, PhD

4:14 PM O-180 ESTIMATION OF RETRIEVAL DATE IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CYCLES Fady I. Sharara, BS, MD

4:25 PM O-181 HIGHER METAPHASE II (MII) OOCYTE QUALITY IDENTIFIED BY AN ARTIFICIAL INTELLIGENCE (AI) OOCYTE IMAGE ANALYSIS TOOL IN GnRH ANTAGONIST VERSUS GnRH AGONIST CONTROLLED OVARIAN STIMULATION (COS) PROTOCOLS Jullin Fjeldstad, BSc, MSc

OSt-14 Reproductive Medicine (Non-Infertility)- Benign Gynecological Disease & Menopause

3:30 PM O-182 BONE MINERAL DENSITY AFTER TWO YEARS OF TREATMENT WITH RELUGOLIX COMBINATION THERAPY AND ONE-YEAR POST-TREATMENT FOLLOW-UP IN WOMEN WITH ENDOMETRIOSIS: SPIRIT PROGRAM Michael R. McClung, MD

3:41 PM O-183 HYPERTENSION, CARDIOVASCULAR RISK FACTORS, AND UTERINE FIBROID DIAGNOSIS
ORAL ABSTRACTS

IN MIDLIFE: STUDY OF WOMEN’S HEALTH ACROSS THE NATION (SWAN) Susanna D. Mitro, PhD

3:52 PM O-184 ASSOCIATION OF ENDOMETRIOSIS AND INFLAMMATORY BOWEL DISEASE (IBD), FINDINGS FROM EPIDEMIOLOGICAL EVIDENCE TO GENETIC LINKS Runxin Gan, MD

4:03 PM O-185 ASSOCIATIONS OF ANTI-MÜLLERIAN HORMONE IN MID-REPRODUCTIVE YEARS WITH BONE MINERAL DENSITY AND BONE Turnover MARKERS DURING MIDLIFE: A LONGITUDINAL STUDY Bhuchitra Singh, MD, MPH, MS, MBA

4:14 PM O-186 THE MEDIATOR COMPLEX SUBUNIT 12 (MED-12) GENE AND UTERINE FIBROIDS: A SYSTEMATIC REVIEW Bhuchitra Singh, MD, MPH, MS, MBA

4:25 PM O-187 ACHIEVING MENOPAUSAL HEALTH EQUITY NETWORK: EVALUATION OF A WEB-BASED INTERVENTION TO IMPROVE OB/GYN KNOWLEDGE OF MENOPAUSE RELATED RACIAL AND ETHNIC HEALTH DISPARITIES Shilpa Kalluru, MD, MPH

4:36 PM O-249 SPECIFICS OF AUTONOMIC REGULATION, PERCEIVED STRESS, AND ANXIETY IN INTERNALLY DISPLACED WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) WITHOUT OBESITY Vitaly Solskyy, MD, PhD

OST-15 Recurrent Pregnancy Loss 2

3:30 PM O-188 DOES TIME TO RESOLUTION OF HUMAN CHORIONIC GONADOTROPIN (HCG) AFTER EUPLOID EMBRYO TRANSFER WITH SUBSEQUENT SPONTANEOUS ABORTION (SAB) PREDICT RETAINED PRODUCTS OF CONCEPTION (RPOC)? Dina Hamer, BA

3:41 PM O-189 CUMULATIVE SECOND LIVE BIRTH IN A RECURRENT PREGNANCY LOSS POPULATION: PROGNOSTIC FACTORS AND IMPACT OF OTHER ADVERSE OBSTETRIC OUTCOMES. Bahi Fayek, MBBCch, MD, MSc

3:52 PM O-190 MALE FIRSTBORN AND SUBSEQUENT PREGNANCY LOSS – A REAPPRAISAL USING REAL-WORLD DATA Jacqulyn Roger, BS

4:03 PM O-191 ASSESSMENT OF RISK FACTORS AND EMBRYO MORPHOKINETICS FOR PLOIDY AND EMBRYO QUALITY IN THE PATIENTS WITH RECURRENT PREGNANCY LOSS Tutku Melis Aygün, BSc

4:14 PM O-192 INVESTIGATING THE INCIDENCE OF THE 22q11.2 DELETION SYNDROME IN MISCARRIAGE Melissa K. Maisenbacher, MS

4:25 PM O-193 SEQUENTIAL INFLAMMATORY DYSREGULATION TRIGGERED BY IL-17 PRODUCTION AS A PREDICTIVE BIOMARKER FOR ALLOGENIC REJECTION OF EUPLOID EMBRYOS IN PATIENTS WITH RECURRENT PREGNANCY LOSS Nadera Mansouri Attia, PhD

OST-16 Reproductive Urology

3:30 PM O-194 TELEHEALTH STERILIZATION CONSULTATION DOES NOT IMPACT LIKELIHOOD OF VASECTOMY: A RETROSPECTIVE INSTITUTIONAL ANALYSIS Nicholas Deebel, MD

3:41 PM O-195 COMPARATIVE ANALYSIS OF SEMEN MICROBIOME IN MEN WITH NON-OBSTRICTIVE AZOOSPERMIA AND FERTILE CONTROLS USING NEXT GENERATION SEQUENCING Katherine Campbell, BS

3:52 PM O-196 SPERM MULTIMICS ANALYSIS REVEALS WIDESPREAD CHROMATIN AND EPIGENETIC CHANGES IN MALE FACTOR INFERTILITY Michelle M. Denomme Tignanelli, BS, PhD

4:03 PM O-197 THE ASSOCIATION OF SPERM MORPHOLOGY WITH PLACENTAL CHARACTERISTICS AMONG SINGLETON LIVEBIRTHS CONCEIVED WITH FERTILITY TREATMENTS Panagiota Cherouveim, MD, MS

4:14 PM O-198 A NOVEL EPIGENETIC-BASED TEST TO PREDICT TESE AND MTESE OUTCOMES Kristin Brogaard, PhD

OST-17 Reproductive Justice- Access to Care

3:30 PM O-199 PROVISION OF MAIL-IN AT-HOME SEMEN ANALYSIS KITS IN CLINIC IMPROVES TEST COMPLETION RATES Alisha T. Tolani, MD

3:41 PM O-200 WOMEN WITH SEVERE OBESITY ARE LESS LIKELY TO SEEK INFERTILITY CARE: A CROSS-SECTIONAL ANALYSIS OF THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES), 2013-2020 Adam T. Evans, MD

3:52 PM O-201 RACIAL AND ETHNIC DETERMINANTS OF ACCESS TO INFERTILITY CARE IN A STATE WITH A COMPREHENSIVE INFERTILITY MANDATE Veronica Wang, MS, PhD

4:03 PM O-202 IMPROVING EFFECTIVE MEDICATION ABORTION CARE WITH SHARED DECISION-MAKING IN A FAMILY PLANNING CLINIC Heather Cordle, DNP, NP-C

4:14 PM O-203 CRACKING THE EGG FREEZING DISPARITY: EXPLORING THE UNDERUTILIZATION OF
ELECTIVE OOCYTE CRYOPRESERVATION (EOC) AMONG BLACK PATIENTS IN THE GREATER CHICAGO AREA

Janelle M. Jackman, MBBS

4:25 PM  O-204 PATIENTS WITH BODY MASS INDEX OF 40-44.9 AND ≥45kg/m² CAN SAFELY UNDERGO EGG RETRIEVAL AND EXPECT SIMILAR ART OUTCOMES

Marissa Bonus, MD

Wednesday, October 18, 2023

OSW-01 Surgery

10:45 AM O-205 RISK OF HISTERECTOMY AT THE TIME OF MYOMECTOMY – AN UNDERESTIMATED SURGICAL RISK
Kathryn D. Coyne, MD

10:56 AM O-206 INCIDENCE AND MANAGEMENT OF RECURRENT IMPLANTATION FAILURE FOR UTERUS TRANSPLANTATION RECIPIENTS IN THE UNITED STATES
Emily H. Frisch, MD

11:07 AM O-207 HYSTEROSCOPIC FINDINGS IN PATIENTS WITH INFERTILITY AND ABNORMAL UTERINE BLEEDING: UNVEILING THE PREVALENCE OF SUBTLE UTERINE LESIONS
Diego D. Manavella, MD, PhD

11:18 AM O-208 COMPARISON OF PROPFOF-FENTANYL AND MIDAZOLAM-REMIFENTANIL COMBINATIONS IN OOCYTE PICK-UP PROCEDURE
Nazli Albayrak, MD

11:29 AM O-209 LONG-TERM RISK OF REINTERVENTION AFTER UTERINE PRESERVING SURGICAL FIBROID TREATMENTS AND VARIATION BY SOCIODEMOGRAPHIC FACTORS
Susanna D. Mitro, PhD

11:40 AM O-210 SURVEY OF REPRODUCTIVE SURGEONS ON INTRAUTERINE ADHESION (IUA) PREVENTION AFTER HYSTEROscopic PROCEDURES
Victoria W. Fitz, MD, MS

11:51 AM O-211 INCREASING PATIENT COMFORT AND SATISFACTION WITH VIRTUAL REALITY TECHNOLOGY DURING OOCYTE RETRIEVAL
Marie-Helene Godin Pagé, MSc

12:02 PM O-212 AMNIOGRAFT PLACEMENT AT THE TIME OF HYSTEROscopy FOR INTRAUTERINE ADHESIONS (IUA) MAY IMPROVE PREGNANCY RATE (PR) AND LIVE BIRTH RATE (LBR) IN SEVERE CASES WITH HISTORY OF FAILED HYSTEROscopy
Rebecca K. Chung, MD

OSW-02 ART- Technique

10:45 AM O-213 DIAGNOSES OF AUTOSOMAL RECESSIVE CONDITIONS IN DONOR-CONCEIVED OFFSPRING IN THE CONTEXT OF CARRIER SCREENING PRACTICES: A COLLABORATION BETWEEN THREE LARGE U.S. SPERM BANKS
Lauren Isley, MS, CGC

10:56 AM O-214 OBSTETRIC OUTCOMES IN WOMEN OF VERY ADVANCED MATERNAL AGE: AN ANALYSIS OF 72,594 DONOR OOCYTE-DERIVED EMBRYO TRANSFER CYCLES FROM THE SART REGISTRY
Kaitlin A Doody, MD

11:07 AM O-215 IT'S NOT ONE STRIKE AND YOU'RE OUT!: HIGH CLINICAL PREGNANCY RATE AMONG RECIPIENT COUPLES WHO NEEDED A REPLACEMENT LOT OF VITRIFIED DONOR EGGS
Amalia Namath, MD

11:18 AM O-216 TRENDS, CHARACTERISTICS, AND OUTCOMES OF GESTATIONAL CARRIER PREGNANCIES IN THE UNITED STATES
Rachel S. Mandelbaum, MD

11:29 AM O-217 NATIONAL TRENDS, GEOGRAPHIC DISTRIBUTION, AND OUTCOMES OF ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES USING A GESTATIONAL CARRIER, 2014–2020
Lisa M. Shandley, MD, MSCR

11:40 AM O-218 HOW MANY IS TOO MANY? OPTIMAL NUMBER OF OOCYTES TO FERTILIZE IN DONOR OOCYTE IN VITRO FERTILIZATION CYCLES TO MINIMIZE SUPERNUMERARY EMBRYOS
Samantha Spring, MD

11:51 AM O-219 DONOR OOCYTE IN VITRO FERTILIZATION PREGNANCIES CARRIED BY GESTATIONAL SURROGATES: BENEFITS AND RISKS OF TRANSFERRING TWO BLASTOCYST STAGE EMBRYOS RATHER THAN ONE TO HIGH-PROGNOSIS PATIENTS
Said T. Daneshmand, MD

OSW-03 Pre-Clinical & Basic Research- Reproductive Biology Human

10:45 AM O-221 HUMAN INDUCED PLURIPOTENT STEM CELL-
DERIVED OVARIAN SUPPORT CELLS IMPROVE THE MATURATION RATE OF IMMATURE HUMAN OOCYTES IN VITRO Maria Marchante, PhD

10:56 AM O-222 SINGLE-CELL TRANSCRIPTOMICS OF POST-IMPLANTATION HUMAN EMBRYOS REVEAL LINEAGE DYNAMICS AND PLOIDY-DEPENDENT SIGNATURES Sheila Kwok, HBSc

11:07 AM O-223 HUMAN CUMULUS CELL KINOMIC PROFILES VARY DISTINCTLY WITH PHYSIOLOGIC AGE AND DIFFERENTIAL OVARIAN RESERVE: A NOVEL APPROACH TO THE STUDY OF OVARIAN AGING Jennifer B. Bakkensen, MD

11:18 AM O-224 HIGH RISK, LOW REWARD: CANNABIS TREATMENT INDUCES MULTIPARAMETRIC DYSFUNCTION IN HUMAN ENDOMETRIAL AND TROPHOBLAST CELLS WITH COMPLEX IMPLICATIONS FOR PLACENTATION AND FUTURE FERTILITY Miriel Ho, PhD

11:29 AM O-225 IN-VITRO TREATMENT OF HUMAN OOCYTES WITH CANNABIS ALTERS GENES INVOLVED IN CHROMOSOMAL ORGANIZATION AND SEGREGATION - A SINGLE CELL RNASEQ STUDY Cynthia Duval, PhD

11:40 AM O-226 miRNA CARGO OF EXTRACELLULAR VESICLES SECRETED BY THE MATERNAL ENDOMETRIUM REGULATES GENES RELATED TO EMBRYO COMPETENCE DURING THE IMPLANTATION PROCESS IN HUMAN BLASTOCYSTS Marina Segura-Benítez, MSc

11:51 AM O-227 IMPROVEMENT IN RESCUE IN VITRO MATURATION OUTCOMES USING CO-CULTURE WITH INDUCED PLURIPOTENT STEM CELL-DERIVED OVARIAN SUPPORT CELLS Sabrina Piechota, BSc

12:02 PM O-228 DECIPHERING THE NEGATIVE IMPACTS OF UTERINE FIBROIDS ON ENDOMETRIAL RECEPTIVITY USING 3D ORGANOID SYSTEM; MOLECULAR MECHANISMS AND POTENTIAL THERAPEUTICS Mohamed Ali, PhD

OSW-04 Infertility- Outcomes

10:45 AM O-229 THE IMPACT OF OBESITY ON IN VITRO FERTILIZATION (IVF), OBSTETRICAL, AND NEONATAL OUTCOMES IN PATIENTS UNDERGOING IVF Jenny S. George, MD

10:56 AM O-230 REDUCTION IN TIME TO PREGNANCY FOLLOWING IVF WITH A FRESH EMBRYO TRANSFER IN YOUNG WOMEN WITH HIGH RESPONSE TO CONTROLLED OVARIAN STIMULATION: AN ANALYSIS OF CYCLES FROM SART DATABASE FROM 2014 – 2019 Emily A. Jacobs, MD

11:07 AM O-231 PREGNANCY COMPLICATIONS AND PLACENTAL HISTOLOGY IN IN-VITRO FERTILIZATION PREGNANCIES WITH HIGH ESTRADIOL LEVELS DURING STIMULATION Michael H. Dahan, MD

11:18 AM O-232 CUMULATIVE LIVE BIRTH RATES WITH AUTOLOGOUS OOCYTES PLATEAU WITH FEWER NUMBER OF CYCLES FOR EACH YEAR ADVANCING BEYOND AGE 42: ANALYSIS OF 2014-2020 SARTCORS DATABASE Sarah F. Wang, MD

11:29 AM O-233 UTILITY OF A COMMERCIAL CLAIMS DATABASE FOR STUDYING IN-VITRO FERTILIZATION (IVF) COVERED BY HEALTH INSURANCE Marissa Steinberg Weiss, MD, MSc

11:40 AM O-234 COVID-19 VACCINATION AND SUBSEQUENT INFERTILITY DIAGNOSES IN UNITED STATES MILITARY SERVICE MEMBERS Karolina Wadolowska, MD, MS

11:51 AM O-235 BEST LAID PLANS: GOOD PERINATAL OUTCOME AFTER IVF WITH PGT-A Danielle E. Strom, MD

12:02 PM O-236 OVARian STIMULATION WITH FE 999049 IS EFFICACIOUS AND SAFE IN WOMEN 35-42 YEARS OF AGE: PRIMARY FINDINGS OF THE RITA-2 REGISTRATION TRIAL Kevin J. Doody, MD

OSW-05 Genetics- General

10:45 AM O-237 MALE GENOME EDITING AT THE GAMETE LEVEL TO CORRECT PATHOLOGICAL MUTATIONS IN A MOUSE MODEL Angela Bryanne De Jesus, BA

10:56 AM O-238 NON-ALCOHOLIC FATTY LIVER DISEASE, PREGNANCY LOSS AND PRETERM BIRTH: A MENDELIAN RANDOMIZATION STUDY Eiliangshan Mu, MD

11:07 AM O-239 PRONUCLEAR NUMERATION DOES NOT ACCURATELY REFLECT THE TRUE NUMBER OF PARENTAL GENOMES Lauren Henry, BS

11:18 AM O-240 BLINDED REANALYSIS OF NEXT-GENERATION SEQUENCING (NGS) NON-EUPLOID EMBRYOS USING SINGLE NUCLEOTIDE POLYMORPHISM (SNP) ARRAY-BASED PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) Sarah D. Cascante, MD, BA

11:29 AM O-241 R-SPONDIN 1 GENE VARIANT ASSOCIATED WITH INFERTILITY IN FEMALE MILITARY SERVICEMembers: A MENDelian RANDOMIZATION STUDY Latina D. Cano, MD

11:40 AM O-242 ANNUAL REPORT OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE FOUNDATION FUND” Carina J. Magli, MD
ORAL ABSTRACTS

WITH 46,XX DIFFERENCE OF SEX DEVELOPMENT Robert A. Roman, MD

11:40 AM  O-242 A SYSTEMATIC REVIEW OF ENDOMETRIOSIS EPIGENETICS Bronwyn S. Bedrick, MD, MSCI

11:51 AM  O-243 ASSOCIATION BETWEEN SPECIFIC CHROMOSOME ABNORMALITIES AND GESTATIONAL AGE AND STAGE OF SPONTANEOUS ABORTIONS Rebecca Zhuo, MD

12:02 PM  O-244 LANDSCAPE OF PATHOGENIC MUTATIONS IN POLYCYSTIC OVARY SYNDROME: TOWARDS COMPREHENSIVE GENOMIC EVALUATIONS Priyal Sharma, PhD

Wednesday, October 18, 2023

OSW-06 Mental Health 3

11:45 AM  O-245 USE OF FERTILITY MOBILE PHONE APPLICATIONS AND QUALITY OF LIFE Emily Allard-Phillips, MD

11:56 AM  O-246 EXPLORING FERTILITY TREATMENT EXPERIENCES OF SAME-SEX COUPLES USING THE SEXUAL MINORITY STRESS MODEL Sarah R. Holley, PhD

OSW-07 Nursing 3

11:45 AM  O-247 INCREASING FERTILITY PATIENT HYPERTENSION SCREENING: A QUALITY IMPROVEMENT PROJECT Stephanie M. Elliott, MSN, NP, RN

11:56 AM  O-248 IMPLEMENTATION AND PRELIMINARY FINDINGS OF FERTIQOL, A FERTILITY QUALITY OF LIFE TOOL, VIA AN APP-BASED FERTILITY SERVICE Francesca Steyn, BSc (Hons) Nursing

ASRM Career Pathways Program

ASRM is excited to welcome students from schools across the New Orleans area to participate in the ASRM Career Pathways Program! Our goal with this program is to shed light on careers in reproductive health, medicine, and science while also establishing a valuable network of mentors to guide and support those interested in pursuing a career in this field. This year, we’re extending our program to two different days to accommodate more students.

- Thanks to the generous support of EMD Serono, ASRM will host a hands-on session for undergraduate students majoring in a STEM program. This session will take place Sunday on the Louisiana State University Health Sciences Center New Orleans campus. Students from Dillard, Xavier, and Tulane will be in attendance.

- On Monday, ASRM will host LSU and Tulane medical students during the ASRM 2023 Scientific Congress & Expo. Each student will be paired with a mentor and will attend events and sessions throughout the day, engaging with reproductive health content, networking with professionals in the field, and socializing with other trainees.
PSM-01 ART 1
10:45 AM P-1 IS IT TIME TO RECONSIDER HOW TO MANAGE IMMATURE OOCYTES? Marga Esbert, PhD

10:50 AM P-2 MACHINE LEARNING APPROACH WITH RANDOM FOREST AND SYNTHETIC MINORITY OVER-SAMPLING TECHNIQUE MAY BE OPTIMAL IN NON-INVASIVE EUPLOIDY DETECTION: A PRELIMINARY STUDY Nguyen-Tuong Ho, MD

10:55 AM P-3 THE DISCRIMINATIVE CRISPR/CAS 9 BASED GENOME EDITION OF ENDOMETRIAL CELLS AND BLASTOCYSTS CAN REVEAL GENES NEW TO IMPLANTATION PROCESS IN MOUSE Gizem Nur Nur Sahin, PhD

11:00 AM P-4 LACK OF RACIAL AND ETHNIC DIVERSITY IN CRYOPRESERVED DONOR SPERM IN THE UNITED STATES Lauren Gibbs, MD

11:05 AM P-5 RELIABILITY OF LEUPROLIDE OVULATION TRIGGER ASSESSED BY CONTEMPORANEOUS URINARY AND BLOOD TESTING FOR IMPROVED PATIENT ACCESS TO CARE Liubov Pileva, MD

11:10 AM P-6 IDEAL SPINDLE LOCATION AT TIME OF ICSI PREDICTS HIGHER NORMAL FERTILIZATION AND EUPLOID BLASTOCYST RATES Alexandra Brickley, MS

11:15 AM P-7 ORAL GnRH ANTAGONIST SHR7280 FOR THE PREVENTION OF PREMATUR E LUTEINIZING HORMONE (LH) SURGE IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION (COH) IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Ying Song, MD

11:20 AM P-8 CONTINUOUS OVARIAN STIMULATION: A PROOF OF CONCEPT STUDY EXPLORING THE UNINTERRUPTED USE OF CORIFOLLITROPIN ALPHA IN A DUOSTIM CYCLE FOR ENHANCED EFFICIENCY AND PATIENT CONVENIENCE (ALICANTE PROTOCOL) Juan C. Farfan, MD PhD

11:25 AM P-9 AUTOMATED MORPHOLOGY GRADING OF BLASTOCYST STAGE EMBRYOS FROM A SINGLE IMAGE USING DEEP LEARNING Zeyu Chang, MS

11:30 AM P-10 ASSOCIATION BETWEEN SERUM LH LEVEL AND REPRODUCTIVE OUTCOMES IN FIXED GONADOTROPIN RELEASING HORMONE GnRH) ANTAGONIST PROTOCOL PRETREATMENT WITH ESTRIADIOL Ying Chen, PhD

11:35 AM P-11 EMBRYO TRANSFER CATHETER DEVICES: A REVIEW OF ADVERSE EVENT REPORTS TO THE FOOD AND DRUG ADMINISTRATION Anita Monique Madison, MD, MPH

11:40 AM P-12 PERCEPTIONS AND REFLECTIONS OF EMBRYO DONATION RECIPIENTS: A QUALITATIVE STUDY Mona El-Gayar, MD

11:45 AM P-13 OPTIMAL ANTI-MÜLLERIAN HORMONE LEVEL IN OOCYTE DONORS: A NATIONAL DATABASE ANALYSIS Papii Sarkar, MD

11:50 AM P-14 EFFECT OF TRIGGER-TO-OOCYTE COLLECTION INTERVAL ON COLLECTED OOCYTE COUNT IN PROGESTIN-PRIMED OVARIAN STIMULATION (PPOS) AND GnRH ANTAGONIST CYCLES Erkan Kalafat, MD, MSc

11:55 AM P-15 IMPACT OF LOW LACTATE EMBRYO CULTURE MEDIUM ON LIVE BIRTH AND PERINATAL OUTCOME Daria Davydova, PhD

12:00 PM P-16 ABSENCE OF THE SECOND POLAR BODY 5 H AFTER INSEMINATION IN CONVENTIONAL IVF CYCLE IS A PREDICTOR OF REDUCED EMBRYO DEVELOPMENTAL COMPETENCE Yamamoto Shun, BS

12:05 PM P-17 COMPARATIVE RE-VITRIFICATION (RVTF) OF HUMAN BLASTOCYSTS AIMED AT VALIDATING ULTRA-FAST VITRIFICATION AND RAPID (ONE-STEP) ELUTION (RE) APPROACHES Mitchel C. Schiewe, BS, MS, PhD

12:10 PM P-18 SUCCESSFUL DEVELOPMENT AND VALIDATION OF A ROBOT FOR MICRODROPLET PLATE PREPARATION IN IN VITRO FERTILIZATION (IVF) LABORATORY Miriam Temmeh Lattin, BA

PSM-02 Fertility Preservation 1
10:45 AM P-19 PRE IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY AND MONOGENIC (PGT-A/ M) OUTCOMES ARE SIMILAR WHEN COMPARING BRCA1 VS BRCA2: COUNSELING FOR THE NEXT GENERATION Jenna Reich, MD

10:50 AM P-20 FERTILITY AND SEXUAL HEALTH COUNSELING FOR YOUNG ADULTS WITH PEDIATRIC CANCERS Jenna Reich, MD

10:55 AM P-21 URINARY BENZOPHENONE-3 CONCENTRATIONS AND OVARIAN.reserve IN SUBFERTILE WOMEN Emily L. Silva, BS
11:00 AM P-22 HUCMSC-DERIVED EXOSOMES PROTECT SPERMATOGONIAL STEM CELL NICHE THROUGH MIR-17, MIR-19a, AND MIR-17-92 CLUSTERS ASSOCIATED WITH MAPK/ERK PATHWAYS IN A NOVEL LEYDIG-SERTOLI CO-CULTURE SYSTEM Farzana Begum Liakath, PhD

11:05 AM P-23 WHICH PATIENTS NEED AROMATASE INHIBITORS DURING OVARian STIMULATION FOR FERTILITY PRESERVATION? ER-ALPHA EXPRESSION AS A SURROGATE FOR ESTROGEN RESPONSIVENESS Hilary S. Friedlander, MD

11:10 AM P-24 REGENERATIVE POTENTIAL OF UCMSC DERIVED EXOSOMES IN AMELIORATING CHEMOTHERAPY INDUCED DAMAGE IN HUMAN SERTOLI CELLS BY INCREASING CELL PROLIFERATION, REDUCING APOPTOSIS, OXIDATIVE STRESS AND DNA DAMAGE Omer Raheem, MD, MSc

11:15 AM P-25 OVARian STIMULATION ALTERS LEUKOCYTE TELOMERE LENGTH (LTL) IN WOMEN UNDERGOING IVF TREATMENT Rebecca Slutsky, BS

11:20 AM P-26 LESSONS LEARNED FROM OOCYTE THAW (OT): DO PLANNED OOCYTE CRYOPRESERVATION (OC) STIMULATION PARAMETERS OR CRYOPRESERVATION (CRYO) DURATION PREDICT THAW SUCCESS? Emily Michelle Weidenbaum, MD

11:25 AM P-27 FERTILITY PRESERVATION FOR YOUNG GIRLS – WHEN YOUR ZIP CODE IS MORE IMPORTANT THAN YOUR DIAGNOSIS Myriam Safrai, MD, BSc

11:30 AM P-28 OOCYTE RETRIEVAL AMONG CANCER PATIENTS Chelsea Anderson, PhD

11:35 AM P-29 MICROFLUIDIC SELECTION ENHANCES CRYOSURVIVAL OF SPERMATOZOA Olena M. Kocur, BA

11:40 AM P-30 ADMINISTRATION OF MODIFIED RNA ENCODING ANTI-MULLERIAN HORMONE (MODRNA-AMH) BEFORE CYCLOPHOSPHAMIDE BRIDGES PROTEIN LOSS UNTIL RESUMPTION OF SECRETION BY A CRITICAL MASS OF GROWING FOLLICLES Limor Man, MD, MSc

11:45 AM P-31 LOW RETURN TO CARE RATES AMONGST WOMEN WITH ONCOLOGICAL DIAGNOSES AND CRYOPRESERVED OOCYTES. A SART DATA ANALYSIS. Alison J. Meyers, BA

11:50 AM P-32 EXPLORING THE DETERMINANTS OF RECURRENT HOSPITALIZATIONS IN WOMEN WITH OVARian HYPERSTIMULATION SYNDROME: A COMPREHENSIVE ANALYSIS Vania Nwokoko, MD

11:55 AM P-33 NATIONAL ONCOFERTILITY REGISTRIES AROUND THE GLOBE: A PILOT SURVEY Mahmoud Salama, MD, PhD

12:00 PM P-34 IS THERE A DIFFERENCE IN ANTI-MULLERIAN HORMONE LEVELS AMONG PATIENTS UNDERGOING MEDICAL VS. NONMEDICAL OOCYTE OR EMBRYO CRYOPRESERVATION CYCLES? Alixandra L. Domney, MD, MPH

12:05 PM P-35 ESTROGEN MATTERS IN THE GRAY MATTER: FERTILITY PRESERVATION FOR CENTRAL NERVOUS SYSTEM TUMORS SHOULD INCLUDE LETROZOLE Hilary S. Friedlander, MD

12:10 PM P-36 CONTRACEPTIVE USE DOES NOT INFLUENCE VITRIFIED OOCYTE YIELD IN PATIENTS UNDERGOING OOCYTE CRYOPRESERVATION Carlos Hernandez-Nieto, MD

10:45 AM P-44 USER EXPERIENCE WITH ASRM MAC 2021 – AN ONLINE INTERACTIVE TOOL FOR DIAGNOSING AND MANAGING MULLERIAN ANOMALIES Valeriya Prytkova, BS

10:50 AM P-38 OOCYTE THAW (OT)/PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IS MORE COST EFFECTIVE AND IMPROVES LIVE BIRTH (LB) ODDS COMPARED TO IN VITRO FERTILIZATION (IVF)/PGT-A ALONE AT AN OLDER AGE Sarah D. Cascante, MD, BA

10:55 AM P-39 A COST ANALYSIS OF HCG TRIGGER ALONE VERSUS DUAL TRIGGER FOR ACHIEVING LIVE BIRTH FOLLOWING IN VITRO FERTILIZATION Esther H. Chung, MD

11:00 AM P-40 U.S. UTILIZATION OF PGT-A ACCORDING TO CLINIC OWNERSHIP-PRIVATE, ACADEMIC/ HOSPITAL/ MILITARY, AND EQUITY VENTURE CAPITAL Pasquale Patrizio, MD

11:05 AM P-41 ACTUAL COST COMPARISON OF THE COMMON INTRAUTERINE INSEMINATION (IUI) CYCLE PROTOCOLS Kelsey Manfredi, MD, MS
11:10 AM P-42 HOW DO AMERICAN REPRODUCTIVE ENDOCRINOLOGISTS’ (REI) FINANCIAL COMPENSATION COMPARE IN ACADEMICS AND PRIVATE PRACTICE WHEN TAKING INTO CONSIDERATION OTHER FIELDS OF MEDICINE? Argyrios Kolokythas, MD, MSc

11:15 AM P-43 IMPACT OF THE DOBBS DECISION ON OB/GYN FELLOWSHIP RANK LISTS Marisa Gigg, BA, MD

11:20 AM P-37 FIRST LIVE BIRTH FOLLOWING A TWO-WAY TRANSPORT IVF USING A PORTABLE INCUBATOR: A NOVEL PROTOCOL, LEARNED AND EXECUTED, IN THE COVID-19 PANDEMIC ERA Zaher Merhi, MD, HCLD

11:30 AM P-46 A COMPARISON OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY TRAINING ACROSS SIX MAJOR HIGH-INCOME COUNTRIES Jayapriya Jayakumaran, MD

11:35 AM P-47 PUTTING NUMBERS BEHIND THE ANECDOTES: INFERTILITY AND PREGNANCY COMPLICATIONS AMONG PHYSICIANS AND MEDICAL STUDENTS Melody A. Rasouli, MD, MBA

11:40 AM P-48 KNOWLEDGE AND PRACTICES OF ONCOFERTILITY AMONG MILITARY ONCOLOGISTS AND OBSTETRICIAN-GYNECOLOGISTS Kiley Hunkler, MD, MSt, MSc

11:45 AM P-49 CHATGPT AND IVF: HOW CAN WE IMPROVE IVF OUTCOMES IN OPENAI ERA? Shunping Wan, PhD

11:50 AM P-50 FROM FRUSTRATION TO FERTILITY: A LOOK AT HOW PATIENTS’ ACTIVE ENGAGEMENT TRANSFORMS THEIR FERTILITY CARE JOURNEY Leah M. Roberts, MD

11:55 AM P-51 DEFINING TELEMEDICINE MEDICAL APPROPRIATENESS IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) AND ASSESS UTILIZATION OF TELEMEDICINE WITH CONSIDERATION OF TOP DIAGNOSIS Susan Nasab, MD

12:00 PM P-52 STUDENTS’ PERCEPTIONS REGARDING SPERM DONATION: DILEMMAS REFLECTIONS WITH DOMINANT DEMOGRAPHIC EFFECT Itai Gat, MD

PSM-04 Pre-Clinical & Basic Research 1

10:45 AM P-53 EVALUATION OF SPERM MOTILITY AND OXIDATIVE STRESS IN L-CARNITINE AND COENZYME Q10 ENHANCED SEROTONIN BASED SPERM WASHING MEDIUM Nazli Albayrak, MD

10:50 AM P-54 THE EFFECT OF CHRONIC ORAL EXPOSURE TO BONNY LIGHT CRUDE OIL (BLCO) ON IMPLANTATION AND PREGNANCY OUTCOMES IN WISTAR RATS Louis C. C. Ajonuma, MD, PhD

10:55 AM P-55 PROLONGED INGESTION OF CRUDE OIL SPILL CONTAMINATED WATER AFFECTS MALE REPRODUCTIVE SYSTEM, HORMONES AND ACCESSORY ORGANS IN WISTAR RATS Louis C. C. Ajonuma, MD, PhD

11:00 AM P-56 HYPOXIA CONDITION AND MITOQUINONE TREATMENT RESTORE CELL PROLIFERATION AND MITOCHONDRIAL MEMBRANE POTENTIAL OF GRANULOSA CELLS DERIVED FROM ENDOMETRIOSIS PATIENT DURING IN VITRO CULTURE Gentry Cork, MS

11:05 AM P-57 TRANSCRIPTOME COMPARISONS OF REGENERATIVE TROPHOBLAST MODELS ARE LARGELY IN CONCORDANCE WITH TROPHOBLASTS FROM PERI-IMPLANTATION HUMAN EMBRYOS WHILE MAINTAINING SUBTLE DIFFERENCES Ye Yuan, PhD

11:10 AM P-58 COMBINATORY EFFECTS OF UNILATERAL OOPHORECTOMY PLUS CYCLOPHOSPHAMIDE TREATMENT ON OVARIAN RESERVE AND FERTILITY IN A MOUSE MODEL Taylor Badger, BS

11:15 AM P-59 DELTA-9-TETRAHYCANNABINOL EXPOSURE ALTERS SPERM DNA METHYLATION IN Rhesus Macaques Jasper C. Bash, MD

11:20 AM P-60 SYSTEMIC IMMUNE DIFFERENCES IN PATIENTS UNDERGOING FROZEN EMBRYO TRANSFERS THAT RESULT IN LIVE BIRTH Sarah Baumgarten, BA

11:25 AM P-61 OBESITY INDUCED LUTEAL PHASE ENDOMETRIAL PROFILE CHANGES IN A WELL-PHENOTYPED POPULATION Ali A. Bazzi, MD

11:30 AM P-62 SEMEN VISCOSITY COULD INFORM ON SPERM VITALITY AND SPERM DNA DENATURATION (SDD). A RETROSPECTIVE STUDY INCLUDING 10,633 PATIENTS FROM JANUARY 2013 TO JUNE 2022 Mustapha Benkhalifa, PhD

11:35 AM P-63 IMPACT OF OVARIAN STIMULATION AND IN VITRO FERTILIZATION ON METABOLIC PARAMETERS AND BLOOD PRESSURE OF ADULT MICE OFFSPRING Thalita S. Bertelli, PhD
POSTER PRESENTATIONS AND ABSTRACTS

11:40 AM P-64 ROLE OF MATERNAL OVARIAN AGING ON A MURINE MODEL OF IVF BY SINGLE-CELL SEQUENCING Liubin Yang, MD PhD

11:45 AM P-65 mRNA TRANSLATION PROGRAM IS DISRUPTED IN OOCYTES DURING MATERNAL AGING Nozomi Takahashi, MD, PhD

11:50 AM P-66 THE EVOLUTIONARILY CONSERVED PROTEIN ANKEF1 CONFERS SPERM MIDPIECE FLEXIBILITY AND IS ESSENTIAL FOR MALE FERTILITY Chelsea M. Canon, MD

11:55 AM P-67 GLOBAL PROTEOME PROFILE OF DEFECTIVE DECIDUALIZATION Irene Muñoz Blat, MSc

12:00 PM P-68 EVALUATION OF CELL-FREE DNA (cfDNA) IN EMBRYO SPENT MEDIA (ESM) AND ITS POTENTIAL FOR NON-INVASIVE EMBRYO ASSESSMENT Helen Xu, PhD

12:05 PM P-69 THE PLACENTAL TRANSCRIPTOME AND METHYLOME IN A MOUSE MODEL OF IN VITRO FERTILIZATION: DOWN-REGULATION OF PLACENTAL INFLAMMATORY PATHWAYS FOLLOWING TRANSFER INTO A SUPEROVULATED UTERINE ENVIRONMENT Elizabeth Clain, MD

12:10 PM P-70 EFFECTS OF THE ER BETA AGONIST LY ON ATTACHMENT AND INVASION OF ENDOMETRIAL CELLS Claire M. Schenken, BS, MPH

PSM-05 Infertility 1

10:45 AM P-71 REPRODUCTIVE POTENTIAL OF DOUBLE INNER-CELL MASS EMBRYOS: A CASE SERIES AND MATCHED ANALYSIS IN SINGLE EUPLOID BLASTOCYST TRANSFERS Carlos Hernandez-Nieto, MD

10:50 AM P-74 FEMALE IMPACT OF DELAY OF CARE ON MALE-FACTOR INFERTILITY PATIENTS Jordan G. Kassab, MS

10:55 AM P-75 INTRACYTOPLASMIC SPERM INJECTION VERSUS CONVENTIONAL IN VITRO FERTILIZATION IN UNEXPLAINED INFERTILITY Aya Iwamoto, MD, MS

11:00 AM P-76 AT-HOME SEMEN COLLECTION KIT FOR CLINIC DROP-OFF IS A COST-EFFECTIVE, RELIABLE, AND CONVENIENT ALTERNATIVE TO TRADITIONAL ON-SITE COLLECTION Miriam Temmeh Lattin, BA

11:05 AM P-77 AUTOLOGOUS PLATELET RICH PLASMA (PRP) INTRAOVARIAN INJECTION TO IMPROVE OVARIAN RESERVE PARAMETERS AND REPRODUCTIVE POTENTIAL IN POOR OVARIAN RESPONDER (POR) WOMEN UNDER 40 YEARS OLD Pietro Molinaro, MD

11:10 AM P-78 PREGNANCY FOLLOWING ASSISTED REPRODUCTIVE TECHNOLOGY IN MORBIDLY OBESE PATIENTS: ASSESSMENT OF FETO-MATERNAL OUTCOMES Chelsey A. Harris, MD

11:15 AM P-79 ENDOMETRIAL MACROPHAGES AND EMBRYO IMPLANTATION Rumiana Ganeva, MSc

11:20 AM P-80 SERUM PROGESTERONE PRIOR TO AND AFTER FROZEN EMBRYO TRANSFER CYCLES DO NOT CORRELATE WITH LIVE BIRTH RATES IN PROGRAMMED CYCLES UTILIZING INTRAMUSCULAR PROGESTERONE FOR LUTEAL SUPPORT Meghan Yamazaki, DO

11:25 AM P-81 ABSOLUTE UTERINE-FACTOR INFERTILITY - GESTATIONAL CARRIER OR UTERINE TRANSPLANT? — A COST EFFECTIVENESS ANALYSIS Meghan Yamazaki, DO

11:30 AM P-82 A NOVEL NOMOGRAM FOR PREDICTING THE CHANCE OF LIVE BIRTH FOR WOMEN UNDERGOING THEIR FIRST IVF CYCLE Yan Ouyang, MD, PhD

11:35 AM P-83 FINAL OOCYTE MATURATION TRIGGER PROTOCOL IN POOR, NORMAL AND HIGH RESPONDERS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF LIVE BIRTH RATES, LABORATORY OUTCOMES AND ADVERSE EFFECTS Yusuf Beebeejaun, MRCOG, MHD, MBBS, BSc(Hons)

11:40 AM P-84 GONADOTROPIN-RELEASING HORMONE AGONIST ADMINISTRATION PRIOR TO FROZEN-THAWED EMBRYO TRANSFER IMPROVES PREGNANCY OUTCOMES IN WOMEN WITH OVARIAN ENDOMETRIOSIS: A RETROSPECTIVE COHORT STUDY Nguyen-Tuong Ho, MD

11:45 AM P-85 MORE THAN JUST PLOIDY STATUS: DAY OF VITRIFICATION AND INNER CELL MASS GRADE ARE ASSOCIATED WITH LIVE BIRTH IN EUPLOID EMBRYOS Yuqi Bian, BA

11:50 AM P-86 PROSPECTIVE VALIDATION OF AN IN-HOUSE DEVELOPED LIVE BIRTH PREDICTIVE MORPHOKINETIC ALGORITHM. IS IT WORKING AND TRANSFERABLE BETWEEN CLINICS? Rachel Smith, BSc
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:55 AM</td>
<td>P-87 TEMPORAL TRENDS IN SPERM PARAMETERS OF FERTILE MEN: A SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS Rossella Cannarella, MD, PhD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>P-88 THE PROGNOSTIC POTENTIAL OF CYCLE PARAMETERS ON DAY OF TRIGGER IN LETROZOLE AND NON-LETROZOLE MODIFIED NATURAL CYCLE FROZEN EMBRYO TRANSFER Jessica Almgren-Bell, BA</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>P-89 EFFECT OF REDUCING THE VITRIFICATION AND WARMING TIMES ON BLASTOCYST SURVIVAL AND PREGNANCY RATES Khalied Kaskar, HCLD, PhD</td>
</tr>
<tr>
<td>1:35 PM</td>
<td>P-90 INJECTION-FREE CONTROLLED OVARIAN STIMULATION: FEASIBILITY OF A SUBCUTANEOUS CATHETER IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION FOR IN-VITRO FERTILIZATION OR OOCYTE CRYOPRESERVATION Rachel S. Mandelbaum, MD</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>P-91 IN VITRO FERTILIZATION (IVF) AND INTRATUMORINE INSEMINATION WITH OR WITHOUT OVULATION INDUCTION (IUI+OI) TREATMENTS AND THEIR IMPACT ON PLACENTAL CHARACTERISTICS Panagiotis Cherouveim, MD, MS</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>P-92 PATERNAL AGE IS NOT RELATED WITH OBSTETRICS AND PERINATAL OUTCOMES OF CHILDREN FROM COUPLES OF INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITH AUTOLOGOUS SPERM AND AUTOLOGOUS OOCYTES Ana Navarro Gomez-Lechon, MSc</td>
</tr>
<tr>
<td>1:50 PM</td>
<td>P-93 AN EVALUATION OF TERATOSPERMIA (TS) ON EMBRYO OUTCOMES UTILIZING FRESH DONOR OOCYTES UTILIZING INTRACYTOPLASMIC SPERM INJECTION (ICSI) AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) Lisa A. McNamee, MD</td>
</tr>
<tr>
<td>1:55 PM</td>
<td>P-94 MII OOCYTES OBTAINED FROM CYCLES WITH A HIGH PROPORTION OF IMMATURE OOCYTES UNDER CONTROLLED OVARIAN STIMULATION HAVE LOW FERTILIZATION AND DEVELOPMENTAL COMPETENCES Masashi Shioya, MSc</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>P-95 FROZEN EMBRYO TRANSFERS WITH ZONA-FREE BLASTOCYSTS HAVE SIGNIFICANTLY LOWER PREGNANCY AND LIVE BIRTH RATES Ying Ying, PhD</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>P-96 TITLE: THE IMPACT OF SPERM SOURCE ON THE EMBRYO CELL DIVISION’S TIME: A TIME-LAPSE ANALYSIS Marta Ribeiro Hentschke, MD, PhD</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>P-97 AN UPDATED ANALYSIS OF THE ASSOCIATION BETWEEN ESTRADIOL LEVELS AT TIME OF TRANSFER AND SMALL FOR GESTATIONAL AGE INFANTS Jacob Fletcher, DO</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>P-98 RECIPIENT AGE DOES NOT AFFECT UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) OR PREGNANCY OUTCOMES IN FROZEN EMBRYO TRANSFERS USING FRESH OR PREVIOUSLY FROZEN DONOR OOCYTES Emily Auran Clarke, MD</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>P-99 IS THERE A RELATIONSHIP BETWEEN MITOSCORE, CLINICAL PREGNANCY AND LIVE BIRTH RATE? Talia Neally, BA</td>
</tr>
<tr>
<td>2:25 PM</td>
<td>P-100 UTILITY OF DIFFERENT SPERM DNA FRAGMENTATION TESTS FOR THE ASSESSMENT OF MALE FACTOR AND REPRODUCTIVE OUTCOMES IN AUTOLOGOUS CYCLES Juan A. Garcia-Velasco, MD, PhD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>P-101 FEASIBILITY OF INJECTING IMMATURE M1 OOCYTES IN TERMS OF BLASTOCYST AND EUPLOIDY RATES Haley N. Teets, BS</td>
</tr>
<tr>
<td>2:35 PM</td>
<td>P-102 IMPROVEMENT IN SPERM DNA FRAGMENTATION INDEX IS OBSERVED AT 15 MINUTES INCUBATION TIME BUT NOT WITH LONGER INCUBATION TIMES USING THE MICROFLUIDICS SPERM SORTING SYSTEM Firuza R Parikh, MD</td>
</tr>
<tr>
<td>2:40 PM</td>
<td>P-103 PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) OF A DONOR OOCYTE DOES NOT IMPROVE LIVE BIRTH RATE (LBR) FOLLOWING FROZEN EMBRYO TRANSFER (D-FET) REGARDLESS OF BLASTOCYST MORPHOLOGIC GRADE (MG) Alyson Dennis, BA</td>
</tr>
</tbody>
</table>
PSM-07 Fertility Preservation 2

1:30 PM P-104 HOW DO PATHOGENIC VARIANTS OF BRCA1/2, CHEK2, AND PMS2 AFFECT THE OUTCOME OF IVF AND PGT-A/M CYCLES IN YOUNG WOMEN WITH BREAST CANCER (YWBC) AND THOSE WHO ARE CANCER FREE? Maya Sharon-Weiner, MD

1:35 PM P-105 INVESTIGATION OF THE EFFECT OF SMOKING ON BASELINE ANTI-MULLERIAN HORMONE (AMH) LEVELS IN YOUNG WOMEN NEWLY DIAGNOSED WITH BREAST CANCER IN A PROSPECTIVE PAN-CANADIAN STUDY Maya Sharon-Weiner, MD

1:40 PM P-106 OOCYTE CRYOPRESERVATION (OC) CYCLES WERE NOT IMPACTED BY THE HUMAN MENOPAUSAL GONADOTROPIN (HMG) SHORTAGE Skyler Finning, MD

1:45 PM P-107 PLANNED OOCYTE CRYOPRESERVATION OUTCOMES IN PHYSICIANS COMPARED TO NON-PHYSICIANS Marissa G. Holden, BA, MD

1:50 PM P-108 INSURANCE COVERAGE AND PERCEPTIONS OF FERTILITY TREATMENT IN OB/GYN RESIDENCY Megha Prasad, BA

1:55 PM P-109 SIGNIFICANT INTER-PATIENT VARIATIONS IN FOLLICULAR SEX STEROIDS AND PEPTIDE HORMONES IN WOMEN TRANSPLANTED WITH CRYOPRESERVED OVARIAN TISSUE - A CASE SERIES Stine Gry Kristensen, PhD

2:00 PM P-110 PERINATAL OUTCOMES ARE BETTER FOLLOWING FROZEN EMBRYO TRANSFER VERSUS FRESH EMBRYO TRANSFER FROM FROZEN OOCYTES IN AUTOLOGOUS IVF CYCLES Ravi Agarwal, MD

2:05 PM P-111 IMPACT OF EMPLOYER COVERAGE OF PLANNED OOCYTE CRYOPRESERVATION ON DECISION-MAKING IN MEDICAL TRAINING Hana Grace Murphy, BA

2:10 PM P-112 DO AGE-SPECIFIC RECOMMENDATIONS FOR ELECTIVE OOCYTE CRYOPRESERVATION PROVIDE REALISTIC EXPECTATIONS? David Boedeker, DO, MHA

2:15 PM P-113 PREDICTING THE PROBABILITY OF RETURN AFTER OOCYTE CRYOPRESERVATION: A MACHINE LEARNERS APPROACH USING THE SART DATABASE Yuval Fouks, MD

2:20 PM P-114 WINDOW OF OPPORTUNITY: RATE OF REFERRAL TO INFERTILITY PROVIDERS AMONG REPRODUCTIVE AGE WOMEN WITH NEWLY DIAGNOSED GYNECOLOGIC CANCERS Emily H. Frisch, MD

2:25 PM P-115 FERTILITY AFTER ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA AND ENDOMETRIAL CANCER: OVULATION INDUCTION MAY SHORTEN TIME TO CONCEPTION Lindsay A. Hartup, MD

2:30 PM P-116 DEMOGRAPHIC AND ETHNIC CHARACTERISTICS OF PATIENTS UNDERGOING ELECTIVE OOCYTE CRYOPRESERVATION AT A PRIVATE FERTILITY CENTER Janelle M. Jackman, MBBS

2:35 PM P-117 CONCEPTION RATES AFTER CANCER USING CRYOPRESERVED EMBRYOS Hazel B. Nichols, PhD

2:40 PM P-118 A CASE REPORT OF GATA2 DEFICIENCY AND OUTCOME OF OOCYTE PRESERVATION Christina J. Ge, MD

PSM-08 Special Populations

1:30 PM P-119 RECIPROCAL IVF: HOW OFTEN IS IT BEING INCLUDED ON SART MEMBER WEBSITES? Chloe Heather Van Dorn, MPH

1:35 PM P-120 CRITICAL DEMOGRAPHIC CHANGES AMONG SPERM DONATION RECIPIENTS OVER THREE DECADES Itai Gat, MD

1:40 PM P-121 THE EFFECTS OF EDUCATION ON TRANSGENDER CARE IN AN URBAN FERTILITY CLINIC Dana Sullivan, DNP, BSN

1:45 PM P-122 THOUGHTS AND OPINIONS ABOUT FERTILITY PRESERVATION AND FAMILY BUILDING FROM THE TRANSGENDER COMMUNITY – AN INTERVIEW BASED APPROACH Katelin G. McDilda, MD

1:50 PM P-123 TIME TO CLINICAL PREGNANCY LEADING TO LIVE BIRTH IN CO-IVF VERSUS IVF CYCLES INVOLVING HETEROSEXUAL COUPLES AND SINGLE FEMALES Arthur Edwin Hale III, MS

1:55 PM P-124 VALIDATING DRIED BLOOD SPOT ASSAYS FOR ANTI-MÜLLERIAN HORMONE ASSESSMENT IN CHILDREN Kathryn L. McElhinney, MD

2:00 PM P-125 SUPPORTING OUR TROOPS: 20 YEARS OF FERTILITY TRENDS AMONG ACTIVE DUTY AND VETERAN SERVICEMEMBERS SEEKING FERTILITY CARE AT A MAJOR URBAN FERTILITY CENTER Samantha Lauren Estevez, MD

2:05 PM P-126 IN VITRO FERTILIZATION AND OOCYTE CRYOPRESERVATION OUTCOMES IN TRANSGENDER INDIVIDUALS WITH AND WITHOUT PRIOR TESTOSTERONE THERAPY
<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Number</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:10 PM</td>
<td>P-127</td>
<td>BARRIERS INFLUENCING DECISION TO PURSUE FERTILITY PRESERVATION PRIOR TO GENDER-AFFIRMING SURGERY AMONG TRANSGENDER MEN/GENDER NON-BINARY PERSONS</td>
<td>Austin Johnson, MD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>P-128</td>
<td>FERTILITY TREATMENTS AMONG THE TRANSGENDER COMMUNITY: DEMOGRAPHICS, TYPE OF TREATMENTS AND CLINICAL OUTCOMES</td>
<td>Mireia Florensa, MSc</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>P-129</td>
<td>FOLLICULAR FLUID OF ADOLESCENTS UNDERGOING FERTILITY PRESERVATION IS MORE PRO-INFLAMMATORY COMPARED TO OOCYTE DONORS</td>
<td>Sophia Ayomide Akinboro</td>
</tr>
<tr>
<td>2:25 PM</td>
<td>P-130</td>
<td>PARENTHOOD DESIRE (PD) AND KNOWLEDGE OF ASSISTED HUMAN REPRODUCTION (AHR) IN CHILDLESS SEXUAL MINORITY QUEER MEN (SMQM)</td>
<td>Amar A. Mamone, BMSc</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>P-131</td>
<td>TEMPORAL TRENDS IN AGE AT MENARCHE AMONG FEMALES BORN BETWEEN 1931 AND 2005 IN A US-BASED DIGITAL COHORT</td>
<td>Zifan Wang, PhD, MS</td>
</tr>
<tr>
<td>2:35 PM</td>
<td>P-132</td>
<td>FERTILITY PRESERVATION COUNSELING AND REFERRAL RATES PRIOR TO INITIATION OF GENDER AFFIRMING HORMONE THERAPY IN TRANSGENDER AND NON-BINARY ADOLESCENTS</td>
<td>Marissa G. Holden, BA, MD</td>
</tr>
<tr>
<td>2:40 PM</td>
<td>P-133</td>
<td>TESTICULAR VOLUME IN 268 CHILDREN AND ADOLESCENTS FOLLOWED-UP FOR CHILDHOOD OBESITY - A RETROSPECTIVE CROSS-SECTIONAL STUDY</td>
<td>Rossella Cannarella, MD, PhD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>P-134</td>
<td>THE VALUE OF ANDROGEN MEASURES FOR DIAGNOSING CLASSIC POLYCYSTIC OVARIAN SYNDROME (PCOS) IN AN UNSELECTED POPULATION</td>
<td>Lauren Pace, MD</td>
</tr>
<tr>
<td>1:35 PM</td>
<td>P-135</td>
<td>HOW FREQUENTLY IS ULTRASOUND REQUIRED TO DIAGNOSE THE PRESENCE OR ABSENCE OF POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A CLINICAL POPULATION?</td>
<td>Lauren Pace, MD</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>P-136</td>
<td>EARLY PROGESTERONE RISE IN THE FOLLICULAR PHASE: PREDICTOR OF ANOVULATION?</td>
<td>Aparna A. Divaraniya, PhD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>P-137</td>
<td>NOVEL ANTI-MULLERIAN HORMONE RECEPTOR 2 BINDING PEPTIDE (AMHR2BP) SIMULATES AMH MECHANISM OF ACTION</td>
<td>Laura Detti, MD</td>
</tr>
<tr>
<td>1:50 PM</td>
<td>P-138</td>
<td>OBSTETRIC CHARACTERISTICS AND OUTCOME OF PREGNANT PATIENTS WITH TURNER SYNDROME</td>
<td>Zachary S. Anderson, MD</td>
</tr>
<tr>
<td>1:55 PM</td>
<td>P-139</td>
<td>IN-VITRO GATA2 OVEREXPRESSION REVERSES DECIDUALIZATION DEFECTS BY IMPROVING ENDOMETRIAL RECEPTIVITY MARKERS IN HUMAN ENDOMETRIAL STROMAL CELLS FROM PATIENTS WITH ADENOMYOSIS</td>
<td>Zoran J. Pavlovic, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>P-140</td>
<td>FUNCTIONAL HYPOTHALAMIC AMENORRHEA AND PROINFLAMMATORY CYTOKINES</td>
<td>Mariam Saadedine, MD</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>P-141</td>
<td>PLASMA AND WATER FLUORIDE CONCENTRATIONS IN RELATION TO LEVELS OF SEX HORMONES AMONG US ADOLESCENTS</td>
<td>Rachel Fricker, BS</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>P-142</td>
<td>COVID-19 INFECTION AND VACCINATION DURING PREGNANCY AND RISK OF ADVERSE NEURODEVELOPMENT IN EARLY CHILDHOOD: RESULTS FROM THE ASPIRE STUDY</td>
<td>Eleni Jaswa, MD, MSc</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>P-143</td>
<td>FERTILITY, FOOD AND FITNESS IN FUNCTIONAL HYPOTHALAMIC AMENORRHEA: A MIXED-METHODS STUDY</td>
<td>Melody A. Rasouli, MD, MBA</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>P-144</td>
<td>SYMPTOMATIC UTERINE FIBROID TREATMENT: A PILOT STUDY BETWEEN A LONG ACTING GNRH ANTAGONIST AND AN ORAL GNRH ANTAGONIST</td>
<td>Fabio Scarpellini, MD</td>
</tr>
<tr>
<td>2:25 PM</td>
<td>P-145</td>
<td>FUNCTIONAL HYPOTHALAMIC AMENORRHEA AND VASCULAR FUNCTION: IS ESTROGEN ENOUGH? RESULTS FROM A RANDOMIZED CONTROLLED TRIAL</td>
<td>Chrisandra Shufelt, MD, MS</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>P-146</td>
<td>PREGNANCY-RELATED FACTORS AND UTERINE FIBROID INCIDENCE: THE STUDY OF ENVIRONMENT, LIFESTYLE &amp; FIBROIDS (SELF), A PROSPECTIVE ULTRASOUND STUDY AMONG SELF-IDENTIFIED BLACK/AFRICAN AMERICAN WOMEN</td>
<td>Donna D. Baird, PhD, MPH</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>P-147</td>
<td>NON-INVASIVE ANALYSIS OF VITRIFIED-WARMED BLASTOCYSTS: PREDICTION OF ONGOING PREGNANCY BASED ON PROTEOMIC PROFILING</td>
<td>Lorena Bori Arnal, PhD</td>
</tr>
<tr>
<td>1:35 PM</td>
<td>P-148</td>
<td>CLEAVAGE STAGE EMBRYO FRAGMENTATION SCORE IS ASSOCIATED WITH PREGNANCY LOSS AFTER EUPLOID EMBRYO TRANSFER</td>
<td>Laura Detti, MD</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS AND ABSTRACTS

1:40 PM  P-149  THE EFFECT OF INTRAOVARIAN PLATELET-RICH PLASMA INJECTION ON THE DEVELOPMENT OF OVARIAN FOLLICLES IN THE RAT IN VIVO MODEL OF PREMATURE OVARian INSUFFICIENCY

1:45 PM  P-150  COMPARING PREGNANCY RATES FOR IVF WITH PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY AND IUI IS NOT ENOUGH: DISPARITY IN MISCARRIAGE RATES FURTHER FAVORS IVF WHEN EVALUATING TIME TO LIVE BIRTH

1:50 PM  P-151  DO THE DIFFERENT LUTEAL PROGESTERONE SUPPORT REGIMENS AFFECT THE SERUM PROGESTERONE LEVELS AND LIVE BIRTH RATES IN FROZEN-THAWED EMBRYO TRANSFER CYCLES? A RANDOMIZED PROSPECTIVE STUDY

1:55 PM  P-152  LUTEAL PHASE STIMULATION FOLLOWING FOLLICULAR PHASE OOCYTE RETRIEVAL INCREASES THE TOTAL NUMBER OF OOCYTES RETRIEVED AND BLASTOCYST FORMED IN WOMEN WITH DOR AND SPLIT COHORTS

2:00 PM  P-153  VARIATION IN PRACTICE PATTERNS SURROUNDING VITAMIN D TESTING AND SUPPLEMENTATION AMONG INFERTILITY PATIENTS

2:05 PM  P-154  FIRST TRIMESTER SUBCHORIONIC HEMATOMA AND EARLY PREGNANCY LOSS IN PATIENTS UNDERGOING FERTILITY TREATMENT

2:10 PM  P-155  IMPACT OF SMOKING ON PREGNANCY OUTCOMES IN INFERTILE WOMEN IN THE NETHERLANDS: AN INDIVIDUAL PATIENT DATA ANALYSIS

2:15 PM  P-156  MODIFIED NATURAL ENDOMETRIAL PREPARATION MAXIMIZES FET OUTCOMES

2:20 PM  PP-157  ASSOCIATION OF FOLLICULAR PHASE LENGTH (FPL) AND EARLY PREGNANCY LOSS (EPL) IN WOMEN WITH UNEXPLAINED INFERTILITY UNDERGOING OVARian STIMULATION WITH INTRAUTERINE INSEMINATION (OS-IUI) CYCLES

2:25 PM  P-158  IS THERE A BENEFIT TO EUPLOID DOUBLE EMBRYO TRANSFER IN PATIENTS WITH A HISTORY OF AT LEAST 1 FAILED SET?

2:30 PM  P-159  NONRECEPTIVE ENDOMETRIAL RECEPTIVITY ASSAY RESULT DID NOT PREDICT FAILED IMPLANTATION: A NESTED NON-SELECTION STUDY WITHIN A RANDOMIZED CLINICAL TRIAL

2:35 PM  P-160  BLASTOCYST QUALITY BUT NOT ANEUPLOIDY IS AFFECTED BY ADVANCED PATERNAL AGE IN DONOR OOCYTE IVF CYCLES

2:40 PM  P-161  UTILIZING NUMBER OF 2PNs TO OPTIMIZE CUMULATIVE PREGNANCY OUTCOMES IN FRESH AND FREEZE-ALL CYCLES WITH AND WITHOUT PREIMPLANTATION GENETIC TESTING FOR ANEUPLOID (PGT-A)
<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>PSM-11</td>
<td>Welcoming Remarks</td>
<td></td>
</tr>
<tr>
<td>3:35 PM</td>
<td>P-162</td>
<td>IS BETA HUMAN CHORIONIC GONADOTROPIN (B-HCG) RISE ASSOCIATED WITH PLACENTAL PATHOLOGY FOLLOWING IN VITRO FERTILIZATION (IVF)-CONCEIVED SINGLETON LIVEBIRTHS?</td>
<td>Panagiotis Cherouveim, MD, MS</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>P-164</td>
<td>CORRELATION BETWEEN LIVE BIRTH AND SERUM ESTRADIOL CONCENTRATION ON THE DAY OF EXOGENOUS PROGESTERONE START IN HORMONE REPLACED SINGLE FROZEN EMBRYO TRANSFER</td>
<td>Adriana Nicholson Vest, MD, PhD</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>P-165</td>
<td>IMPACT OF HGH PREOVULATORY ESTRADIOL ON REPRODUCTIVE OUTCOMES IN GONADOTROPIN-RELEASING HORMONE AGONIST-TRIGGERED CYCLES WITH FRESH EMBRYO TRANSFER: A RETROSPECTIVE STUDY</td>
<td>Abdelhamid Bennmachiche, MD</td>
</tr>
<tr>
<td>3:50 PM</td>
<td>P-166</td>
<td>REDEFINING THE NORMAL: THE NECESSITY TO RE-EVALUATE BASAL FSH RANGES FOR ACCURATE OVARIAN RESPONSE PREDICTION</td>
<td>Raquel Del Gallego, MSc</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>P-167</td>
<td>CENTER-VARIATION OF PATIENTS’ CLINICAL PROFILES IS ASSOCIATED WITH IVF LIVE BIRTH OUTCOMES</td>
<td>Trevor J. Swanson, PhD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>P-168</td>
<td>AN EX VIVO POLYCYSTIC OVARY TO DECIPHER PCOS-RELATED HYPERANDROGENISM AND OTHER OVARIAN DISORDERS</td>
<td>Ying Zhang, MD, PhD</td>
</tr>
<tr>
<td>4:05 PM</td>
<td>P-169</td>
<td>OVEREXPRESSION OF B-CELL LYMPHOMA 6 (BCL6) DOES NOT CORRELATE WITH A NON-RECEPTIVE ENDOMETRIAL RECEPTIVITY ANALYSIS (ERA) RESULT ON IMPLANTATION WINDOW ENDOMETRIAL BIOPSIES</td>
<td>David Huang, MD</td>
</tr>
<tr>
<td>4:10 PM</td>
<td>P-170</td>
<td>COMPARISON OF OUTCOMES FROM CONTROLLED OVARIAN HYPERSTIMULATION (COH) CYCLES USING HUMAN MENOPAUSAL GONADOTROPINS (HMG) VERSUS DILUTE HUMAN CHORIONIC GONADOTROPINS (DHCG)</td>
<td>Peter G. Lindner, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>P-171</td>
<td>LIVEBIRTH ACHIEVED IN A CASE OF HYPERGONADOTROPIC HYPOGONADISM NONOBSTRUCTIVE AZOOSPERMIA, TREATED WITH GnRH AGONIST AND GONADOTROPHINS</td>
<td>Amanda Souza Setti, MSc</td>
</tr>
<tr>
<td>4:20 PM</td>
<td>P-172</td>
<td>CLINICAL OUTCOMES AND MORPHOKINETICS AFTER INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING EXTRACTED TESTICULAR SPERM OR EJACULATED SEVERE OLIGO-ASTHENOTERATOZOOSPERMIA (OAT) SPERM: A COMPARATIVE STUDY</td>
<td>Jungmi Jang, MSc</td>
</tr>
<tr>
<td>4:25 PM</td>
<td>P-173</td>
<td>DOES RECURRENT IMPLANTATION FAILURE EXIST? PREVALENCE AND OUTCOMES OF FIVE CONSECUTIVE EUPLOID BLASTOCYST TRANSFERS IN 123,987 PATIENTS</td>
<td>Pavan Gill, MD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>PSM-12</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>3:35 PM</td>
<td>P-174</td>
<td>EFFICACY OF MEDICAL AND SURGICAL INTERVENTIONS TO DECREASE BLOOD LOSS DURING LAPAROSCOPIC MYOMECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS.</td>
<td>Maria Ofelia Sordia Pineyro, MD</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>P-175</td>
<td>PREGNANCY AND DELIVERY OUTCOMES AFTER ABDOMINAL MYOMECTOMY (AM) VS LAPAROSCOPIC MYOMECTOMY (LM): AN EVALUATION OF AN AMERICAN POPULATION DATABASE</td>
<td>Perrine Ginod, MD, resident</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>P-176</td>
<td>TRANSVAGINAL OVARIAN DRILLING PRIOR TO IN VITRO FERTILIZATION MARKEDLY INCREASES THE PERCENT AND YIELD OF EUPLOID BLASTOCYSTS IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME</td>
<td>Moses Bibi, BS</td>
</tr>
<tr>
<td>3:50 PM</td>
<td>P-177</td>
<td>MANAGEMENT OF ENDOMETRIOSIS OF THE APPENDIX</td>
<td>Sivani Aluru, MD</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>P-178</td>
<td>PREGNANCY AND LIVE BIRTH OUTCOMES IN PATIENTS WITH SECONDARY INFERTILITY UNDERGOING LAPAROSCOPIC Isthmocele REPAIR: A RETROSPECTIVE STUDY OF A PROSPECTIVELY MAINTAINED DATABASE</td>
<td>Mary McKenna, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>P-179</td>
<td>RESCUE OOCYTE RETRIEVAL EFFICIENTLY RECOVERS THE OOCYTE FROM EARLIER RUPTURED FOLLICLES IN CONTROLLED OVARIAN STIMULATION</td>
<td>Zitao Liu, MD, PhD</td>
</tr>
<tr>
<td>4:05 PM</td>
<td>P-180</td>
<td>IS THERE SUCH A THING AS TOO EARLY? EFFECT OF EARLY EMBRYO TRANSFER AFTER HYSTEROSCOPIC POLYPECTOMY ON LIVE BIRTH AND OTHER PREGNANCY OUTCOMES</td>
<td>Ariel J. Dunn, MD</td>
</tr>
<tr>
<td>4:05 PM</td>
<td>P-181</td>
<td>EVERY MINUTE COUNTS: THE ASSOCIATION OF OPERATIVE TIME AND POSTOPERATIVE</td>
<td></td>
</tr>
</tbody>
</table>
COMPLICATIONS FOR PATIENTS UNDERGOING MINIMALLY INVASIVE AND ABDOMINAL MYOMECTOMY Jeremy Applebaum, MD

4:10 PM P-182 EFFECT OF SPERMATIC VEIN SIZE ON OUTCOME OF VARICOCELE LIGATION Khalid Jassim Alkubaisi, BA, MBBCCH

4:15 PM P-183 PATIENT SATISFACTION AND LONG-TERM CLINICAL OUTCOMES IN ADOLESCENT SUB-INGUINAL MICROSCOPIC VARICOCELECTOMY Francis Petrella, MD

4:20 PM P-184 REPAIR OF ISTHMOCELE CONTAINING RETAINED PRODUCTS OF CONCEPTION AFTER FROZEN EMBRYO TRANSFER Dustin Dutcher, BS

4:25 PM P-185 THE ROLE OF PELVIC IMAGING IN THE DIAGNOSIS AND TREATMENT OF DEEP ENDOMETRIOSIS Nicolas A. Johnson, MD

PSM-13 Genetics 1

3:30 PM P-186 MITOPHAGY-REGULATING GENE PARKIN IS REQUIRED FOR FEMALE FERTILITY Adolfo Rodriguez Eguren, MSc

3:35 PM P-187 VALIDATION STUDY OF ORCHID’S WHOLE GENOME SCREENING PREIMPLANTATION GENETIC TESTING Maria H. J. Katz, MSc

3:40 PM P-188 NANOPORE BASED NON-INVASIVE PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) ON SPENT CULTURE MEDIUM, A PRE-CLINICAL STUDY Franziska Hanzer, BSc

3:45 PM P-189 INCREASED NEXT GENERATION SEQUENCING (NGS) POWER CAN LEAD TO SIGNIFICANT IMPROVEMENTS IN PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) RESULTS Kristine McWilliams, HCLD, MD, PhD


3:55 PM P-191 DOUBLE EMBRYO TRANSFER (DET) WITH MOSAIC EMBRYOS HAVE EQUIVALENT LIVE BIRTH AND MULTIPLE PREGNANCY RATES AS EUPLOID DET Amelia G. Kelly, MD

4:00 PM P-192 BLASTOCYST QUALITY IS CORRELATED WITH THE INCIDENCE OF CHAOTIC RESULTS ON PGT-A Paulina Nassab, MS, CGC

4:05 PM P-193 RESULTS OF CONCURRENT PREIMPLANTATION GENETIC TESTING FOR MONOGENIC CONDITIONS (PGT-M), STRUCTURAL REARRANGEMENTS (PGT-SR), AND ANEUPLOIDY (PGT-A); SETTING PATIENT EXPECTATIONS Jeannie Klavanian, MSc

4:10 PM P-194 COMPARATIVE ANALYSIS OF WHOLE EXOMES SEQUENCING DATA TO CALL GENE VARIANTS WITHIN A GENE LIST ASSOCIATED TO MONOGENIC INFERTILITY IN FEMALE IVF PATIENTS VS FEMALE GAMETE DONORS Julio Martin, PhD

4:15 PM P-195 EFFECT OF OOCYTE CRYOPRESERVATION IN IVF CYCLES AND EMBRYO ANEUPLOIDY Amanda Maia Alvarenga, BSc

4:20 PM P-196 AN EVALUATION OF A PREDICTIVE MODEL FOR EMBRYO EUPLOIDY BASED ON LOCALIZATION OF OOCYTE MEIOTIC SPINDLE FOR SUCCESSFUL IVF IN PGT-A CYCLE Sola Yoon, BS

4:25 PM P-197 UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS AMONGST INFERTILITY PATIENTS MEETING HEREDITARY CANCER SCREENING CRITERIA Stephanie Willson, MD

4:30 PM P-198 RETESTING EMBRYOS INITIALLY REPORTED AS CHAOTIC BY PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A): WHAT IS SURVIVAL AND EUPLOIDY RATE? Lucy Xi Chen, MD

4:35 PM P-199 UNRAVELLING THE TRANSCRIPTOMIC CONTRIBUTION OF THE MATERNAL HAPLOID GENOME IN EARLY EMBRYO DEVELOPMENT WITH A UNIPARENTAL SINGLE CELL LEVEL APPROACH Pedro De Castro, MSc

4:40 PM P-200 COMPARISON OF IVF OUTCOMES FROM USE OF 2 DIFFERENT PGT-A LABORATORIES Carlos Navarro Martinez, MD

PSM-14 Pre-Clinical & Basic Research 2

3:30 PM P-201 SINGLE-CELL SEQUENCING ANALYSIS REVEALS THE UNIQUE DEATH PATTERN OF TESTICULAR SOMATIC CELLS IN NON-OBSTRUCTIVE AZOOSPERMIA PATIENTS Haicheng Chen, Dr

3:35 PM P-202 FUNCTION OF LONG-NON CODING RNA MD1 IN LEIOMYOMA PATHOGENESIS Tsai-Der Chuang, PhD

3:40 PM P-203 ADVANCES IN ENDOMETRIOSIS THERAPY: UPTAKE OF SYSTEMATICALLY DELIVERED MAGNETIC NANO- PARTICLES BY SPONTANEOUS ENDOMETRIOTIC LESIONS IN
Rhesus Macaques

3:45 PM P-204 differential expression of mRNA in endometrial organoids growth with and without platelet-rich plasma: investigating the molecular effects of platelet-rich plasma in vitro

Ov D. Slayden, PhD

3:50 PM P-205 ovarian aging is associated with enhanced ovarian FKBP51 expression: a molecular insight for age-related female fertility

Michelle Kappy, MD

3:55 PM P-206 evaluation of single strand DNA (ssDNA) damage in sperm using novel repair assisted damage detection (RADD) technique

Dror Meirow, Prof

4:00 PM P-207 the effect of oxygen concentration on telomeres in mouse blastocysts developed from zygotes

Fang Wang, PhD

4:05 PM P-208 functional implications of extrachromosomal circular DNA (eccDNA) in the male germline

Andrew J. Claffey, MD

4:10 PM P-209 cumulus matrix enriched medium affects sperm motility

B Sc

4:15 PM P-210 dispensing the smokescreen: CoQ10 improves decidualization of induced pluripotent stem cell derived endometrial stromal fibroblasts and ameliorates aberrant vascularization mediated by vapi

Liquid

4:20 PM P-211 aspirin successfully alleviates the gonadotoxicity of cyclophosphamide and doxorubicin in a murine model

Chu-Chun Huang, MD, PhD

4:25 PM P-213 functional assessment of human endometrial organoid responsiveness to a sequentially controlled hormonal treatment mimicking menstrual cycle

Yanyu Jiang, MD

4:30 PM P-214 mitigating age-related ovarian dysfunction with MIT-001: an anti-inflammatory agent

Jae Ho Lee, PhD

4:35 PM P-215 elucidating somatic interstitial cell and ovarian follicle crosstalk: insights from a cross species model

Min Xu, PhD

PSM-15 Art 3

3:30 PM P-216 association of maternal age with human embryonic division and clinical outcomes

Dae-Han Kim, Master

3:35 PM P-217 comparison of quick versus traditional warming protocols post-vitrification: cryo-survival & frozen embryo transfer (FET) outcomes

Sameen Raza, BS

3:40 PM P-218 improvements to intracytoplasmic sperm injection facilitated by a micron-3D printed device

Megan P. Inge, BSc(Hons), MSc(Clinical Embryology)

3:45 PM P-219 progestin ovulation suppression for in vitro fertilization – an inclusive prospective cohort trial

Linnea R. Goodman, MD

3:50 PM P-220 there is no dose dependent effect on oocyte maturity in autologous oocyte cryopreservation (OC) cycles with co-administration of letrozole (LET)

Nirali Jain, MD

3:55 PM P-221 pregnancy outcomes of in vitro fertilization cycles with embryo donation compared to double gamete donation

Shelun Tsai, MD

4:00 PM P-222 beyond the egg: sperm source and sperm age do not impact cumulative live birth rates (CLBR) in oocyte cryopreservation (OC) patients (PTS)

Jillian Pecriorelli, MD

4:05 PM P-223 might piezo-ICSI be an alternative to conventional ICSI in patients with low fertilization rates?

Yigit Cakiroglu, MD

4:10 PM P-224 paternal obesity is associated with delayed blastocyst development in euploid embryos

Katya J Macias, MS

4:15 PM P-225 the effect of incubation period after warming on reproductive outcomes of frozen single blastocyst transfer

Eun A. Park, MS

4:20 PM P-226 the rebiopsy and refreeze of blastocyst negatively impacts the single euploid embryo transfer (SET) outcomes

Min Xu, PhD
**POSTER PRESENTATIONS AND ABSTRACTS**

**4:25 PM  P-227 BLASTOCYST FORMATION RATES COMPARING EJACULATED SPERM WITH OR WITHOUT THE USE OF ZYMOT** Robert Rydze, MD, MS

**4:30 PM  P-228 PRETERM BIRTH IN ASSISTED REPRODUCTION: THE MEDIATING ROLE OF HYPERTENSIVE DISORDERS IN PREGNANCY** Sindre Hoff Hoff Petersen, MD, PhD

**4:35 PM  P-229 WHAT IS THE OPTIMAL MODIFIED NATURAL FROZEN EMBRYO TRANSFER PROTOCOL?** Courtney Hargreaves, MD

**4:40 PM  P-230 IDENTIFYING FACTORS THAT DIMINISH THE EFFECTIVENESS OF A SPERM SEX SELECTION TECHNIQUE IN COUPLES UNDERGOING INTRAUTERINE INSEMINATION** Stephanie Cheung, MS

---

**Tuesday, October 17, 2023**

**PST-01 ART 4**

**10:45 AM  P-231 IMPORTANCE OF ADVANCED BLASTOCYST STAGE VERSUS ICM OR TE GRADES IN OLDER AGE GROUP FOR ACHIEVING CLINICAL PREGNANCY** Hyung Min Kim, PhD

**10:50 AM  P-232 INTRACYTOPLASMIC SPERM INJECTION IN NON-MALE FACTOR INFERTILITY MAY HAVE UNINTENDED CONSEQUENCES ON MATERNAL-FETAL OUTCOMES WHEN COMPARED TO CONVENTIONAL IN VITRO FERTILIZATION** Zachary Ferraro, MD, PhD

**10:55 AM  P-233 A NATIONWIDE SURVEY ASSESSING THE PREDISPOSITION TOWARDS GESTATIONAL SURROGACY (GS) AMONG REPRODUCTIVE AGE WOMEN IN ARGENTINA** Adan Nabel, MD

**11:00 AM  P-234 FIVE-YEAR FOLLOW-UP OF BABIES BORN DERIVED FROM MONO-PRONUCLEAR ZYGOTES** Haruhisa Tsuji, MS

**11:05 AM  P-235 MULTI-OMICS ANALYSIS OF SEMINAL PLASMA IN NOA MEN TO PREDICT SUCCESSFUL TESTICULAR SPERM RETRIEVAL** Lily Ng, BS

**11:10 AM  P-236 TIMING OF MICRO-TESE IN NOA PATIENT DOES NOT AFFECT ICSI CLINICAL OUTCOME** Lily Ng, BS

**11:15 AM  P-237 EFFECTS OF ANONYMOUS FROZEN DONOR SPERM PURCHASED FROM COMMERCIAL DONOR SPERM COMPANIES ON INVOCELL CYCLE OUTCOMES** Callie Barnwell Barnwell Gibson, PhD

**11:20 AM  P-238 MATERNAL AGE HAS NO IMPACT ON PREGNANCY AFTER TRANSFERRING A SINGLE EUPOID FROZEN BLASTOCYST ANALYZED BY NEXT-GENERATION SEQUENCING** Yousef M. Y. Alhelou, MSc

**11:25 AM  P-239 RAPID VS STANDARD: ULTRAFAST WARMING OF VITRIFIED BLASTOCYSTS DOES NOT ALTER BLASTOCYST COMPETENCY AND STRESS RESPONSE** Olga Chaplia, PhD

**11:30 AM  P-240 A DEEP LEARNING ARTIFICIAL INTELLIGENCE SYSTEM DEVELOPED FOR MANAGEMENT OF OVARIAN STIMULATION IN IVF** John J. Zhang, MD, PhD

**11:35 AM  P-241 LIVE BIRTH FROM IN VITRO FERTILIZATION WITHOUT INJECTIONS OR SERUM HORMONE ASSESSMENT** John J. Zhang, MD, PhD

**11:40 AM  P-242 IVF STIMULATION OPTIMIZED, PERSONALIZED, AND SIMPLIFIED USING AN ADVANCED DECISION-SUPPORT TOOL** Urmila Diwekar, PhD

**11:45 AM  P-243 OUTCOMES OF REPEAT CONTROLLED OVARIAN HYPERSTIMULATION FOLLOWING INITIAL CANCELLATION** Alyson M. Digby, BSc, MD, FRCSC

**11:50 AM  P-244 A SENTIMENT ANALYSIS OF YOUTUBE VIDEOS FROM DONOR-CONCEIVED PEOPLE, UTILIZING ARTIFICIAL INTELLIGENCE (CHATGPT)** Sharon Galperin, MD

**11:55 AM  P-245 AN ARTIFICIAL INTELLIGENCE (MONKEYLEARN) ASSESSMENT OF SENTIMENTS FROM YOUTUBE VIDEOS OF DONOR-CONCEIVED PEOPLE** Sharon Galperin, MD

**12:00 PM  P-246 OBJECTIVE EVALUATION OF EMBRYO QUALITY**
QUALITY USING ARTIFICIAL INTELLIGENCE-BASED CHLOETM SCORE SYSTEM: PREDICTIVE VALUE FOR LIVE BIRTH RATES FOLLOWING DAY 5 SINGLE EMBRYO TRANSFER  
Yuwen Weng, MS

12:05 PM  P-247 EMBRYO THAWING FOR SINGLE OR REPEAT BIOPSY DOES NOT HAVE AN IMPACT ON CLINICAL OUTCOMES FOLLOWING FROZEN EMBRYO TRANSFERS (FET)  
Victoria S. Jiang, MD

12:10 PM  P-248 BLASTULATION RATE IS ASSOCIATED WITH CUMULATIVE SUSTAINED IMPLANTATION AFTER IN VITRO FERTILIZATION (IVF) AND EUPOID FROZEN EMBRYO TRANSFER (FET)  
Lea C. George, MD

PST-02 Pre-Clinical & Basic Research 3

10:45 AM  P-249 SELECTING HEALTHY MALE GAMETES PRIOR TO FERTILIZATION IN A MURINE MODEL OF MARFAN SYNDROME  
Philip Xie, BSc

10:50 AM  P-250 ARTIFICIAL EMBRYONIC ENVELOPE TO SUPPORT HOLOBLASTIC ROTATIONAL CLEAVAGE OF ZONA-FREE CONCEPTUSES  
Philip Xie, BSc

10:55 AM  P-251 IDENTIFICATION OF MALE GAMETES WITH A SPECIFIC GENOTYPE TO PRODUCE OFFSPRING WITH A DESIRED PATERNAL HAPLOTYPE  
Philip Xie, BSc

11:00 AM  P-252 THE EFFECT OF LOVASTATIN AS UP-REGULATED LIPOPROTEIN METABOLISM ENHANCES FOLLICULAR DEVELOPMENT IN MOUSE OVARIIES  
Jae Ho Lee, PhD

11:05 AM  P-253 STEROYL-CoA DESATURASE INHIBITION IS ASSOCIATED WITH DECREASED UTERINE LEIOMYOMA CELL VIABILITY  
Allison S. Komorowski, MD

11:10 AM  P-254 IN VITRO MATURED OOCYTES CO-CULTURED WITH HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED OVARIAN SUPPORT CELLS DISPLAY TRANSCRIPTOMIC QUALITY SIMILAR TO IN VIVO MATURED OOCYTES  
Alexa Giovannini, BSc

11:15 AM  P-255 ACUTE ADMINISTRATION OF MATRIX METALLOPEPTIDASE 9 ENHANCES MYOMETRIAL CONTRACTION  
Craig Ulrich, BS, PhD

11:20 AM  P-256 THE INVOLVEMENT OF RNA N6-METHYLADENOSINE AND HISTONE METHYLATION MODIFICATION IN DECIDUALIZATION AND ENDOMETRIOSIS-ASSOCIATED INFERTILITY  
Xiang Lin, MD

11:25 AM  P-257 NAT10-MEDIATED N4-ACETYLCYTIDINE OF RNA CONTRIBUTES TO TRANSLATIONAL REGULATION OF OOCYTE QUALITY IN MODULATING MURINE LUPUS  
Yun Xie, MD

11:30 AM  P-258 EUOTIC ENDOMETRIAL RE-1 SILENCING TRANSCRIPTION FACTOR IS REDUCED IN PATIENTS WITH ENDOMETRIOSIS AND IS ASSOCIATED WITH CHANGES IN NEURONAL MARKERS AND PAIN-LIKE BEHAVIOR IN A KNOCKOUT MOUSE MODEL  
Paige Minchella, BS

11:35 AM  P-259 MATERNAL, REPRODUCTIVE, AND PERINATAL FACTORS AND THE RISKS OF BIRTH DEFECTS  
Barbara Luke, ScD, MPH

11:40 AM  P-261 SINGLE-CELL RNA-SEQUENCING OF HUMAN OOCYTES ISOLATED FROM EARLY-STAGE FOLLICLES AND THE IMPACTS OF CRYOPRESERVATION ON THE OOCYTE TRANSCRIPTOME  
Jordan H. Machlin, BS, PhD

11:45 AM  P-262 REPEATED ANTIOXIDANT SUPPLEMENTATION OF CULTURE MEDIA IMPROVES BLASTOCYST FORMATION IN HOMOLOGOUS SIBLING ZYGOTES FROM INFERTILE PATIENTS UNDER DIFFERENT O2 CONCENTRATIONS  
Israel Maldonado, BSc, ScD

11:50 AM  P-263 FINE INHALABLE PARTICULATE MATTER (PM2.5) PRESENT IN AIR POLLUTION AND ITS EFFECTS ON MALE GERM CELLS  
Leticia Kaory Tamashiro, BSc

11:55 AM  P-264 CURCUMIN, CURCUMINOIDS, VITAMIN D AND PRODUCTION OF EXTRACELLULAR MATRIX PROTEINS IN UTERINE FIBROIDS  
Minnie Malik, PhD

12:00 PM  P-265 MELATONIN OVERCOMES THE TOXICITY OF OXIDANT ACCUMULATION IN FOLLICULAR FLUID OF WOMEN WITH ENDOMETRIOSIS AND PREVENTS METAPHASE II MOUSE OOCYTE MICROTUBULE-ORGANIZING CENTER DETERIORATION  
Daniel N. Moussa, MD

12:05 PM  P-266 MATERNAL SPINDLE TRANSFER RESTORES THE EMBRYO DEVELOPMENTAL COMPETENCE OF POOR-QUALITY OOCYTES IDENTIFIED NON-INVASIVELY BY HYPERSPECTRAL IMAGING: PROOF OF CONCEPT IN THE MOUSE MODEL  
Nuno Costa Borges, PhD

PST-03 Genetics 2

10:45 AM  P-267 USEFULNESS OF CHROMOSOMAL
<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 AM</td>
<td>P-268</td>
<td>Noninvasive Preimplantation Genetic Testing for Aneuploidies (NIPT-A) X Analysis of the Whole Embryo: High Degree of Concordance Between the Genetic Results</td>
<td>Hakan Kadir Yelke, MSc</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>P-269</td>
<td>PGT-A Is Worth in Women Older Than 35 Years Even If Only 1 or 2 Blastocysts Are Obtained. A Propensity Score Matching Study</td>
<td>Joao B. A. Oliveira, MD, MSc, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>P-270</td>
<td>Basal FSH Levels Are Associated with Embryo Aneuploidy Incidence in Pre-Advanced Maternal Age But Not in Advanced Maternal Age Patients</td>
<td>Mauricio B. Chehin, MD, PhD</td>
</tr>
<tr>
<td>11:05 AM</td>
<td>P-271</td>
<td>Non-invasive PGT for Aneuploidy Detection Using Cell-Free DNA: Effect of Patient Age and Blastocyst Morphology on Concordance with Blastocyst Analysis</td>
<td>Sho Takeda, BS</td>
</tr>
<tr>
<td>11:10 AM</td>
<td>P-272</td>
<td>Impact of Embryo Biopsy for PGT-M Testing on Pregnancy Outcomes</td>
<td>Evelina Manvelyan, MD</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>P-274</td>
<td>Reproductive Outcomes of Females Carrying a FMR1 Mutated Gene</td>
<td>Jesus Aguilar, PhD</td>
</tr>
<tr>
<td>11:20 AM</td>
<td>P-275</td>
<td>Can Computer Vision Identify Features Not Visible to the Human Eye That Can Assist in Non-invasively Identifying Aneuploid Embryos?</td>
<td>Daniella Gilboa, MSc</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>P-276</td>
<td>Distinguishing Mitotic and Meiotic Origin of Trisomy in Trophoderm Biopsies Without Parental DNA</td>
<td>Bhavini Rana, BA</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>P-277</td>
<td>Assessment of Concordance Rates Between Non-invasive PGT-A and Traditional PGT-A of Human Embryos</td>
<td>Durga Gedela Rao Dr, MBBS, MD</td>
</tr>
<tr>
<td>11:35 AM</td>
<td>P-278</td>
<td>Reporting Chromosomal Mosaicism Reduces the Diagnostic Accuracy of Preimplantation Genetic Testing: Results from the Extended in Vitro Culture of 230 Human Embryos</td>
<td>Mina Popovic, MSc, PhD</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>P-279</td>
<td>Analysis of Inter-individual Variation in Chromatin Bivalency in the Human Male Germ Line</td>
<td>Rachel Heuer, BS</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>P-280</td>
<td>Sex Discordance in Frozen Embryo Transfer (FET) Cycles: A Marker for Quality Assurance (QA)</td>
<td>Evelyn Minis, MD</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>P-281</td>
<td>Filling the Gaps: Collaboration Between Reproductive Clinics and Telehealth Genetic Providers to Support Patient Genetic Needs</td>
<td>Pamela Callum, MS</td>
</tr>
<tr>
<td>11:55 AM</td>
<td>P-282</td>
<td>The Ploidy Prediction by Non-invasive Preimplantation Genetic Testing for Aneuploidy in IVF Prognosis</td>
<td>Hui-Hsin Shih, MS</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>P-283</td>
<td>Consistency of Embryo Cell-Free DNA Results with Paired Trophoderm Biopsies and Whole Day-6 Blastocysts in Different Culture Conditions</td>
<td>Carmen Rubio Ulluesa, PhD</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>P-284</td>
<td>Querying the Genome of Follicular Cells to Shed Light on Severe Oogenesis Defects</td>
<td>Stephanie Cheung, MS</td>
</tr>
</tbody>
</table>

**PST-04 Reproductive Medicine - Non-Infertility 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>P-285</td>
<td>Effects of Metformin Alone versus Metformin and Tirzepatide on Weight Loss in Patients with Polycystic Ovarian Syndrome (PCOS)</td>
<td>Alexa M. Sassin, MD</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>P-286</td>
<td>Association of Serum Anti-Mullerian Hormone Levels with Vascular Function May Differ by History of Conception After in Vitro Fertilization: Pilot Study</td>
<td>Elizabeth Clain, MD</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>P-287</td>
<td>Progesterone Receptor Expression May Play a Key Role in the Progression of Endometriosis</td>
<td>Melissa P. McHale, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>P-288</td>
<td>Association of Dietary Glycemic Index and Glycemic Load with Antral Follicle Counts Among Patients with Subfertility</td>
<td>Makiko Mitsunami, MD, MMSc, PhD</td>
</tr>
<tr>
<td>11:05 AM</td>
<td>P-289</td>
<td>Characterization of Progesterone Resistance in a Prospective Cohort of Surgically Confirmed Patients with or Without Endometriosis</td>
<td>Bhuchitra Singh, MD, MPH, MS, MBA</td>
</tr>
</tbody>
</table>
11:10 AM  P-290 PHTHALATES EXPOSURE TRIGGERS CRITICAL PRO-INFLAMMATORY CYTOKINES EXPRESSION TOWARDS FIBROID PHENOTYPE IN PRE-FIBROID MYOMETRIAL STEM CELL- DERIVED 3D ORGANOID SYSTEM Somayeh Vafaei, PhD

11:15 AM  P-291 CAUSAL EFFECTS OF GUT MICROBIOME ON ENDOMETRIOSIS: A TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY Ziyu Liu, Dr

11:20 AM  P-292 SEXUAL DYSFUNCTION IN REPRODUCTIVE-AGED LATINX FEMALES: INSIGHTS FROM ENVIRONMENT, LEIOMYOMAS, LATINAS, AND ADIPOSITY STUDY (ELLAS) Emma C. Manuel, MD, MPh

11:25 AM  P-293 INVESTIGATING THE ASSOCIATION BETWEEN BMI, ADIPOKINES, AND INFLAMMATORY MARKERS IN LATINX FEMALES: DATA FROM THE ENVIRONMENT, LEIOMYOMAS, LATINAS, AND ADIPOSITY STUDY (ELLAS) Nicholas S. Raja, MD

11:30 AM  P-294 POLYCYSTIC OVARIAN SYNDROME (PCOS) IMPACT ON OBSTETRICAL MORBIDITY Ranjitha Vasa, MD

11:35 AM  P-295 DECELERATED GRAY MATTER DETERIORATION WITH AGE IN YOUNG WOMEN WITH PCOS Mei-Jou Chen, MD, PhD

11:40 AM  P-296 IDENTIFICATION OF IMMUNOLOGIC PREDICTIVE BIOMARKERS OF ENDOMETRIOSIS USING A NON-INVASIVE IMMUNE SCREENING TEST IN ASSOCIATION WITH MACHINE LEARNING MODELING Nadera Mansouri Attia, PhD

11:45 AM  P-297 THE IMPACT OF OVARIAN RESERVE ON BONE DENSITY IN PEDIATRIC CANCER SURVIVORS DURING EARLY ADULTHOOD Daniel Miranian, BSc, MD

11:50 AM  P-298 36-MONTH BONE MINERAL DENSITY RESULTS IN WOMEN TREATED WITH ELAGOLIX + ADD-BACK THERAPY FOR HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS Vicki L. Schnell, MD

11:55 AM  P-299 ORAL LEUPROLIDE (Ovarest®) ACHIEVES PROFOUND SUPPRESSION OF ESTRADIOL AND PAIN RELIEF COMPAREABLE TO THAT OF APPROVED INJECTABLE LEUPROLIDE FORMULATIONS IN WOMEN WITH ENDOMETRIOSIS AND PELVIC PAIN Gary A. Shangold, MD

12:00 PM  P-300 REAL-WORLD IMPLEMENTATION OF AN INNOVATIVE MULTIMODALITY LIFESTYLE MANAGEMENT PROGRAM FOR PATIENTS WITH POLYCYSTIC OVARY SYNDROME Jiris Tienlyyn Lee, MD

12:05 PM  P-301 THE ASSOCIATION BETWEEN ORGANOPHOSPHATE FLAME RETARDANTS (OPFRS) AND OVARIAN RESERVE IN WOMEN OF CHILDBEARING AGE Hao Ting Lien, MD

12:10 PM  P-302 DIFFERENTIAL TRANSCRIPTIONAL PROFILES IN PHENOTYPICALLY DISTINCT ENDOMETRIOSIS LESIONS SHOW INCREASED LYMPHOCYTE ACTIVITY, CYTOKINE PRODUCTION, AND INFLAMMATORY MARKERS IN RED LESIONS Maya L. Seshan, BS

PST-05 Infertility 3

10:45 AM  P-303 LIMITED ADOPTION OF CURRENT POLYCYSTIC OVARY SYNDROME (PCOS) RELATED INFERTILITY TREATMENT GUIDELINES BY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) SPECIALISTS IN THE UNITED STATES (U.S.) Anne E. Kim, MD

10:50 AM  P-304 LOWER LIVE BIRTH RATES WITH INCREASING MATERNAL AGE IN DONOR OOCYTE CYCLES Riwa Sabbagh, MD

10:55 AM  P-305 RISK FACTORS FOR BIOCHEMICAL PREGNANCY LOSS IN COUPLES UNDERGOING INFERTILITY TREATMENT Ashley S. Kim, MD

11:00 AM  P-306 SEASONAL EFFECTS ON IVF-ICSI-PGTA CYCLE OUTCOMES: A RETROSPECTIVE MULTI-CENTER STUDY Ilan Tur-Kaspa, MD

11:05 AM  P-307 ELEVATED AMH LEVELS ARE ASSOCIATED WITH LOWER LIKELIHOOD OF RESPONSE TO OVULATION INDUCTION AGENTS IN INFERTILE WOMEN Olutummike Kuyoro, MD

11:10 AM  P-308 CAN THE ADMINISTRATION OF PROGESTERONE TO INHIBIT THE LH-SURGE BE STARTED ON THE FIFTH DAY OF OVARIAN STIMULATION? A RANDOMIZED CONTROLLED TRIAL IN OOCYTE DONORS Monica Aura Ph, Physician

11:15 AM  P-309 CORRELATION OF HYSTEROSCOPIC PATHOLOGY WITH SALINE INFUSION SONOHYSTEROGRAM (SIS) FINDINGS Madeline J. Graham, MS3

11:20 AM  P-310 HUMAN SPERM MICRORNA PROFILING
CORRELATED WITH HEAD MORPHOLOGY
Nino Guy Cassuto, MD


11:35 AM P-313 MACHINE LEARNING PREDICTION MODEL FOR EARLY PREGNANCY DIAGNOSIS Kassie Jean Bollig, MD

11:40 AM P-314 FERTILITY OUTCOMES ACROSS THE RURAL-URBAN CONTINUUM Devon M. Langston, MD

11:45 AM P-315 OVARIAN STIMULATION WITH RECOMBINANT HUMAN LUTEINIZING HORMONE AND FOLLICLE STIMULATING HORMONE COMBINATION TREATMENT: A DESCRIPTIVE ANALYSIS OF EMBRYONIC MORPHOKINETIC DATA Amanda Souza Setti, MSc

11:50 AM P-316 UNDERSTANDING THE IMPLICATIONS OF FOLLICULAR OUTPUT RATE (FORT) AND FOLLICLE TO OOCYTE INDEX (FOI) ON EMBRYO MORPHOKINETICS Amanda Souza Setti, MSc

Tuesday, October 17, 2023

PST-06 Recurrent Pregnancy Loss

1:30 PM P-321 PLACENTAL SITE NODULES AND REPRODUCTIVE OUTCOMES: A CLINICOPATHOLOGIC CASE SERIES Meaghan Jain, MD

1:35 PM P-322 ASSOCIATION BETWEEN EARLY PREGNANCY IMMUNOPHENOTYPE AND SUBSEQUENT VIABILITY Conor Harrity, MBBCH

1:40 PM P-323 CERVICAL LENGTH AND THICKNESS OF CESAREAN SECTION SCAR ARE PREDICTORS FOR PRETERM LABOR IN WOMEN WITH PREVIOUS CESAREAN SECTION Tarek Farghaly, MD

1:45 PM P-324 AMH AS A PREDICTOR OF LIVE BIRTH FOR PATIENTS WITH UNEXPLAINED RECURRENT PREGNANCY LOSS Edward McClellan, MD

1:50 PM P-325 AN INVESTIGATION INTO RISK FACTORS FOR BIOCHEMICAL AND CLINICAL PREGNANCY LOSS IN THE IVF POPULATION Francesca Barrett, MBA, MD

1:55 PM P-326 ELEVATED LEVELS OF TUMOR NECROSIS FACTOR-A IN RECURRENT IMPLANTATION FAILURE PATIENTS ARE ASSOCIATED WITH ADVERSE PREGNANCY OUTCOME Chiawei Kao, MS

2:00 PM P-327 RELATIVE RISK OF CLINICAL PREGNANCY LOSS BY AGE IN UNTESTED VS PRE-IMPLANTATION GENETIC TESTED (PGT-A) EMBRYOS Keri Bergin, MS

2:05 PM P-328 A RANDOMISED CONTROLLED TRIAL ON RECURRENT IMPLANTATION FAILURE TREATMENT IN A STUDY MODEL BASED ON WOMEN WHO FAILED EGG DONATION CYCLES USING LOW-DOSE GM-CSF. POSSIBLE MECHANISM OF ACTION Marco Sbracia, MD

2:10 PM P-329 MÜLLERIAN ANOMALIES CLASSIFICATION – MAC 2021: APPLICATION AND PROGNOSTIC IMPACT IN A RECURRENT PREGNANCY LOSS POPULATION Bahi Fayek, MBBCh, MD, MSc

2:15 PM P-330 PREGNANCY OUTCOMES AFTER CERVICAL CERCLAGE USING SINGLE SUTURE VERSUS 10
## Poster Presentations and Abstracts

### Double Suture: A Systematic Review and Meta-Analysis

Yasmin Dias, MD

2:20 PM

### The Effect of Maternal BMI on Euploidy and Embryo Morphokinetics in Recurrent Pregnancy Loss Patients

Tutku Melis Aygün, BSc

2:25 PM

### Pre-Genetic Testing for Aneuploidy (PGT-A) is a Beneficial Intervention in Women with Idiopathic Recurrent Pregnancy Loss

Durga Gedela Rao Dr, MBBS, MD

2:30 PM

### Detection of Defects: Does Low Serum Human Chorionic Gonadotropin (hCG) Level Predict Future Fetal Anomalies Following Frozen Embryo Transfer (FET)?

Emily Michelle Weidenbaum, MD

1:35 PM

### Gabapentin for Pain Management After Uterine Aspiration: A Systematic Review and Meta-Analysis

Yasmin Dias, MD

1:40 PM

### #BirthControl: A Cross-Sectional Study on the Quality of Contraceptive Information on TikTok

Aleksandria Dangeva, BS Student

1:45 PM

### Seasonal Impact of Fertility Patients that Receive Methotrexate

Miriam Tarrash, MD

1:50 PM

### Female Attitudes Toward Male Contraceptives

Sawyer Reed, BS, MSPAS

1:55 PM

### Incidence of Ectopic Pregnancy During the Phase III Clinical Trials for Drospirenone 4mg as an Oral Contraceptive

Megan L. Gilbert, MSN

2:00 PM

### Post-Roe World: The Effects on Contraception and Sterilization Requests

Sarah Dutt, BS

2:05 PM

### Drospirenone 4mg and Its Influence on Dysmenorrhea Intensity: Results from a Phase III Clinical Trial

Michael Krychman, MD

2:10 PM

### Pregnancy Experiences 1-5 Years after Termination of Pregnancy for Fetal or Genetic Indications: A Qualitative Study

Monica L. Kao, MD, MPH

2:15 PM

### The New Device for the Predator of Sperm Retrieval in Microdissection Testicular Sperm Extraction (Micro-TESE)

Tomomoto Ishikawa, MD, PhD

2:20 PM

### Counseling Patients with Male Factor Infertility: In Vitro Fertilization Attrition Rates for Patients Who Utilize Testicular Sperm

Lauren Kendall Rauchfuss, MD

2:25 PM

### Evaluation of Androgen Receptor Saturation and Function in Erectile Dysfunction

Kajal Khodamoradi, PhD

2:30 PM

### Prospective Study

Rossella Cannarella, MD, PhD

1:35 PM

### Subclinical Inflammation Linked to Elevated AMH Levels and Decreased IVF Pregnancy Rates

Himanshu Arora, BSc, MSc, PhD

1:40 PM

### Utilization of Combining Microscopic Testicular Sperm Extraction (MTese) and Density Gradient for Sperm Retrieval and Pregnancy Outcomes in Men with Nonobstructive Azoospermia (NOA)

Nicholas Deebel, MD

1:45 PM

### Factors Associated with Restarting Androgenic Anabolic Steroids After Cessation in Men with Infertility: A Retrospective Analysis

Nicholas Deebel, MD

1:50 PM

### Is Ambient Air Pollution Associated with the Sperm DNA Fragmentation Index (DFI) and Oxidative Stress Adducts (OSA)? An Analysis of 15,915 Samples Across the USA

Jeffery Che-Wei Chang, MD, MPH

1:55 PM

### Sperm Obtained via Microsurgical Testicular Sperm Extraction (MTESE) Results in a Similar Blastulation Rate and Ongoing Pregnancy Rate as Sperm Obtained via Testicular Sperm Aspiration (TESA)

Haley G. Genovese, MD

2:00 PM

### A Randomized Controlled Trial of Home Semen Testing in Men Beginning Attempts to Conceive: Initial Semen Testing Results

Joshua A. Halpern, MD, MS

2:05 PM

### Distribution of Testosterone to Estradiol Ratios in Fertile and Subfertile Men: A Large Cohort Analysis

Solomon Hayon, MD

2:10 PM

### The SGLT2 Inhibitor Dapagliflozin Improves Erectile Dysfunction in Patients with Type 2 Diabetes Mellitus:

1:30 PM

### A Prospective Study

2:20 PM

### Subclinical Inflammation Linked to Elevated AMH Levels and Decreased IVF Pregnancy Rates

1:35 PM

### Utilization of Combining Microscopic Testicular Sperm Extraction (MTESE) and Density Gradient Processing to Optimize Sperm Retrieval and Pregnancy Outcomes in Men with Nonobstructive Azoospermia (NOA)

1:40 PM

### Factors Associated with Restarting Androgenic Anabolic Steroids After Cessation in Men with Infertility: A Retrospective Analysis

1:45 PM

### Is Ambient Air Pollution Associated with the Sperm DNA Fragmentation Index (DFI) and Oxidative Stress Adducts (OSA)? An Analysis of 15,915 Samples Across the USA

1:50 PM

### Sperm Obtained via Microsurgical Testicular Sperm Extraction (MTESE) Results in a Similar Blastulation Rate and Ongoing Pregnancy Rate as Sperm Obtained via Testicular Sperm Aspiration (TESA)

2:00 PM

### A Randomized Controlled Trial of Home Semen Testing in Men Beginning Attempts to Conceive: Initial Semen Testing Results

2:05 PM

### Distribution of Testosterone to Estradiol Ratios in Fertile and Subfertile Men: A Large Cohort Analysis

2:10 PM

### The SGLT2 Inhibitor Dapagliflozin Improves Erectile Dysfunction in Patients with Type 2 Diabetes Mellitus:

1:30 PM
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:25 PM</td>
<td>P-354</td>
<td>THE EFFECT OF SURGICALLY-DERIVED SPERM ON EMBRYO COMPACTION PATTERNS</td>
<td>Bailey McGuinness, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PST-09</td>
<td>Reproductive Urology 2</td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>P-355</td>
<td>EFFICACY OF DAILY EJACULATION IN MEN WITH RAISED SPERM DNA FRAGMENTATION</td>
<td>Durga Gedela Rao Dr, MBBS, MD</td>
</tr>
<tr>
<td>1:35 PM</td>
<td>P-356</td>
<td>ASSESSING THE PROBABILITY OF SUCCESSFUL SPERM RETRIEVAL WITH MICROSCOPIC TESTICULAR SPERM EXTRACTION (M-TESE) BASED ON JOHNSEN SCORE AND THE INCIDENCE OF HYPOGONADISM POST MICRO-TESE</td>
<td>Durga Gedela Rao Dr, MBBS, MD</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>P-357</td>
<td>SEASONAL VARIATION IN SERUM TESTOSTERONE LEVELS: EVIDENCE FROM TWO LARGE INSTITUTIONAL DATABASES</td>
<td>David Miller, MD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>P-358</td>
<td>TEMPORAL TRENDS OF SEMEN QUALITY AND FERTILITY RATES OVER THE COURSE OF A DECADE: DATA FROM KING COUNTY, WASHINGTON</td>
<td>David Miller, MD</td>
</tr>
<tr>
<td>1:50 PM</td>
<td>P-359</td>
<td>MARIJUANA, TESTOSTERONE AND ALCOHOL USE IN INDIVIDUALS SUBMITTING FELLOW™ MAIL-IN SEMEN ANALYSES: UTILIZING USER-REPORTED SURVEY DATA TO DESCRIBE CONTEMPORARY BEHAVIOR OF FERTILITY PATIENTS</td>
<td>Jeff C. Morrison, MD</td>
</tr>
<tr>
<td>1:55 PM</td>
<td>P-360</td>
<td>ASSESSING INFERTILITY LITERACY AND KNOWLEDGE GAPS AMONG PATIENTS WITH CYSTIC FIBROSIS</td>
<td>Nicholas Deebe, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>P-361</td>
<td>OZONE SAUNA (OS) AND PULSE ELECTROMAGNETIC FIELD (PEMF) DELIVERED VIA THE HOCATT MACHINE COULD IMPROVE SEMEN PARAMETERS IN MEN: A PILOT STUDY</td>
<td>Hadi Ramadan, MD</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>P-362</td>
<td>VARICOCELE REPAIR AND BMI: WEIGHING IN ON SUCCESS</td>
<td>Samir Merheb, MD</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>P-363</td>
<td>PERINATAL EXPOSURE TO HIGH DIETARY ADVANCED GLYCAITION END PRODUCTS AFFECTS BODY FAT DISTRIBUTION AND GLUCOSE HOMEOSTASIS IN MALE MICE OFFSPRING</td>
<td>Zaher Merhi, MD, HCLD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>P-364</td>
<td>HIGH CAPABILITY OF CHATGPT TO ANSWER COMMON PATIENT QUESTIONS ENCOUNTERED BY REPRODUCTIVE UROLOGISTS</td>
<td>Sharath Reddy, MD</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>P-365</td>
<td>ASSOCIATION BETWEEN ADVANCING PATERNAL AGE AND PREGNANCY OUTCOMES IN INTRAUTERINE INSEMINATION CYCLES</td>
<td>Papri Sarkar, MD</td>
</tr>
<tr>
<td>2:25 PM</td>
<td>P-366</td>
<td>ASSOCIATION BETWEEN MALE PARTNER ALCOHOL USE AND SPONTANEOUS ABORTION: A PRECONCEPTION COHORT STUDY</td>
<td>Nicolas Seranion, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>P-367</td>
<td>ANALYSIS OF SEMINAL QUALITY OF PATIENTS WHO SEEK INFERTILITY TREATMENT</td>
<td>Henrique Cunha Vireia, BSc</td>
</tr>
<tr>
<td>2:35 PM</td>
<td>P-368</td>
<td>IMPACT OF HISTORY OF IN VITRO FERTILIZATION (IVF)/INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLES USING ASPIRATED SPERM: NON-OBSTRUCTIVE AZOOSPERMIA (NOA) VS AZOOSPERMIA SECONDARY TO VASECTOMY</td>
<td>Robin H. Von Davies, MMSci, MSRC</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>P-369</td>
<td>DO SOCIOECONOMIC FACTORS INFLUENCE THE DECISION TO PURSUE FERTILITY PRESERVATION?</td>
<td>Marja Brolinson, MD</td>
</tr>
<tr>
<td>1:35 PM</td>
<td>P-370</td>
<td>THE POTENTIAL FOR LARGE LANGUAGE MODELS TO PERSONALIZE PATIENT ORIENTED CLINICAL INFORMATION TO RECOMMENDED READING LEVELS</td>
<td>Joseph Chervenak, MD, MBA</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>P-371</td>
<td>AN INTERPRETABLE ARTIFICIAL NEURAL NETWORK-BASED PATIENT COUNSELING ALGORITHM FOR INDIVIDUALIZED INTRAUTERINE INSEMINATION (IUI) OUTCOMES</td>
<td>Zoran J. Pavlovic, MD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>P-372</td>
<td>WHICH RECIPIENT FACTORS INFLUENCE TIME TO FIND AN OOYCE DONOR MATCH?</td>
<td>Shelun Tsai, MD</td>
</tr>
<tr>
<td>1:50 PM</td>
<td>P-373</td>
<td>DESPERATE FOR DONORS: AN INVESTIGATION OF THE RACIAL AND ETHNIC DISPARITIES AMONG DONOR SPERM BANKS IN THE US</td>
<td>Cassie L. Hobbs, MD</td>
</tr>
<tr>
<td>1:55 PM</td>
<td>P-374</td>
<td>WHEN EVERY DOSE COUNTS: COMMON MEDICATION ERRORS IN INFERTILITY CARE</td>
<td>Leah M. Roberts, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>P-375</td>
<td>INTERVENTION TO IMPROVE MEDICATION INJECTION EDUCATION AND CONFIDENCE IN PATIENTS UNDERGOING FERTILITY TREATMENT</td>
<td>Jennifer Burgart, MD, MS</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>P-376</td>
<td>TRANSPARENCY TO THE PATIENT: IMPROVING PATIENT EXPERIENCE, ENGAGEMENT AND UNDERSTANDING BY ASSESSING THE</td>
<td></td>
</tr>
</tbody>
</table>
 IMPACT OF ACCESS TO OWN EMBRYO VIDEOS Tyler Soy, MS

2:10 PM P-377 EVALUATING THE IMPACT OF THE COVID-19 PANDEMIC ON THE STATE AND REGIONAL UTILIZATION OF FERTILITY SERVICES IN THE UNITED STATES Leslie B. Ramirez, HCLD, PhD

2:15 PM P-378 REPRODUCTIVE HEALTHCARE PROVIDERS’ AND INTIMATE PARTNER VIOLENCE (IPV) ADVOCATES’ PERSPECTIVES ON REPRODUCTIVE HEALTHCARE IN INDIVIDUALS WHO EXPERIENCE IPV Molly Oken, BS

2:20 PM P-379 FEASIBILITY AND EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION ON NAVIGATING HEALTH INSURANCE BENEFITS FOR IN VITRO FERTILIZATION: A RANDOMIZED CONTROLLED TRIAL Olumayowa M. Dayo, MD, MPH

2:25 PM P-380 A SURVEY STUDY EVALUATING DONOR GAMETE UTILIZATION RATES, PATIENT SATISFACTION AND FERTILITY TREATMENT OUTCOMES ACCORDING TO DESIRED RACE AND ETHNICITY OF THE GAMETE DONOR Sloane Mebane, MD

2:30 PM P-381 SOCIOECONOMIC AND DEMOGRAPHIC DISPARITIES OF FERTILITY PRESERVATION ACCESS BY CITY Eliana Fine, MD

2:35 PM P-382 CHARACTERISTICS OF PATIENTS SEEKING CARE FOR INFERTILITY IN DEMOCRATIC REPUBLIC OF CONGO Ali Borazjani, MD PhD

2:40 PM P-383 IS ETHNICITY ASSOCIATED WITH THE DECISION TO PURSUE AND UTILIZE CRYOPRESERVED AUTOLOGOUS OOCYTES? Rona Yu, BS

Tuesday, October 17, 2023

PST-11 Mental Health & Reproductive Justice

3:30 PM P-384 INFLUENCING FACTORS AND PATIENT DECISIONS REGARDING MOSAIC AND ANEUPLOID EMBRYO TRANSFER Shelby Neal, MS

3:35 PM P-385 UNCERTAIN FERTILITY AND DISTRESS AMONG FEMALE SURVIVORS OF CHILDHOOD CANCER Brooke Cherven, PhD, MPH, RN

3:40 PM P-386 UNDERSTANDING PARENTS EMOTIONS SURROUNDING DISCLOSURE TO THEIR DONOR-CONCEIVED CHILDREN DURING PARTICIPATION IN THE TELL TOOL INTERVENTION Kirby Adlam, Phd, APRN, CNM

3:45 PM P-387 QUALITY OF LIFE IN THE DIFFERENT PHENOTYPES, IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME BEFORE AND AFTER MEDICAL TREATMENT Marisela Castaneda Diaz, MD

3:50 PM P-388 DAILY AND PSYCHOSOCIAL SYMPTOMS OF UTERINE FIBROIDS IN BLACK WOMEN AND LATINAS: A QUALITATIVE APPROACH Minerva Orellana, PhD, MS

3:55 PM P-389 COMPARISON OF EMBRYOLOGIST STRESS, FATIGUE, AND BURNOUT CURRENTLY REPORTED BY U.K. AND U.S. EMBRYOLOGISTS Michael G. Collins II, PhD

3:00 PM P-390 TRENDS IN EMBRYO DISPOSITION PRE AND POST DOBBS DECISION Mariah Buzzell, BA

3:05 PM P-391 NEW PATIENT FERTILITY CONSULTATION TRENDS PRE- AND POST-COVID-19 PANDEMIC Bryn E. Willson, MD

3:10 PM P-392 NAVIGATING IVF POST-DOBBS: PGT-A AND ABORTION Danielle E. Strom, MD

3:15 PM P-393 RACIAL DISPARITIES IN ACCESS TO FERTILITY PRESERVATION FOR ONCOFERTILITY PATIENTS ARE ALLEVIATED IN THE SETTING OF A COMPREHENSIVE FERTILITY MANDATE Melody So, MD

3:20 PM P-394 ASSOCIATION BETWEEN TIME TO CONCEPTION AND NEIGHBORHOOD DISADVANTAGE AS MEASURED BY SOCIAL DEPRIVATION INDEX SCORES IN NULLIPAROUS GRAVIDAE Alexa M. Sassin, MD

3:25 PM P-395 STRUCTURAL AND INTERPERSONAL INFLUENCES ON REPRODUCTIVE HEALTH BEHAVIORS AMONG MEN WHO HAVE SEX WITH MEN IN ISRAEL Jensen Reckhow, MD, MPH

3:30 PM P-396 DOES LEVEL OF EDUCATIONAL ATTAINMENT INFLUENCE THE PURSUIT OF ELECTIVE FERTILITY PRESERVATION AND USE OF CRYOPRESERVED OOCYTES? Alexandra Campedelli, BA
4:35 PM  P-397 ASSESSING FUNDING AND PUBLIC INTEREST INTO MALE AND FEMALE INFERTILITY: ANALYSIS OF NIH REPORTER & GOOGLE TRENDS DATABASES Shane A. Tinsley, BA

4:40 PM  P-398 WHAT RECURSCE DO PATIENTS HAVE WHEN THEY ARE DENIED INSURANCE COVERAGE FOR FERTILITY CARE? AN ANALYSIS OF THE DEPARTMENT OF MANAGED HEALTHCARE INDEPENDENT MEDICAL REVIEW DATABASE BETWEEN 2001-2023 Alisha T. Tolani, MD

PST-12 Fertility Preservation 3

3:30 PM  P-399 EVALUATING ELECTIVE EGG FREEZERS’ PHYSICAL EXPERIENCES, SOCIAL SUPPORT, AND POST-TREATMENT SATISFACTION: A MIXED METHODS STUDY Diane M. Tober, PhD, MA

3:35 PM  P-400 CLINICAL FACTORS ASSOCIATED WITH CARE SATISFACTION AMONG ELECTIVE EGG FREEZERS Diane M. Tober, PhD, MA

3:40 PM  P-401 ELECTIVE EGG FREEZERS’ DECISIONS AND INTENTIONS REGARDING USE OF FROZEN EGGS Diane M. Tober, PhD, MA

3:45 PM  P-402 HISTOLOGICAL REGRESSION OF ENDOMETRIAL NEOPLASIA IN PATIENTS UNDER FERTILITY PRESERVATION TREATMENT WITH LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) + SYSTEMIC PROGESTIN Marisela Castaneda Diaz, MD

3:50 PM  P-403 COST-EFFECTIVENESS OF PRE-VASECTOMY SPERM CRYOPRESERVATION Andrew D. Shumaker, MD

3:55 PM  P-404 COMPARISON OF CLINICAL PREGNANCY FOLLOWING CLEAVAGE STAGE EMBRYO VITRIFICATION USING 1,2 PROPAINEOL-FREE VS. 1,2 PROPANEDIOL CRYOPROTECTANTS Jung Eun Lim, MS

4:00 PM  P-405 OOCYTES FROM ELECTIVE OOCYTE VITRIFICATION CYCLES HAVE OUTCOMES SIMILAR TO FRESH OOCYTES; AN ANALYSIS OF 32621 CRYOPRESERVED OOCYTES John Stevens, BSc

4:05 PM  P-406 EFFECT OF RECOMBINANT AMH ON MOUSE OVARIAN FOLLICLE IN VITRO CULTURE Soo Young Yoon, PhD

4:10 PM  P-407 HIGHLY PURIFIED-HMG VERSUS RFSH IN OVARIAN HYPERSTIMULATION IN WOMEN UNDERGOING ELECTIVE FERTILITY PRESERVATION Hadar Amir, MD, PhD

4:15 PM  P-408 CORRELATION OF CRYOPRESERVATION DURATION AND CLINICAL/PRENATAL OUTCOMES AFTER SINGLE VITRIFIED WARME TED BLASTOCYST TRANSFER Mungunshagai Baatarsuren, MSc

4:20 PM  P-409 THE IMPACT OF RADIATION-INDUCED ABSOCOPAL EFFECTS ON MOUSE OOCYTE DEVELOPMENT Yongru DU, PhD

4:25 PM  P-410 EVALUATING ATTITUDES AND KNOWLEDGE OF FERTILITY PRESERVATION AMONG GYNECOLOGIC ONCOLOGISTS Sarah Hmaidan, DO

4:35 PM  P-412 LATE MATURING OOCYTES PROVIDE AN ADDITIONAL RESOURCE FOR EGG VITRIFICATION WITH RESULTING EUPLOID BLASTOCYST TRANSFERS CAPABLE OF HIGH OUTCOMES Terry Schlenker, BSc, MA

4:40 PM  P-413 AUTOLOGOUS SPERM FREEZING – IS IT TIME FOR A PARADIGM RESTART? Itai Gat, MD

PST-13 Genetics 3

3:30 PM  P-414 PATIENT DECISION MAKING IN THE FACE OF SEGMENTAL ANEUPLOIDY: AN OBSERVATION OF THE IMPACT OF GENETIC COUNSELING ON SEGMENTAL ANEUPLOID EMBRYO DISPOSITION Amber Gamma, BSc, MS

3:35 PM  P-415 ASSOCIATION BETWEEN TRANSFER RNA-DERIVED FRAGMENTS AND VARICOCELE Asli Metin Mahmutoglu, PhD

3:40 PM  P-416 DAY OF HATCHING AND VARIABILITY IN MOSAICISM, NO-RESULT, AND NO-AMPLIFICATION RATES FOLLOWING PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY Iris Tienlynn Lee, MD

3:45 PM  P-417 AFFECT OF CHROMOSOME RECOMBINATION IN TARGET GENES ON PGT-M DIAGNOSIS USING KARYOMAPPING ANALYSIS Ye Seul Hong, MS

3:50 PM  P-418 LOW DNA AND INCONCLUSIVE RESULTS AFTER PGT-A: RELATIONSHIP WITH DAY OF BIOPSY( DAY 5 VS DAY 6) AND EMBRYO QUALITY Mohammed H. Ibrahim, MSc

3:55 PM  P-419 FACTORS THAT COULD INFLUENCE PGT-A
RESULTS: AMH LEVELS AND THEIR IMPACT ON EMBRYO PLOIDY Cecilia Fernandez, PhD

4:00 PM P-420 DISCORDANT NON-INVASIVE PGT-A RESULTS AND CLINICAL OUTCOME Eliza Curnow, BSc, HCLD, MS, PhD

4:05 PM P-421 PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) INDICATIONS IN A DONOR RECIPIENT POPULATION: A FIVE-YEAR REVIEW FROM A LARGE U.S. SPERM BANK Lauren Isley, BSc, MSc, PhD

4:10 PM P-422 PARENT OF ORIGIN AND CLASSIFICATION OF SEGMENTAL CHROMOSOME ANEUPLOIDIES FROM 1,092 TROPHOCTODERM BIOPSIES Colleen A. Lynch, BSc, MSc, PhD

4:15 PM P-423 CUMULATIVE LIVE BIRTH RATE PER RETRIEVAL IS SIGNIFICANTLY HIGHER WITH PGT-A VS. NO PGT-A WITH SINGLE BLASTOCYST TRANSFER IN WOMEN 35 TO 40 YEARS, BUT NOT < 35: AN ANALYSIS OF 56,469 CYCLES FROM SART Benjamin S. Harris, MD, MPH

4:20 PM P-424 TROPHOCTODERM BIOPSY IS ASSOCIATED WITH PERTURBATIONS IN PLACENTAL DNA METHYLATION IN PREGNANCIES AFTER FROZEN-THAWED EMBRYO TRANSFER Monica A. Mainigi, MD

4:25 PM P-425 ELEVATED SPERM DNA FRAGMENTATION IS NOT CORRELATED WITH EMBRIONIC Mosaicism in Patients Undergoing IVF with PGT-A Tamar Alkon-Meadows, MD

4:30 PM P-426 THE AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS (ACMG) TIERED APPROACH TO CARRIER SCREENING: EXPERIENCE WITHIN A DIVERSE PATIENT POPULATION Dana Neitzel, MS, CGC

4:35 PM P-427 CONCORDANCE OF REPEAT BIOPSY RESULTS AMONG EMBRYOS WITH 6 OR MORE ANEUPLOIDIES Joshua Lim, MS

4:40 PM P-428 BRCA MUTATION PATIENTS YIELD HIGHER EUPOID EMBRYO RATES THAN CONTROLS Nicole Guardino, MS

PST-14 Pre-Clinical & Basic Research 4

3:30 PM P-429 SINGLE-CELL ATLAS OF DEFECTIVE DECIDUALIZATION Irene Muñoz Blat, MSc

3:35 PM P-430 EXTRACELLULAR VESICLE PROFILING OF SPENT HUMAN BLASTOCYST MEDIA BY NANOSCALE FLOW CYTOMETRY Thomas O’Leary, HCLD, PhD

3:40 PM P-431 HUMAN MYOMETRIAL AND UTERINE FIBROID STEM CELL-DERIVED ORGANOIDs Paul Punzón-Jiménez, MSc

3:45 PM P-432 ALLELE SPECIFIC CHROMOSOME REMOVAL BY CRISPR/Cas9 TO CORRECT TRISOMY 18 Evan A. Reshef, MD

3:50 PM P-433 EMBRYO SELECTION BY AI: ARE WE PLAYING FAIR? INTERROGATING THE SEX BIAS QUESTION THROUGH EMBRYO DEVELOPMENTAL MORPHOKINETICS AND PGT-A DATA Session

3:55 PM P-434 EMBRYO EUPLOIDY RATES ARE NOT INCREASED BY THE REPEATED ADDITION OF ANTIOXIDANTS TO THE CULTURE MEDIA WHEN COMPARED TO INITIAL ANTIOXIDANTS SUPPLEMENTATION Liliana Berenice Ramirez Domínguez, MS

4:00 PM P-435 THE ASSOCIATION OF ADIPOKINES AND INFLAMMATORY MARKERS WITH ANTI-MULLERIAN HORMONE (AMH) LEVELS IN A LATINA/LATINX POPULATION Samantha B. Schon, MD, MS

4:05 PM P-436 THE ASSOCIATION OF ADIPOKINES AND INFLAMMATORY MARKERS WITH ANTI-MULLERIAN HORMONE (AMH) LEVELS IN A LATINA/LATINX POPULATION Samantha B. Schon, MD, MS

4:10 PM P-437 EMBRYO SELECTION BY AI: ARE WE PLAYING FAIR? INTERROGATING THE SEX BIAS QUESTION THROUGH EMBRYO DEVELOPMENTAL MORPHOKINETICS AND PGT-A DATA Session

4:15 PM P-438 THE ASSOCIATION OF ADIPOKINES AND INFLAMMATORY MARKERS WITH ANTI-MULLERIAN HORMONE (AMH) LEVELS IN A LATINA/LATINX POPULATION Samantha B. Schon, MD, MS

4:20 PM P-439 INVESTIGATING KINASE SIGNALING PATHWAYS IN ENDOMETRIOSIS: A CUMULUS CELL CASE-CONTROL STUDY UTILIZING A NOVEL KINOME ARRAY Gillian Rubenstein, BS

4:25 PM P-440 ADVANCED REPRODUCTIVE AGE HAS LITTLE IMPACT ON MITOCHONDRIAL METABOLISM Margarita Ruseva, MSc

4:30 PM P-441 CONGENITAL MALFORMATIONS: A POPULATION-BASED STUDY OF RELATIONSHIP BETWEEN MONOSOMY 16 AND INTRACRANIAL ABNORMALITIES Margarita Ruseva, MSc

4:35 PM P-442 CONGENITAL MALFORMATIONS: A POPULATION-BASED STUDY OF RELATIONSHIP BETWEEN MONOSOMY 16 AND INTRACRANIAL ABNORMALITIES Margarita Ruseva, MSc
POSTER PRESENTATIONS AND ABSTRACTS

OF BONE MARROW MESENCHYMAL STEM CELLS FROM INFERTILE WOMEN
Dandan Wang, master

4:40 PM  P-443 MEIOTIC ANEUPLOIDY SEVERITY IS ASSOCIATED WITH ALTERED MORPHOKINETICS OF OOCYTE MATURATION
Catherine Kratka, Undergraduate

PST-15 Infertility 4

3:30 PM  P-444 A SLOWER HUMAN CHORIONIC GONADOTROPIN (HCG) RISE IN EARLY PREGNANCY WAS NOT ASSOCIATED WITH THE DEVELOPMENT OF ABNORMAL PLACENTATION IN PATIENTS WHO CONCEIVED USING ASSISTED REPRODUCTIVE TECHNOLOGY
Chantal Durgana, BS

3:35 PM  P-445 SPERM DNA FRAGMENTATION TESTING AND TREATMENT IN THE CONTEXT OF INTRAUTERINE INSEMINATION: RESULTS OF A GLOBAL PRACTICE SURVEY
Jose Antonio Moreno, MHA

3:40 PM  P-446 OXIDATION-REDUCTION POTENTIAL ASSAY FOR THE OXIDATIVE STRESS MEASUREMENT: DOES IT HELP IN THE INFERTILE MALE DIAGNOSIS?
Marga Esbert, PhD

3:45 PM  P-447 ENDOMETRIAL RECEPTIVITY ASSAY AND OBESITY: ARE LIVE BIRTH RATES AFTER SINGLE FROZEN EUPLOID EMBRYO TRANSFER IMPROVED?
Megan Molina, MD

3:50 PM  P-448 A SPERM FUNCTION ASSAY IDENTIFIES PREVIOUSLY-UNDIAGNOSABLE MALE FACTOR IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART)
Rebecca Holmes, DPhil, HCLD

3:55 PM  P-449 PROSPECTIVE STUDY OF SEMEN QUALITY AND FECUNDABILITY IN NORTH AMERICAN COUPLES
Sharonda M. Lovett, MPH

4:00 PM  P-450 REFERENCE CHARTS OF ULTRASONOGRAPHIC BIOMETRIC VARIABLES FOR EARLY PREGNANCY IN SPONTANEOUS AND ART-CONCEIVED SINGLETON PREGNANCIES
Alexander M. Quaas, MD, PhD

4:05 PM  P-451 ASSOCIATIONS BETWEEN PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS) EXPOSURE AND SEMEN QUALITY PARAMETERS AMONG MEN ATTENDING A FERTILITY CLINIC
Leah Martin, BS, MS

4:10 PM  P-452 RISK OF MORTALITY IN FAMILY MEMBERS OF MEN SEEKING FERTILITY ASSESSMENT
Joemy M. Ramsay, PhD

4:15 PM  P-453 CLINICAL VALUE OF ENDOMETRIAL DATING FOR PERSONALISED EMBRYO TRANSFER IN WOMEN WITH REPEATED IMPLANTATION FAILURE
Dimitar Parvanov, PhD

4:20 PM  P-454 THE ULTRA TRIAL: TRANSVAGINAL ULTRASOUND-GUIDED OVARIAN ABLATION USING THE MAY HEALTH SYSTEM IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS)-RELATED INFERTILITY: UP TO TWELVE MONTHS FOLLOW UP
Karl R. Hansen, MD, PhD

4:25 PM  P-455 AIR POLLUTION IN CRITICAL WINDOWS OF EXPOSURE AND SPONTANEOUS MISCARRIAGE IN A PRECONCEPTION COHORT
Anne Marie Z. Jukic, PhD

4:30 PM  P-456 TROPHECTODERM BIOPSY FOR PREIMPLANTATION GENETIC TESTING (PGT) FOLLOWING SINGLE FROZEN-THAWED EMBRYO TRANSFER (FET) IS NOT ASSOCIATED WITH ADVERSE OBSTETRIC OUTCOMES
Yael R. Stovezky, BA

4:35 PM  P-457 HOW HIGH CAN WE GO? GONADOTROPIN RESPONSE VARIES BASED ON RACIAL OR ETHNIC IDENTITY
Tyler Soy, MS

4:40 PM  P-458 BACK TO BACK OVARIAN STIMULATION SHORTENS TREATMENT DURATION WITHOUT COMPROMISING OUTCOMES
Gayathree Murugappan, MD
PSW-01 ART 5

10:45 AM P-459 IS INTELLIGENT DATA ANALYSIS SCORE (IDASCORE®) ABLE TO DIFFERENTIATE EMBRYOS DERIVED FROM FRESH OR VITRIFIED-WARMED OOCYTES? Christophe Sifer, PharmD

10:50 AM P-460 TWO DIMENSIONAL ULTRASOUND RESULTS IN UNDERESTIMATION OF THE OVARIAN FOLLICLE SIZE COMPARED TO AUTOMATED THREE DIMENSIONAL IMAGING IN WOMEN UNDERGOING IVF George Lainas, MD

10:55 AM P-461 DOES THE INCUBATION WITH HUMAN SERUM ALBUMIN ENRICHED MEDIUM IMPROVE WARNED OOCYTE COMPETENCE? Marissa Riqueros Arévalo, MSc

11:00 AM P-462 MICROFLUIDIC-BASED SPERM SELECTION: EFFECT ON SPERM DNA FRAGMENTATION AND EMBRYO DEVELOPMENT Maria Luiza Pardiñas, MSc

11:05 AM P-463 ENDOMETRIOSIS: SEVERE PAIN SYMPTOMS DO NOT IMPACT ART (ASSISTED REPRODUCTIVE TECHNOLOGY) OUTCOMES Chloé Maignien, MD

11:10 AM P-464 CALCIUM IONOPHORE SHOWS NO SIGNIFICANT IMPACT ON FERTILIZATION RATE OR BLASTOCYST DEVELOPMENT USING PATIENT SPLIT CYCLES Catherine Nathanson, BS

11:15 AM P-465 CONTINUOUS CLOMIPHENE RELIABLY BLOCKS LUTEINIZING HORMONE SURGE IN PATIENTS UNDERGOING IN VITRO FERTILIZATION: A RETROSPECTIVE, CROSS-SECTIONAL STUDY Kendall M. H. Bielak, MD

11:20 AM P-466 COMPARISON OF THREE IN-VITRO FERTILIZATION (IVF) PROTOCOLS UTILIZING HUMAN CHORIONIC GONADOTROPIN (HCG) OR GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST TRIGGERS ON MATURE METAPHASE II OOCYTE YIELD Halle R. Goodwin, MD

11:25 AM P-467 LIVE BIRTH RATE AFTER USING MICROFLUIDIC SPERM SEPARATION DEVICE FOR SPERM PREPARATION IN ALL IN-VITRO FERTILIZATION (IVF) AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLES Venkata Sai Sahithi Koithamuru, MD

11:30 AM P-468 IS OOCYTE DONATION ASSOCIATED WITH INCREASED IMPLANTATION AND PREGNANCY RATES IN ADVANCED REPRODUCTIVE AGE WOMEN UNDERGOING EUPLOID EMBRYO TRANSFER? Stephanie Willson, MD

11:35 AM P-469 A RETROSPECTIVE STUDY COMPARING OOCYTE QUALITY AND PREGNANCY OUTCOMES BETWEEN DOUBLE-DOSE (500 mcg), RECOMMENDED-DOSE (250 mcg) HCG TRIGGER VERSUS DUAL-TRIGGER (GnRH-AGONIST WITH HCG) IN ADVANCED-AGE WOMEN Bee Joe, MS

11:40 AM P-470 CORRELATION BETWEEN SPERM FRAGMENTATION AND VITAMIN D IN INFERTILE PATIENTS Ana Cristina Allemand Maneba, MSc

11:45 AM P-471 MOUSE EMBRYO MORPHOKINETICS TO ESTABLISH THE SAFETY OF USING AEROSOLIZED HYPOCHLOROUS ACID AS A DISINFECTANT OF AIRBORNE PATHOGENS IN THE EGG RETRIEVAL PROCEDURE ROOM Peter Uzelac, MD, HCLD

11:50 AM P-472 DEVELOPMENTAL ARREST RATE IN EMBRYOS OBTAINED FROM A COHORT OF RETRIEVED OOCYTES CORRELATES WITH AGE BUT NOT WITH ANEUPLOIDY RATE IN TROPHOECTODERM BIOPSIES: A STUDY OF 15,495 EMBRYOS Andres Reig, MD

11:55 AM P-473 PREDICTING CLINICAL PREGNANCY OUTCOMES IN FRESH CYCLE IVF-ET: AN ARTIFICIAL INTELLIGENCE-BASED APPROACH WITH SPECIFIC CYCLE PARAMETERS Haerin Paik, MD

12:00 PM P-474 ARTIFICIAL INTELLIGENCE FOR OPTIMAL IN VITRO FERTILIZATION MORPHOKINETICS Emily H. Frisch, MD

12:05 PM P-475 HUMIDIFIED PLASTIC CHAMBER ELIMINATES MEDIA EVAPORATION AND OSMOLALITY INCREASE DURING UNINTERRUPTED CULTURE IN A DRY INCUBATOR Rebecca A. Kile, BS, MS

12:10 PM P-476 ASSESSING MOUSE EMBRYO METABOLIC ACTIVITY AND METABOLIC MODULATION THROUGH NAD(P)H WITH NON-INVASIVE ADAPTED CONFOCAL MICROSCOPY Hope Newman, Graduate diploma in reproductive science

PSW-02 Infertility 5

10:45 AM P-477 CHANGING TRENDS IN SPERM PARAMETERS AMONG MEN SEEKING INFERTILITY
EVALUATION: A SINGLE-CENTER STUDY IN SOUTHEASTERN U.S. Maya Nicolle Crawford, MD

10:50 AM P-478 CONVENTIONAL IVF AND ICSI IN PATIENTS WITH NON-SEVERE MALE INFERTILITY ACROSS POOR AND DIFFERENT SUB-OPTIMAL OVARIAN RESPONSE PATIENTS Rui Yang, Doctor

10:55 AM P-479 IMPACT OF FERTILITY PRESERVATION IN GYNECOLOGICAL MALIGNANCIES: ASSESSING INFERTILITY, PREGNANCY OUTCOMES, QUALITY OF LIFE, AND DECISION REGRET FOLLOWING FERTILITY-SPARING SURGERY Nazli Albayrak, MD

11:00 AM P-480 PERINATAL OUTCOMES IN SINGLETON IVF PREGNANCIES COMPPLICATED BY VAGINAL BLEEDING BEFORE 20 WEEKS GESTATIONAL AGE Ruth Habte, MD

11:05 AM P-481 DIRECTION AND LATERALITY OF UTERINE PERISTALSIS WAVES DURING THE PERIOVULATORY PHASE Kelsey Ll Anderson, MD

11:10 AM P-482 ARTIFICIAL INTELLIGENCE POWERED ANDROLOGY DIAGNOSTICS OFFERS TOTAL SOLUTION FOR SEMEN ANALYSIS Chun I. Lee, MD, PhD

11:15 AM P-483 EFFECTS OF INCREASING ANTIMULLERIAN HORMONE LEVEL ON IN-VITRO FERTILIZATION AND FROZEN EMBRYO TRANSFER OUTCOMES Papri Sarkar, MD

11:20 AM P-484 PERSONALIZED EMBRYO TRANSFER IN CONSIDERATION WITH EMBRYONIC DEVELOPMENTAL SPEED IMPROVES REPRODUCTIVE OUTCOMES FOR PATIENTS WITH RECURRENT IMPLANTATION FAILURE Yasuhiro Ohara, MD

11:25 AM P-485 EXOSOME PROFILING REVEALS WIDESPREAD ENVIRONMENTAL POLLUTANT EXPOSURE IN SEMINAL PLASMA AND PREVIOUSLY UNKNOWN ASSOCIATIONS WITH MALE FERTILITY Haotian Wu, PhD

11:30 AM P-486 DOES STIMULATING OVULATION WITH LETROZOLE DURING FROZEN EMBRYO TRANSFER (FET) CYCLES IMPROVE PREGNANCY RATES IN OVULATORY WOMEN? Jessica Ka Wai Cheung, MD

11:35 AM P-487 IN LETROZOLE-STIMULATED FET CYCLES, HOW WorRIED SHOULD WE BE ABOUT A LOW ESTRADIOL LEVEL? Jessica Ka Wai Cheung, MD

11:40 AM P-488 INTRAUTERINE INSTALLATION AND HYSTEROscopic INJECTION OF AUTOLOGOUS PLATELET-RICH PLASMA FOR PATIENTS WITH A PERSISTENT THIN ENDOMETRIUM: THE SILVER LINING? Nings Yu, MD, MS

11:45 AM P-489 THE RISK OF PERINATAL CARDIOVASCULAR COMPLICATIONS IN PREGNANCIES CONCEIVED BY ASSISTED REPRODUCTIVE TECHNOLOGY Dovile Vilda, PhD

11:50 AM P-490 EFFECT OF MICROsURGICAL SUBINGUINAL VARICOCELE REPAIR IN INFERTILE PATIENTS WITH ISOLATED TERATOZOOSPERMIA Sami Mohd AL-Said, MD

11:55 AM P-491 EFFECT OF MICROsURGICAL SUBINGUINAL VARICOCELE REPAIR IN INFERTILE PATIENTS WITH ISOLATED ASTHENOZOOSPERMIA Sami Mohd AL-Said, MD

12:00 PM P-492 TARGETING PD1/PD-L1/PD-L2 SIGNALING IN ENDOMETRIOSIS Ramanaiah Mamillapalli, PhD

12:05 PM P-493 REAL-WORLD UTILIZATION OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) AND CONTROLLED OVARIAN STIMULATION (COS) – A RETROSPECTIVE CLAIMS DATABASE STUDY FROM 2016 TO 2022 Emily S. Jungheim, MD, MS

12:10 PM P-494 THE USE OF A NOVEL SPERM SELECTION METHOD FOR INTRAUTERINE INSEMINATION OF COUPLES WITH IDIOPATHIC INFERTILITY Olena M. Kocur, BA

PSW-03 Fertility Preservation 4

10:45 AM P-495 LETROZOLE (LET) TREATMENT DURING CONTROLLED OVARIAN HYPERSTIMULATION (COH) ALTERS THE ENDOCRINE MICROENVIRONMENT WITHOUT NEGATIVE IMPACT ON OOCYTE OUTCOMES Nirali Jain, MD

10:50 AM P-496 THERE IS NO SIGNIFICANT DIFFERENCE IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) OUTCOMES IN BREAST CANCER (BC) PATIENTS BEFORE OR AFTER CHEMOTHERAPY Nirali Jain, MD

10:55 AM P-497 EVALUATION OF PATIENT DECISION-MAKING PROCESS AND DECISION REGRET ON METHOD OF CANCER-RELATED FERTILITY PRESERVATION (FP): Jillian Pecoriello, MD

11:00 AM P-498 EXAMINATION OF COUNSELING ON METHOD OF CANCER-RELATED FERTILITY PRESERVATION (FP): AGE AND PARTNER
11:05 AM P-499 OOCYTE MATURITY (MII) RATES DO NOT VARY BETWEEN BRCA1 AND BRCA2 CARRIERS UNDERGOING OOCYTE CRYOPRESERVATION Nirali Jain, MD

11:10 AM P-500 EX-VIVO OOCYTE RETRIEVAL FOR FERTILITY PRESERVATION IN AN ADOLESCENT PATIENT WITH RECURRENT OVARIAN DYSGERMINOMA Addison William Alley, MD

11:15 AM P-501 TARGETING ONCOFERTILITY CONCERNS AMONG CONTEMPORARY THERAPEUTICS Chase Mallory, MD

11:20 AM P-502 BREAST CANCER PATIENTS PURSUING FERTILITY PRESERVATION WITH PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) DO NOT HAVE LOWER RATES OF EUPLOID EMBRYOS COMPARED TO AGE-MATCHED CONTROLS Alison Pruzan, MD

11:25 AM P-503 DOES LENGTH OF TIME IN CRYOSTORAGE AFFECT THE REPRODUCTIVE POTENTIAL OF VITRIFIED HUMAN OOCYTES? Sarah C. Roger, MD

11:30 AM P-504 TO THAW OR NOT TO THAW? WHEN IS THE QUESTION! Kim Skura, BSc

11:35 AM P-505 LIVE BIRTH RATE AFTER USE OF CRYOPRESERVED EMBRYOS AT THE TIME OF CANCER DIAGNOSIS IN FEMALE SURVIVORS Ella M. Berger

11:40 AM P-506 TREAT THE THYROID, SAVE THE OOCYTES? Stefany Hernandez, MD

11:45 AM P-507 SHORT-TERM TIME-LAPSE MONITORING OF IN VITRO CULTURED SECONDARY HUMAN OVARIAN FOLLICLES Laleh Hosseini, MSc, PhD

11:50 AM P-508 PRACTICE PATTERNS AND COST OF FEMALE FERTILITY PRESERVATION PRIOR TO GONADOTOXIC THERAPY AMONG IN VITRO FERTILIZATION (IVF) CENTERS IN THE UNITED STATES (US) Daniel Miranian, BSc, MD

11:55 AM P-509 DEVELOPED AND VALIDATED A NOMOGRAM FOR PREDICTING ONGOING PREGNANCY IN VITRIFIED-WARMED SINGLE EMBRYO TRANSFER CYCLES Jae Kyun Park, PhD

12:00 PM P-510 UTILIZATION OF OOCYTE CRYOPRESERVATION SERVICES IN A U.S. GEOGRAPHIC LOCATION WITH PREDOMINANCE OF ETHNIC MINORITIES Suset Rodriguez, MD

12:05 PM P-511 INTERNATIONAL ATTITUDES TOWARDS SOCIAL AND MEDICAL OOCYTE CRYOPRESERVATION Stylianos Vagios, MD

PSW-04 Reproductive Medicine- Non-Infertility 3

10:45 AM P-512 BEYOND RACE AND ETHNICITY: UTILIZING GENETIC ANCESTRY AND MEASURES OF SOCIAL VULNERABILITY IN A DIVERSE POPULATION TO CHARACTERIZE DISPARITIES IN THE DIAGNOSIS OF ENDOMETRIOSIS Leigh A. Humphries, MD

10:50 AM P-513 THE RETINOIC ACID PATHWAY IN UTERINE FIBROIDS IS NOT AFFECTED BY ULIPRISTAL ACETATE Jaime A. Roura-Monllor, MD, MS

10:55 AM P-514 CENTERING (PATIENTS WITH) FIBROIDS (CPWF) - AN INNOVATIVE PATIENT EDUCATION PROGRAM AND SUPPORT GROUP MODEL OF CARE FOR PATIENTS WITH UTERINE FIBROIDS Estefania D. Rivera Mufaford, MD, MHS

11:00 AM P-515 CAN WE PREDICT TIME TO RESOLUTION OF ECTOPIC PREGNANCIES TREATED WITH METHOTREXATE? Hillary Pearson, MD

11:05 AM P-516 SUBMUCOSAL UTERINE FIBROIDS ARE ASSOCIATED WITH BACTERIAL VAGINOSIS Joyce M. Cheng, BA

11:10 AM P-517 AGE AT MENARCHE IS NOT ASSOCIATED WITH OVARIAN RESERVE MARKERS AS ASSESSED AT THE TIME OF EVALUATION FOR FERTILITY TREATMENTS Panagiota Cherouveim, MD, MS

11:15 AM P-518 INVESTIGATING THE ROLE OF PERITONEAL MESOTHELIAL CELLS IN ENDOMETRIOSIS LESION FORMATION Virginia-Arlene Acosta Go, MD

11:20 AM P-519 ENDOCRINOLOGICAL AND OVARIAN PROFILE IN ASSIGNED FEMALE AT BIRTH TRANSGENDER PEOPLE ACCORDING TO DIFFERENT ANDROGEN HORMONE TREATMENTS Aina Borrás, MD PhD

11:25 AM P-520 IMPAIRED ARGININE METABOLISM AND INCREASED OXIDATIVE STRESS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND OBESITY Jean-Claire Dillon, MD

11:30 AM P-521 AN UNUSUAL CAUSE OF DYSMENORRHEA: DELAYED DIAGNOSIS OF A NON-COMMUNICATING UTERINE HORN Lindsay A. Hartup, MD

11:35 AM P-522 IMPACT OF RACE ON PREGNANCY
COMPLICATIONS IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Margaret A. Harrison, MD

11:40 AM P-523 PREVALENCE OF SYMPTOMS RELATED TO ENDOMETRIOSIS AMONG INDIVIDUALS WITH MARFAN SYNDROME AND LOEYS-DIETZ SYNDROME Cydni Akesson, BA

11:45 AM P-524 DECLINE IN SERUM ANTI MULLERIAN HORMONE LEVELS AND INCREASE OF SERUM PROLACTIN LEVELS IN YOUNG NORTH AFRICAN WOMEN AGED BETWEEN 25 AND 35 YEARS OLD DURING THE PERIOD BETWEEN 2013 AND 2021 Hatem Bahri, Dr

11:50 AM P-525 EFFECTS OF DYSREGULATED GLUCOSE METABOLISM ON THE OCCURRENCE AND ART OUTCOME OF ENDOMETRIOSIS Jianpeng Chen, MD

11:55 AM P-526 CORRELATION OF PCOS PHENOTYPES WITH PREGNANCY AND NEONATAL OUTCOMES: A SECONDARY ANALYSIS OF THE PPCOSII Jessica L. Chan, MD

PSW-05 Infertility 6

10:45 AM P-527 25-HYDROXYVITAMIN D AND FECUNDABILITY IN A PRECONCEPTION COHORT Anita Subramanian, PhD

10:50 AM P-528 EFFECTS OF SUPRAPHYSIOLOGIC ESTRADIOL (E2) LEVELS ON PLACENTAL CHARACTERISTICS AMONG PATIENTS UNDERGOING IN-VITRO FERTILIZATION (IVF)/FRESH EMBRYO TRANSFER (ET) Evelyn Minis, MD

10:55 AM P-529 PRENATAL PER- AND POLYFLUOROALKYL SUBSTANCE (PFAS) LEVELS ARE HIGHER IN WOMEN WITH INFERTILITY: A STUDY OF 1627 PARTICIPANTS Evelyn Minis, MD

11:00 AM P-530 THE RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND ANTI-MULLERIAN HORMONE (AMH) LEVELS IN A LATINA/LATINX POPULATION Emily L. Ferrell, MD, MS

11:05 AM P-531 LIVE DELIVERED PREGNANCY RATES FOLLOWING THE TRANSFER OF FROZEN-THAWED DAY 3 EMBRYOS DERIVED FROM DONOR OOCYTES ACCORDING TO THE MID-LUTEAL PHASE ENDOMETRIAL ECHO PATTERNS Brooke Neumann, DO

11:10 AM P-532 ATOSIBAN MAY HAVE NO BENEFICIAL EFFECT ON EMBRYO TRANSFER OUTCOMES IN WOMEN WITHOUT UTERINE ABNORMALITIES: A PROPENSITY SCORE MATCHING STUDY Nguyen-Tuong Ho, MD

11:15 AM P-533 THE EFFECT OF GONADOTROPIN DOSE ON THE RISK OF BEING A POSEIDON GROUPS 1 AND 2 SUBOPTIMAL RESPONDER IN IN-VITRO FERTILIZATION STIMULATION CYCLES – CAN DOSE IMPROVE OOCYTE YIELD? Alyssa Hochberg, MD, MPH

11:20 AM P-534 THE ASSOCIATION BETWEEN ADVANCED MATERNAL AGE AND ABNORMAL ENDOMETRIAL RECEPIETIVITY IN DONOR-EGG IVF PREGNANCY OUTCOMES Miranda Duster, BS

11:25 AM P-535 DOES EMBRYO CRYOPRESERVATION DURATION IMPACT EMBRYO THAW SURVIVAL AND LIVE BIRTH OUTCOMES FOR EUPLOID EMBRYOS? Grace Elizabeth Whiteley, DO

11:30 AM P-536 BIOMARKERS TO ASSESS THE QUALITY OF CUMULUS-OOCYTE COMPLEXES: A SYSTEMATIC REVIEW Gaele Massoud, MD

11:35 AM P-537 FETAL INDICATIONS FOR INDUCTION OF LABOR AMONG IVF AND NON-IVF NTSV (NULLIPAROUS, TERM, SINGLETON, VERTEX) PREGNANCIES Rachel Salomonovich, MD

11:40 AM P-538 DOES ENDOMETRIAL COMPACTION IMPACT THE PREGNANCY OUTCOMES OF IVF/ICSI CYCLES? A SYSTEMATIC REVIEW AND META-ANALYSIS Joao B. A. Oliveira, MD, MSc, PhD

11:45 AM P-539 DISPARITIES IN UTILIZATION AND TIMING OF INFERTILITY CARE, 2002-2019 Morgan Snow, BA

11:50 AM P-540 REPRODUCTIVE OUTCOMES OF WOMEN WITH REPEATED IMPLANTATION FAILURES WITH IVIG TREATMENT Einav Peero Dr, MD

11:55 AM P-541 DO MID-LUTEAL ESTRADIOL LEVELS IMPACT ONGOING PREGNANCY RATE IN HORMONE REPLACEMENT TRANSFER FROZEN EMBRYO TRANSFER (HRT-FET) CYCLES? Birgit Alsbjerg, MD

12:00 PM P-542 PROSPECTIVE ANALYSIS OF AN EPIGENETIC BIOMARKER PREDICTIVE OF SPERM QUALITY (SPERMQT) Kristin Brogaard, PhD

12:05 PM P-543 COMPARISON OF SECONDARY SEX-RATIO BETWEEN DIFFERENT INCUBATORS, SECONDARY SEX-RATIO IS IMPROVING IN ART? Akhil Garg, PhD Student

12:10 PM P-544 PREGNANCY COMPLICATIONS AND PLACENTAL HISTOLOGY IN IN-VITRO FERTILIZATION PREGNANCIES WITH A PREVIOUS CESAREAN DELIVERY Hadas Ganer Herman, MD
All oral and poster presenters at the ASRM 2023 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disclosure Type</th>
<th>Author and Family Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Company Officer</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>2. Direct Stockholder</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>3. Full-Time Company Employee</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>4. Grant Recipient</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>5. Honoraria</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
<tr>
<td>6. Paid Consultant</td>
<td>Alvero, R. J. Hannah Life Technologiesb (Scientific Advisor with stock options); Orchid Biosciencesb (Scientific Advisor with stock options); Parity Health Incb (Scientific Advisor with stock options) 4, A. Gametob</td>
</tr>
<tr>
<td>7. Speaker’s Bureau</td>
<td>Abbara, A. Myovant Sciencesa</td>
</tr>
<tr>
<td>8. Other</td>
<td>Adeleye, A. Carrota; Flo Healtha</td>
</tr>
<tr>
<td>9. Self</td>
<td>Aghajanova, L. OrchidHealtha (Advisory Board Member)</td>
</tr>
<tr>
<td>10. Immediate Family Member</td>
<td>Aguirre, M. C. Nonea (None)</td>
</tr>
<tr>
<td>11. Institution</td>
<td>Alsbjerg, B. Gedeon Richtera; Mercka</td>
</tr>
</tbody>
</table>
Bousfiha, M.  
Fairtility^23a

Brannigan, R. E.  
American Board of Urology^8a(Examination Committee Senior Consultant); American Urological Association^8a(AUA Update Series Editorial Committee Member)

Brennan, D. C.  
Care Dx^45a; SanoRx^6a; Vera Therapeutics^6a

Briggs, S.  
Ro^23a

Brogaard, K.  
Inherent Biosciences^22a

Burkin, H.  
Strykagen^6b

Callum, P.  
Cooper Surgical^66a; NorthStar Fertility/Everie^66a; Tandem Genetics^12a; Tandem Genetics^8b(End Part Time Employee)

Cameron, K. E.  
Becton Dickinson^7b

Carmi, S.  
HiTimes^21b; InfinityX^5a; MyHeritage^6a

Castelló, D.  
Igenomix^a

Castellon Garcia, J.  
IGENOMIX S.L^3a

Caswell, W.  
Donor Egg Bank, USA^8a(Employee)

Chan, A.  
AbbVie^23a

Chang, Z.  
Alife Health^3a

Chen, B. A.  
American College of Obstetrics & Gynecology^26a(ACOG Online Learning in Ob-Gyn Advisory Committee chair); Mylan^26a(research funding managed by my institution); Sebela^26a(research funding managed by my institution); Society of Family Planning^26a(Complex Family Planning Council committee member)

Chen, H.  
Jiangsu Hengrui Pharmaceuticals Co., Ltd^3a

Cheng, P. J.  
FirmTech, Inc^2a

Cho, J.  
Alife Health^3a

Choi, N.  
CHA Biotech^3a

Christianson, J. A.  
Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction^8a(Chair of the SUFU Basic Science Committee)

Chung, E. H.  
Turtle Health^6a

Cohen, B.  
Arex Life Sciences^12a

Copperman, A. B.  
Progyny^22a

Corirossi, A.  
GeneScreen Counseling, LLC^3a

Craig, L. B.  
Ferring Pharmaceuticals^13a(site investigator for a study); Ferring Pharmaceuticals^6a

Culwell, K.  
EvoFem Biosciences^123a; Sebela Women’s Health^7a

Czyrznicki, A.  
Juno Genetics US Inc^3a

Dabaja, A. A.  
ACGME RRC member^8a(committee member term to start later this year /next year)

Dahan, M. H.  
Elsevier^8a(Editor of a Text Book on Infertility); EMD Serono^67a; Ferring^67a; Journal of Clinical and Experimental Obstetrics and Gynecology^28a(Editor and Chief of the Journal); Organon (As Merck)^8a; OriginElle Fertility Center^1a; OvaSciences^6a; Web of Science Inc^8a(Editor of a textbook on IVM)

Delfino, K.  
Journal of Urology, Board of Statisticians^6a

Dhillon, W. S.  
Imperial Health Charity^6a; MRC^6a; Myovant Sciences Ltd^6a; NIHR^4a

Diakiew, S. M.  
Presagen/Life Whisperer Diagnostics^23a

Diamond, M. P.  
Advanced Reproductive Care^28a(Board of Directors); Augusta University^8a(Patent Pending)

Díaz, Y.  
Novagen^3a

Dicondina, R.  
CooperSurgical^12a

Ding, X.  
Repro-T^6a(Scientific Advisory Board Member)

Divaraniya, A. A.  
Oova, Inc.^1a

Driwekar, U.  
Stochastic Research Technologies LLC^12a

Dodge, L. E.  
TMRW Life Sciences, Inc.^6a
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dokras, A.</td>
<td>Ablacare/ Mayhealth&lt;sup&gt;6a&lt;/sup&gt;; AEPCOS Society&lt;sup&gt;8a&lt;/sup&gt; (Associate Executive Director); EliLilly&lt;sup&gt;6a&lt;/sup&gt;; Ferring&lt;sup&gt;6a&lt;/sup&gt;; GSK/ Haleon&lt;sup&gt;6a&lt;/sup&gt;; Veera Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Domar, A. D.</td>
<td>Curio&lt;sup&gt;6a&lt;/sup&gt;; EMD Serono&lt;sup&gt;6a&lt;/sup&gt;; Ferring&lt;sup&gt;7a&lt;/sup&gt;; Inception Fertility&lt;sup&gt;3a&lt;/sup&gt;; Oto&lt;sup&gt;4a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Doody, K. J.</td>
<td>Ferring Pharmaceutical&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Dupree, J. M.</td>
<td>ASRM&lt;sup&gt;6a&lt;/sup&gt; (Program Committee Member); Blue Cross Blue Shield of Michigan&lt;sup&gt;6a&lt;/sup&gt;; Lipocine&lt;sup&gt;2b&lt;/sup&gt;; NIH&lt;sup&gt;6a&lt;/sup&gt;; Posterity Health&lt;sup&gt;8a&lt;/sup&gt; (Scientific Advisory Board); SSMR&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Eisenberg, M.</td>
<td>Doveras&lt;sup&gt;8a&lt;/sup&gt; (advisor); Ro&lt;sup&gt;8a&lt;/sup&gt; (advisor)</td>
</tr>
<tr>
<td>Elci, O. U.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Eloisa, E.</td>
<td>Novagen&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Esteves, S. C.</td>
<td>Brazilian Society of Urology&lt;sup&gt;2a&lt;/sup&gt; (Co-Head, Department of Education and Research); Med.E.A.&lt;sup&gt;6a&lt;/sup&gt; (Co-Head, Department of Education and Research); Merck&lt;sup&gt;4567a&lt;/sup&gt;; World Health Organization&lt;sup&gt;8a&lt;/sup&gt; (Advisory Board Member, WHO Infertility Guidelines)</td>
</tr>
<tr>
<td>Ewing, B.</td>
<td>Ro&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fabbro, M.</td>
<td>NOVAGEN&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fanton, M.</td>
<td>Alife Health&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Farland, L. V.</td>
<td>PCRS&lt;sup&gt;4a&lt;/sup&gt; (Invited Speaker, Expenses paid); Smith and Nephew&lt;sup&gt;2b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Feinberg, E. C.</td>
<td>Ferring&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Feng, S.</td>
<td>Jiangsu Hengrui Pharmaceuticals Co., Ltd&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fernandez, C.</td>
<td>Cegyr&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fernandez, M.</td>
<td>Gameto&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Figueroa, A. B.</td>
<td>Gameto&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fischetti, C. E.</td>
<td>Centaur Labs&lt;sup&gt;23a&lt;/sup&gt;; LevelEx&lt;sup&gt;4a&lt;/sup&gt;; Philips Ultrasound&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Feldstad, J.</td>
<td>Future Fertility&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Forestieri, N. E.</td>
<td>National Birth Defects Prevention Network&lt;sup&gt;9a&lt;/sup&gt; (Board member)</td>
</tr>
<tr>
<td>Fox, K. A.</td>
<td>Elsevier (AJOG MFM)&lt;sup&gt;9a&lt;/sup&gt; (Deputy Editor); International Society for the Placenta Accreta Spectrum&lt;sup&gt;1a&lt;/sup&gt;; NICHD&lt;sup&gt;6a&lt;/sup&gt;; Pan American Society for the Placenta Accreta Spectrum&lt;sup&gt;1a&lt;/sup&gt;; SMFM&lt;sup&gt;3a&lt;/sup&gt;; Wolters Kluwer&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fuzesi, P.</td>
<td>Asian Egg Bank&lt;sup&gt;123a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Galain, M.</td>
<td>Novagen&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gameiro, S.</td>
<td>European Society for Human Reproduction and Embryology&lt;sup&gt;4a&lt;/sup&gt;; Ferring Pharmaceuticals A/S, TMRW Life Sciences&lt;sup&gt;6a&lt;/sup&gt;; Ferring Pharmaceuticals A/S, TMRW Life Sciences&lt;sup&gt;6a&lt;/sup&gt;; Gedeon Richter&lt;sup&gt;5a&lt;/sup&gt;; Grants from Merck Serono Ltd, ESHRE&lt;sup&gt;4a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gargiulo, A. R.</td>
<td>Boston Scientific, Inc.&lt;sup&gt;6a&lt;/sup&gt;; Medicaroid, Inc.&lt;sup&gt;6a&lt;/sup&gt;; Pregmune, Inc.&lt;sup&gt;8a&lt;/sup&gt; (Head of Scientific Advisory Board)</td>
</tr>
<tr>
<td>Gerhardt, C.</td>
<td>Society of Pediatric Psychology&lt;sup&gt;8a&lt;/sup&gt; (President-elect)</td>
</tr>
<tr>
<td>Gilbert, M. L.</td>
<td>Exelixis USA, Inc&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gilbert, M. L.</td>
<td>Exelixis USA, Inc&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gilboa, D.</td>
<td>ALIVE&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Giovannini, A.</td>
<td>Gameto&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Giudice, L. C.</td>
<td>Gesyna&lt;sup&gt;6a&lt;/sup&gt;; MERCK&lt;sup&gt;2a&lt;/sup&gt;; Myovant&lt;sup&gt;8a&lt;/sup&gt;; PFIZER&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glass, K. B.</td>
<td>Canadian Fertility and Andrology Society&lt;sup&gt;8a&lt;/sup&gt; (Fertility Preservation Special Interest Group Chair)</td>
</tr>
<tr>
<td>Gleicher, N.</td>
<td>Fertility Nutraceuticals&lt;sup&gt;2a&lt;/sup&gt;; Patents&lt;sup&gt;8a&lt;/sup&gt; (Co-owner of several awarded and pending U.S. patents)</td>
</tr>
<tr>
<td>Goldman, R. H.</td>
<td>UpToDate&lt;sup&gt;8a&lt;/sup&gt; (Peer-Reviewer)</td>
</tr>
<tr>
<td>Goldstein, S. R.</td>
<td>Astellas Pharma&lt;sup&gt;5a&lt;/sup&gt;; Cook OB/GYN&lt;sup&gt;8a&lt;/sup&gt;; GE Ultrasound&lt;sup&gt;8a&lt;/sup&gt; (Equipment Loan); Myovant Sciences&lt;sup&gt;5a&lt;/sup&gt;; Scynexis&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Goodman, L. R.</td>
<td>LiNA Medical&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gordon, T.</td>
<td>CooperSurgical&lt;sup&gt;123a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gore, J.</td>
<td>Seagen&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gray Valbrun, T.</td>
<td>The White Dress Project&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Gross, K. X.  Endo Pharmaceuticals3a; Sexual Medicine Society North America1a (Committee Vice chair)
Grover, S. A.  Ferring Pharmaceuticals3a
Guo, K.  Ferring Pharmaceuticals3a
Guo, A.  Ferring Pharmaceuticals3a
Guo, V.  Juno Genetics US Inc3a
Hall, J. M.  Life Whisperer Diagnostics Inc.12a; Life Whisperer Diagnostics Pty Ltd12a; Presagen Holdings Pty Ltd12a
Han, G.  CHA Biotech3a
Hariton, E.  Alife Health1a; Best Shot Inca; Cercle A16a; Evernow4a; Fertility Integral12a; Levy Health6a; Modern Fertility / Ro6a; Modern Fertility / Ro12a; Oya Care6a; Rescripted6a
Hariton, G. L.  A IVF6a; BioSkryb Genomics23a; Cryos International1a
Hayward, B.  EMD Serono3a
He, C.  Apricity3a
Heinrich, S. L.  Fertilis Pty Ltd3a
Heiser, P. W.  Ferring Pharmaceuticals, Inc.3a
Heo, J.  Kai health2a
Hickman, C.  Apricity12a; Aria Fertility12a; Avenues12a; Fairertility1216a; IVF Professionals12a; Ovomcare Gmbh12a
Hill, M. J.  Thread Robotics8a (Research Advisor)
Homer, M. V.  U. S. Fertility2a; USF Pharmaceutical Contracting Alliance2a
Hong, Y.  CHA Biotech3a
Honig, S. C.  Clarus67a; coloplast6a; endo7a; Fellow2a; genentech6a; HIMS6a; Posterty health7a
Hornberger, K.  Seattle Sperm Bank8a (Part Time Company Employee)
Hotaling, J. M.  abbvie, pfizer, novartis, elli lilly (wife as rheumatologist)10a; Advanced Conceptions2a; Andro3602a; Carrot Fertility8a; FirmTech12a; inherent bio2a; Maximus2a; Paterna bio12a; StreamDx2a; Turtle Health26a
Houtritz, R.  FertilAI123a
Houtritz, A.  FertilAI26a
Hovanes, K.  Natera23a
Howard, K. L.  Natera, Inc.23a
Huang, J.  PCOS Innovations LLC1a
Huddleston, H. G.  Allara 6a; Ember2a; May Health6a
Hudson, C.  DxNow, Inc6a
Hurliman, A. K.  Pinnacle Fertility2a
Hwang, K.  Reprotech6a; SSMR8a (Officer)
Isley, L.  CooperSurgical123a
Jahnke, H.  Maven Clinic23a
Jalas, C.  Juno Genetics 3a
Jenkins, C. P.  Quest/ReproSource3a
Jensen, J. T.  Abbvie, Bayer Healthcare, Daré, Estetra SPRL, Hope Medicine, Organon, Medicines360, Merck, Myovent, and Sebela4a; Bayer6a; Eovem5a; Mayne6a; Myovant8a; Sebela6a; TherapeuticsMD6a
Jeon, M.  CHA Biotech3a
Jiang, X.  Analysis Group, Inc.3a
Jindal, S. K.  TMRW8a (Advisory Board)
Joag, S.  Stochastic Research Technologies12b; Stochastic Research Technologies LLC1a
Johnson, N.  Abbott6a; ASPIRE8a (Executive board member); Guerber6a; Myovant Pfizer6a; World Endometriosis Society8a (Executive board member)
Jones, A.  Ovation Fertility23a
<table>
<thead>
<tr>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kang, H.</td>
<td>CHA Biotech&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kao, M. L.</td>
<td>Organon&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kelly, L.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kim, M.</td>
<td>CHA Biotech&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kim, H.</td>
<td>Kai health&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kim, J.</td>
<td>Medtronic&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kioumourtzoglou, M.</td>
<td>Health Effects Institute&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Klavanian, J.</td>
<td>Natera&lt;sup&gt;23a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kohihepp, F.</td>
<td>Merck Healthcare KGaA&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kramme, C.</td>
<td>Gameo&lt;sup&gt;123a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Krychman, M.</td>
<td>Exeltis&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Krystal, A.</td>
<td>Janssen, Neurocrine, Big Health, Eisai, Idorsia, Axsome, Evecxia, Jazz, Neurawell, Otsuka, Sage, Takeda&lt;sup&gt;2a&lt;/sup&gt;; Janssen, Neurocrine, Harmony, Attune&lt;sup&gt;4a&lt;/sup&gt;; Neurawell, Big Health&lt;sup&gt;8a&lt;/sup&gt;/Stock Options</td>
</tr>
<tr>
<td>Kushnoor, D.</td>
<td>Myriad Women’s Health&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lalwani, S. I.</td>
<td>Ferrin pharmaceuticals&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lanes, A.</td>
<td>BORN Ontario&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Laronda, M. M.</td>
<td>International Society for Biofabrication&lt;sup&gt;5a&lt;/sup&gt;/board member</td>
</tr>
<tr>
<td>Lathi, R. B.</td>
<td>Biorad&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Leader, B.</td>
<td>Conceptiv, LLC12a; Quest Diagnostics&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, J.</td>
<td>CHA Biotech&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, H.</td>
<td>CHA biotech&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, S.</td>
<td>CHA Biotech&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, C.</td>
<td>Kai health&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, H.</td>
<td>Kai Health, Inc.&lt;sup&gt;123a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee, I. T.</td>
<td>Veera Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Legro, R. S.</td>
<td>Covis&lt;sup&gt;6a&lt;/sup&gt;; Guerbet&lt;sup&gt;6a&lt;/sup&gt;; Insudd&lt;sup&gt;6a&lt;/sup&gt;; Novo Nordisk&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lencz, T.</td>
<td>American College of Neuropsychopharmacology&lt;sup&gt;8a&lt;/sup&gt;/Web Editor; International Society of Psychiatric Genetics&lt;sup&gt;8a&lt;/sup&gt;/Chair, Ethics, Positions, and Public Policy Committee</td>
</tr>
<tr>
<td>Leondires, M. P.</td>
<td>EMD Serono&lt;sup&gt;7a&lt;/sup&gt;; Next Gen Genetics&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Letourneau, J. M.</td>
<td>EMD Serono&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lipshultz, I.</td>
<td>Lipocineia</td>
</tr>
<tr>
<td>Lispi, M.</td>
<td>Merck Healthcare KGaA&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Little, S. E.</td>
<td>Delfina&lt;sup&gt;6b&lt;/sup&gt;/Advisor and holds private equity; Hologic&lt;sup&gt;6a&lt;/sup&gt;; Medicem&lt;sup&gt;4a&lt;/sup&gt;; Pulsenmore&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Loewke, K. E.</td>
<td>Alife Health, Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Love, A. K.</td>
<td>Fertils Pty Ltd&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Luka, A.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Luz, A.</td>
<td>Fertili&lt;sup&gt;12a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ma, L.</td>
<td>Jiangsu Hengrui Pharmaceuticals Co., Ltd&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ma, L.</td>
<td>Juno Genetics US Inc&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mahony, M. C.</td>
<td>3 Daughters Health&lt;sup&gt;6a&lt;/sup&gt;; DxNow, Inc.&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Maisenbacher, M. K.</td>
<td>3 Daughters Health&lt;sup&gt;6a&lt;/sup&gt;; DxNow, Inc.&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Malinbacher, M. K.</td>
<td>Fertilai&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Malin, P.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Maman, E.</td>
<td>Fertilai&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Maor, R.</td>
<td>AlVF&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Marchante, M.</td>
<td>Gameo&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Maseelall, P. B.</td>
<td>Pinnacle fertility (Medical board member)</td>
</tr>
<tr>
<td>McClung, M. R.</td>
<td>AbbVie(^a); Alexion(^b); Amgen(^c)</td>
</tr>
<tr>
<td>McCulloh, D. H.</td>
<td>Biogenetics Corporation(^a); Biogenetics Laboratory(^b); Buffalo IVF(^c); Gameto, Inc(^d); New York University Langone Fertility Center(^e); ReproART:Georgian American Center for Reproductive Medicine(^f); Sanford Reproductive Endocrinology(^g); Sperm and Embryo Bank of New York(^h)</td>
</tr>
<tr>
<td>McLean, K.</td>
<td>Ro/Modern Fertility(^i)</td>
</tr>
<tr>
<td>McLennan, H. J.</td>
<td>Fertilis Pty Ltd(^a)</td>
</tr>
<tr>
<td>McWilliams, K.</td>
<td>CooperSurgical(^a)</td>
</tr>
<tr>
<td>Mehta, A.</td>
<td>Posterity Health(^b); (Medical Advisory Board Member)</td>
</tr>
<tr>
<td>Meltzer, J. T.</td>
<td>Natera(^a)</td>
</tr>
<tr>
<td>Meng, Y.</td>
<td>Analysis Group(^a)</td>
</tr>
<tr>
<td>Mercuri, N.</td>
<td>Future Fertility(^a)</td>
</tr>
<tr>
<td>Meriano, J.</td>
<td>Future fertility(^a)</td>
</tr>
<tr>
<td>Merrikin, K.</td>
<td>Natera, Inc.(^a)</td>
</tr>
<tr>
<td>Meseguer, M.</td>
<td>AIVF(^a); Angelini(^a); Raider(^a); Therax(^a); Vitrolife(^a)</td>
</tr>
<tr>
<td>Miller, P. B.</td>
<td>Abbvie Pharmaceuticals(^a)</td>
</tr>
<tr>
<td>Miller, J.</td>
<td>CooperSurgical(^a)</td>
</tr>
<tr>
<td>Miller, K. A.</td>
<td>aLiFE Health, Inc(^a); Genomic Prediction Inc.(^a); Igenomix(^a)</td>
</tr>
<tr>
<td>Miller, C. E.</td>
<td>AbbVie(^a); AblaCare(^a); Allergena; Blue Seas Med Spa(^a)(Investor); Gynesonic(^a); LiNA Medical(^a); Medtronic(^a); Olympus(^a); RF Medical, Co. Ltd.(^a); Seikagaku Corporation(^a); Temple Therapeutics B.V.(^a)</td>
</tr>
<tr>
<td>Moran, E.</td>
<td>FertiAI(^a)</td>
</tr>
<tr>
<td>Morbeck, D. E.</td>
<td>Alpha Scientists(^a); Fujifilm Irvine Scientific(^a); Kindbody(^a); Vitrolife(^a)</td>
</tr>
<tr>
<td>Morris, M. E.</td>
<td>Micropoint(^a); Oviva(^a)</td>
</tr>
<tr>
<td>Mounts, E. L.</td>
<td>Juno Genetics(^a)</td>
</tr>
<tr>
<td>Mumford, S. L.</td>
<td>Society for Epidemiologic Research(^a); (Member at Large on Executive Committee)</td>
</tr>
<tr>
<td>Nassab, P.</td>
<td>Igenomix(^a)</td>
</tr>
<tr>
<td>Nayot, D.</td>
<td>Future Fertility(^a)</td>
</tr>
<tr>
<td>Neff, L. M.</td>
<td>Amryt(^a); Eli Lilly and Co(^a)</td>
</tr>
<tr>
<td>Neitzel, D.</td>
<td>Invitae(^a)</td>
</tr>
<tr>
<td>Nel-Themaat, L.</td>
<td>Noor sciences(^a)</td>
</tr>
<tr>
<td>Nelson, S. M.</td>
<td>Access Fertility(^a); Ferring Pharmaceuticals(^a); Merck(^a); Ro(^a); Roche(^a); TFP(^a)</td>
</tr>
<tr>
<td>Ng, J.</td>
<td>AbbVie Inc.(^a)</td>
</tr>
<tr>
<td>Nguyen, E. T.</td>
<td>Univfy Inc.(^a)</td>
</tr>
<tr>
<td>Nicholson, B.</td>
<td>Hera Biotech Inc(^a)</td>
</tr>
<tr>
<td>Noblett, A.</td>
<td>Gameto(^a)</td>
</tr>
<tr>
<td>Nodar, F.</td>
<td>Cegyr(^a)</td>
</tr>
<tr>
<td>Noel, N.</td>
<td>Health in Her Hue(^a)</td>
</tr>
<tr>
<td>Oken, E.</td>
<td>Novartis, Inc(^b); Takeda(^b)</td>
</tr>
<tr>
<td>Oktay, K. H.</td>
<td>Innovation Fertility(^a)</td>
</tr>
<tr>
<td>Olson, A.</td>
<td>Inherent Biosciences(^a)</td>
</tr>
<tr>
<td>Opsahl, M.</td>
<td>Poma Fertility, PLLC(^a)</td>
</tr>
<tr>
<td>Ottey, S.</td>
<td>American Society for Reproductive Medicine(^a); (Employer is the recipient of an ASRM grant); PCOS Challenge: The National Polycystic Ovary Syndrome Association(^a)</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliations</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pal, L.</td>
<td>Ferring pharmaceutical(^5\a)(Advisory board); Flo health(^4\a)</td>
</tr>
<tr>
<td>Papier, S. D.</td>
<td>ALMER(^5\a)</td>
</tr>
<tr>
<td>Park, S.</td>
<td>CHA Biotech(^2\a)</td>
</tr>
<tr>
<td>Park, J. K.</td>
<td>Ferring Pharmaceuticals(^7\a); INVO Bioscience(^8\a)(Scientific Advisor); MFB Fertility(^8\a)(Medical Advisor)</td>
</tr>
<tr>
<td>Patterson, W. R.</td>
<td>American Society for Reproductive Medicine(^8\a)(Nonprofit organization is a recipient of an ASRM grant); PCOS Challenge: The National Polycystic Ovary Syndrome Association(^1\a)</td>
</tr>
<tr>
<td>Paulsen, B.</td>
<td>Gameto, Inc.(^3\a)</td>
</tr>
<tr>
<td>Perry, J. S.</td>
<td>Myovant Sciences(^23\a)</td>
</tr>
<tr>
<td>Perugini, M.</td>
<td>Life Whisperer(^22\a); Presagen(^23\a)</td>
</tr>
<tr>
<td>Perugini, D.</td>
<td>Life Whisperer(^22\a); Presagen(^23\a)</td>
</tr>
<tr>
<td>Petrozza, J. C.</td>
<td>IMMA(^8\a)(Unpaid consultant); NESA(^6\a)</td>
</tr>
<tr>
<td>Pfeifer, S. M.</td>
<td>ASPIRA (^a); ASPIRA (^a); Granata Bio(^b)</td>
</tr>
<tr>
<td>Poll, S.</td>
<td>Invitae(^23\a)</td>
</tr>
<tr>
<td>Potts, K. S.</td>
<td>Gameto(^3\a)</td>
</tr>
<tr>
<td>Quaas, A. M.</td>
<td>Ferring Pharmaceuticals(^5\a)</td>
</tr>
<tr>
<td>Racicot, K.</td>
<td>ReproSource(^3\a)</td>
</tr>
<tr>
<td>Rambhatla, A.</td>
<td>Boston Scientific(^6\a); Coloplast(^4\a)</td>
</tr>
<tr>
<td>Rana, B.</td>
<td>Genomic Prediction, Inc.(^3\a)</td>
</tr>
<tr>
<td>Ratts, V.</td>
<td>Aesculap Implant Systems(^5\b); Bill and Melinda Gates Foundation(^6\a); Kaliber(^2\b); Medtronic(^4\b)(Royalties); Midwest Imaging(^2\a); MRI Partners of Chesterfield(^2\b); Nocimed(^2\b); Optum Fertility Solutions Expert Panel(^8\a)(Expert panel member); OuroBoros(^2\b); Pain and Rehabilitation Specialists, LLC(^2\b); Paradigm Spine(^2\b); St. Louis Spine and Orthopedic Surgery Center(^2\b)</td>
</tr>
<tr>
<td>Resetkova, N.</td>
<td>Levy Health(^a)(medical advisor); ReScripted Fertility(^2\a); WIN Fertility(^8\a)(medical advisor)</td>
</tr>
<tr>
<td>Reuvenny, S.</td>
<td>FertilAI(^3\a)</td>
</tr>
<tr>
<td>Richter, K. S.</td>
<td>San Diego Fertility Center(^d)</td>
</tr>
<tr>
<td>Rienzi, L.</td>
<td>GeneralLife(^8\a)(Scientific Director and minority shareholder); Merck, Merck Serono, Origio, MSD, Ferring, Ibsa, Gedeon Richter, Cooper Surgical, Cook(^5\c); Nterilizer(^8\a)(Scientific Board); Reproductive BioMedicine Online(^8\a)(Editor)</td>
</tr>
<tr>
<td>Rockwell, G.</td>
<td>Gameto(^3\a)</td>
</tr>
<tr>
<td>Rodriguez, S. A.</td>
<td>iGentify(^8\a)(Scientific Advisor); Sequence(^4\b\a)</td>
</tr>
<tr>
<td>Rodriguez-Alonso, B.</td>
<td>Igenomix(^2\a)</td>
</tr>
<tr>
<td>Romanksi, P. A.</td>
<td>Pacific Coast Reproductive Society(^8\a)(Director)</td>
</tr>
<tr>
<td>Roura-Monllor, J. A.</td>
<td>Dominion Fertility(^2\a); Frame Fertility(^2\b)</td>
</tr>
<tr>
<td>Rowe, M.</td>
<td>Takara Bio USA, Inc.(^3\a)</td>
</tr>
<tr>
<td>Rubin, A.</td>
<td>Enteris BioPharma Inc.(^6\a)</td>
</tr>
<tr>
<td>Ruby, A. H.</td>
<td>The Sperm Bank of California(^23\a)(Non-profit Executive Director)</td>
</tr>
<tr>
<td>Russell, H. I.</td>
<td>Art Lab IVF Training Center(^6\a); Mellowood Medical (^6\a)</td>
</tr>
<tr>
<td>Sakkas, D.</td>
<td>ALIFE(^8\a)(Options); EMD Serono(^7\a); Legacy(^8\a)(Options)</td>
</tr>
<tr>
<td>Salem, W. H.</td>
<td>Maven Clinic(^6\a)</td>
</tr>
<tr>
<td>Sanchez, N.</td>
<td>Merck(^6\a)</td>
</tr>
<tr>
<td>Sasaki, K.</td>
<td>Johnson and Johnson(^6\a)</td>
</tr>
<tr>
<td>Sauberbrun-Cutler, M.</td>
<td>Alara health(^8\a)(Consultant)</td>
</tr>
<tr>
<td>Saunders, R. D.</td>
<td>ACOG(^8\a)(District Secretary)</td>
</tr>
<tr>
<td>Scheib, J.</td>
<td>The Sperm Bank of CA(^8\a)(employee parttime)</td>
</tr>
<tr>
<td>Scheiber, M. D.</td>
<td>Ferring Pharmaceuticals(^7\a)</td>
</tr>
<tr>
<td>Authors</td>
<td>Affiliations</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Schenkman, E.</td>
<td>Adonis Egg Bank^{a0}; Adonis IVFa; Fairtillity^{3b}(Consultant); Mellowood Medical^{3a}(Consultant); Takara Bio^{3a}</td>
</tr>
<tr>
<td>Schissel, M.</td>
<td>Three Rivers Public Health Department^{6a}; Three Rivers Public Health Department^{2a}</td>
</tr>
<tr>
<td>Schnorr, J.</td>
<td>Cycle Bio^{3b}(Founder)</td>
</tr>
<tr>
<td>Schone, E.</td>
<td>Cassava Sciences Inc^{2b}; ELEVANCE HEALTH INC^{2a}; JOHNSON &amp; JOHNSON^{2b}; Johnson &amp; Johnson^{2b}</td>
</tr>
<tr>
<td>Schreffels, M.</td>
<td>Sebela Women’s Health Inc^{3a}</td>
</tr>
<tr>
<td>Schwarze, J.</td>
<td>Merck KGaA^{8a}(Medical Director)</td>
</tr>
<tr>
<td>Seitz, S.</td>
<td>Fairfax Cryobank^{3a}</td>
</tr>
<tr>
<td>Seli, E.</td>
<td>Foundation for Embryonic Competence^{4b}</td>
</tr>
<tr>
<td>Seriola, A.</td>
<td>SCRANTON BV^{4a}</td>
</tr>
<tr>
<td>Shah, B. S.</td>
<td>Ferring Pharmaceuticals^{3a}</td>
</tr>
<tr>
<td>Shah, R.</td>
<td>international society for impotence research^{8a}(co chair of committee for guidelines); Macleod Pharma^{7a}</td>
</tr>
<tr>
<td>Shangold, G. A.</td>
<td>Enteris BioPharma Inc^{12a}</td>
</tr>
<tr>
<td>Shannon, P.</td>
<td>Ferring Pharmaceuticals^{6a}</td>
</tr>
<tr>
<td>Shu, C.</td>
<td>Jiangsu Hengrui Pharmaceuticals Co., Ltd^{2a}</td>
</tr>
<tr>
<td>Siddique, N.</td>
<td>Future Fertility^{3a}</td>
</tr>
<tr>
<td>Silverberg, K.</td>
<td>Baxter^{6a}; EMD Serono^{6a}; Ovation Fertility^{12a}; Progyny^{12a}</td>
</tr>
<tr>
<td>Simon, C.</td>
<td>Igenomix^{12a}</td>
</tr>
<tr>
<td>Simon, J. A.</td>
<td>AbbVie, Bayer Healthcare, Dare Biological, Enteris BioPharma, Mylan/Viatris, Myovant Sciences, ObsEva, Pfizer, Inc., Viveve Medical^{1a}; Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Myovant Sciences, Pfizer, Pharmavit, Scynexis, TherapeuticsMD^{2a}; Bayer Healthcare, Besins Healthcare, California Institute of Integral Studies (CIIS), Dare Biological, DEKA M.E.L.A S.r.l., Femasys, KaNDy/NerRRe Therapeutics, Khyria, Madorra, Mitsubishi Tanabe Pharma Development America, Pfizer, Inc., QUE Oncology, Scynexis; Sermonix Pharmaceuticals^{2a}</td>
</tr>
<tr>
<td>Singer, E. A.</td>
<td>Astellas/Medivation^{4a}; Aura Biosciences^{6a}; Johnson &amp; Johndon^{6a}; Merck^{6a}; Vyriad^{6a}</td>
</tr>
<tr>
<td>Smith, K. N.</td>
<td>Ferring^{7a}</td>
</tr>
<tr>
<td>Smith, J. F.</td>
<td>Fellow Health^{1a}; Inherent Biosciences^{8a}(Scientific advisor); Posterior Health^{12a}(Scientific Advisor)</td>
</tr>
<tr>
<td>Snabes, M. C.</td>
<td>AbbVie^{2a}</td>
</tr>
<tr>
<td>Snider, A.</td>
<td>Igenomix^{3a}</td>
</tr>
<tr>
<td>Sommer, G. J.</td>
<td>Laboratory Corporation of America^{3a}; Sandstone Diagnostics, Inc^{23a}</td>
</tr>
<tr>
<td>Song, W.</td>
<td>Analysis Group, Inc.^{3a}</td>
</tr>
<tr>
<td>Srouji, S. S.</td>
<td>Ferring^{8a}(Served on Ferring advisory board once)</td>
</tr>
<tr>
<td>Steele, D.</td>
<td>Biogen^{8b}(My spouse works for Meetings &amp; Incentives Worldwide, which is an event planning/management company which is contracted to plan events for the listed organization)</td>
</tr>
<tr>
<td>Stern, K.</td>
<td>Virtus^{1b}</td>
</tr>
<tr>
<td>Stevanato, J.</td>
<td>Merck Healthcare KGaA^{3a}</td>
</tr>
<tr>
<td>Stewart, E. A.</td>
<td>WEB MD^{a}</td>
</tr>
<tr>
<td>Stillman, R. J.</td>
<td>CapExMD^{2a}; Presagen^{3b}(Clinical and Scientific Advisory Board); Therolgix^{2a}</td>
</tr>
<tr>
<td>Sun, Y.</td>
<td>Jiangsu Hengrui Pharmaceuticals Co., Ltd^{2a}</td>
</tr>
<tr>
<td>Sykes, N. J.</td>
<td>Antica Press, LLC^{18a}(Part time employee); NPNW Consulting^{18a}(Part time employee)</td>
</tr>
<tr>
<td>Takacs, P.</td>
<td>Fempharma LLC^{6a}</td>
</tr>
<tr>
<td>Tao, X.</td>
<td>Juno Genetics US Inc^{2a}</td>
</tr>
<tr>
<td>Thai, L.</td>
<td>PCOS Challenge: The National Polycystic Ovary Syndrome Association^{4a}</td>
</tr>
<tr>
<td>Thakore, S.</td>
<td>Swiss Precision Diagnostics - Clearblue Medical Advisory Board^{2a}</td>
</tr>
<tr>
<td>Thavaseelan, S.</td>
<td>Boston Scientific^{8a}</td>
</tr>
<tr>
<td>Thomas, J. W.</td>
<td>Abbvie^{23a}</td>
</tr>
<tr>
<td>Thomas, M. A.</td>
<td>Agile^{a}; Levocept^{a}</td>
</tr>
<tr>
<td>Authors</td>
<td>Affiliations</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>Thompson, J. G.</td>
<td>Fertilis Pty Ltd&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thornton, K. L.</td>
<td>ALife&lt;sup&gt;8a&lt;/sup&gt; (clinical advisor); Boston Museum of Science&lt;sup&gt;8a&lt;/sup&gt; (museum advisory board); Labcorp&lt;sup&gt;8a&lt;/sup&gt; (Clinical Advisory Board); Pharmaceutical Contracting Alliance&lt;sup&gt;8a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thurston, R. C.</td>
<td>Astellas Pharma&lt;sup&gt;6a&lt;/sup&gt;; Bayer&lt;sup&gt;6a&lt;/sup&gt;; Happify Health&lt;sup&gt;6a&lt;/sup&gt;; Hello Therapeutics&lt;sup&gt;6a&lt;/sup&gt; (Medical Advisory Board); Vira Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Treff, N. R.</td>
<td>EMD Serono&lt;sup&gt;7a&lt;/sup&gt;; FutureLife&lt;sup&gt;6a&lt;/sup&gt;; Genomic Prediction Inc&lt;sup&gt;12a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Trew, G. H.</td>
<td>ARC Medical&lt;sup&gt;2a&lt;/sup&gt;; Ferring&lt;sup&gt;6a&lt;/sup&gt;; TFP Fertility&lt;sup&gt;22a&lt;/sup&gt;; Theramex&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Trolice, M. P.</td>
<td>Alto Pharmacy&lt;sup&gt;2a&lt;/sup&gt;; Cryos International&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tsai, S.</td>
<td>ME&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tur-Kaspa, I.</td>
<td>Embryonics&lt;sup&gt;8a&lt;/sup&gt; (Medical Advisory Board); Ferring&lt;sup&gt;8a&lt;/sup&gt; (Advisory Boards)</td>
</tr>
<tr>
<td>Turek, P. J.</td>
<td>AlphaSperm, Inc&lt;sup&gt;12a&lt;/sup&gt;; Arex Bioscience&lt;sup&gt;6a&lt;/sup&gt;; Arex Bioscience, Inc&lt;sup&gt;2a&lt;/sup&gt;; BioQ, Inc&lt;sup&gt;12a&lt;/sup&gt;; CellArts, Inc&lt;sup&gt;12a&lt;/sup&gt;; Contraline, Inc&lt;sup&gt;6a&lt;/sup&gt;; Doximity, Inc&lt;sup&gt;6a&lt;/sup&gt;; Future Family&lt;sup&gt;2a&lt;/sup&gt;; Give Legacy Inc&lt;sup&gt;2a&lt;/sup&gt;; Inherent Biosciences&lt;sup&gt;6a&lt;/sup&gt;; Inherent Biosciences, Inc&lt;sup&gt;6a&lt;/sup&gt;; MandalMed, Inc&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Turok, D. K.</td>
<td>Bayer Women’s Healthcare&lt;sup&gt;4a&lt;/sup&gt;; Cooper Surgical&lt;sup&gt;4a&lt;/sup&gt;; Medicine&lt;sup&gt;560a&lt;/sup&gt;; Organon&lt;sup&gt;6a&lt;/sup&gt;; Sebela Women’s Health Inc&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Uhm, S.</td>
<td>Organon&lt;sup&gt;6a&lt;/sup&gt;; Society of Family Planning&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vassena, R.</td>
<td>Spanish Fertility Society&lt;sup&gt;8a&lt;/sup&gt; (ExCo member)</td>
</tr>
<tr>
<td>Vaughan, D. A.</td>
<td>Ferring&lt;sup&gt;6a&lt;/sup&gt;; Testasy&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vechery, A.</td>
<td>Modern Fertility&lt;sup&gt;28a&lt;/sup&gt; (Co-Founder); Society for Science&lt;sup&gt;8a&lt;/sup&gt; (Member of Board of Directors)</td>
</tr>
<tr>
<td>Venable, S.</td>
<td>AbbVie&lt;sup&gt;4a&lt;/sup&gt;; Bayer&lt;sup&gt;4a&lt;/sup&gt;; Hologic&lt;sup&gt;4a&lt;/sup&gt;; Myovant/Pfizer&lt;sup&gt;6a&lt;/sup&gt;; Omnia&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vidalí, A.</td>
<td>Pregmune&lt;sup&gt;112a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vitek, W. S.</td>
<td>Turtle Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wagman, R. B.</td>
<td>MYOVANT SCIENCES&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Waite, M. B.</td>
<td>Fertilis Pty Ltd&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wallace, S. J.</td>
<td>Fertilis Pty Ltd&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wells, D.</td>
<td>Juno Genetics&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Westphal, L.</td>
<td>Kindbody&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Widen, E.</td>
<td>Genomic Prediction, Inc&lt;sup&gt;236a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wiens, K.</td>
<td>Natera&lt;sup&gt;22a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wilmarth, M.</td>
<td>Ovation Fertility&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wise, L. A.</td>
<td>AbbVie, Inc&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wozniak, K.</td>
<td>Southern California Assisted Reproductive Biologists&lt;sup&gt;8a&lt;/sup&gt; (Board Member)</td>
</tr>
<tr>
<td>Wyns, C.</td>
<td>Ferring&lt;sup&gt;48a&lt;/sup&gt; (advisory board member); Gedeon-Richter&lt;sup&gt;48a&lt;/sup&gt; (advisory board member); Merck&lt;sup&gt;8a&lt;/sup&gt; (advisory board member)</td>
</tr>
<tr>
<td>Xu, J.</td>
<td>Genomic Prediction, Inc&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Xu, H.</td>
<td>Takara Bio&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Yamakami, L. Y.</td>
<td>Merck&lt;sup&gt;78a&lt;/sup&gt; (Paid Preceptorship)</td>
</tr>
<tr>
<td>Yang, M.</td>
<td>Analysis Group, Inc&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Yao, M. W.</td>
<td>Univfy Inc&lt;sup&gt;8a&lt;/sup&gt; (ASRM Corp Council); Univfy Inc&lt;sup&gt;1238a&lt;/sup&gt; (Director and Inventor)</td>
</tr>
<tr>
<td>Young, S. L.</td>
<td>CiceroDx&lt;sup&gt;6a&lt;/sup&gt; (patent license)</td>
</tr>
<tr>
<td>Zepeda, A.</td>
<td>Fairlility&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhan, Y.</td>
<td>Juno Genetics&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhang, H.</td>
<td>AVANSIGHT&lt;sup&gt;2b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhao, A.</td>
<td>Analysis Group, Inc&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhong, Y.</td>
<td>Myovant Science&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zogaj, A.</td>
<td>CooperSurgical&lt;sup&gt;12a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
AUTHOR AND FAMILY DISCLOSURES INDEX: VIDEO SESSIONS

All oral and poster presenters at the ASRM 2023 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<table>
<thead>
<tr>
<th>Author</th>
<th>Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goodman, L. R.</td>
<td>LiNA Medical&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hill, M. J.</td>
<td>Thread Robotics&lt;sup&gt;b&lt;/sup&gt;(Research Advisor)</td>
</tr>
<tr>
<td>Jones, C.</td>
<td>EMD Serono Canada&lt;sup&gt;a&lt;/sup&gt;(The GREI Fellowship Fund at the University of Toronto receives grants from these institutions for which I am the Fellowship Program Director)</td>
</tr>
<tr>
<td>Pfeifer, S. M.</td>
<td>ASPIRA ➤; ASPIRA ◄; Granata Bio&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Romanski, P. A.</td>
<td>Pacific Coast Reproductive Society&lt;sup&gt;b&lt;/sup&gt;(Director)</td>
</tr>
<tr>
<td>Stone, R. L.</td>
<td>AstraZeneca&lt;sup&gt;a&lt;/sup&gt;; Pacira Pharmaceuticals&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tsai, S.</td>
<td>ME&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Monday Morning Must: Fall in “Line” for Quick New Orleans-Style Fun!

Join us on Monday, October 16, during the morning break for an unforgettable “second line” parade procession featuring local musicians, ASRM dignitaries, sponsors, and all attendees who want to participate! Immediately following the second plenary, we will "strike up the band" and parade from the Great Hall through the Expo Hall. Bringing fun and authentic New Orleans flair, this procession may be the highlight of your whole meeting, so don’t miss it!

Sponsored by Organon
2023
ASRM PRESIDENT'S
GALA
Benefiting the
ASRM Research Institute

Thank You Sponsors

PREMIER SPONSOR
FERRING
PHARMACEUTICALS

CHAMPION SPONSOR
inception

PARTNER SPONSORS
Baylor College of Medicine and Texas
Children’s Hospital Pavilion for Women
Boston IVF
CCRM Fertility
ASRM Corporate Member Council
EMD Serono
Kindbody
Organon LLC
Tzedek Association
UCSF Center for Reproductive Health

IMPACT SPONSOR
USFertility

ADVOCATE SPONSOR
First Fertility
Future Family
ReUnite Rx
University of Michigan
MENOPUR® (menotropins for injection)

INDICATION FOR USE
MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program.

IMPORTANT SAFETY INFORMATION

• MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.

• MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.

• The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

Please see full Prescribing Information for MENOPUR.


© 2023 Ferring B.V. 08/23 US-MR-230028
Visit the EMD Serono booth at ASRM 2023 and see how we’ve pioneered in fertility, and created a legacy of trust with healthcare professionals worldwide.

Discover how, by working hand-in-hand with fertility experts, we are the trusted partner to support them to deliver their best care to patients on the journey to parenthood.

Continue to choose us.

1. Manzi et al. International Journal of Molecular Sciences. Accepted May 2022
ASRM Is Paperless!

We highly recommend downloading our free Congress App before the ASRM 2023 Scientific Congress & Expo. You can create your own schedule, view room changes, and download information to be used offline. There will also be free wifi hotspots available at the Convention Center.

At registration you will receive a printed pocket schedule and exhibit map with your Delegate Packet at the registration desk.

THERE WILL NOT BE A PRINTED FINAL PROGRAM BOOK OR PRINTED ABSTRACT LISTING.
Exhibitors

• Exhibitors Booth Index  152-153
• Expo Floor Plan  154-155
• Industry Sponsored Sessions  134-135
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accurate srl</td>
<td>802</td>
</tr>
<tr>
<td>Aeon Biotherapeutics Corp.</td>
<td>2003</td>
</tr>
<tr>
<td>Alifed</td>
<td>1443</td>
</tr>
<tr>
<td>Alifa USA, Inc.</td>
<td>1839</td>
</tr>
<tr>
<td>Alignaage Fertility</td>
<td>1345</td>
</tr>
<tr>
<td>Alkwin Medical Devices Inc.</td>
<td>245</td>
</tr>
<tr>
<td>Alto Pharmacy</td>
<td>1005</td>
</tr>
<tr>
<td>America Medic &amp; Science</td>
<td>1537</td>
</tr>
<tr>
<td>American Association of Bioanalysts</td>
<td>1243</td>
</tr>
<tr>
<td>Anchor Molecular Inc</td>
<td>1449</td>
</tr>
<tr>
<td>Androvia LifeSciences</td>
<td>1338</td>
</tr>
<tr>
<td>ARC Fertility</td>
<td>1113</td>
</tr>
<tr>
<td>Artisan Medical Solutions</td>
<td>1408</td>
</tr>
<tr>
<td>Asian Egg Bank</td>
<td>1701</td>
</tr>
<tr>
<td>ASRM Central</td>
<td>1223</td>
</tr>
<tr>
<td>ASTEC Co. Ltd</td>
<td>1923</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>2009</td>
</tr>
<tr>
<td>Azalea Health</td>
<td>144</td>
</tr>
<tr>
<td>BabySentry</td>
<td>1412</td>
</tr>
<tr>
<td>Baspair</td>
<td>1931</td>
</tr>
<tr>
<td>Baylor College of Medicine - Consultagene</td>
<td>1349</td>
</tr>
<tr>
<td>Berry Fertility</td>
<td>849</td>
</tr>
<tr>
<td>Billings Clinic</td>
<td>148</td>
</tr>
<tr>
<td>Boreas Monitoring Solutions</td>
<td>1845</td>
</tr>
<tr>
<td>Brown &amp; Brown Lone Star Insurance Serce Inc.</td>
<td>1730</td>
</tr>
<tr>
<td>Cariad Medical Technology Co., Ltd.</td>
<td>1723</td>
</tr>
<tr>
<td>Carrot Fertility</td>
<td>1836</td>
</tr>
<tr>
<td>Catalyst Healthcare Marketing</td>
<td>1612</td>
</tr>
<tr>
<td>Cellbox Solutions GmbH</td>
<td>248</td>
</tr>
<tr>
<td>CellOxess, LLC</td>
<td>1407</td>
</tr>
<tr>
<td>Cicero Diagnostics, Inc.</td>
<td>804</td>
</tr>
<tr>
<td>CIVCO Medical Solutions</td>
<td>1903</td>
</tr>
<tr>
<td>Clear Passage Therapy Franchises</td>
<td>948</td>
</tr>
<tr>
<td>Conceive Inc</td>
<td>349</td>
</tr>
<tr>
<td>Cook Medical Incorporated</td>
<td>422</td>
</tr>
<tr>
<td>CooperSurgical</td>
<td>922</td>
</tr>
<tr>
<td>CRINSURANCE</td>
<td>2023</td>
</tr>
<tr>
<td>CryoFuture</td>
<td>128</td>
</tr>
<tr>
<td>CryoMate Inc</td>
<td>1630</td>
</tr>
<tr>
<td>Cryoport</td>
<td>845</td>
</tr>
<tr>
<td>Cryos International - USA</td>
<td>1623</td>
</tr>
<tr>
<td>CS Medical</td>
<td>348</td>
</tr>
<tr>
<td>Cycle Clarity</td>
<td>2001</td>
</tr>
<tr>
<td>DeTech</td>
<td>1343</td>
</tr>
<tr>
<td>Digital Instruments, Inc.</td>
<td>1240</td>
</tr>
<tr>
<td>Donor Conceived Community</td>
<td>1749</td>
</tr>
<tr>
<td>DrCatalyst</td>
<td>649</td>
</tr>
<tr>
<td>Eastern Virginia Medical School</td>
<td>1002</td>
</tr>
<tr>
<td>eIVF</td>
<td>1104</td>
</tr>
<tr>
<td>Embryo Connections</td>
<td>648</td>
</tr>
<tr>
<td>Embryo Solution LLC</td>
<td>2006</td>
</tr>
<tr>
<td>Embryodirector.com</td>
<td>1001</td>
</tr>
<tr>
<td>Embryotech Laboratories, Inc.</td>
<td>836</td>
</tr>
<tr>
<td>EMD Serono</td>
<td>1337</td>
</tr>
<tr>
<td>Empower Pharmacy</td>
<td>448</td>
</tr>
<tr>
<td>Encompass Fertility</td>
<td>1829</td>
</tr>
<tr>
<td>EngagedMD</td>
<td>1606</td>
</tr>
<tr>
<td>Esco Technologies Inc.</td>
<td>1523</td>
</tr>
<tr>
<td>ESHRE</td>
<td>1236</td>
</tr>
<tr>
<td>Eurofins CellTx</td>
<td>1542</td>
</tr>
<tr>
<td>EVERSANA</td>
<td>1907</td>
</tr>
<tr>
<td>Evident Scientific</td>
<td>848</td>
</tr>
<tr>
<td>ExEm Foam</td>
<td>428</td>
</tr>
<tr>
<td>Fairfax Cryobank and Fairfax EggBank</td>
<td>1611</td>
</tr>
<tr>
<td>Fairhaven Health</td>
<td>1101</td>
</tr>
<tr>
<td>Fertility</td>
<td>138</td>
</tr>
<tr>
<td>Fertility Clinic</td>
<td>139</td>
</tr>
<tr>
<td>Fellow</td>
<td>1144</td>
</tr>
<tr>
<td>Femasys Inc.</td>
<td>937</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals Inc.</td>
<td>1023</td>
</tr>
<tr>
<td>FertiAI</td>
<td>1743</td>
</tr>
<tr>
<td>FertilFind</td>
<td>149</td>
</tr>
<tr>
<td>Fertility Pharmacy of America</td>
<td>236</td>
</tr>
<tr>
<td>Fertility Pro</td>
<td>2007</td>
</tr>
<tr>
<td>Fertility Technology Resources, Inc.</td>
<td>1000</td>
</tr>
<tr>
<td>FertilityEHF</td>
<td>1823</td>
</tr>
<tr>
<td>First Fertility</td>
<td>145</td>
</tr>
<tr>
<td>Form Health</td>
<td>744</td>
</tr>
<tr>
<td>Formosa Medical Group</td>
<td>1848</td>
</tr>
<tr>
<td>Frame</td>
<td>1342</td>
</tr>
<tr>
<td>Freedom Fertility Pharmacy</td>
<td>837</td>
</tr>
<tr>
<td>Fresenius Kabi USA</td>
<td>1448</td>
</tr>
<tr>
<td>Frida Fertility</td>
<td>705</td>
</tr>
<tr>
<td>FUJIFILM Irvine Scientific</td>
<td>1011</td>
</tr>
<tr>
<td>Fulgent Genetics</td>
<td>949</td>
</tr>
<tr>
<td>Future Fertility</td>
<td>1738</td>
</tr>
<tr>
<td>GE HealthCare</td>
<td>1309</td>
</tr>
<tr>
<td>Genea Biomedx</td>
<td>1149</td>
</tr>
<tr>
<td>GenEmbryomics</td>
<td>142</td>
</tr>
<tr>
<td>GeneScreen Counseling, LLC</td>
<td>944</td>
</tr>
<tr>
<td>Genomic Prediction, Inc.</td>
<td>1605</td>
</tr>
<tr>
<td>Give Legacy, Inc.</td>
<td>136</td>
</tr>
<tr>
<td>Global Premier Fertility</td>
<td>1801</td>
</tr>
<tr>
<td>Hamilton Thorne, Inc.</td>
<td>122</td>
</tr>
<tr>
<td>Hamilton Thorne, Inc.</td>
<td>123</td>
</tr>
<tr>
<td>Hann’s Fertility Pharmacy</td>
<td>449</td>
</tr>
<tr>
<td>Hillal Biotechnology Inc.</td>
<td>1748</td>
</tr>
<tr>
<td>IFFS</td>
<td>1348</td>
</tr>
<tr>
<td>Illia IVF Software</td>
<td>2008</td>
</tr>
<tr>
<td>IMT Matcher</td>
<td>1045</td>
</tr>
<tr>
<td>Inception Fertility</td>
<td>709</td>
</tr>
<tr>
<td>Indian Egg Donors</td>
<td>1212</td>
</tr>
<tr>
<td>Innovation Fertility</td>
<td>903</td>
</tr>
<tr>
<td>Innovation Fertility</td>
<td>905</td>
</tr>
<tr>
<td>Innovative Health Diagnostics</td>
<td>2000</td>
</tr>
<tr>
<td>Inti Labs</td>
<td>1042</td>
</tr>
<tr>
<td>Invitae Corporation</td>
<td>1237</td>
</tr>
<tr>
<td>Invitrocare, Inc.</td>
<td>1706</td>
</tr>
<tr>
<td>INVO Bioscience</td>
<td>1513</td>
</tr>
<tr>
<td>IVF Connect</td>
<td>344</td>
</tr>
<tr>
<td>IVF On Demand (IVFOD)</td>
<td>943</td>
</tr>
<tr>
<td>IVF Store</td>
<td>Biotech</td>
</tr>
<tr>
<td>IVF USA, Ltd.</td>
<td>748</td>
</tr>
<tr>
<td>IVFCloud</td>
<td>1702</td>
</tr>
<tr>
<td>Juno Genetics</td>
<td>904</td>
</tr>
<tr>
<td>Kai Health</td>
<td>1648</td>
</tr>
<tr>
<td>Kaneka</td>
<td>1444</td>
</tr>
<tr>
<td>Karl Storz Endoscopy-America</td>
<td>1301</td>
</tr>
<tr>
<td>Kedrian Biopharma Inc.</td>
<td>1843</td>
</tr>
<tr>
<td>Kitazato Corporation</td>
<td>223</td>
</tr>
<tr>
<td>Labcorp</td>
<td>1036</td>
</tr>
<tr>
<td>LG Pharmaceutical Corp.</td>
<td>1741</td>
</tr>
<tr>
<td>Life Whisperer</td>
<td>1200</td>
</tr>
<tr>
<td>LifeAire Systems LLC</td>
<td>1012</td>
</tr>
<tr>
<td>LiNA Medical</td>
<td>1830</td>
</tr>
</tbody>
</table>

The Past, The Present, and The Pipeline
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mandell's Clinical Pharmacy</td>
<td>645</td>
</tr>
<tr>
<td>Maven Clinic</td>
<td>741</td>
</tr>
<tr>
<td>MDR Fertility Pharmacy</td>
<td>1507</td>
</tr>
<tr>
<td>Medical Electronic Systems, LLC</td>
<td>1105</td>
</tr>
<tr>
<td>Meitheal Pharmaceuticals, Inc.</td>
<td>1842</td>
</tr>
<tr>
<td>Mellowood Medical-Ideas</td>
<td>1601</td>
</tr>
<tr>
<td>Men Having Babies, Inc.</td>
<td>1736</td>
</tr>
<tr>
<td>Microgenesis Corporation</td>
<td>1249</td>
</tr>
<tr>
<td>Midwest Reproductive Symposium International</td>
<td>1442</td>
</tr>
<tr>
<td>Mindray North America</td>
<td>1837</td>
</tr>
<tr>
<td>Minitude USA, Inc.</td>
<td>137</td>
</tr>
<tr>
<td>Monarch Medical Products, Inc.</td>
<td>249</td>
</tr>
<tr>
<td>Myart Medical Ltd.</td>
<td>1549</td>
</tr>
<tr>
<td>Myovant Sciences and Pfizer</td>
<td>1531</td>
</tr>
<tr>
<td>Nableivf</td>
<td>1637</td>
</tr>
<tr>
<td>Nanosonics, Inc.</td>
<td>1807</td>
</tr>
<tr>
<td>Narishige International USA, Inc.</td>
<td>1400</td>
</tr>
<tr>
<td>Natera, Inc.</td>
<td>1313</td>
</tr>
<tr>
<td>National Embryo Donation Center</td>
<td>901</td>
</tr>
<tr>
<td>NextGen Genetics</td>
<td>1643</td>
</tr>
<tr>
<td>NextGen Lifelabs</td>
<td>1037</td>
</tr>
<tr>
<td>Nikon Instruments Inc.</td>
<td>1204</td>
</tr>
<tr>
<td>Northstar Fertility Group</td>
<td>1049</td>
</tr>
<tr>
<td>Nwwo Life Technology</td>
<td>548</td>
</tr>
<tr>
<td>NvGen MDx</td>
<td>1545</td>
</tr>
<tr>
<td>Okolab SRL</td>
<td>1649</td>
</tr>
<tr>
<td>Oova Inc.</td>
<td>1906</td>
</tr>
<tr>
<td>Orchid</td>
<td>1344</td>
</tr>
<tr>
<td>Organon LLC</td>
<td>723</td>
</tr>
<tr>
<td>Ovara</td>
<td>1040</td>
</tr>
<tr>
<td>Ovatlon Fertility: Genetics, Donor Services and Gestational Carriers</td>
<td>1501</td>
</tr>
<tr>
<td>Ovobank US</td>
<td>238</td>
</tr>
<tr>
<td>PatientFi</td>
<td>2030</td>
</tr>
<tr>
<td>PCRS - Pacific Coast Reproductive Society</td>
<td>1109</td>
</tr>
<tr>
<td>PharmaWatch</td>
<td>801</td>
</tr>
<tr>
<td>phasetwo</td>
<td>800</td>
</tr>
<tr>
<td>Philips Healthcare</td>
<td>2027</td>
</tr>
<tr>
<td>Pinnacle Fertility</td>
<td>2013</td>
</tr>
<tr>
<td>Posterone Health</td>
<td>749</td>
</tr>
<tr>
<td>Pregnum</td>
<td>1548</td>
</tr>
<tr>
<td>Progenesis</td>
<td>1713</td>
</tr>
<tr>
<td>Progyny</td>
<td>1305</td>
</tr>
<tr>
<td>Proov</td>
<td>126</td>
</tr>
<tr>
<td>QuickSTAT, A Kuehne + Nagel Company</td>
<td>131</td>
</tr>
<tr>
<td>Roeyco Lab Equipment Systems Management Ltd.</td>
<td>1838</td>
</tr>
<tr>
<td>Recurrent Pregnancy Loss Association (RPLA)</td>
<td>1244</td>
</tr>
<tr>
<td>Rees Scientific Corp</td>
<td>1003</td>
</tr>
<tr>
<td>Reprobiogen Inc.</td>
<td>1141</td>
</tr>
<tr>
<td>Reproductive Genetic Innovations</td>
<td>230</td>
</tr>
<tr>
<td>Reproductive Possibilities LLC</td>
<td>1700</td>
</tr>
<tr>
<td>Reproductive Sciences Management Company</td>
<td>1644</td>
</tr>
<tr>
<td>Reproductive Solutions</td>
<td>743</td>
</tr>
<tr>
<td>REPROLIFE</td>
<td>623</td>
</tr>
<tr>
<td>ReproSource Fertility Diagnostics</td>
<td>1137</td>
</tr>
<tr>
<td>ReproTech, LLC</td>
<td>1913</td>
</tr>
<tr>
<td>RESOLVE: The National Infertility Association</td>
<td>1143</td>
</tr>
<tr>
<td>Reunite RX</td>
<td>900</td>
</tr>
<tr>
<td>Rocket Medical PLC</td>
<td>1004</td>
</tr>
<tr>
<td>SafePoint Scientific</td>
<td>1901</td>
</tr>
<tr>
<td>Salve Technologies Limited</td>
<td>703</td>
</tr>
<tr>
<td>Samsung</td>
<td>1010</td>
</tr>
<tr>
<td>SCSA Diagnostics</td>
<td>1006</td>
</tr>
<tr>
<td>Seattle Sperm Bank</td>
<td>1100</td>
</tr>
<tr>
<td>Shivani Scientific Industries (P) LTD</td>
<td>2031</td>
</tr>
<tr>
<td>SMP Pharmacy Solutions</td>
<td>805</td>
</tr>
<tr>
<td>Society for the Study of Reproduction</td>
<td>1245</td>
</tr>
<tr>
<td>Spectrum Technologies- Your Pure Sperm Source</td>
<td>1707</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>1048</td>
</tr>
<tr>
<td>Sunlight Medical Inc.</td>
<td>1704</td>
</tr>
<tr>
<td>Tandem Genetics</td>
<td>1239</td>
</tr>
<tr>
<td>The FDA Consultants</td>
<td>143</td>
</tr>
<tr>
<td>The Maya’s Wings Foundation</td>
<td>549</td>
</tr>
<tr>
<td>The Permanente Medical Group</td>
<td>941</td>
</tr>
<tr>
<td>The World Egg &amp; Sperm Bank</td>
<td>1404</td>
</tr>
<tr>
<td>Theralogix</td>
<td>1809</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>1208</td>
</tr>
<tr>
<td>Thomas Medical (A MedGyn Company)</td>
<td>1336</td>
</tr>
<tr>
<td>TMRW</td>
<td>1413</td>
</tr>
<tr>
<td>TOKAI HIT</td>
<td>1044</td>
</tr>
<tr>
<td>Tosoh Bioscience</td>
<td>1806</td>
</tr>
<tr>
<td>Univfy Inc.</td>
<td>1731</td>
</tr>
<tr>
<td>US Fertility</td>
<td>637</td>
</tr>
<tr>
<td>UV Smart Technologies BV</td>
<td>1905</td>
</tr>
<tr>
<td>Vanguard Communications</td>
<td>1910</td>
</tr>
<tr>
<td>VFP Pharmacy Group</td>
<td>1800</td>
</tr>
<tr>
<td>Vitrolife, Inc.</td>
<td>523</td>
</tr>
<tr>
<td>Walgreens</td>
<td>737</td>
</tr>
<tr>
<td>WINFertility</td>
<td>1909</td>
</tr>
<tr>
<td>XilitriX North America</td>
<td>1631</td>
</tr>
<tr>
<td>Xyter Corporation</td>
<td>1737</td>
</tr>
<tr>
<td>YAD-TECH Inc.</td>
<td>701</td>
</tr>
<tr>
<td>Yikon Genomics</td>
<td>1544</td>
</tr>
<tr>
<td>ZyMot Fertility</td>
<td>910</td>
</tr>
</tbody>
</table>
The Past, The Present, and The Pipeline

EXPO HALL

Meeting Rooms

Roundtables 1-14

Networking Lounge

ASRM DRIVE AISLE

ASRM 2023 Expository Hall Map
VEOZAH™ (fezolinetant) For the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

Presented by: Astellas Pharma US, Inc.
Date/Time: Monday, October 16, 2023, 12:20 PM – 1:20 PM
Location: NOCC Room R06
Speaker: Sharon Winer, MD, MPH, FACOG
Session Overview: In this session, we will review a new, FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.

The Past, Present and Future of PGT-M

Presented by: CooperSurgical
Date/Time: Monday, October 16, 2023, 12:20 PM – 1:20 PM
Location: NOCC Room R05
Speakers: Albulena Zogaj MS (moderator); Kristine McWilliams MD, PhD, HCLD (ABB); Tony Gordon, PhD; Christopher Weier, PhD
Session Overview:
• Past (1990s-2022): History, Technology, Early Clinical outcomes, De novo diseases and complex development
• Present (2022-now): PGT-M by NGS vs PGT-M by NGS w/PTA. Data, research, and benefits.
• Future (2024-forward): Direct sequencing for PGT-M. Merging PGT-M and PGT-A. Clinical impact and benefit of PTA.

Preimplantation Genetic Testing: How NGS solutions are advancing PGT

Presented by: Thermo Fisher Scientific
Date/Time: Tuesday, October 17, 2023, 12:20 PM – 1:20 PM
Location: NOCC Room R05
Speakers: Cengiz Cinnioglu, PhD, Amy Jordan, MS, LCGC, Meera Shah, M.D.
Session Overview: Methodology for testing the genetic makeup of preimplantation embryos has advanced significantly in the past several years with the development of NGS-based instruments. In this symposium, you’ll hear perspectives from a PGT lab founder and CEO, a genetic counselor, and a clinician on what’s new to the field and how we can increase success rates.
For years, IVF was covered under an umbrella protected by Roe vs Wade ruling, allowing legalized abortion in the United States. The Dobbs decision by the Supreme Court in June of 2022 changed the landscape of reproductive medicine. Now, each State can decide whether abortion is prohibited or legal. Different states have different language in their state laws defining when life begins, and what is considered an abortion. Advocacy has always been an important aspect of improving access to fertility treatments in the United States, because insurance mandates that cover fertility services are also regulated at a State Level. In a State with a “comprehensive insurance mandate” (covering IVF) access for treatment is 8.8 per 1,000 women (between 14-42) versus 3.2 per 1,000 women in a State with no insurance mandate. This session will discuss how our state and federal government works –” for the people, by the people”. The hows and whys to get involved in advocacy and how industry and the clinicians can both play an important role.

Understand:

- Why is advocacy important and how has it evolved?
- Healthcare and reproduction is not limited to "one-side of the aisle"
- As a member of an industry, IVF center or ancillary service provider, how can you get involved
- The basics of our democracy and how your voice counts

Speakers:
David L. Stern, MBA, CEO, Boston IVF Fertility Network
Sean B. Tipton, MA ASRM Chief Advocacy, Policy and Development Officer

Moderator:
Inger Britt Carlsson, PhD, Chair, Corporate Member Council

David Stern has over 30 years of women’s health experience and has devoted the majority of his career to the fertility industry. He has held executive leadership positions and built successful teams while launching numerous products in pharmaceutical and biotech markets world-wide. Currently, David serves as the CEO of Boston IVF, one the largest IVF center networks in the United States with 11 full service IVF centers and over 14 satellite centers nationwide.

On Tuesday, advocacy is everywhere!

Unleash the activist within you by visiting our four Advocacy stations during the Congress on Tuesday, October 17! For more info, look for the full-page ad in the program or go to https://asrmcongress.org/attendees/events/advocacy-is-everywhere/
Over the course of three days (October 16-18), collect codes from locations around the New Orleans Convention Center for a chance to win prizes including a Meta Quest 2, Apple AirPods, and Amazon gift cards.

The Fine Print:
Attendees must be registrants of the ASRM 2023 Scientific Congress & Expo to be eligible to play. You do not have to be present to win. Limit 1 prize per person, unless otherwise noted. If you are not present at the time of the drawing, you will be contacted, and your prize will be mailed to you.

Prize drawings will be held at the ASRM Booth in the Expo Hall, Wednesday, October 18 at 12:00 PM CT.

Winners of the Passport Game and Step Challenge will also be notified also via the Alerts section of the app. Check your delegate packet and the ASRM 2023 meeting app for additional information.

How to Play:
1. Download the ASRM 2023 app from the Apple or Google Play store and log in.
2. Create your user profile.
3. Collect all codes around the New Orleans Convention Center (see code locations).
4. Refresh your app one hour before the drawing.

CODE LOCATIONS
Advocacy Day Station 1
Advocacy Day Station 2
Advocacy Day Station 3
Advocacy Day Station 4
ASRM Booth
ASRM Donor Lounge
Carrot Fertility, Booth 1836
Expo Theater
Expo Hall Coffee Break Stations (Supported by ZyMōt Fertility, Inc.)
Invitae, Booth 1237
Networking Lounge
Opening Ceremony
Poster Café
Registration Area
Society Social Hour
Over the course of three days (October 16-18), collect codes from locations around the New Orleans Convention Center for a chance to win prizes including a Meta Quest 2, Apple AirPods, and Amazon gift cards.

The Fine Print:
Attendees must be registrants of the ASRM 2023 Scientific Congress & Expo to be eligible to play. You do not have to be present to win. Limit 1 prize per person, unless otherwise noted. If you are not present at the time of the drawing, you will be contacted, and your prize will be mailed to you. Prize drawings will be held at the ASRM Booth in the Expo Hall, Wednesday, October 18 at 12:00 PM CT. Winners of the Passport Game and Step Challenge will also be notified via the Alerts section of the app. Check your delegate packet and the ASRM 2023 meeting app for additional information.

Download the ASRM 2023 app from the Apple or Google Play store and log in.
Create your user profile.
Collect all codes around the New Orleans Convention Center (see code locations).
Refresh your app one hour before the drawing.

ASRM QBOOST LIVE
Step into the ring and ace our pop quiz to earn a QBoost t-shirt and the chance to win a bonus prize!

How to Play:
1. Visit the ASRM Networking Lounge in the Expo Hall during the specified times and locate the QBoost Live event. (Look for the big wheel!)
2. When it’s your turn, spin the wheel to determine your question topic.
3. Visit the ASRM Networking Lounge in the Expo Hall during the specified times and locate the QBoost Live event. (Look for the big wheel!)
4. When it’s your turn, spin the wheel to determine your question topic. Answer the question correctly to earn a free QBoost t-shirt!*

Answer three questions on the topic correctly and enter for a chance to win ASRM 2024 bonus prizes for next year’s Congress!

*While supplies last. Limit 1 per person.

ASRM 2023 STEP CHALLENGE
Enjoy some healthy fun with your peers by joining the ASRM Step Challenge at ASRM 2023! Earn chances to win prizes for reaching Challenge Goals and working your way up the Leaderboard.

How to Participate:
1. Download the “Heka Well” app from the Apple or Google Play store.
2. Launch the Challenge app and select the “ASRM Step Challenge” from the list.
3. Complete the in-app registration and pair your supported activity tracker.
4. To sync your step data to the app, select “Tap to sync points” at the top of the dashboard.
5. Sync your point data at least one time per 24 hour period and before the Challenge end time to make sure all your points count!

Get up to 35,000 steps by the end of the challenge and be entered to win one of five surprise gifts bags.
Surpass 35,000 steps by the end of the challenge and be entered to win one of three Beats noise cancelling earbuds!
What happens in New Orleans doesn't have to stay there.

Replay the Congress over and over!

Purchase the ASRM 2023 Recorded Content Bundle and get access to recordings from:

- Plenaries
- Symposia
- Clinical Sessions
- Interactive Sessions

Add the Recorded Content Bundle at the Registration desk, or purchase after the Congress in the ASRM Store at www.asrm.org.

Recorded content, which includes video recordings of speakers and slides, will be available in ASRM Academy between November 15, 2023 and October 1, 2024.

Course does not provide a certificate of completion or credits.
See You in New Orleans!

FUTURE ASRM SCIENTIFIC CONGRESS & EXPO DATES

Denver, Colorado
October 19-23, 2024

San Antonio, Texas
October 25-29, 2025